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 Aortic valve disease (AVD) affects millions of people of all ages around the world.  
Current treatment for AVD consists of valvular replacement with a non-living prosthetic 
valve, which is incapable of growth, self-repair, or remodeling.  While tissue engineering 
has great promise to develop a living heart valve alternative, success in animal models 
has been limited.  This may be attributed to the fact that understanding of valvular cell 
biology has not kept pace with advances in biomaterial development.  Aortic valve 
leaflets are exposed to a complex and dynamic mechanical environment unlike any in 
the vasculature, and it is likely that native endothelial and interstitial cells respond to 
mechanical forces differently from other vascular cells.  The objective of this thesis was 
to compare valvular cell phenotype to vascular cell phenotype, and assess the influence 
of steady shear stress on valvular cell biology.  This thesis demonstrates that valvular 
endothelial cells respond differently to shear than vascular endothelial cells, by aligning 
perpendicular to the direction of steady shear stress, and by the differential regulation of 
hundreds of genes in both static and fluid flow environments.  Valvular interstitial cells 
expressed a combination of contractile and synthetic phenotypes not mimicked by 
vascular smooth muscle cells.  Two three-dimensional leaflet models were developed to 
assess cellular interactions and the influences of steady laminar shear stress.  Valvular 
co-culture models exhibited a physiological response profile, while interstitial cell-only 
constructs behaved more pathologically.  Steady shear stress enhanced physiological 
functions of valvular co-cultures, but increased pathological response of interstitial cell-
only constructs.  These results showed that valvular cells, whether cultured separately or 
together, behaved distinctly different from vascular cells.  It was also determined that 
 xvi
shear stress alone cannot induce tissue remodeling to more resemble native valve 
leaflets.  The leaflet models developed in this thesis can be used in future experiments 
to explore valvular cell biology, assess the progression of certain forms AVD, and 
develop targeted diagnostic and therapeutic strategies to hopefully eliminate the need 








 Cardiovascular disease (CVD) is the leading cause of death in the United States 
and the developed world. CVD is an umbrella term that includes many more specific 
diseases and conditions, including coronary heart disease, stroke, and less common 
forms such as congenital heart defects and rheumatic heart disease (RHD).  In the 
United States in 2001, over 61 million people were suffering from one or more CVD[5], 
with over $200 billion spent each year on hospitalizations and lost wages[5].  The United 
States has a relatively modest death rate for cardiovascular diseases, however, with 
Russia and Eastern Europe having the highest death rates.    Approximately 1 million 
Americans are living with a congenital heart defect (CHD), and more than 40,000 babies 
are born each year (1-2% of all live births) with a CHD.  Due to advances in the 
development and distribution of antibiotics, deaths from RHD has plummeted over 70% 
in the U.S., from 15,000 in 1950 to only about 4,000 in 1999[5].   
 While the prevalence of “western” style CVD in less developed countries is much 
rarer, some of the less common diseases in the U.S. are major issues.  In India, for 
example, up to 130,000 babies are born with congenital heart defects and over 50,000 
new cases of rheumatic fever each year[6].  In developing countries, rheumatic fever is 
the most frequent cause of heart disease in the 5-13 age group, causing 25-40% of all 
CVD, and 33-50% of all hospital admissions[5].   
 Many CVD are associated with pathologies of the aortic valve, due to its 
prominent position above the left ventricle and critical function of maintaining normal left 
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ventricular ejection.  The aortic valve opens and closes approximately 3 billion times in a 
70 year lifespan, a fatigue life virtually unreachable by nonliving materials.  Any valvular 
impairment will lead to left ventricular dysfunction (a strong predictor of mortality[12]) if 
not corrected in a timely manner, and vice versa.  Approximately 12,000 Americans died 
in 2002 from aortic valve related causes, and over 52,000 were hospitalized.  That same 
year, approximately 96,000 valve replacement operations were conducted in the U.S., 
the majority for the aortic valve[5].  The prevalence of aortic valve disease in patients 
may be underestimated due to a “selection bias” that may occur at diagnosis or autopsy.  
Clinicians may only list the pathologies they consider most significant in a patient, and 
therefore neglect valve related diseases[9].  There are very few studies that have 
compared the relative prevalence of different types of aortic valve disease (AVD) within 
a patient population.  A comparison between studies that do exist of countries of 
different stages of development is shown in Figure 1-1.  The United States[7, 8] and 
Japan[9] represent two types of developed countries, while Pakistan[10] and 
Ethiopia[11] represent lesser developed countries.  While it is difficult to compare 
medical information from multiple countries, because of differences in diagnostic 
techniques, experience of the medical technicians, and differences in patient 
populations, an analysis can be made to compare the relative prevalence of general 
disease classifications.  It is clearly evident from Figure 1-1 that the prevalence of 
degenerative type diseases (calcification, senile valve) is associated with more 
developed countries, while inflammatory diseases (rheumatic heart disease) is 
associated with poorer countries.  The lack of degenerative valve pathologies in lesser 
developed countries may reflect the shorter life span of these populations, as well as a 
lack of experience with this type of failure, not necessarily a lesser incidence.  Clearly, 
aortic valve diseases are a global concern.   
 2














United States Japan Pakistan Ethiopia
Figure 1-1: Distribution of aortic valve disease etiologies as classified by 
clinicians in different countries.  Taken from[7-11]. 
 
1.1: Aortic Valve Physiology 
 
 Structure of the Aortic Root.  The aortic valve is composed of three semilunar 
cusps attached to a fibrous annulus embedded in the fibers of the left ventricular septum 
(Figure 1-2A).  The functional unit of the valve, however, includes both the cusp and its 
respective aortic sinus complex.  The sinuses of Valsalva are three elliptical depressions 
in the aortic wall, from which the coronary ostia initiate.  The aortic annulus is a coronet-
like fibrous structure to which the aortic cusps, or leaflets, are attached.  Figure 1-2B 
shows the arrangement of the components of the aortic valve.  The cusps attach to the 
annulus with semi-elliptical profile, meeting at commissure points.   
Aortic Valve Leaflet Structure.  The valve leaflets are very thin, flexible 
structures, which come together to seal the valve when it closes.  The bulk of the leaflet 









Figure 1-2: The aortic valve.; A: Identification of the major features of the aortic 
valve.  Adapted from Gray’s Anatomy; B: The location of the aortic valve (AV) o
the heart (www.iun.edu)  C: Leaflet structure (Movat’s Pentachrome).  
V=ventricularis, S=spongiosa, F=fibrosa. 
n 
as shown in Figure 2C.  The relative proportions of the thickness of these layers vary 
along the radial length of the leaflets, and the amount and organization of the fibrous 
components (collagen and elastin) are also different.  The fibrosa is located on the aortic 
side of the leaflet, and is composed of collagen sheets and bundles arranged in the 
circumferential direction with very little elastin[21].  The thinner ventricularis covers the 
ventricular surface of the leaflet, and has considerably more elastin than the fibrosa, but 
both components are organized with somewhat less directionality than in the fibrosa 
when fully relaxed[21]. Between the fibrosa and the ventricularis is the spongiosa, 
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comprised of a large amount of glycosaminoglycans (GAGs) and a few loosely 
connected fibrous proteins[20].  It is thicker near the aortic wall, and thins to virtually 
absent at the free margin of the leaflet.  It is unclear whether any vasculature is present 
in normal healthy human aortic valve leaflets.  Diffusion limitations require capillaries 
spaced roughly every 250 µm to prevent hypoxia.  Bovine aortic valve leaflets have 
vasculature, while porcine and ovine leaflets generally do not.  Some cases of leaflet 
vascularity in humans has been documented, but this may be a result of pathological 
angiogenesis from thickening of the leaflets[22-24]. 
 Function of the Aortic Valve Leaflets.  The aortic valve leaflets function in 
concert with the aortic root to ensure smooth opening and closing, and therefore root 
mechanics should not be neglected when considering valve function.  A schematic of 
aortic valve and root dynamics is shown in Figure 1-3.  The leaflets are mutually 
Figure 1-3: Schematic of aortic valve leaflet and root dynamics during 
the cardiac cycle.  Line indicates relative blood velocity at the level of 
the valve.  Taken from[4]. 
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apposed during diastole, and a small overlap of leaflet tissue, called the lunula, ensures 
a closed volume for efficient filling of the left ventricle.  The valve annulus expands 
during this time, pulling the leaflets taught to prevent prolapse[25].  Further increase in 
annular radius at end diastole and into the isovolumic contraction phase of the cardiac 
cycle pulls the leaflets from their commissures such that a small stellate orifice results, 
even without the presence of transvalvular flow[26].  The valve orifice changes quickly 
from stellate, to triangular, to finally a circular pattern as blood is ejected from the 
ventricle, opening the aortic valve in less than 1/60 of a second.  The aortic root adjusts 
from a conical to a cylindrical shape during ejection, providing optimal hemodynamics at 
the larger flow volume[27].  The aortic valve closes much more gradually relative to 
opening, the dynamics depending on the transvalvular pressure and the parameters of 
the vortexes that develop within the sinuses of Valsalva.  The reduction of forward blood 
velocity causes a bifurcation of the flow field to develop, and part of the flow circulates 
behind the leaflets, creating a vortex[28].  These vortexes help circulate oxygenated 
blood through the coronary arteries, as well as create a small pressure gradient across 
the leaflet, which help bring the leaflets to a smooth and efficient closure. 
 
1.2: Aortic Valve Mechanics 
 
 Tissue Mechanics in Vivo.  The majority of the stresses and strains 
experienced by the leaflets occur during diastole and early opening of the valve.  
Although an exact measurement of these stresses in vivo is very difficult to perform, a 
reasonable approximation can be made based on elementary mechanics.  Thubrikar and 
colleagues approximated the stresses in vivo by assuming that the majority of the 
pressure load is supported by a combination of bending and membrane stretching [29].  
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Considering bending and stretching as independent components, they developed a 
model of the in vivo leaflet stresses, which was a function of the transvalvular pressure: 
 
Stress = (PR/T) +/- E x (T/2R) 
 
where P is the transvalvular pressure, R is the radius of the leaflet, T is the thickness, E 
is the tissue modulus of elasticity, and the bending stresses are either tensile (+) or 
compressive (-) depending on the side of the leaflet.  The relative contributions of the 
components changed as the leaflet changed curvature during the opening phase.  They 
concluded that the total stresses in the leaflet in systole were on the order of 50 kPa in 
systole and 500 kPa in diastole.  The aortic surface of the leaflet (fibrosa) bore the 
diastolic load, while the ventricular surface (ventricularis) bore the systolic load.  From 
their calculations of membrane stress, they determined that the leaflet stretches 
approximately 10% circumferentially from systole to diastole.  More careful 
considerations of the geometry of the load bearing surfaces during systole and diastole 
have generated estimates of maximum physiological leaflet stress between 200 - 400 
kPa [20, 30].  Using similar methods, in vivo leaflet strains have been calculated to be 
0.1 in the circumferential direction and 0.4 in the radial direction (Brewer, 1977; 
Thubrikar et al., 1980, Missirlis, 1973). 
 Material properties of the aortic valve leaflet.  Characterization of these 
material properties has proven difficult because the physiological strain rate of leaflet 
tissue is as high as 2.5/s[31, 32], and instruments capable of applying physiological 
strain rates to leaflet tissues have only recently been developed.  Both pseudoelastic 
and viscoelastic material property data is presented below.  
Pseudoelastic properties: Although biaxial testing techniques are preferable for 
analyzing anisotropic tissues, the majority of published studies determining leaflet 
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material properties performed uniaxial tensile test at very low strain rates, and of those 
still fewer analyzed human leaflets.  Both data on human and porcine aortic valve 
leaflets are presented for comparison.  Figure 1-4A shows the representative 
pseudoelastic stress-strain response[33] of leaflet tissue in circumferential and radial 
directions.  While the values of each of the components of the graph, shown in Figure 1-
4B, differ between studies, the responses all show similar distinct features.  First, an 
initial elastic phase, with a modulus Ee, a transition strain at an extensibility of εt, and an 
inelastic modulus Ei.  These results indicate fairly good agreement between the material 
properties of human and porcine leaflet tissues, thus supporting the use of the porcine 
aortic valve as a model of human valve behavior.  Material properties appear dependent 
on strain rate, and the ratio of circumferential to radial modulus increases with increasing 
strain rate. The biaxial test data mirrors that of the uniaxial tests with the exception of the 
higher radial extensibility.  This data clearly demonstrates the biphasic nonlinear 
response of the leaflet tissue hypothesized earlier.  The high compliance at low strains 
and high modulus at high strains enables the tissue to be optimally flexible and rigid 
during systole and diastole.  Ultimate tensile stress loads of aortic valve leaflets range 
from 2.0 to 4.0 MPa [39], which is ten times greater than the physiological stresses that 
occur in vivo.  This phenomenon is ideal for materials that must endure many loading 
cycles without fatigue.  
Stress Relaxation Tests – The previously tabulated data, as well as other data by 
researchers[30, 32, 39] demonstrate a significant dependence of stress on strain rate, a 
hallmark of viscoelastic materials.  Both linear and quasilinear viscoelastic (QLV) 
constitutive models[33] have been applied to aortic valve leaflet tissues, as well as more 
complex models[42].  Viscoelastic tests are difficult to apply tovalvular tissues, because 
it is impossible to apply an instantaneous step change in stress or strain, which is 








Study (Year) Strain rate 1/s 
Ee, rad 




kN/m2 εt, circ 
Ei, circ 
kN/m2
Clark (1973)[34]1 1.69E-3 11.03 0.24 1707 19.49 0.13 5866 
Missirlis (1976)[35]1 2.67E-3 --- 0.28 2276 --- 0.11 7092 
Missirlis (1978)[31]2 3.3E-3 --- 0.60 1089 --- 0.33 3355 
Sauren (1983)[32]2 2.5 167 0.07 1000 3333 0.03 25000 
Rousseau (1983)[36]2  1.0 --- --- --- 133.33 0.10 14000 
Lee (1984)[37]2 0.833 --- 0.37 1666 --- 0.09 5000 
Mavrilas (1991)[38]1 2.5 --- 0.07 1570 --- 0.07 14600 
Leeson-Dietrich 
(1995)[39]2
4.0 --- 0.33 1860 --- 0.13 19640 
Christie, 1992[20]2 --- 2.688 0.63 333.3 10.6 0.13 2333.3 
Figure 1-4: Mechanical properties of aortic valve leaflets in the circumferential (c) 
and radial (r) direction.  σ = stress, ε = strain, E = effective modulus, t = transition.  
1human leaflets, 2porcine leaflets, --- not determined. 
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the stress relaxation of human aortic valve leaflets, several studies have defined early 
relaxation in porcine leaflets, and a summary of the early time constants of therelaxation 
responses in the literature is given in Table 1-1.  Stress relaxation is important because 
it characterizes the ability of the leaflet to transmit diastolic stress to the aortic root.  This 
property highlights the ability of the leaflet tissue to dynamically reorganize its 
microstructure.  The level of stress remaining in the tissue prior to opening of the leaflets 
must be carried by the flexion of the leaflet base.  Thus it is critical that adequate stress 
relaxation occur in diastole to ensure long-term function of the leaflets.     
Table 1-1: Stress relaxation time constants for aortic valve leaflets 
in the radial and circumferential directions. 
Study (year) % Stress remaining/s Radial 
% Stress remaining/s 
Circumferential 
Lee et al. (1984)[30]   -2.94 -5.00 
Leeson-Dietrich et al. (1995)[39]  -6.00 -5.90 
Vesely et al (1995)[40]     -5.93 -4.62 
Duncan et al. (1996)[41]     -4.0 -6.2 
 
 
Internal Shear –  Internal shear is a material property that assesses the ability for layers 
of leaflet tissue to slip relative to one another.  Talman and Boughner found that the 
shear modulus within the leaflet is minimal through the physiological level of strain (~ 0 
kPa for |ε| < 0.2), indicating low viscosity through the spongiosa, which allows for eff 
icient transmission of stress as the leaflet flexes[43]. 
 Aortic Valve Function Related to Tissue Microstructure.  The presented data 
supports the proposed hypothesis that there are two relatively distinct mechanical 
regimes in which the leaflets operate.  The leaflet behaves relatively inelastically in 
diastole (supported by the fibrosa), while elastic in systole (supported by the 
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ventricularis).  These responses can be related to the microstructure of the different 
tissue layers.  Since collagen fibers offer minimal resistance to extension while in a 
highly crimped state, the elastin fibers of the ventricularis must dominate the elastic 
response of the leaflet at lower strains of the elastic phase in systole.  The diastolic 
pressure loads, supported by the fibrosa, are then resisted by the now completely 
unfurled collagen fibers.  These observations have been confirmed experimentally by 
tensile tests of normal and digested leaflets[21].  The increased radial leaflet extensibility 
observed in biaxial tests results from a planar reorganization of circumferentially 
orientation collagen fibers that would have been cut during radial sectioning[44, 45] in 
uniaxial tests. 
 
1.3: Aortic Valve Cell Biology. 
 
 The principal cell types in aortic valve leaflets are interstitial cells and endothelial 
cells.  Smaller populations of smooth muscle cells[46] and nerve cells have also been 
noted[5, 47, 48].  Few studies have been conducted to characterize these cells, save for 
in vitro studies of cytoskeletal[49] and surface marker expression[50] and histological 
analyses[51].  In vitro experimentation with valvular cells has been difficult because no 
commercially available source exists, and manual isolation of pure populations has 
proved difficult.  Important studies that do exist relative to this introduction are 
summarized below. 
 Aortic Valve Interstitial Cells.  Interstitial cells are responsible for organizing 
and remodeling matrix proteins to withstand the dynamic tissue strains mentioned 
previously.  They appear as elongated cells in vivo, and are present in all of the leaflet 
layers with varying densities.  They have been generally classified as myofibroblastic, 
possessing prominent stress fibers and some secretory vesicles[52].  It has been 
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suggested that two morphologically distinct interstitial phenotypes exist, one more 
contractile and the other secretory, but only in vitro experimental evidence exists[53].  
Valve leaflets respond to a number of vasoactive agents, suggesting that interstitial cells 
share some active contractile responses with smooth muscle cells[54].  Schneider and 
Deck observed that normal aortic valve interstitial cells secrete proteins and 
glycosaminoglycans at a dramatically increased rate in comparison to other cell types in 
vivo, with a significantly higher index of proliferation[55].  These results suggest that 
interstitial cells phenotypically resemble more of a hybrid between fibroblasts and 
smooth muscle cells than either phenotype.  In pathology, interstitial cells may respond 
to endothelial denuding injuries by increased proliferation, as has been reported with 
mitral valve interstitial cells[56].  Aortic valve interstitial cell dysfunction characterized by 
thymosin beta4 upregulation and secretion of TGFβ1 have been implicated in the 
pathogenesis of valvular calcification[57, 58] and serotonin (5-HT) disorders[59].   
 Aortic Valve Endothelial Cells.  Aortic valve endothelial cells, like other 
endothelial cells, are responsible for maintaining a non-thrombogenic blood contact 
surface, as well as transmit nutrient and biochemical signals to the interstitial cells[60]. 
Aortic valve endothelial cells form single cell monolayers on leaflet surfaces, express 
von Willebrand factor[61], produce nitric oxide[62] and prostacyclin activity[50], and 
possess cell junctions similar to arterial endothelial cells[50].  Deck observed that 
valvular endothelial cells are oriented circumferentially across leaflets, perpendicular to 
the direction of blood flow, in contrast to vascular endothelium, which aligns parallel to 
flow[63].  Endothelial cells of the aortic valve arise from different sources than either 
arterial endothelial or ventricular endocardial cells in development, which suggests that 
these cells may be different in some respects from other endothelial cell types[64].  
Dysfunction in aortic valve endothelial cells has been highlighted in some recent studies 
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as being an important initiator of inflammatory responses related to the initiation of 
valvular disorders[65-68].   
 From this cursory analysis, it is apparent that aortic valve cells are significant 
regulators of normal valve functions.  It is currently unknown whether valvular cells are 
truly unique phenotypes of cardiovascular nature, or merely vascular cells in a different 
mechanical environment.       
 
1.4: Aortic Valve Pathology/Etiology 
 
 A list of valvular disease etiology classifications and some examples is given in 
Table 1-2.  While some have a genetic component either inherited or developed during 
cardiogenesis, others are acquired or completely epigenetic, developed later in life.  
Some valvular diseases are acquired as a consequence of other pathologies, such as in 
chronic renal failure[69] or AIDS[70].  Clinical evaluation of aortic valve disease is 
usually done through echocardiography, with a diagnosis of valve stenosis (constriction), 
regurgitation (retrograde flow), or both.  The exact disease cause varies depending on 
the specific pathology classification, examples of which are explained below in greater 
detail.  
 Congenital Heart Defects.  Many congenital heart defects have minimal long 
term consequences, while others are life threatening from birth.  More deaths occur due 
to cardiac defects than any other birth defect.  Some of the more prevalent defects to the 
aortic valve (shown in Figure 1-5) include bicuspid aortic valve, ventricular septal 
defects, Tetralogy of Fallot, and coarctation of the aorta.  Each of these defects can 
compromise the function of the heart, particularly the aortic valve.  A bicuspid aortic 
valve (BAV) has only two leaflets attached to the aortic root instead of three.  BAV 
leaflets are larger and thicker than normal leaflets, and as a result distribute  
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Table 1-2: Sources of aortic valve stenosis and regurgitation. 
Adapted from[1]. 
Heriatable – Congenital 
Heritable disorders of the connective tissues (Marfan’s, Ehlers Danlos) 
Genetic mutations (Kir2.1, NKX2.5)  
Congenital heart defects (bicuspid aortic valve, tetralogy of Fallot) 
Inflammatory – Immunological 
Rheumatic fever 
Infective endocarditis 
Acquired Immune Deficiency Syndrome (AIDS) 
Cardiovascular syphilis 
Non-bacterial thrombotic endocarditis 
Myocardial Dysfunction 
Ischemic heart disease 
Dilated cardiomyopathy 
Hypertrophic cardiomyopathy 
Diseases and Disorders of Other Organ Systems 
Polycystic kidney disease 
Systemic lupus erythematosus 
Rheumatoid arthritis 
Chronic renal failure 
Aging 
Calcific aortic stenosis 
Aortic sinus aneurysm 
Post-Interventional Valvular Lesion 
Valvulotomy 
Valve reconstructive surgery 
Valve replacement 
Drugs and Physical Agents 
Chronic use of ergotamine products 
Radiation induced valvular disease 
Trauma induced valvular disease 
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hemodynamic and mechanical stresses poorly [71].. 
   Ventricular septal defects (VSD) are imperfect closures of the ventricular wall 
during development, causing circulation shunts that severely impair normal unidirectional 
blood flow.  Depending on the size and location of the defect, the aortic valve may be 
adversely affected[72].  Tetralogy of Fallot (ToF) has four components: a VSD, stenotic 
pulmonary root, increased muscular left ventricle, and an aortic valve above the VSD.  
Babies with ToF are often blue at birth because of the inability to supply oxygen rich 
blood to the rest of the body.  Most of these patients require open heart surgery at a 
young age to repair the defects[73].  Coarctation of the aorta (CoA) is a severe 
narrowing of the aortic root (stenosis), causing dramatic increases in ventricular 
pressure, wall shear stresses, and impaired blood delivery to the lower body[74].  The 





Figure 1-5: Congenital heart defects. A: Ventricular septal defect 
(medlib.med.utah.edu); B: Tetralogy of Fallot (www.acc.org); C: 
Bicuspid aortic valve (www.esp-inc.com); D: Coarctation of the aorta 
(www.som.tulane.edu). 
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congenital heart defect type are difficult to discern, owing to differences in diagnosis 
techniques, terminologies, and adequate case numbers.  BAV is most often diagnosed, 
but this may be due to the fact that it does not present serious clinical complications at 
birth, is rather obvious morphologically, and can be detected later in life or at autopsy 
with relative ease.  Other more serious defects can occur in concert, making diagnoses 
of the primary defect virtually impossible.  In the United States, VSD occurs in 14-17 
percent of defects, followed by ToF (9-12 percent) and CoA (8-11 percent)[5].    
 Heritable Disorders.  Some congenital defects to the aortic valve are heritable.  
Many common connective tissue disorders, such as the Marfan Syndrome and Ehlers-
Danlos Syndromes, also present aortic valve complications.  Marfan Syndrome is an 
autosomal dominant connective tissue disorder that is caused by mutations in the 
fibrillin-1 gene, resulting in improper valve tissue development, in addition to eye and 
skeletal disorders[75].  Ehlers-Danlos syndromes are a group of heterogenic connective 
tissue disorders associated with mutations in genes coding for collagens and lysl-
oxidases[76].  A rare autosomal recessive cardiac valvular form of Ehlers-Danlos 
Syndrome has been found by Schwarze and colleagues to be caused by mutations in 
the COL1A2 gene, resulting in aortic insufficiency, mitral valve prolapse, and ventricular 
enlargement[77]. There is also evidence of heritability of bicuspid aortic valve[78].  
Andelfinger traced the genetic locus of this trait to chromosome 17, encoding for an 
inwardly rectifying calcium channel Kir2.1.   Further studies in frogs with the same Kir2.1 
mutation showed a dominant negative effect and lack of inward rectification[79].  Other 
heritable genetic mutations are associated with more heterotypic valvular pathologies.  
Benson and colleagues identified several mutations in the transcription factor NKX2.5 in 
26 individuals suffering with cardiac defects, including atrioventricular block, ventricular 
septal defect, and Tetralogy of Fallot[80].  This gene is also involved with Epstein’s 
anomaly, which is heritable.    Numerous studies conducted in animals have identified 
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putative genetic regulators of cardiac valve development, such as bone morphogenetic 
proteins[81], transcription factors[82], and growth factors[83].  Most of these types of 
studies involved gene knockout models that become embryonically lethal with severe 
cardiac defects and other complications.  These studies are somewhat limited, however, 
in that this only identifies a particular gene as a critical component to valve development.  
Many human preterm miscarried pregnancies are the result of severely complicated 
defects with little chance of survival or intervention success[84].  Defects in live births, 
however, are usually much less severe than the complete loss of valves seen in some of 
these animal cases. 
 Acquired Pathologies.  Several acquired diseases specifically affect heart 
valves, many of these are associated with bacterial infections that cause lesions 
preferentially on valve leaflets.  Over time, leaflet tissues become remodeled 
pathologically, and can no longer respond appropriately to mechanical forces.  
Eventually, leaflets contract and the valve becomes severely regurgitant.  Two major 
diagnoses of acquired valvular disease are infective endocarditis (IE) and rheumatic 
heart disease (RHD).  Infective endocarditis is an inflammatory-like reaction caused by 
the presence of a variety of bacterial vegetations on valve leaflets, including 
staphylococci, streptococci, and enterococcus strains[85].  Many patients with a 
congenital heart defect have an increased propensity for bacterial infection from any 
vascular surgery, including routine dental work[86].  Rheumatic heart disease often 
results from rheumatic fever, which is defined as a poststreptococcal multisystem 
disease characterized by migratory arthritis, subcutaneous nodules, chorea, and other 
symptoms occurring separately or in concert[87].  The valvular pathology, however, is 
somewhat similar to that of IE.    Bacterial lesions which envaginate the leaflets remodel 
the local matrix architecture, compromising its integrity, resulting in diseased valves[88].  
It is not completely understood how these strains of bacteria specifically adhere to 
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valvular tissues, remodel the extracellular matrix, and interact with the native cell 
populations.   
 Epigenetic Causes.  The majority of heart valve disease not diagnosed in 
childhood occurs later in life with no apparent etiology.  Late-onset valvular heart 
disease is an umbrella term which encompasses a variety of symptoms, including aortic 
valve stenosis, regurgitation, tissue calcification and degeneration.  Because there is no 
standard classification scheme (nosology), the incidences of specific types of tissue 
pathology are not well characterized, and many of the aforementioned symptoms occur 
in concert[1].  There has been increasing attention to, and evidence to support, the 
theory that many aspects of late onset valvular heart disease are really just extensions 
of vascular atherosclerosis.  Researchers have identified atherosclerotic-like lesions in 
valves, as well as some potential inflammatory mediators[89, 90].      
 Disease Progression.  While some valvular diseases are acute, such as from 
thoracic trauma[91, 92], disease progression in heart valves is more often slow, only 
compromising function at advanced stages.  Early events include valvular endothelial 
dysfunction[65, 68, 93] and interstitial cell activation[94, 95].  Biochemical factors 
secreted by these cells then modify the local extracellular matrix and change cell 
proliferation rates[96, 97].  In some cases, lipid accumulation occurs leading to cell death 
and the nucleation of calcium deposits[98].  Eventually, valvular cells lose the ability to 
remodel the valve matrix, and constant mechanical insult leads to tissue microdamage.  
Left unchecked, this damage eventually propagates to gross tissue pathology resulting 
in aortic regurgitation and/or stenosis.  A regurgitant valve (Figure 1-6A) does not close 
properly, allowing a percentage of blood to leak back into ventricle during diastolic filling.  
A stenotic aortic valve (Figure 1-6B) is constricted, restricting blood flow out of the left 
ventricle.  Both of these conditions cause the ventricle to pump harder to supply enough 
blood to the rest of the body, leading to left ventricular pressure overload.  Like any 
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A B
Figure 1-6: Diagnoses of aortic stenosis (A, www.circulation.or.kr) 
and regurgitation (B, www.medical.philips.com) 
exercised muscle, the ventricular wall becomes thickened under the increased load, 
eventually impairing bioelectrical conduction, causing ventricular wall atrophy, and 
resulting in congestive heart failure[99].     
 
1.5: Current Treatment Options 
 
 Treatment of heart valve pathology began as an operation to salvage left 
ventricle function, with little understanding or concern of valvular functions.  The fact that 
many valvular pathologies progress slowly is both a blessing and a curse.  Many 
patients do not know that they have a serious valvular complication until it is too late to 
treat without interventional surgery.  Therapy for heart valve disease includes valve 
sparing surgery or prosthetic valve replacement, and in some cases both.  As 
understanding of the complex functions of the aortic valve grew, so also did advances in 
surgical techniques and prosthetic designs to preserve valvular structure and prosthetic 
valve design to mimic valvular hemodynamics. 
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 Valve Sparing Surgery.  Because normal aortic root and valvular leaflet function 
is ideal, and in some cases leaflets are not affected by valvular pathology, preserving 
native valve leaflet and sinus tissue could dramatically benefit patients[3].  A number of 
aortic valve leaflet sparing and salvage surgeries have been developed specifically for 
cases of aortic regurgitation (insufficiency) caused by root dilatation or dissection, 
conditions that cannot accommodate a prosthetic replacement.  Surgeries include valve 
reimplantation and aortic root remodeling techniques.  The reimplantation technique 
(Figure 1-7A), first developed by Tirone David[100], involves dissecting the aortic valve 
intact, removing the diseased aortic root, and combining the healthy valve within a 
Dacron tube.  The remodeling technique (Figure 1-7B) involves dissecting the diseased 
aorta while preserving aortic valve attachment to the left ventricle[101].  Post-operative 
mortality is reasonably low (0-6%), with long-term survival rates (72-78%) and freedom 
from reoperation (90-97%) acceptable, with recurrence of aortic dilatation and 
insufficiency is a common failure mode[102, 103].  The experience and expertise of the 
surgeon is of paramount importance for these complicated surgeries, and therefore 
valve sparing surgeries can only be done at a few centers around the world.  Most 
valvular interventions therefore involve replacement with a prosthetic valve.    
A B
Figure 1-7: Aortic valve reimplantation (A) and remodeling (B) 
techniques.  Adapted from[3]. 
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 Prosthetic Valve Replacement.  Prosthetic aortic valve replacement has 
existed since the early 1960’s, beginning with the successful implantation of a 
mechanical valve in the subcoronary sinus by Dr. Dwight Harken[104].  Over the last 40 
years, there have been over 70 different types of mechanical and bioprosthetic valves 
used in hundreds of thousands of patients around the world[105].  Four main groups of 
options exist for surrogate valves: mechanical (Figure 1-8 Top), bioprosthetic (Figure 1-8 
Bottom), homograft, and pulmonary autograft.  Each of these valve groups has their 
advantages and limitations, and therefore surgeons try to match the valve choice with 
the patient’s particular clinical condition.   
 The continuous and demanding requirements for aortic valve function lead 
engineers and surgeons to first try mechanical devices for valvular replacement.  Figure 
1-8A shows an approximate evolution of the mechanical valve since the early 1960’s.  





Figure 1-8: Mechanical (A-C) and bioprosthetic (D-F) valves 
(www.rjmatthewsmd.com).  A: Tilting disk valve, B: Caged ball valve; C: 
Bileaflet valve; D: Porcine aortic valve (stented); E: Bovine pericardial 
valve (stented); F: Porcine aortic root (stentless).  
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valves, and more recently bileaflet valves[105].  While each valve design prevents 
regurgitation, differences in hemodynamic parameters exist between them.  The ideal 
mechanical valve will restrict the least amount of blood flow out of the left ventricle, while 
minimizing fluid shear stresses and turbulent flow regimes, which can cause hemolysis 
and cell death[106].  The progression from caged ball to more leaflet-like valves 
represents an appreciation gained by engineers for the normal aortic valve function: 
each new design having a larger orifice area while guarding the hinge mechanisms from 
flow[105].  Early valves were constructed out of stainless steel, titanium, and silicone, 
and newer valves are constructed out of more biologically inert materials such as 
pyrolytic carbon.   Currently, the tilting disk and bileaflet valves are predominantly used, 
each with well over 200,000 implantations in the aortic position.  The major drawback for 
these valves is the need for continual anticoagulant therapy to prevent blood clot 
formation, which could spontaneously clog the valve and lead to instant death[16]. 
  The use of bioprosthetic valves arose out of concern for the side effects 
accommodating anticoagulant therapy.  Porcine aortic valves were considered an ideal 
substitute because of the similar hemodynamic and mechanical environment of that 
species.  Once Carpentier and colleagues introduced the concept of glutaraldehyde 
fixation in 1968, that durable, non immunogenic xenograft valves became readily 
available[107].  Bioprosthetic valves come in two major forms: stented and stentless.  
Stented valves contain a rigid cassette to which the valve leaflets are sewn, while the 
stentless valves leaves the aortic root largely preserved.  While stented valves are much 
easier to implant, stentless valves are more compliant, and can better accommodate 
normal leaflet function[2].  Additional bioprosthetic valve designs include bovine 
pericardial and complete porcine aortic root designs.  These valves do not require the 
anticoagulation therapy needed in mechanical valves, but suffer instead from tissue 
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degeneration from mechanical wear[45], and calcification from glutaraldehyde and cell 
residues[98]. 
 Homograft (or allograft) valves are human aortic or pulmonary valves that are 
obtained at autopsy, sterilized, and stored until needed for implantation.  These valves 
are generally preferred over other valves because they are identical to the valve being 
replaced.  The obvious drawback for these valves is that they are in extremely short 
supply.  Advances in collection, sterilization and storage techniques have dramatically 
extended the “shelf life” of these valves, and with the advent of cryopreservation, have 
some cell viability at implantation[108]. 
 Pulmonary Autograft – The Ross Procedure.  It was recognized rather early 
on that the pulmonary valve is similar morphologically to the aortic valve, and may serve 
as a living replacement of a diseased aortic valve.  The pulmonary circulation is the 
higher pressure side of the heart throughout cardiovascular development, so it was 
thought that this valve would function well in the high pressure aortic position in adults.  
The adult pulmonary circulation experiences pressures only on the order of 15 mmHg, 
and could therefore tolerate a prosthetic substitute much more readily.  The first 
pulmonary autograft (same human) into the aortic position was performed by Dr. Ross in 
1962, and since then the Ross procedure has received praise and concern throughout 
the world[109].  Some surgeons prefer it to other techniques because it provides a living 
valve in the critical aortic region, while other surgeons shun the procedure because it 
demands extreme technical expertise and failure would then result in two damaged 
valves.  As a result, this surgery is performed in only a few centers around the world, yet 
with highly favorable results[110]. 
 Current Treatment Limitations.  While these valvular replacements help 
preserve other cardiac functions, they eventually fail due to a number of reasons.  A 
comparison of long term survival and freedom from valve-related events for the different 
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types of valve replacements is shown in Figure 1-9.  The pulmonary autograft (Ross 
Procedure) is clearly superior in terms of survival and freedom from operation (>80% at 
10 years).  Mechanical and homograft valves exhibit slightly higher survival rates than 
xenograft valves, but all three of these valves have equal incidences of valvular events 
requiring medical attention.  Nevertheless, survival with any of the prosthetic valves is 
greater than 50% after 10 years (Figure 1-9A,B).  An analysis of the failure modes 
incurred by each valve is given in Table 1-3.  Mechanical valves are superior for 
durability, but suffer from bleeding events associated with the anticoagulation therapy 
and clotting from blood contact with the valve materials.  Tissue valves are generally free 
from either bleeding events, but suffer instead from tissue degeneration and calcification.  
The aortic root and ascending aorta can be independently damaged secondary to aortic 
valve replacement, leading to root dilatation and aneurysm formation.  All prosthetic 
valves pose an increased susceptibility to bacterial infection[111]. 
  While 10-15 years of survival is generally acceptable for older patients (>70 yrs. 
old), this outcome is clearly not acceptable for younger adults.  More active young adults 
subject the aortic valve to changing heart rates and blood pressures, limiting the options 
available to them for valvular replacement.  This is best seen in statistics on heart valve 
replacement procedures with children, shown in Figure 1-9C,D.  Few studies exist that 
compare valve replacement options in children, but it is apparent from these that tissue 
valves are far inferior to mechanical or autograft valves in terms of freedom from events.  
Over 50% of all tissue derived valves (xenograft, homograft) require reoperation before 
10 years post operation.  Even though these failed prosthetic valves can be operated on 
successfully (as evidenced by minimal differences in survival), repeat open heart 
surgeries severely impair the quality of life of the patient. Unfortunately, the remaining 
options are also severely limited.  The more preferred Ross can only be performed in a  
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Figure 1-9: Survival and freedom from valve related events from aortic valve 
replacements in adults (A,B) and children (C,D).  Data taken from[13-19]. 
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Table 1-3: Prominent failure modes of mechanical and biological 
prosthetic heart valves. 













 limited number of facilities, and mechanical prostheses require constant anticoagulant 
therapy that again severely limits the activities a young child can engage in.  Even if 
advances in non-coagulating materials were developed, several repeat open heart 
surgeries will still be required to accommodate the growth of the child and his/her aortic 
root.  Patient/prosthesis mismatch can be a severe complication.  Many cardio-thoracic 
surgeons attempt to create a system for the assignment of valvular substitutes that takes 
into consideration a patient’s age and cardiovascular risk, an example of which is given 
in Figure 1-10[2].  The Ross procedure is preferred over other options until age 35, when 
use of other substitutes is more encouraged.  Nevertheless, these statistics paint a 
dismal picture for most patients suffering from aortic valve disease, and the increasing 
life expectancy of Americans is only going to make better heart valve replacement 
options more critical for the future. 
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Figure 1-10: Strategy for choosing valve replacements.  Taken from[2].
1.6: Heart Valve Tissue Engineering 
 
 The ideal valvular substitute on a surface level would be a tissue-like valve that is 
durable enough to thrive in the aortic position long term, is non-thrombogenic, and can 
grow and remodel according to the needs of the patient, eventually becoming identical to 
the valve it replaced[112].  Tissue engineering has emerged as a promising technology 
to respond to this demand.  This field explores the combination of living cells, a matrix-
like scaffold, and stimulation factors to create a living tissue that, once implanted, can 
remodel according to the body’s needs and after time function normally[113, 114].  
Tissue engineering is being applied to address concerns in orthopedics[115], secretory 
organs[116], neurological disorders[117], and cardiovascular pathologies[118].  Although 
not as advanced as cardiovascular tissue engineering, heart valve tissue engineering 
has progressed dramatically over the last decade[119].  The primary focus of heart valve 
tissue engineering has been the aortic valve, not only because of its significant clinical 
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importance, but also because of its near symmetry and single line of attachment to the 
aortic root.  Most research has focused on the development of scaffold materials that 
can withstand the dynamic mechanical environment of the aortic valve, while 
accommodating cell ingrowth and remodeling.  Three basic strategies have been 
employed: biodegradable polymeric scaffolds, decellularized valvular conduits, and 
completely biological matrix scaffolds. 
 Biodegradable Polymers.  The most widely used strategy involves 
biodegradable synthetic polymers repopulated with autologous cell types.    Over time, 
the polymer degrades by normal metabolic activity, and is replaced by biological matrix.  
The choice of polymer substrate varies according to the desired mechanical properties, 
melting temperatures, and degradation times.  Some polymers that have been used 
include PGLA, PHO, and PHA, separately or in combination[120].  The initial successes 
in leaflet replacement studies in lambs using synthetic polymers [121] have spawned 
over a decade of research with this strategy, eventually culminating in landmark 
pulmonary valve implant studies in adult sheep[122].  After 20 weeks in the pulmonary 
circulation, these valves resembled normal leaflet morphology, had similar mechanical 
properties compared to normal leaflets, and no incidences of preterm death.  While 
these results were exciting and promising, there still was significant transvalvular 
pressures (10-15 mmHg) associated with regurgitation due to leaflet shrinkage.  Since 
these pressures are on the order of systemic pulmonary circulation pressures, these 
valves may have been mimicking valve motions without actually maintaining function.  
Ultimately, this strategy may be limited in that the end products from the degrading 
polymers may change local pH, causing undesired cell death and differentiation[123].  
Nevertheless, a biodegradable polymer based valvular substitute has been successfully 
implanted in the pulmonary position in Europe, and short term followup indicates 
excellent pulmonary function[124]. 
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 Decellularized Valvular Conduits.  Decellularized aortic valve conduits make 
an attractive choice of matrix scaffold because the complete native leaflet tissue 
ultrastructure may provide unique biochemical and matrix signals for invading cells to 
encourage differentiation into leaflet cells.  In this method, excised porcine aortic roots 
are soaked with a series of chemicals to remove cellular fragments while preserving 
tissue ultrastructure, providing an ideal matrix structure for recellularization.  The 
challenge is the washing the tissue to completely remove residual detergents without 
additional tissue destruction.  This matrix can then be recellularized by invading cells, 
which then remodel the matrix according to local stimuli.  This method was first 
presented by Bader and colleagues in 1998[125] and commercialized by Cryolife with 
the SynerGraft decellularized valve, which is a detergent decellularized porcine aortic 
valve fabricated into a stentless implant[126].  Results in animal trials showed promising 
hemodynamic parameters and evidence of host repopulation, which lead researchers to 
begin human clinical trials in Europe for pulmonary valve indications.  Short term 
experience in adults (6 months) indicates reasonable leaflet coaptation and 
hemodynamic parameters in adults[127], but disastrous results were reported in 
children.  Massive immune response and spontaneous failures directly relating to rapid 
SynerGraft tissue degeneration led to the deaths of three children early into the study, 
immediately prompting the halt of the trial[128].  Interestingly, no cellular ingrowth was 
found on any of the excised valves.   
 Biological Matrix Scaffolds.  The least developed strategy involves creating a 
scaffold with completely biological matrix components.  Some examples that have been 
explored in cardiovascular tissue engineering include collagen[129], fibrin[130], and 
small intestinal submucosa (SIS)[131].  The advantage is that these materials can be 
obtained in large supply from xenogenic sources, can readily accommodate cellular 
ingrowth, and do not have cytotoxic degradation products.  While removing many of the 
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concerns of the previous options, this strategy is limited by mechanical fragility of the 
material[132], and the inability to create complex tissue geometries.  No published 
results exist using completely biologically derived matrices in heart valve tissue 
engineering, but exciting advances have been reported in small diameter blood vessel 
construction using a cell sheet technology first developed by Nicholas L’Heureux in 
1993[133].  Cells are grown in culture for several weeks, by which time they have 
secreted a considerable amount of matrix, forming a detachable cell sheet.  Multiple 
layers of these sheets then form a laminate structure that can be rolled into tubular 
geometries.  While these vessels exhibit improved mechanical properties compared to 
other biologically derived scaffolds, long term animal studies have not been published to 
date.  Edwards Lifesciences was  recently exploring the development of completely 
biological tissue engineered aortic valve using cell sheet technology and SIS 
biomaterials, capitalizing on sewing techniques used in their pericardial bioprosthetic 
valves.   
 Shi and colleagues have proposed the development of a composite 
approach[134].  They combine a biomimmetic hyaluronan gel with stacked collagen fiber 
bundles arranged in a layered structure similar to the native aortic valve.  While they 
report relatively strong collagen bundles (> 1 MPa), and the production of elastin, they 
are formed using neonatal rat cells, which may not be mimicked by human cells.  It is 
also unclear how these layers will be attached to each other while maintaining shear 
forces.  Ultimately, the fact that this valve design contains a non-biodegradable polymer 
(hyaluronan gel) prevents it from possible use in pediatric applications.   
 Cell Sources.  A number of cell sources have been used in heart valve tissue 
engineering applications.  Early research focused on vascular cell sources, such as 
arterial smooth muscle and endothelial cells, which have been well characterized and 
easily isolated.  Shinoka and colleagues conducted a series of leaflet replacement 
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studies in an ovine model investigating allogeneic and autologous cell sources for heart 
valve tissue engineering, and found that autologous arterial cells were preferable to 
allogeneic sources and dermal fibroblasts[121, 135, 136].  Heart valve tissue 
engineering may necessitate the use of some other cell type for reconstitution of tissue, 
because leaflet tissue is largely non-sacrificial.  Maisch and colleagues have developed 
a protocol for isolating valvular interstitial cells from a tricuspid valve biopsy, and were 
able to generate sufficient cell numbers for seeding a valve substitute[137].  The risk of 
postoperative death and unclear long term prognosis of tricuspid valve function suggest 
caution for this technique, but it demonstrates the feasibility of producing large cell 
numbers from a biopsy.  The authors were not able to generate tricuspid valve 
endothelial cells from this technique.  Rabkin and colleagues investigated the evolution 
of cellular phenotype of their blood vessel cell populated polymeric valve substitute, and 
found that after 16-20 weeks in the lamb pulmonary circulation the blood vessel cells 
were very similar to native valvular cells in terms of marker expression[51].  While 
autologous blood vessel cells provide an immediate source for repopulation, stem cells 
may be superior in that they theoretically provide an unending source of cells that may 
be able to differentiate into mature valvular phenotypes.  Preliminary experience using 
bone marrow derived stem cells suggests that these cells can differentiate according to 
mechanical signals and become more like valvular cells, but it is unclear that these cells 
are mature enough after in vitro stimulation for implantation[138].  The possibility of 
adipocyte transdifferentiation suggests the possibility of early leaflet calcification through 
lipid accumulation[139]. 
 Mechanical Stimulation.  It is well known that cells and tissues respond to 
mechanical forces by growth, strengthening, and remodeling responses.  Cardiovascular 
tissues are situated in a continuously mechanical environment, the aortic valve being a 
prime example.  The use of mechanical forces in the stimulation of engineered tissue 
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remodeling has been explored in bone[140], blood vessel[129], and heart valve 
applications.  Pulse duplicator systems have been developed to expose engineered 
valvular tissues to gradually increasing pressures and flows to encourage accelerated 
scaffold remodeling in vitro prior to implantation[141-143].  Studies with these systems 
reported improved mechanical properties and extracellular matrix production during in 
vitro stimulation compared to static controls.  Valvular conduits stimulated mechanically 
in vitro for two weeks before implantation demonstrated improved performance in vivo, 
leading researchers to conclude that in vitro preconditioning should be standard for heart 
valve tissue engineering[144].   
 While these systems recreate some aspects of heart valve fluid mechanics, 
virtually nothing can be learned about the roles of specific mechanical forces on tissue 
strengthening and remodeling from these coupled devices.  It is possible that one 
particular mechanical or hemodynamic force plays a large role in shaping valvular tissue, 
while others are more deleterious.  Creating devices to mechanically stimulate 
engineered tissue is a challenge because of difficulties stemming from their extreme 
fragility.  Pulsatile stretch bioreactors have been developed for vascular applications, 
imposing predominantly circumferential strain through cyclic lumenal pressure 
changes[129].  Recently, a three-point bending apparatus was developed to expose 
tissue strips to uniform flexure[145].  Preliminary studies have tested biodegradable 
polymer meshes seeded with cells, and indicate some remodeling responses.  It is 
unclear, however, how the flexure loads are distributed across the length of the strips. 
The observed responses may be localized to the region of the central bending pin, while 
the rest of the tissue acts like a hinge and remains statically cultured.  Native valvular 
leaflets and biologically derived matrix scaffolds have virtually no buckling resistance, 
making three point bending bioreactor designs somewhat limited.   
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 Tissue Engineering As a Model System.  While the current clinical applicability 
of tissue engineered cardiovascular substitutes is limited, advances in the study of 
cardiovascular physiology can be made using tissue engineering in vitro.  Indeed, the 
evolution of blood vessel cell biology study platforms has progressed from isolated cell 
populations cultured on coated rigid substrates to more physiological three dimensional 
substrates with relevant cell phenotypes in co-culture under well defined mechanical 
forces[146].  These tissue models have the advantage that well controlled mechanical 
and exogenous biochemical stimulation can be applied knowing all cellular and matrix 
components a priori[147].  This enables better induction of mechanistic pathways of 
biological response.  Because tissue engineered models of vascular systems can be 
created in a matter of days, biological inquiry can then progress more quickly and less 
expensively than animal models, with less variability.  Initial studies using vascular tissue 
engineering have demonstrated similar responses to what are observed in vivo, with the 
potential for greater understanding clearly evident[146, 148].   
 
1.7: Objective of this Research 
 
 The data presented earlier indicate a significant clinical need for a solution to 
aortic valve disease.  It is unclear how many of the causes of aortic stenosis and 
insufficiency progress undetected by current methods until they too require invasive 
surgery.  This fact coupled with the limited success to date of tissue engineered valvular 
substitutes in vivo underscores a fundamental lack of understanding of valvular cell 
biology.  It is becoming apparent that valvular physiology is distinct from vascular 
physiology, and therefore valvular cell biology may be different as well.  It is unclear 
whether the vascular cell populated tissue engineered valves fail because of a 
fundamental biological attribute of valvular cells that is absent, or a pathological 
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biological response to the very different valvular mechanical environment, or both.  If an 
understanding of normal valvular cell biology and the influence of mechanical forces can 
be developed, then perhaps an understanding of aortic valve disease initiation can be 
learned and therapies targeted before it progresses, removing all need for prosthetic 
valve implantation.  Tissue engineering can be of great service to this end, as a relevant 
physiological model can be developed to perform well controlled mechanical and 
chemical stimulations, and assess biological response[149].  The objective of this thesis 
was to develop a valvular leaflet model using tissue engineering technologies, and 
investigate valvular cell response to a well defined mechanical force.  To achieve this, 
several research goals were set, and the results of each are presented and discussed in 
separate chapters.  They are summarized as follows: 
 
Goal 1: Isolate and characterize pure populations of normal aortic valve cells:  Native 
valvular cells are not easily obtained or commercially available, so techniques to isolate 
valvular cells were developed and applied to porcine aortic valve tissues.  Cells were 
then characterized according to cytoskeletal marker expression, functional assays, and 
morphology.  These results are located in Chapter 2. 
 
Goal 2: Compare the phenotype of aortic valve interstitial cells and arterial smooth 
muscle cells in three dimensional culture:  Since primarily arterial smooth muscle cells 
were used to populate tissue engineered heart valve scaffolds, contractile and synthetic 
phenotype comparison was conducted between these cells and aortic valve interstitial 
cells.  Tissue compaction, contractile marker expression, and matrix production were 
assessed, and the results presented in Chapter 3. 
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Goal 3: Compare the biological response of aortic valve and arterial endothelial cells to 
steady laminar shear stress:  Many vascular and valvular pathologies begin with 
endothelial dysfunction, and it is likely that differences may exist between these cells in 
how they respond to mechanical forces.  Aortic valve endothelial cells and aortic 
endothelial cells were exposed to steady laminar shear stress, with static cultures 
serving as controls.  Cell morphology, focal adhesion development, and initial signal 
pathway results are presented and discussed in Chapter 4. 
 
Goal 4: Compare the genetic response of aortic valve and arterial endothelial cells to 
steady laminar shear stress:  The complete phenotypic response of a cell population to a 
stimulus can be profiled using microarray technology.  RNA profiles from shear 
conditioned and statically cultured endothelial cells were compared using cDNA 
microarrays and gene ontology software, and significant gene changes confirmed using 
real time PCR.  The results are presented and discussed in Chapter 5. 
 
Goal 5: Develop a three dimensional co-culture model of aortic valve cells and analyze 
the biological response to a well defined mechanical force:  Collagen I hydrogels were 
used to develop a three dimensional co-culture model using aortic valve cells.  Models 
with and without endothelial cells were exposed to steady laminar shear stress, with 
static cultures serving as controls.  Cell proliferation, marker expression, and matrix 
synthesis results are presented and discussed in Chapter 6.  
 
The significance and consequences of the results of these studies are presented in 
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 One of the challenges to in vitro experimentation is acquiring reliable and 
homogeneous cell populations.  While cells isolated from animal tissues are assumed to 
be “normal” due to the fact that they were isolated from healthy animals.  Cells isolated 
from human valves may be problematic because some of the other valves were 
diseased, the heart was removed for transplant, or the tissue was required at autopsy.  
Rabkin and colleagues analyzed the expression of various markers of normal and 
diseased (myxomatous) valves[1].  They found dramatic increases in the expression of 
contractile markers and proteases.  Nevertheless, these sources are probably the only 
ones available for research purposes.  In addition, to minimize variability between cell 
batches, it is important to obtain cells from the same population of species.  Since 
valvular tissue is not sacrificial (as for a peripheral blood vessel) in humans, and may be 
compromised by old age and/or pathology, we focused on manually isolating cells from 
accessible animal tissues.   
 There is some heterogeneity between human and other animal valve tissues, 
mainly associated with the degree of vascularity and hemodynamics.  Human aortic 
valve leaflets are normally avascular, as are porcine and ovine cusps, but bovine leaflets 
have a number of capillaries through them[2].  The presence of capillaries is generally 
associated with either diffusion requirements or pathological angiogenesis.  Cells can 
only survive within about 250 µm of a capillary or blood contacting surface.  The average 
thickness of aortic valve leaflets is on the order of 500 µm, but somewhat thicker at the 
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attachment region.  Thicker leaflets tend to have some capillaries, mainly near the basal 
third of the leaflet.  Pig heart circulation mechanics are most similar to humans, followed 
closely by sheep and dog.  Additionally, the porcine aortic valve differs from the human 
valve only in the existence of a small muscle shelf under one of the leaflets, which has 
been attributed to the fact that pigs are quadrupeds.  For these reasons, we decided to 
use porcine aortic valve tissue for cell isolation. 
 
2.1: Valvular Endothelial Cell Isolation and Characterization 
 
 Isolation.  Isolation of endothelial cells is by no means a trivial procedure.  
These cells are very fragile once removed from physiological conditions, and any 
disruption of the underlying matrix often liberates contaminating cells from the rest of the 
tissue.  There are only a few reports of successful isolation and culture of valvular 
endothelial cells in the literature, the specifics of which are summarized in Table 2-1.  
Each technique involves either enzymatic digestion of the underlying basal matrix, or 
 
Table 2-1: Literature reported protocols of valvular endothelial cell isolation.
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chemical dissociation of the endothelial adhesive bonds.  The resulting liberated cells 
are purified through additional processing, and cultured in vitro.  The objective of these 
studies was to develop a method to isolate a pure population of endothelial cells from 
valvular tissue that would not require manual selection or clonal expansion.  These 
techniques, while often necessary, compromise the ability to assume that the derived 
cells are representative of the whole population and reduce the number of passages  
obtainable in vitro prior to senescence or phenotype shift.  
 Preliminary isolation experiments were qualitatively assessed for three 
parameters: numbers of cells isolated, purity of the isolation, and propensity to become 
contaminated.  It was determined early on that hearts needed to be thoroughly washed, 
transported, and stored in fresh sterile PBS on ice.  The use of antibiotics or antifungal 
agents at this stage was probably killing the endothelium as well as any bacteria.  The 
isolation protocols attempted and their results are briefly summarized in Table 2-2.  
During this process, several steps in these procedures were found to be optimal and 
therefore were made common to all dissociation techniques attempted.  Prior to cell 
isolation serial rinses of the tissue in PBS with decreasing concentrations of 
Antibiotic/Antimycotic solution (5%, 2%, and 1%) were used to clean the tissue of any 
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residual bacteria and/or blood material.  Cell scrapers (Fisher), lifters (Corning), and 
sterile cotton swabs (Puritan) were evaluated for their ability to dislodge cells, and it was 
concluded that the cotton swabs were superior in this regard.  Any resulting cell 
solutions were centrifuged (200 g, 5 mins.) into a pellet, which was then plated.  Different 
base mediums were also assayed for cell growth, including M199 (Invitrogen), 
MCDB131 (VWR), and DMEM (Invitrogen).  DMEM was found to be optimal for valvular 
cell growth when supplemented with 10% Fetal Bovine Serum (FBS, Hyclone), 1% 
Penicillin-Streptomycin (Hyclone), and 1% L-Glutamine (Mediatech), and this formulation 
was used as the standard medium for all the valvular cell culture presented.   
 The results of these experiments showed that EDTA (or Trypsin-EDTA) 
incubation for up to 60 minutes was unsuccessful at dislodging cells, and it is possible 
that cells were being killed during the process.  Collagenase digestion was more 
successful at removing cells, but contaminating interstitial cells became a problem once 
the cells were adhered.  From an evaluation of all the techniques, it was determined that 
a 10 minute digestion in 600 U/ml collagenase was best at retrieving a usable number of 
pure valvular endothelial cells.   
 The optimal protocol used in isolating valvular endothelial cells is summarized 
below and also included in detail in the Appendix.  Intact porcine hearts or isolated aortic 
roots were obtained at a local slaughterhouse (Holifield farms, Porterdale, GA) and 
immediately placed in cold sterile phosphate buffered saline (PBS, Invitrogen).  The 
aortic valve was excised within 12 hours post-mortem, and the leaflets were trimmed to 
1/3 of their length away from their apposition to the base of the aortic root (Figure 2-1).  
Leaflets were then rinsed several times in a series of solutions containing gradually 
reduced amounts of antibiotic-antimycotic (A-A, Invitrogen, 5%, 3%, 1%, 10 min. each).  
The leaflets were moderately vortexed before each solution transfer.  The leaflets were 
then placed in 30 mm dishes (3 leaflets per dish), and incubated with a collagenase II 
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Figure 2-1: Porcine aortic valve leaflet isolation. 
solution (Worthington, 600 U/mL in serum free medium) for approximately 10 minutes.  
The surfaces of the leaflets were then gently scraped with sterile cotton swabs, and the 
resulting cell solution pelleted in a bucket centrifuge at 200 g’s for 5 minutes.  The 
pelleted cells were then plated onto tissue culture flasks pre-coated with collagen type I 
(Becton-Dickenson, Rat tail, 50 µg/mL).  Cells were cultured with Dulbecco’s Modified 
Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, 
Hyclone), 1% penicillin-streptomycin (Hyclone), and 1% L-Glutamine (Mediatech) at 
37°C and 5% CO2.  Primary culture media was also briefly supplemented with 50 
units/mL Heparin (Sigma) and 0.1% Mycoplasma Removal Agent (MRA, ICN).  Medium 
was changed every 48 hours, and cells were split 1:3 upon confluence.  Porcine aortic 
valve endothelial cells (PAVECs) required an adhesive protein for attachment and 
growth, unlike aortic endothelial cells (PAECs).  Gelatin, collagen I, and fibronectin were 
all supportive of cell growth.  The aforementioned procedure was also successful at 
isolating PAECs, and it was possible to isolate both PAVECs and PAECs from the same 
animal.   
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 Characterization.  Porcine aortic valve endothelial cells (PAVECs) exhibit a 
typical endothelial morphology (Figure 2-2).  Cells are generally cobblestone with 
contact inhibited growth.  Generally cells became confluent in about 4 days of culture, 
and could be cultured up to 8 passages using the aforementioned isolation technique.   
Valvular endothelial cell phenotype was assessed initially through typical endothelial 
marker expression, morphology, and functional characteristics.  Several published 
reports have identified some aspects of valvular endothelial cell phenotype, which are 
summarized in Table 2-3.  While most of these markers are common to many 
endothelial cell sources, it was unclear if there were any differences in the expression 
between the cell types.  A preliminary panel of assays was then used to determine and 
compare endothelial phenotype between valvular and vascular endothelial cells.  
Endothelial cells from the porcine ascending aorta (PAECs) were similarly isolated from  




Table 2-3: Valvular endothelial cell characterization. 
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Table 2.3 continued: 
Matrix/Factor 
Secretion Expression Animal Valve Passage Notes Ref. 
Fibronectin + Bovine Mitral 4  [4] 
Fibronectin - Porcine Aortic 3 to 4 Aortic EC 10 fold more [3] 
Gelatin-bound 
protein +/- Porcine Aortic 3 to 4 Aortic EC 10-30 fold more [3] 




+ Porcine Aortic 3 to 4 aortic 0.034 [3] 
Chondroitin 
Sulfate + Bovine Mitral 4 In medium [4] 
Hyaluronic Acid + Bovine Mitral 4 In cells and medium [4] 
Heparin + Bovine Mitral 4 In cells [4] 
Heparin Sulfate + Bovine Mitral 4 In cells [4] 
 
 
the same pig population and used as the control vascular endothelial cell for these 
studies.  Endothelial phenotype was assessed through indirect immunofluorescent 
staining and acetylated LDL uptake (a-LDL).  Endothelial cell phenotype is generally 
determined by aLDL uptake, positive von Willebrand factor (vWF) expression, and 
negative α-smooth muscle actin (α-SMA) expression.  For a-LDL comparisons, PAECs 
and PAVECs were incubated with 10 mg/mL a-LDL (Biomedical Technologies #BT-902) 
in serum-free media for 4 hours.  A detailed protocol for immunofluorescent staining is 
given in the appendix.  For these experiments, PAVECs and PAECs were seeded onto 
coverslips coated with collagen I and grown to confluence, after which they were rinsed 
in PBS and fixed in 3.7% paraformaldehyde (Tousimis).  Cells were then permeablized 
with 0.1% Triton X-100 (Sigma), and blocked with 1% neonatal goat serum (Sigma) for 
one hour.  The coverslips were then incubated with either anti-α-smooth muscle actin 
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(Sigma #F3777, 1:100) or anti-von Willebrand factor (vWF, Sigma #F3520, 1:100) for 
one hour.  These cells were then incubated with a fluorescently labeled secondary 
antibody for one hour.  The coverslips were then flipped onto glass slides and sealed.  
The samples were imaged using laser confocal microscopy for qualitative expression of 
the aforementioned markers.  Figure 2-3 shows the expression comparison between the 
PAECs and PAVECs.  Both of these endothelial cell types were similarly positive for a-
LDL uptake and von Willebrand Factor expression, but negative for α-Smooth Muscle 
Actin.  This compared favorably with previous published reports, and led us to conclude 
that these cells were in fact endothelial cells.  This degree of expression was maintained 
at least to passage 8.  Later passage cells were not assayed for expression, because 
primary culture endothelial cells tended to enter senescent cell death at this point, and 
are no longer useful for any experiments. 
 
B CA 
Figure 2-3.  Aortic valve endothelial cell characterization.  A: acetylated-LDL uptake.  
B: von Willebrand Factor expression.  C: α-smooth muscle actin expression.  Scale 
bar = 50 µm. 
 Endothelial Isolation from Different Sides of the Leaflet.  The aforementioned 
isolation technique pools valvular endothelial cells isolated from both sides of the leaflet.  
To isolate cells from one side of the leaflet at a time, a system was developed to confine 
the collagenase digestion to a single surface, shown in Figure 2-4.   It consists of a 150 
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mm glass dish with four smaller (60 mm) dishes inside, all lined with foil.  Paraffin beads 
were placed inside the dishes, the outside dish covered, and the ensemble autoclaved.  
Once all of the paraffin was melted, the dish ensemble was allowed to cool on a flat 
surface.  This created a thin layer that could support needle punctures.  In this way, 
single sides of the leaflets could be held open by immobilizing them with sterile needles.  
Collagenase was then applied to the exposed surface using the same protocol described 
previously, with the process repeated to the other surface.  Endothelial cell isolation from 









2.2: Valvular Interstitial Cell Isolation and Characterization 
 
 Isolation.  All of the cells underneath the surface of the leaflet are classified as 
interstitial cells, and they can therefore be easily isolated once the endothelial cells have 
been removed.  Several reports of interstitial cell isolation exist in the literature, and the 
results are summarized in Table 2-4.  These methods were basically divided into two 
categories: explant and digestion.  Explant methods involve mincing the tissue into tiny 
pieces, and adhering them to a culture substrate.  Cells then grow out of these tissue 
pieces over time.  The tissue pieces are then removed, leaving just the cells to grow.  
The digestion method involves incubating the tissue in enzymes which degrade the 
principal matrix components, and the cells fall out of the matrix into solution.  The 
resulting cell suspensions can then be plated normally.  While both methods are equally 
effective at retrieving cells, some researchers have pointed out that explant methods 
may select for certain phenotypes.  Migratory and chemotactic cells may move out of the 
tissue more abundantly than other cells, thus enriching the resulting cell population with 
those cells.  Some researchers have found that there “may” be two types of valvular 
interstitial cells, denoted as “cuboidal” and “spindle-shaped”[11].  Cuboidal cells appear 
as contact inhibited monolayers, while spindle-shaped cells are elongated, have 
prominent stress fibers, and form multicellular layers.  These classifications are given 
based on in vitro culture, however, and only appeared after several passages.  It is 
possible that the “cuboidal” cells could be endothelial-like cells, although the cells did not 
take up acetylated-LDL to the same degree as aortic endothelial cells.  Additionally, 
these interstitial cells were isolated using an explant technique, which selects for 
migratory cells, and may enrich for a certain cell phenotype that may otherwise not be 
noticed. 
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 Because of the potential problems associated with explant mediated cell 
isolation, collagenase digestion was used to retrieve interstitial cells.  The isolation 
protocol is briefly summarized below and is included in the Appendix.  The protocol was 
designed so that interstitial cells could be isolated immediately following endothelial cell 
removal.  Once the endothelium was removed, the remaining portions of the leaflets 
were then incubated for 24 hours in culture medium (as described previously) 
supplemented with 3% ABAM at 37°C under continuous gentle shaking.  Cultures that 
were negative for any bacterial contamination were then digested overnight (15-18 hrs) 
in fresh collagenase (600 U/ml) at 37°C again under gentle shaking.  The resulting cell 
suspension was pelleted in a bucket centrifuge (200 g, 5 mis.), and plated onto tissue 
culture treated flasks.  The cells were fed the standard culture medium, which was 
changed every 48 hours, and split 1:3 upon confluence. 
 Valvular Interstitial Cell Characterization.  Valvular interstitial cells grow and 




Table 2-4: Literature reports of valvular interstitial cell isolation and culture. 
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contact inhibited (Figure 2-5).  Several studies have isolated interstitial cells from valves 
and analyzed phenotypic marker expression, agonist response, and matrix secretion 
during in vitro culture.  The results of these studies are summarized in Table 2-5.  
Generally, valvular interstitial cells express markers similar to both smooth muscle cells 
and fibroblasts.  Interstitial cells respond to contractile agents to a similar degree as 
smooth muscle cells, express some immature contractile cytoskeletal proteins, but also 
secrete matrix proteins.  Taylor and colleagues compared the expression level of smooth 
muscle and fibroblast markers between different human valves, pericardium, and 
dermis[15].  They showed that a-smooth muscle actin expression was most prevalent in 
aortic valve interstitial cells, and least in dermal fibroblasts, whereas fibroblast surface 
antigen expression was consistent across cell types.  There were some differences 
between valves, which could be associated with several factors, most prominently 
differences in hemodynamic environment and tissue mechanics.  It appears that no one 
cell type studied could effectively mimic the expression trends of valvular interstitial cells. 
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Table 2.5: Valvular interstitial cell characterizationxpression Species Valve Passage Notes Ref. 
- Rat All Unkn. Rat heart endo. Positive [6] 
- Pig Aortic Tissue Porcine aortic valve endothelial cells positive [5] 
+ Pig Mitral up to 22  [13]  
+/- Pig Mitral up to 22  [13]  
Incomplete Pig Mitral up to 22  [13]  
      
xpression Species Valve Passage Notes Ref. 
+ Pig Aortic 1 to 3 
Not concentrated in any 
portion of the leaflet in 
vivo 
[16] 
+/- Human Mitral Tissue Myxomatous valves more positive [1] 
+/- Pig Aortic 1 to 3  [16] 
- Rat All Unkn.  [6] 
+/- Pig Aortic 1 to 3  [16] 
+ 
78 +/- 28% Human Aortic “Early” 
lesser for other valves 
(50-60%) [15] 
+ Cow Mitral Tissue Stronger for wound [17] 
+/- Human Mitral Tissue At ventricularis subendothelium [1] 
+/- Human Mitral Tissue At ventricularis subendothelium [1] 
+/- Human Mitral Tissue At ventricularis subendothelium [1] 
      
Conc. (M) Species Valve Passage Notes Ref. 
1.00E-06 Pig Aortic 1 to 3 PASMC also responded to this magnitude [16] 
3.20E-07 Pig Aortic 1 to 3 PASMC also responded to this magnitude [16] 
3.20E-07 Pig Aortic 1 to 3 PASMC also responded to this magnitude [16] 
1.10E-04 Pig Aortic 1 to 3 PASMC also responded to this magnitude [16] 
1.10E-04 Pig Aortic 1 to 3 PASMC also responded to this magnitude [16] 
5.00E-02 Pig Aortic 1 to 3 PASMC also responded to this magnitude [16] 
5.00E-09 Pig Aortic 1 to 3 PASMC also responded to this magnitude [16] 
1.00E-06 Rabbit Various 1 to 2  [14]  
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Table 2.5 continued: 
Matrix/Factor 
Secretion Expression Species Valve Passage Notes Ref. 
Fibronectin + Pig Aortic 1 to 3 Adjacent to IC in vivo [16]  
Chondroitin 
sulphate  + Pig Aortic 1 to 3 Diffuse through matrix in vivo [16]  
Prolyl-4-
hydroxylase +/- Pig Aortic Unkn. “Spindle” cells only [12]  
Prostacyclin + Pig Aortic Unkn. Similar to PAEC secretion [12]  
Angiotensin I + Rat Unkn. 3 to 6  [18]  













+/- Human Mitral In Tissue Higher expression in Myxomatous valves [1] 
 
Porcine aortic valve interstitial cells (PAVICs) were differentiated from PAVECs by 
opposite expression of the aforementioned cell markers.  Figure 2-6 shows that PAVICs 
are positive for α-smooth muscle actin, but negative for von Willebrand factor or a-LDL 
uptake.  Given that aortic valve leaflets contain only endothelial or interstitial cells, we 














Figure 2-6: Characterization of porcine aortic valve interstitial cells.  A: 
acetylated-LDL uptake.  B: von Willebrand Factor expression.  C: α-smooth 
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CHAPTER 3 
 





 The focus in heart valve tissue engineering for the last 10 years has been to 
develop a scaffold material capable of withstanding the highly demanding hemodynamic 
and mechanical environment of the aortic valve.  While this objective is certainly critical 
for success in this application, it is equally important that these scaffolds be populated 
with cells capable of performing functions of native valvular interstitial cells.  Previous 
studies have used cells isolated from arterial[1], venous[2], and dermal tissues[3], both 
from autologous and allogeneic sources.  In general, autologous arterial cells have 
performed superior to other differentiated cell types in animal studies[4].  Recently, 
efforts have focused on the use of stem cells as cell source for heart valve tissue 
engineering.  Stem cells retain the potential to differentiate into all cell lineages, and 
theoretically can differentiate into valvular interstitial cells given appropriate stimuli.  
Preliminary results indicate these cells are capable of expressing contractile markers in 
vitro, populating polymeric valve molds, and thriving within a pulsatile bioreactor [5].   
 The previously mentioned studies focused on cells that could be isolated from 
autologous tissue that could be sacrificed.  Autologous valvular tissue is generally not 
available for interstitial cell isolation.  One study isolated interstitial cells from a tricuspid 
valve biopsy, and were able to culture the cells to 10 passages in vitro, while maintaining 
                                            
1 Portions of the material presented in this chapter were published in the May 2004 issue of the Journal of 
Heart Valve Disease. 
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expression of several markers [6].  Two of their animals died in the process, and it is 
probable that the culture period required for generation of enough cells for tissue 
repopulation is prohibitively long.  Isolation of autologous mitral or aortic valve interstitial 
cells from excised tissue during prosthetic valve implant would probably also be 
unsuccessful, because these cells may already be compromised by pathology, and 
repeat open heart surgeries are severely demanding on patients.   
 While native valvular cells probably cannot be used as a cell source for human 
tissue engineered valves, there is surprisingly little known about their phenotype, 
mimicking which would be critical for the long term stability of the tissue.  
Autoradiographic studies done in rats have shown that valvular interstitial cells rapidly 
and actively secrete protein and glycosaminoglycans, with increased cell proliferation 
compared to arterial cells[7].  Studies with mitral valves have shown that valvular 
interstitial cells from different sides of the valve respond differently to endothelial 
denudation injury[8].  It is unclear whether those differences represent heterogeneity in 
the interstitial cell population, differences in signaling from matrix constituents, or 
differences in signal loss from heterogenic valvular endothelium.   
  One question not addressed by the aforementioned studies is how three 
dimensional cell culture, as in a biological scaffold, affects interstitial cell phenotype.  
Phenotypic differences have been shown in smooth muscle cells when cultured in two 
and three dimensional geometries[9].  While relatively small differences in cell 
phenotype may be masked in the short term, it is possible that over long-term culture, 
phenotypic differences may become more apparent.  These differences may be further 
augmented in three dimensional culture or within animal models.  A study by Rabkin and 
colleagues showed that the phenotype of isolated smooth muscle cells changed 
between culture conditions and over time, becoming more and more like valvular 
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interstitial cells[10].  The marker expression was semi-quantified, however, and it is not 
known how interstitial cells would behave in these changing conditions. 
 The objective of this study is to compare the phenotype of cultured aortic valve 
interstitial cells and aortic smooth muscle cells in two and three dimensional culture.  
This study will improve upon previous methods of comparison by quantitatively 
assessing phenotype marker expression using flow cytometry.  Contractile marker 





 Cell Isolation and culture.  Porcine aortic valve interstitial cells (PAVICs) and 
porcine aortic smooth muscle cells (PASMCs) were isolated as described in Chapter 2, 
using the protocol in Appendix A.  Briefly, the endothelium was removed from the tissue 
surfaces by short collagenase digestion (Worthington, 600 U/ml) followed by scraping 
with cotton swabs.  For PAVIC isolation, the leaflet tissue was digested in collagenase 
(Worthington, 600 U/ml) for 24 hours, and the resulting cell solution pelleted, 
resuspended, and plated onto tissue culture plastics.  PASMCs were isolated by 
removing the adventitia layers of the aorta, mincing the tissue into 3x3 mm sections, and 
digesting in collagenase (600 U/ml) for 48 hours.  Cells were then plated onto tissue 
culture plastic. 
 Both PAVICs and PASMCs were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Hyclone), 
1% penicilin/streptomyocin (PS, Hyclone) and 1% L-glutamine (LG, Mediatech).  
Cultures were fed every 48 hours, and split 1:3 at confluence.  Cultures were used for 
experiments between passages 5 and 8.   
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 Three dimensional construct creation.  Three dimensional hydrogel constructs 
were created using either PAVICs or PAVICs as described previously [11] following the 
protocol included in the Appendix.  Briefly, a suspension of 1x106 cells/ml was created 
with 5X DMEM, 10% FBS, type I collagen (Coll I, rat tail, BD Biosciences), and enough 
0.1 M NaOH to neutralize the solution.  The resulting 2 mg/ml collagen I solution forms a 
fibrillar gel network at 37°C and neutral pH.  Approximately 3 ml of solution was 
inoculated into wells of six-well plates and placed into a 37°C, 5% CO2 incubator.  After 
one hour, constructs were liberated from the walls and bottom of the wells and 5 ml of 
media was added to each well.  The disks were allowed to compact freely, and media 
was changed every 48 hours. 
 Construct area measurement.  Construct compaction was measured each time 
media was changed.  Constructs were placed on a clear sterile dish, and circular 
diameter measured by sliding a ruler underneath.  For constructs of non-circular shapes, 
constructs were photographed with the ruler underneath the dish, and areas digitally 
measured using Adobe Photoshop.  For statistical analysis, one way ANOVAs were 
used to determine significant compaction differences across experimental conditions, 
and T tests for differences between cell types. 
 Phenotype analysis.  Cell contractile phenotype was determined using 
fluorescent antibodies to the cytoskeletal markers α-smooth muscle actin (α-SMA, 
Sigma, 1:100), and desmin (Sigma, 1:100).  The distribution of each marker within cells 
was assessed through confocal microscopy, and expression levels were determined 
through flow cytometry.  It is difficult to quantitatively assess expression levels with 
confocal microscopy, while it is impossible to determine expression pattern (within the 
cell) by cytometric analysis.  Marker expression was determined at day 10 for both 2D 
and 3D culture. 
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 For flow cytometry, cells were detached from flasks with trypsin-EDTA (Gibco) at 
confluency, and spun into a pellet.  Cells from three dimensional constructs (3D) were 
isolated using a 60 minute collagenase (600 U/ml) digestion, and the resulting 
suspension was spun into a pellet.  The pellets were then washed twice by resuspending 
in PBS, followed by centrifugation and supernatant aspiration.  Immunofluorescence 
antibody staining was performed according to the protocol given in the appendix.  Briefly, 
cells were fixed in 3.7% paraformaldehyde (Tousimis) for 5 minutes, and permeablized 
with 0.1% Triton X-100 (Sigma) for 5 minutes.  Cells were then incubated in blocking 
buffer (1% neonatal goat serum, NGS, Sigma) for 1 hour.  Cells were then washed in 
PBS before incubation with the primary antibody for one hour.  Cells were then washed 
twice, followed by incubation with a fluorescently conjugated secondary antibody (Anti-
rabbit Alexaflour 488, Molecular Probes, 1:100) for one hour.  Secondary antibody only 
incubations served as control.  Cells were then washed twice, again, and approximately 
200µl of solution was added to a cytometry tube.  Flow cytometry was then performed to 
determine the marker expression distributions using a BD LSR Flow Cytometer (BD 
Biosciences).  The negative control was used to calibrate the signal, and histograms 
were collected from the negative control and four samples from different experimental 
trials.  Population statistics (algebraic mean, standard deviation) were determined and 
used for subsequent statistics as described previously[11].  Two factor Analysis of 
Variance was conducted with a significance level of P = 0.005.  Pairwise comparisons 
were then conducted post hoc with P < 0.005 considered significant.  The decreased P 
value was used as a more stringent requirement to conservatively account for the 
comparison of samples means instead of population distribution.  
 For confocal microscopy studies, cells were either seeded to confluence onto 
glass coverslips coated with collagen I (50 µg/ml), or in entombed in 2 mg/ml collagen 
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constructs.  After 10 days of culture, cells were fixed and stained while adhered to the 
coverslip or in embedded in the constructs using the same procedure described above.  
Samples were also counterstained with Hoechst dye to reveal cell nuclei.  Five 
representative pictures were taken of each sample for qualitative analysis. 
 Extracellular Matrix Synthesis.  Total soluble protein and sulfated 
glycosaminoglycan content was measured at day two and day six.  Total protein content 
was assessed using the BCA Total Protein Assay Kit (Pierce, Cat. No. 23225), while 
total sulfated glycosaminoglycan content was determined using the Blyscan sGAG Kit 
(Biocolor, Cat. No. B1000).  Constructs were washed thoroughly of all residual media 
with room temperature PBS by gentle shaking, lyophilized with a vacuum centrifuge 
(Jouan RC 10.10), and dissolved in a Tris-HCL buffered Proteinase-K (Sigma) solution 
as detailed in the protocol included in the appendix.  The Hoechst DNA assay was used 
to determine construct cell number to normalize protein and GAG content as previously 
described [11].  Briefly, 10 µl of lysate was incubated with Hoechst dye for 15 minutes at 
room temperature, and then measured using a UV Spectrophotometer (Biotech 
Powerwave 340) at 488 nm.  The amount of EDTA in the sample lysis buffer was above 
the acceptable for the BCA assay, so 5 µl of sample was added to 50 ml 1:10 sample 
buffer in dH20.  The BCA reagents were added at a 50:2 (A:B) ratio for increased sample 
gain and absorbance measurements were read at 650nm.  The Blyscan sGAG assay 
was performed according to the manufacturer’s instructions, and samples analyzed at 
560 nm.  Statistical analyses were conducted using single factor Analysis of variance 
within a cell type followed by T tests between cell types.  P < 0.05 was considered 
significant for these tests.  
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3.2: Results 
  
 Two-dimensional culture.  Porcine aortic valve interstitial cells grow in a similar 
manner as porcine aortic smooth muscle cells, with similar growth rates and 
morphological appearance, as shown in Figure 3-1.  Smooth muscle cells (A) tend to be 
slightly larger than interstitial cells (B), and form directional patterns in two dimensional 
culture.  Interstitial cells show less pattern formation, and are somewhat less likely to 
form nodules common to super-confluent smooth muscle cells in flask culture. 
 Three-dimensional culture.  Both smooth muscle and interstitial cells 
compacted the polymerized type I collage gel over the six day period, as shown in 
Figure 3-2A.  Very slight differences in gel compaction were observed at day two (P < 
0.05), but no differences in compaction were recorded at any other time point analyzed. 
A B
Figure 3-1: Porcine aortic smooth muscle cells (A) and porcine aortic valve interstitial 
cells (B) in culture.  Scale bar = 50 µm. 
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Figure 3-2: Construct compaction and cell 
number parameters. 
   
The disks generally maintained a circular profile during compaction, indicating 
homogenous contractile properties and/or cell distribution.  The constructs generally 
decreased in DNA content over the culture period, indicative of a reduction in cell 
number, but there was no difference between cell types (Figure 2B).  Both the 
compaction and cell number of each construct stabilized at six days, and the constructs  
appear to maintain a specific cell density of approximately 4.2 million cells/cm3 (Figure 
2C).  This could be due to specific cell mediated requirements, or limitations of nutrient 
diffusion.     
 Cell marker expression.  Cell phenotype was determined through expression of 
cytoskeletal markers as previously described.  Figure 3-3 shows confocal microscopy 




Figure 3-3: Confocal microscopy images of alpha-smooth muscle actin 
expression.  Panels A and C – PASMC, Panels B and D – PAVIC.  
Panels A and B – 2D culture, Panels C and D – 3D culture.  Scale bar = 
50 µm. 
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culture conditions.  Both cell types express the α-smooth muscle actin in both two and 
three dimensional culture, but to varying degrees.   Flow cytometry results highlighting 
these differences is shown in Figure 3-4.  No differences were observed between the 
cell types (P > 0.005), but differences were observed between culture conditions (P < 
0.005).  A reduction in α-smooth muscle actin expression occurs in three dimensional 
cultures for both cell types, but nearly all cells are still positive as compared to negative 
controls.  The cytometry histograms indicate broad expression peaks, which indicate that 
these cells express α-smooth muscle actin in an inhomogeneous manner.  There 
appears to be a small subpopulation of cells that do not express α-smooth muscle actin 
(arrow).  Caution should therefore be taken when using mean values to quantify 
expression levels, and replicate experiments need to be conducted to ensure accuracy.  
Figure 3-5 shows desmin expression levels as determined by confocal microscopy and 
flow cytometry.  Clearly, smooth muscle cells express desmin to a greater degree than 
interstitial cells, regardless of culture condition, in contrast to the α-smooth muscle actin 
expression.   
 Protein content.  Constructs containing either interstitial or smooth muscle cells 
were assayed for protein content as described previously, and the results are shown in 
Figure 3-6.  Over the course of construct compaction, between days two and six, there is 
a slight (but not significant P > 0.05) decrease in protein content in smooth muscle cell 
constructs, whereas there is a dramatic increase in protein content over the same period 
in interstitial cell constructs (P < 0.05).   Differences in protein content between cell types 
at day two were insignificant (P < 0.05), but by day six interstitial cell constructs had 
more protein than smooth muscle constructs (P < 0.05).  Taken together, these results  
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Figure 3-4:  Quantification of alpha-smooth muscle actin expression using 
flow cytometry.  Panel A – Expression histograms.  Panel B – comparison 
of algebraic mean. * denotes significance (P<0.005).  NC = negative 
control. 
   74


























































Figure 3-5:  Desmin expression as determined by confocal microscopy 
(Top) and flow cytometry (Bottom).  Panels A and C – PASMC, Panels B 
and D – PAVIC.  Panels A and B – 2D culture, Panels C and D – 3D 
culture.  Scale bar = 50 µm. NC = negative control. 
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suggest that the balance of protein synthesis and degradation is shifted towards 
synthesis in the interstitial cells, this in contrast to the degradation observed in smooth 
muscle cells in type I collagen gels.  There may have been some difference in initial 


































Figure 3-6:  Construct total protein content normalized to DNA content. 
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 Glycosaminoglycan content.  Figure 3-7 shows the sulfated 
glycosaminoglycan content of interstitial and smooth muscle cell constructs.  There are 
fewer glycosaminoglycans per DNA in the interstitial constructs at day two compared to 
the smooth muscle constructs (P<0.05).  By day six, however, there is no difference in 
content between the two cell types (P > 0.05).  The smooth muscle constructs do not 
increase in glycosaminoglycan content over the six day period (P > 0.05), whereas the 
interstitial cells do (P < 0.05).  Differences in glycosaminoglycan content at day two may 
indicate differences in cellular GAG content between PAVICs and PASMCs.  These 
results indicate that the balance between synthesis and degradation of 
glycosaminoglycans for interstitial cells is shifted towards synthesis, whereas for smooth 





























Figure 3-7:  Total sulfated glycosaminoglycan content 
normalized to DNA content. 
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3.3: Discussion 
 
 The mechanical environment of the aortic valve is highly complex and 
demanding, and bioprosthetic valve substitutes eventually fail under the loads imposed.  
These non-living valves lack a viable cell component that can remodel and repair the 
tissue matrix as it develops microscale defects under stress, without these growing to 
macro tissue failure.  Tissue engineering approaches to replacing a diseased aortic 
valve incorporate living cells and relevant matrix components to create a viable valve 
that theoretically can grow and remodel with the patient.  This of course would be 
particularly beneficial for pediatric patients.  While this technology shows promise, little is 
known about the biological functions these devices are intended to replace.  Certainly 
adequate tissue mechanical properties are fundamentally critical to the success of these 
devices, but many biological functions may need to be present for long-tem implant 
success.  Understanding these functions will certainly become important in the future. 
 The results from these studies demonstrate some similarities and some 
differences between the phenotypes of aortic valve interstitial cells and aortic smooth 
muscle cells.  Interstitial cell-populated constructs and smooth muscle-cell populated 
constructs both compacted to similar degrees over the culture period, and both cell types 
expressed similar levels of α-smooth muscle actin.  α-SMA is a structural protein present 
in smooth muscle, and its expression is correlated with gel compaction in other cell types 
[12], indicating contractile phenotype.  Significant reduction in α-SMA expression was 
measured in three dimensional gel culture, highlighting the role that matrix interaction 
plays in modulating cell phenotype [9].  Desmin expression was different between the 
two cell types, with aortic smooth muscle cells expression greater than interstitial cell 
expression.  Desmin is an intermediate filament that is involved in supplementing 
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contractile function [13].  From our studies, desmin expression is not correlated directly 
to gel compaction, but to cell type.  The increased expression of desmin may be related 
to the differences in synthetic properties observed, which is discussed later.  There are 
several reports of interstitial cell expression of fibroblast markers in situ, with limited 
expression of  α-smooth muscle actin [14, 15].  Other researchers have shown that cell 
phenotype can be modulated through culture conditions.  α-SMA expression can be 
enhanced through mechanical or biochemical stimulation, and matrix composition is also 
involved in this process [9, 11].  Rabkin et al. demonstrated that long term culture of 
tissue engineered valvular substitutes modulated smooth muscle expression of α-SMA 
similar to what is observed in vivo, but that expression levels of these molecules in vitro 
were initially different [10].  It is therefore probable that culture conditions and time in 
culture are also modulators of marker expression.  It is also important to note the 
relatively broad expression peaks of the different markers, indicating a relatively wide 
range of expression between individual cells within these groups.  There were no 
observations of multiple positive expression peaks in any experiment, suggesting that 
the expression range is associated with a single cell type, and not multiple cell types.  
Many factors can be associated with the range of expression between individual cells, 
which necessitates population statistics on distribution.   
 The marked differences in protein and glycosaminoglycan content indicate an 
ability of the valvular interstitial cell to synthesize matrix in three-dimensional culture 
apart from biochemical or mechanical stimulation.  This was not evident for the smooth 
muscle cells studied in this investigation.  It may be that the increased expression of 
desmin in conjunction with α-SMA may commit the smooth muscle cell to a more 
singularly contractile phenotype, and thus limit the synthetic capabilities.  It should be 
understood that a combination of synthesis and degradation is likely occurring with these 
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cells, and content measures can only indicate the “net” results of this balance.  As the 
gel constructs were created with cells and a collagen solution, limited conclusions can 
be made about initial protein content.  There may also be more protein associated with 
the larger smooth muscle cells.  The changes in protein content do provide a framework 
for more studies to further develop these effects. 
 The limited initial glycosaminoglycan content followed by dramatic increases in 
content of PAVIC constructs not apparent in PASMC constructs demonstrates different 
GAG synthesis capacity of PAVIC in three dimensional cultures.  GAGs are an important 
component of valve leaflets, particularly the spongiosa layer, which is primarily 
responsible for lubrication between the two load bearing layers (ventricularis and fibrosa) 
and reducing internal shear between them [16].  A successful living valve substitute will 
require the ability to synthesize GAGs to maintain this important function. 
 Taken together, these results indicate that valvular interstitial cells possess the 
ability to contract tissue and synthesize matrix components in collagen gels.  Normal 
smooth muscle cells have limited capacity to synthesize matrix, and dedifferentiated 
smooth muscle cells have limited ability to control matrix synthesis, as well as reduced 
contractile ability.  This raises concern about the use of vascular smooth muscle for 
tissue engineered valvular substitutes.  This concern, however, must be balanced with 
the ease of obtaining smooth muscle cells, e.g. from a peripheral vessel, compared to 
interstitial cells, where there is no readily available source.   
 Quantification of phenotypic marker expression levels between cell types is 
nontrivial.  Flow cytometry is a more powerful method to assess expression level over 
epifluorescence or confocal microscopy, because a histogram is created with 
measurements unique to each cell in a sample.  The challenge with this technique is 
comparing between different populations.  In this study, algebraic mean was used to 
represent the populations for statistical purposes.  This was more accurate than 
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arithmetic mean given the log scale X axis, but could be severely limited depending on 
the actual population distributions.  Any deviations from a normal distribution, as would 
be seen in a heterogeneous population, will compromise the validity of using the mean 
value.  Most of the sample distributions appeared normally distributed about the 
algebraic mean, but the sample variances were different.  Statistical analysis of these 
curves would be improved by generating Gaussian curves that approximate the 
distributions, and then determining statistically significant distributions using these 
curves.  Non-normal distributions could be approximated by exponential, binomial, or 
other distributions.   
 The BCA and Blyscan assays only measure a snapshot of sGAG and total 
protein content, and therefore represent net synthesis or degradation rate.  To determine 
actual synthesis or degradation levels, timed radiolabeling studies can be conducted on 
constructs according to the method of Deck and colleagues [7].   
 One challenge in culturing three dimensional constructs is having viable cells 
throughout the engineered tissue.  Most constructs are highly porous when first made, 
but as the cells contract and pull the matrix filaments together, the porosity reduces, and 
diffusion limits become a problem.  Some cells are more sensitive to this than others, but 
constructs may have some nonviable cells within the tissue milieu.  To investigate this 
issue in the constructs studied here, identical constructs were created using either 
PAVICs or PASMCs as described earlier, and cultured for either 4 or 10 days.  They 
were then washed thoroughly in PBS, and incubated with 4 µM of calcein and 4 µM of 
ethidium homodimer (Live Dead, Molecular Probes) for 30 minutes at 37°C.  Calcein 
becomes fluorescent when cleaved by enzymes in the cytoplasm (indicating cells are 
alive), and ethidium is a large fluorescent molecule that normally can’t pass through a 
living cell membrane (indicating dead cells).  These constructs were imaged using 
confocal microscopy, and the results are shown in figure 3-8.  Homogeneous 
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distributions of cells are apparent, but the viability of the PASMCs appears somewhat 
reduced in comparison to PAVICs.  This was somewhat surprising, given the avascular 
nature of aortic valve leaflets.  Upon closer inspection, it appeared that some of the 
PASMCs were expressing both markers, which suggests some cell death occurred 
during the incubation and imaging process.  Many PAVICs are in a matrix rich in 
glycosaminoglycans, in contrast to smooth muscle cells, which see mainly collagen and 
elastin.  Matrix proteins have been shown to be important for cell survival and 
differentiation, and therefore some cells may thrive better in a collagen I matrix than 
others.  More work to elucidate valvular cell behavior when interacting with other matrix 
materials needs to be done. 
 
PAVIC PASMC
10X 20X 10X 20X
Figure 3-8: Confocal microscope images of cell viability.  Number 
indicates objective magnification.  
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CHAPTER 4 
 
COMPARISON OF MORPHOLOGY AND FOCAL ADHESION DEVELOPMENT 




As vascular biology and tissue engineering advancements continue [1], heart 
valve therapy will become a new frontier for bioengineering research [2].  Heart valves 
perform a critical function in maintaining unidirectional flow through the vasculature, and 
as such the cells and tissue that comprise the leaflets of the valve may be uniquely 
suited to endure this demanding environment.  Leaflet tissue is organized differently than 
vascular wall tissue, and evidence has emerged demonstrating that the interstitial cells 
of the leaflet milieu exhibit a different phenotype in comparison to vascular smooth 
muscle cells[3].  Like blood vessels, the surfaces of valve leaflets are lined
endothelial cells, which are critical in maintaining a non-thrombogenic surfa
transport of nutrients, and transduction of mechanical and biochemical signa
Valvular leaflet failure has been traced to endothelial dysfunction and denudation
much pathology unique to the valve originates with the endothelium[6, 7]. 
In vitro research has been instrumental in the discovery of endothelial funct
mechanical environments[8, 9].  Endothelial cells align parallel to the directi
unidirectional flow, through the reorganization of cytoskeletal filaments and 
adhesion complexes [10-12]. Fluid flow also induces secretion of vasoactive agents
as nitric oxide and prostaglandin to maintain vessel tone[13, 14], and these proc
                                                 
1 Portions of the material presented in this chapter were published in the August 2004 issue of 
Arterioscelrosis Thrombosis and Vascular Biology. 










are regulated by complex signaling events[15-17].  Disruption of this signal process, 
through the oscillation of fluid flow direction [18, 19] or signal pathway blockade, inhibits 
cell alignment, focal adhesion reorganization, and agent release[20, 21].  The complete 
picture of this process is still incomplete, but is the focus of much research.     
Valvular endothelial cells are much less understood.  Similar to vascular 
endothelium, these cells exhibit contact inhibition and grow with cobblestone-like 
morphology in vitro [22].  Observations of cell morphology in vivo show alignment 
concomitant with leaflet collagen fibers, but perpendicular to fluid flow [23].  It is currently 
not known whether valvular endothelial cells are phenotypically similar to vascular 
endothelial cells.  Preliminary observations indicate that subpopulations of valvular 
endothelial cells are capable of transdifferentiating into smooth-muscle like phenotypes 
[24].  Genes uniquely expressed in valvular endothelium are also critical for appropriate 
valve development [25].  Heart valve leaflets develop in the embryo by forming 
protrusions within the heart tube, which are then populated through specially 
differentiated mesenchymal cells [26].  The endothelium that eventually remains may 
therefore be distinct from vascular endothelial cells.  Indeed, preliminary evidence 
indicates that valvular endothelial cells exhibit differences in transcriptional profiles in 
comparison to vascular endothelial cells, and valvular endothelial cells are more 
proliferative in vitro[27]. 
The objective of this work was to quantitatively compare the morphological 
responses of valvular and vascular endothelial cells to steady laminar fluid flow in vitro, 
and determine the changes in spatial arrangement of focal adhesion complexes.  We 
report that the valvular endothelial cells align perpendicular to fluid flow, in contrast to 
vascular endothelial cells, which align parallel.  The valvular cell alignment is 
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 Cell isolation and culture.  Porcine aortic valve endothelial cells (PAVECs) and 
porcine aortic endothelial cells (PAECs) were isolated from intact porcine hearts 
according to the protocol given in the appendix.  Briefly, excised leaflets were incubated 
with 600 U/ml collagenase for 10 minutes at 37°C, followed by gentle scraping using 
cotton swabs.   The resulting cell suspension was centrifuged and plated onto tissue 
culture plastic pre-coated with 50 µg/ml collagen I.  Cells were cultured with DMEM 
supplemented with 10% FBS, 1% L-Glut, and 1% Pen-Strep, and split 1:3 upon 
confluence.  Cells at passage 5 were used in all experiments.  Cell phenotype was 
confirmed through expression of von Willebrand factor, acetylated LDL uptake, and non-
expression of α-smooth muscle actin as shown previously in Chapter 2. 
 Shear Stress Experiments.   Cells were detached using trypsin-EDTA solution, 
and seeded onto glass microscope slides precoated with Collagen I (50 µg/ml) at a 
density of 25,000 cells/cm2.  Cells were allowed to adhere and proliferate for 48 hours, 
by which time a confluent monolayer was present.  The slides were then placed into a 
parallel plate flow chamber system[8], shown in Figure 4-1.  The flow system consists of 
a polycarbonate block that has been machined to include inlet, outlet, and flow ports.  A 
glass slide containing cultured cells is placed in an aluminum chamber, containing a 
rubber gasket, and secured with machine screws.  This creates a rectangular chamber 
for fluid flow, the height of which can be changed with the use of polyester spacers.   
Therefore, a channel with defined geometry is created, and using Navier-Stokes 
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equations of fluid flow with constant density, the wall shear stress (τ) can be related to 
flow rate and channel geometry by the formula: 
 
τ = 6Q/µbh2 
 
where Q is the flow rate, µ is the fluid viscosity (0.012 poise), and b and h are channel 
width and height respectively (see Appendix for complete derivation).  The flow chamber 
was connected to a peristaltic pump that controls the flow rate.  A medium reservoir and 
a pulse dampener are also included into the flow circuit, as well as an air filter (Figure 4-
1).  The reservoirs were then filled with 125 mL of culture medium.  Completed circuits 
were then placed in an incubator and attached to the pump.  Steady, unidirectional 
laminar shear stress of 20 dynes/cm2 was applied to monolayers of PAVECS or PAECS 
for either 24 or 48 hours, with static cultures serving as controls.  Few morphological 
response differences have been reported with pulsatile versus steady flow [19], and 
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Figure 4-1:  Parallel plate shear flow system, comprised of the parallel plate flow 
chamber and the peristaltic flow loop. 
comparison in vitro. 
 Morphological analysis.  Five representative images were taken of confluent 
monolayers at predetermined locations on the central region of the slides.  The slides 
were aligned such that the image horizontal corresponded to the direction of flow.  
Image analysis software (LSM Image Browser, Zeiss Corp.) was used to overlay 
polygons delineating cell areas according to f-actin filaments.  The angle between the 
horizontal (flow direction) and the majority of f-actin filaments was also determined.  The 
software calculated the cell area, perimeter, and orientation angle (Figure 4-2).  Two 
indices of cell alignment were used: cell shape index (SI) and orientation angle (OA) [8].  
SI is a non-dimensional parameter that quantifies cell elongation on a scale of 0 to 1, 




where A is the cell area and P is the perimeter.  Orientation angle was the deviation of 
the major actin filament axis from the slide horizontal, which was parallel to the flow 





θ = Orientation angle from flow direction (horizontal) 
Figure 4-2: Measurement of cell area, perimeter, and orientation angle. 
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tabulated for analysis.  Two factor ANOVA statistics were employed with post hoc tests 
for interactions between conditions.  P<0.05 was considered significant for these studies.  
  Focal Adhesion Development.  Additional studies were conducted to determine 
differences in focal adhesion complex arrangement between valvular and vascular 
endothelial cells, and any influences of steady shear stress.  Endothelial monolayers 
from shear and control experiments were stained for focal adhesion components as 
previously described[10] and explained in detail in the Appendix.  Briefly, cells were fixed 
in 3.7% paraformaldehyde and permeablized in 0.1% Triton X-100, and blocked in 1% 
goat serlium.  Cells were then incubated with antibodies to β1 integrin (Chemicon 
#MAB2000, 1:100), focal adhesion accessory molecules (vinculin, Upstate Biotech #05-
386, 1:100) or signang complexes (focal adhesion kinase, Upstate Biotech #06-543, 
1:100), and counterstained for f-actin (rhodamine phalloidin, Molecular Probes #R-415, 
1:400) and cell nuclei (Hoechst, Sigma #33258, 1:100).  At least five representative 
images were taken using confocal microscopy.  
 Western Blotting.  Additional flow and static culture experiments were 
conducted to determine the levels of total focal adhesion protein between cell type and 
condition using Western blotting.  A more detailed protocol is given in the appendix.  
Briefly, cells from shear and static control experiments were lysed in RIPA buffer 
containing protease inhibitors (aprotinin, leupeptin, PMSF, 25µg/ml each) and a 
phosphate analog (sodium orthovanadate, 25 µg/ml) to inhibit phosphatases.  Lysate 
was quantified for total protein using a micro-BCA assay (Pierce), and equal quantities of 
protein were loaded into 7% polyacrylamide gels.  Gels were run at 90V for 90 minutes, 
transferred to nitrocellulose paper, and blocked overnight in 5% nonfat milk.  The 
samples were then incubated blocking buffer with either anti-b1 integrin (1:500), anti-
vinculin (1:1000), or anti-FAK (1:500) antibody for one hour, followed by rinsing in TBS-
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Tween buffer.  Samples were then incubated in biotinylated anti-rabbit or anti-mouse 
antibodies for one hour, rinsed in TBS-Tween, incubated in alkaline phosphotase anti-
biotin for one hour, and rinsed with TBS-Tween.  Alkaline phosphatase was then 
visualized by ECF for 5 minutes, after which the samples were dried and imaged. 
 Signal pathway inhibition.  Any differences in morphology and/or focal 
adhesion development may be related to differences in mechanotransduction pathways.  
Monolayers of PAVECS or PAECS were incubated with either Rho kinase inhibitor (Y-
27632, Calbiochem #688000, 5 µM), PI-3 kinase inhibitor (Wortmannin, Calbiochem 
#681675, 1µM) or calpain inhibitor I (CI-1, Roche #1086090, 20 µM) for 30 minutes prior 
to flow and during 24 hours of flow (20 dynes/cm2).  Static cultures and vehicle-only 
incubation cultures served as controls.  Inhibitor concentrations were determined from 




 Valvular endothelial cells are similar to vascular endothelial cells in static 
culture.    Porcine aortic valve endothelial cells grow similar to vascular endothelial cells 
in static culture (Figure 4-3 A-D), but some filamentous extensions appear to extend 
from the cytoplasm of one PAVECs and overlap the border of another cell (arrows).  This 
morphology  has also been reported with endocardial endothelial cells [28], perhaps 
indicating that valvular endothelial cells share some characteristics with those cells.  
Quantification of cell shape and angle of orientation for PAECs and PAVECs in static 
culture shows that both cell types are randomly oriented (Figure 4-4), with the angle of 
orientation ranging from 0 to 90 degrees.  There is no correlation with shape index.  The 
mean orientation angle for the PAECs in static culture is 41 +/- 21 degrees, while it is 40 
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+/- 25 degrees for PAVECs under static conditions (not significant).  PAECs in static 
conditions have a shape index of 0.84 +/- 0.07, while for PAVECs it is 0.78 +/- 0.08. This 
lower shape index is due to the more stellate pattern the valvular cell presents. The 
shape index is a robust measurement of elongation in polarized cells, but less accurate  
for more stellate cells.  This pattern changes somewhat over time in culture, presumably 
because the cells are spreading further without any influence of flow.  The shape index 
of PAECS does not change because of their lack of extensions and a generally 
polygonal shape.    
 Valvular endothelial cells align differently under steady flow.  As shown in 
Figure 4-3 E-H, porcine aortic endothelial cells align parallel to steady flow, as has been 
well documented.  Porcine valvular endothelial cells, in contrast, align perpendicular to 
steady laminar flow in vitro.  Biochemical staining shows that cytoplasmic actin filaments 
also align perpendicular to the flow direction.  Quantification of these morphological 
changes demonstrates the extent of the alignment caused by shear stress in both cell 
types.  The shape index vs. orientation data from the two cell populations, shown in 
Figure 4-5, clearly diverge after 48 hours of steady flow.  The PAVECs clearly align 
towards 90 degrees, perpendicular to the fluid flow direction, while the PAECs align 
parallel to flow (0 degrees).  The cells that are more elongated are also more oriented 
towards their preferred direction.  The cell populations at 24 hours of flow begin to 
diverge in a similar manner, but the trends are not as pronounced as at 48 hours (online 
supplement).  With laminar shear stress, PAECs orient parallel to the flow direction, and 
the orientation is also more pronounced with time.  After 24 hours, the average angle of 
deviation from the flow direction for PAECs reduces to 25 +/- 22 degrees, and further 
decreases to 11 +/- 8 degrees by 48 hours, denoting nearly complete parallel 
orientation.  PAVECs, in contrast, progress towards a near perpendicular orientation.  
    92
After 24 hours of flow, the orientation angle is 60 +/- 22.42 degrees, which further 












Figure 4-3: Images of PAECs and PAVECs in static and steady fluid flow 
environments.  PAECs are presented panels A, C, E, and G, while PAVECs are in 
panels B, D, F, and H.  Panels A-D are in static culture, while panels E-H are after 48 
hours of 20 dynes/cm2 steady laminar shear stress.  Top panels are phase microscopy 
images, and bottom panels are laser confocal microscopy images.  Cells are stained 
for f-actin (red) and cell nuclei (blue).  Flow direction is horizontal left to right.  Scale 
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Figure 4-4: Cell Orientation changes with experimental condition (Panel A).  Cell shape 
index changes with experimental condition (Panel B).  Bars indicate standard deviation. 
(*) Indicates significance P<0.05, (NS) indicates no significance.  Visually obvious 
significant differences not denoted for clarity. 
changes with the application of steady flow, decreasing with time under flow, indicating 
that the cells are becoming more elongated.  After 24 hours, the shape index for PAECs 
is 0.68 +/- 0.17, while for the PAVECs it is 0.67 +/- 0.12.  After 48 hours of flow, these 
values reduce further to 0.51 +/- 0.15 and 0.64 +/- 0.14 respectively.  These results 
indicate that the elongation of the PAECs continued beyond the 24 hour period, while 
the elongation of the PAVECs stabilized after 24 hours of flow.     
 Confirmation of alignment tendency.  As an additional demonstration of the 
perpendicular alignment tendency of the valvular endothelial cells, a glass coverslip 
seeded to confluence with PAVECs was fixed to a microscope slide with vacuum grease 
(Figure 4-6).  This combination was then exposed to 20 dynes/cm2 for 24 hours, the 
coverslip rotated 90 degrees, and again subjected to flow for 24 hours.  The PAVECs 
aligned perpendicular to flow after the first 24 hours, and then re-aligned perpendicular 
to flow after the second 24 hours (Figure 4-7), demonstrating their dynamic responses to 
fluid flow and a preference for a perpendicular alignment.  The alignment after the  
second 24 hours is not as dramatic as after the first, probably due to the fact that the 
cells had to progress from an oppositely aligned state, instead of a more random 
orientation distribution. 
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Figure 4-5: Cell alignment (Shape Index vs. Orientation) regressions.  Static culture 
control vs.20 dynes/cm2 for static culture (left), 24 hour flow (middle), or 48 hour flow 
condition (right).   
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Seeded coverslip 
90 Degree rotation 
Slide 
Flow direction 
Figure 4-6:  System to rotate cultured endothelial cells under aseptic 
conditions. 




Figure 4-7: Re-orientation of valvular endothelial cells under flow.  PAVECS 
were seeded on a coverslips coated with collagen I were adhered to a 
glass slide using vacuum grease.   The ensemble was then placed in the 
flow system for 24 hours (A).   The coverslip was then rotated 90 degrees, 
and subjected to flow for an additional 24 hours (B).  PAVECs re-oriented 
perpendicular to flow, demonstrating their preference for this arrangement.  
Scale bar = 50 µm. 
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 Cell alignment dependent on actin polymerization.  Experiments were 
conducted to determine the mechanism for valvular endothelial alignment to flow.  
Valvular endothelial cells were incubated with Cytochalasin-D (CD, Sigma #30385, 0.1 
µM) for one hour prior to exposure to flow, and identical concentrations of either 
chemical were included in the flow medium as well.  Alignment was then determined as 
previously described after 48 hours, with static cultures serving as controls.  The 
aforementioned concentrations were determined through 48 hour static culture titration 
assays.  The alignment change of the valvular endothelial cells was found to be 
correlated with the reorganization of actin filaments.  Disruption of actin filaments with 
CD inhibited the alignment changes observed previously (Figure 4-8).  Fragmented actin 
filaments prohibited an accurate determination of alignment parameters, but no tendency 
of cell alignment was observed.   
 Different patterns of focal adhesion develop under flow.  The development 
and reorganization of focal adhesions paralleled changes in morphology for both cell 
types, resulting in different patterns between the two cell types.  The spatial arrangement 
of focal adhesion components, represented by the clustering of β1 integrins (Figure 4-9, 
arrows), accessory molecules (vinculin, Figure 4-10, arrows) and signaling molecules  
Figure 4-8:  PAVECs with disrupted actin polymerization through Cytochalasin D 
failed to align under flow.  Confocal images in 48 hour static (A) and 20 dynes/cm2 
shear stress for 48 hours (B).  Cells stained for f-actin (red) and cell nuclei (blue).  
Scale bar = 50 µm. 
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48hr Flow 48hr Flow
Figure 4-9: β1 integrin expression of PAECs and PAVECs.  Cells stained for β1 integrin 
(green), f-actin (red) and cell nuclei (blue).  Top portion of panels are β1 integrin 
expression only.  Scale bar = 50 µm. 
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Static 24hr Flow 48hr Flow 48hr Flow
Figure 4-10:  Vinculin expression of PAECs and PAVECs.  Cells stained for vinculin 
(green), f-actin (red) and cell nuclei (blue).  Top portion of panels are vinculin 
expression only.  Scale bar = 50 µm. 
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Static 24hr Flow 48hr Flow 48hr Flow
Figure 4-11:  FAK expression of PAECs and PAVECs.  Cells stained for FAK (green), 
f-actin (red) and cell nuclei (blue).  Top portion of panels are FAK expression only.  
Scale bar = 50 µm. 
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(FAK, Figure 4-11, arrows), was concentrated at the upstream and downstream portions 
of flow in PAECs.  The arrangement of focal adhesions in static cultures of PAECs was 
more homogeneous, with some tendency to concentrate at the cell periphery.  All 
adhesion components were co-localized with f-actin termini, indicating they are directly 
involved in supporting the changing cytoskeletal tension under flow.  The reorganization 
of adhesions in PAVECs under flow is not concentrated at the upstream and 
downstream portions of the flow, but rather at the ends of the long axis of the aligned 
cells.  Focal adhesions of PAVECs in static culture are somewhat similar to PAECs, with 
a tendency to concentrate near the periphery of the cell and also within the cellular 
extensions.  Vinculin and FAK co-localize with f-actin termini, along with β1 integrins, 
suggesting mechanical connectivity.  Interestingly, there was significant presence of β1 
integrin without vinculin or FAK at the upstream portion of PAVECs under flow, which 
was incompletely connected to f-actin (arrows).  This suggests that there may be a 
partitioning of mechanical signal in PAVECs that is different in PAECs.  There is most 
likely other focal adhesion components involved in the reorganization process than those 
examined in this study which may account for this.  
 No differences in total levels of focal adhesion proteins with cell type of 
flow condition.  Figure 4-12 shows the results of the Western blots.  It is evident that 
there are no significant differences in any of the focal adhesion complexes studied 
between the cell types, and no significant changes with flow.  This confirms that the 
arrangement of focal adhesion proteins, and not the total amount of adhesion proteins, is 
important for the morphological differences see between these two cell types. 
 Signal pathway involvement in the regulation of cell morphology under 
flow.  Figure 4-13 shows the changes in morphology of PAVECs and PAECs in static 
and flow environments when specific signal kinases or proteases are inhibited.  The 
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 Vinculin 
β1
+ - + - + -   + + - - 
PAEC PAVEC 
FAK
Figure 4-12:  Western blots of β1 integrin, vinculin, and focal 
adhesion kinase.  + or – indicates whether the samples were treated 
with 20 dynes/cm2 steady laminar shear stress for 48 hours (+) or 
culture statically (-) for 48 hours. 
cytoskeletal reorganization of PAECs under flow is blocked by the inhibition of Rho 
kinase, PI 3-kinase, and calpain.  The alignment of PAVECs under flow was also 
disrupted through the inhibition of Rho kinase and calpain, but not PI 3-kinase.  No 
differences in cell orientation were observed in static cultures.  Additional studies were 
conducted to investigate the action of calpain inhibitor I (CI-1) on focal adhesion pattern 
development as represented by vinculin localization.  CI-1 disrupted focal adhesion 
reorganization under flow, and adhesions remained diffuse and peripheral (Figure 4-14).  
The disruption was similar in both cell types, suggesting calpain acts similarly in both 




This study demonstrates that valvular endothelial cells align perpendicular to fluid 
flow in vitro, in contrast to vascular endothelial cells, and that this alignment is mediated 
by the reorganization of focal adhesions within the cell.  Furthermore, the signaling 



























Figure 4-13: Effects of inhibitors on morphological response to flow.  Cells exposed to 
20 dynes/cm2 steady laminar shear stress for 24 hours while in the presence of either 
Rho kinase inhibitor (Y-27632, 5µM), PI 3-kinase inhibitor (Wortmannin, 1 µM), or 
calpain inhibitor (calpain inhibitor I, 20 µM).  Top row, PAECs.  Bottom row PAVECs.  
Phase contrast microscopy images with confocal microscopy inserts.  Cells stained 
for f-actin (red) and cell nuclei (blue).  Flow direction is horizontal left to right.  Scale 
bar = 50 µm.  
pathways that mediate these responses are different for the two cell types.  Vascular 
endothelial alignment is calpain, Rho kinase and PI 3-kinase dependent, while valvular 
endothelial cell alignment is calpain and Rho kinase dependent, but PI 3-kinase 
independent.  To our knowledge, the only other cell type that aligns perpendicular to the 
direction of fluid flow is the vascular smooth muscle cell (SMC) [29].  Paranya et al. [24] 
found that some populations of ovine and human valve endothelial cells could be 
irreversibly induced to produce α-SMA through incubation with TGFβ-1.  The most 
dramatic results were found with clonal expansions of individual cells that may have 
been more progenitor-like.  However, they also found populations of valvular endothelial 
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cells that stained positive for both CD-31 and α-SMA in vivo, possibly indicating a 
differentiating phenotype.  It is also known that vascular SMC secrete paracrine factors, 
such as TGFβ-1 in the presence of fluid flow [30].  These studies suggest that it may be 
possible that valvular endothelial cells differentiate in the presence of fluid flow to a more 
smooth muscle-like phenotype, and therefore align perpendicular to flow and express α-
SMA.  Additional monolayer studies were conducted to determine whether the PAVECs 
were transdifferentiating into a more smooth muscle-like (or valvular interstitial cell-like) 
phenotype.  No expression of α-SMA was detected in static culture, or after 48 hours of 
flow (Figure 4-15), suggesting that these cells do not transdifferentiate under flow.  
There may be other markers, whose expressions describe an intermediate phenotype 
[31], and it may be possible that these cells may be encouraged through flow to exhibit 
the beginning stages of altered differentiation not observed in this study.  It is also 
important to note that these experiments were conducted with early passage endothelial 
cells isolated from both sides of the aortic leaflets.  There may be some differences 
between the endothelium from the aortic and ventricular sides of the leaflets, as has 
been observed with the interstitial cells of the mitral leaflet [32].  Such differences may 
be flow regulated, as seen in the vasculature.  The complex fluid dynamics of the aortic 
valve may suggest a large plurality of different endothelial morphologies in vivo 
depending on location on the leaflet surface, not just between aortic and ventricular 
sides [33].  It would be difficult, however, to determine such differences through the 
types of studies presented here, as relatively large cell populations are required to 
achieve confidence in the results.  Indeed, higher passage valvular endothelial cells 
(greater than P7) do not appear to exhibit this alignment tendency, and progress to a 
more non-aligned or even parallel-aligned state.  Cells expanded in vitro from a very  
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PAEC PAVEC
Static 24h Flow Static 24h Flow
Figure 4-14:  Effects of calpain inhibitor I on focal adhesion reorganization as 
determined by vinculin arrangement.  Cells stained for vinculin (green), f-actin (red), 
and cell nuclei (blue).  Scale bar = 50 µm. 
Figure 4-15: Confocal images of cell monolayers stained for α-SMA (Green), f-actin 
(red) and cell nuclei (blue).  Top row is PAECS, while the bottom row is PAVECS.  
Scale bar = 50 µm.   
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small initial population of isolated cells may therefore not respond similarly to a defined 
flow environment. 
Focal adhesion patterns are important indicators of cell function, as they provide 
sensory and response instruments for cells in contact with extracellular matrix.  The 
predominant integrins for interaction with collagen involve β1 components, the integrin 
examined in these studies.  Focal adhesions are centers for adhesion, migration, and 
signaling in response to mechanical forces such as shear flow.  The differences in 
patterns observed between PAECs and PAVECs suggest differences in sensing of and 
adaptation to the external environment between the cell types.  The resulting changes 
are consistent with in vivo observations, which strongly suggest that there may be 
differential mechanisms controlling responses to fluid flow. 
To investigate these mechanisms further, molecules involved in signal pathways 
were independently inhibited to assess their effects on these two cell types.  Important 
signal pathways that originate at cytoplasmic integrin terminals are Rho kinase and 
phosphatidylinositide 3-kinase (PI 3-kinase).  These have established roles in regulating 
the actin cytoskeleton, cell growth, and migration, and are critical to the morphological 
changes in vascular endothelial cells.    Rho kinase, PI 3-kinase, and calpain are 
involved in a myriad of cytoskeletal functions.  Rho kinase (p160ROCK or ROCK1) is a 
downstream target of Rho, which is part of the Ras family of small GTPases [34].  
Expression of constitutively active Rho inhibits parallel alignment of vascular endothelial 
cells, as does inhibition of the Rho kinase[35, 36].  Rho kinase is also important for 
biphasic migration of sparse endothelial cells in short term response to flow[37].  Y-
27632 is a potent cell-permeable inhibitor of Rho kinase by competing with ATP for the 
binding catalytic site[38].  PI 3-kinase is critical for the modulation of endothelial 
production of nitric oxide in response to shear stress[39].  PI 3-kinase has been reported 
not to influence cell elongation in response to steady shear in sparse cultures[37], but its 
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effects on morphology in confluent cultures under long term (24 hour) shear has not 
been studied.  Wortmannin is a fungal metabolite that irreversibly blocks the catalytic 
activity of PI 3-kinase.  In addition to kinases, calpain I is a cysteine protease that has 
substrates for proteins in focal adhesion components such as talin [40, 41]and 
phosphorylated FAK [42].  It thus may be important in the reorganization of focal 
adhesion complexes and their initiation of signal cascades.  Calpain inhibitor I has been 
shown to inhibit the morphological reorganization of lung epithelial cells after exposure to 
TPA [43].  The results of our study demonstrate that calpain function, and therefore the 
reorganization of focal adhesion complexes, are critical for cellular rearrangement in 
response to shear stress.  Rho kinase inhibition of endothelial reorganization with shear 
is confirmed in aortic endothelial cells and now established with valvular endothelial 
cells.  The differences in morphological response between the two cell types under 
shear with the inhibition of PI 3-kinase suggests a phenotypic difference between the 
two cell types.  A schematic summarizing the major findings in this study is shown in 
Figure 4-16.   
Coupled with the differences in focal adhesion patterns, valvular endothelial cells 
may compartmentalize mechanical signals in a different manner than vascular 
endothelial cells.  This may be related to the differences in the native mechanical 
environment of the two cell types.  Aortic  valve leaflets experience up to 40% strains at 
a strain rate of 25/s, both much greater than the vessel wall [44, 45].  The circumferential 
alignment of endothelial cells observed on leaflet surfaces also corresponds to 
circumferential alignment of collagen fibers.  The confirmation of the endothelial 
alignment in vitro without the confounding effects of underlying matrix alignment, 
coupled with the different signal pathways that have been implicated in the alignment 
process of the two endothelial types strongly suggests differences in the behavior of 
these two cell types, and elucidating these differences will require further study. 

















Figure 4-16: Schematic summarizing the differences in morphological 
response and focal adhesion arrangement between the endothelial cell 
types under flow. 
These results highlight considerations for appropriate cell sourcing of tissue 
engineered valvular substitutes.  Using non-valvular endothelial cells, at least for an 
aortic valve substitute, may sacrifice important functional behavior.   It is currently 
unknown if the dissimilar responses of vascular and valvular endothelial cells to fluid flow 
has any effect on overall leaflet function, but different responses may imply altered 
paracrine signaling to surrounding cells [30].  Assuming that appropriate cell behavior is 
essential for the successful tissue-engineering of substitutes, then a better 
understanding of valvular cell behavior is critical to the development of living 
replacement heart valves. 
The quantification of morphology was done using confocal microscopy images.  
While this method allowed accurate measurement of parameters, it was extremely labor 
intensive.  Furthermore, only five images were used per slide analyzed.  With about 12-
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20 cells measurable per image, and therefore 50 – 100 cells per slide measured, this 
corresponds to less than 0.1% of the cells on the slide, which may not be a useful 
statistical sampling of the cell population.  Furthermore, it was evident that some 
portions of slides contained localized cell alignment tendencies that were somewhat 
different from the rest of the slide.  Given these difficulties, some modifications to the 
experiment protocol could be made to improve accuracy.  First, a software program 
designed to measure and record cell morphology parameters would be written.  This 
would be coordinated with a motorized stage on the confocal microscopy, so that the 
cells on the whole slide can be scanned for image parameters, and data tabulated in a 
spreadsheet form.  Imaging software has been created for similar applications, but relied 
on external cell shape.  Using cytoplasmic filaments is preferable, because it suggests 
the axis of cell traction, and hence orientation.  It was observed not a few times that the 
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CHAPTER 5 
COMPARISON OF GENE EXPRESSION PROFILES BETWEEN VALVULAR AND 




 One important factor in many cardiovascular pathologies is the additional 
presence of valvular deficiencies, particularly to the aortic valve.  While valvular 
complications and vascular disorders are related, there are also diseases unique to 
valves, such as bacterial endocarditis and rheumatic heart disease.  Many vascular 
pathologies, including atherosclerosis, originate at the endothelial surface, which 
highlights this cell layer as an important mediator of physiological and pathological 
functions[1].  The mechanisms as to why these pathologies are specific to valvular 
tissues are unclear, but it is possibly related to the differences in native cell populations 
and tissue structure.    While blood vessels are comprised of endothelial cells, smooth 
muscle cells, and fibroblasts entombed in a lamellar collagen and elastin fiber matrix, 
aortic valve leaflets are much more complex.  Leaflets have a highly organized, tri-layer 
structure composed of native endothelial and interstitial cells.  While much work has 
been done to characterize the phenotype of interstitial cells as reported in Chapter 2, 
little is known about valvular endothelial cells.  Endothelial cells perform many critical 
functions, including the maintenance of a non-thrombogenic surface, transduction of 
mechanical and biochemical signals to underlying cells, and transmission of nutrients 
through the tissue.  The results from Chapter 4 have shown that valvular endothelial 
cells respond to fluid shear in a different manner than vascular endothelial cells.  
Valvular endothelial cells align perpendicular to flow, involving a PI 3-kinase independent 
signal pathway, with focal adhesions concentrating at the opposite ends of the major 
axis of cell alignment.  This was in contrast to aortic endothelial cells, which aligned 
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parallel to flow in a PI 3-kinase dependent manner, with focal adhesions concentrating at 
the upstream and downstream portions of the cells.  Valvular endothelial cells have also 
been shown to differentiate into a more smooth muscle cell-like phenotype[2], and 
proliferate more than vascular endothelial cells[3].   
 These phenotypic differences could be due in part to genetic differences between 
these two cell types.  The profile of gene transcripts in a cell gives an assessment of 
what proteins cells are producing.  Changes in gene expression in response to a 
stimulus precede actual protein changes, but predict cell behavior in short term 
experiments where protein accumulation cannot occur.  Recently, gene arrays have 
become a standard tool to screen the genetic profiles of cells under a stimulus.  Gene 
arrays enable the simultaneous investigation of the expression of thousands of proteins 
at the gene transcript level.  They consist of an array of small islands of RNA fragment 
strands called “spots”, each representing a specific portion of a particular gene.  Often 
these arrays contain complimentary DNA fragments (cDNA), which represent a portion 
of an RNA sample that has been amplified by Polymerase Chain Reaction (PCR).  Gene 
arrays come in two basic forms: oligonucleotide arrays and cDNA microarrays.  
Oligonucleotide arrays are made by spotting small fragments (<50 bases) of RNA 
sequences onto a nylon felt, while cDNA microarrays prints larger fragments (200-400 
bases) onto a glass substrate.  Oligonucleotide arrays are typically analyzed through 
radiolabeling, while cDNA arrays utilize two fluorophores (Cy3 and Cy5).  Each type has 
its own advantages and disadvantages, and selection of a specific platform is based on 
the type of experiments carried out.  Oligonucleotide arrays are preferable for 
determining absolute transcript numbers, whereas cDNA arrays are better suited for 
cross-species analysis (i.e. porcine cells on a human array set) and give relative 
differences in expression between two sample pools.    Several studies have used 
microarrays to profile the genetic response of vascular endothelial cells to shear 
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stress[4-6].  These studies have attempted to isolate genes that are sensitive to fluid 
forces in endothelial cells.  While several genes previously identified as 
mechanosensitive genes, such as nitric oxide synthase (eNOS)[7], cyclo-oxygenase 2 
(COX-2)[8], and vascular endothelial growth factor (VEGF)[9] have been confirmed 
using gene array techniques, many other genes have been identified as being flow 
regulated[5].  The format of gene arrays enables the development numerous research 
hypotheses from essentially “fishing expeditions”, where little or none of the results are 
expected a priori.  Improvements in image analysis software, gene array processing 
algorithms, and statistical packages have led to an information explosion that creates its 
own challenge: interpreting the data.  While hundreds of genes may be differentially 
expressed in a gene array experiment, many of these may in fact be false positives.  
Statistical analyses require multiple data points for each sample, which can rapidly 
become prohibitively expensive.  One aspect of this problem that has been little 
explored, however, is that experimental design is often not optimized to maximize 
statistical power to give high confidence in the results.  It has been shown that two factor 
ANOVA greatly increases the predictive capability of microarrays, and reduces the 
probability of false positives[10].  In addition, further advances in post-processing have 
enabled the comparison of changes in gene categories.  Many availably software 
packages can link genes with their ontological hierarchy, create categories at each level, 
and compare changes in the number of genes in these categories.  This enables a 
multileveled approach in determining genetic phenotype change[11].  
 The objective of this study is to compare the genetic response of valvular and 
vascular endothelial cells to steady laminar shear stress, and characterize the genetic 
differences between the cell types in static and flow conditions.  Statistically designed 
microarray analysis was integrated with new post-processing techniques, and hundreds 
of genes were differentially expressed between the cell types in both flow conditions.  
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Genes were grouped into relevant categories to facilitate new hypothesis generation.  
Real time PCR on was also conducted on selected genes as an independent method to 




 Stress Experimental Setup.  Porcine aortic valve endothelial cells (PAVECs) 
and porcine aortic endothelial cells (PAECs) were isolated from tissue obtained at a local 
slaughterhouse and cultured as previously described in Chapter 4 and explained in 
detail in the Appendix.  Passage 5 monolayers of either PAVECs or PAECs were plated 
on glass slides coated with Collagen I (Becton-Dickenson, Rat tail, 50 µg/mL), and 
allowed to grow to confluence for 48 hours.  Slides were then placed in a parallel plate 
flow system[12] shown in Chapter 4, and subjected to 20 dynes/cm2 for 48 hours, with 
statically cultured slides serving as controls.  While native heart valves experience a 
complex pulsatile shear flow, it is nearly impossible to replicate this environment in a 
controlled manner in vitro.  The challenges in actually measuring the leaflet wall shear 
stress have resulted in a wide range of estimates (15-800 dynes/cm2)[13-17].  Weston 
and colleagues determined a mean value of wall shear stress over the entire cardiac 
cycle of approximately 20 dynes/cm2, which also compared well with laminar boundary 
layer theory for simplified geometries[18].  Because this purpose was to compare the 
response of both valvular and vascular endothelial cell to a mechanical force that could 
be considered physiological for both cell types, we concluded 20 dynes/cm2 was a 
reasonable starting point.  Much more data exists on endothelial cells in steady laminar 
shear than other velocity profiles, enabling a stronger comparison of our results to other 
work.  It was demonstrated previously in Chapter 4 that morphological changes (and 
presumably other transient responses) under flow were completed by 48 hours for both 
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cell types, after which we postulate that reasonably stable genetic profiles would be 
present.  Four experimental groups were created for comparison, and are summarized in 
Figure 5-1.  One comparison was made with PAVECs in shear flow versus static (Group 
1), one comparing PAECs in shear flow versus static, and two comparisons were made 
between cell types cultured statically (Group 3) or under flow (group 4).  These groups 
comprise all paired comparisons relating endothelial cell types and fluid shear stress. 
 RNA Isolation.  A detailed protocol for RNA isolation and quantification is given 
in the Appendix.  Briefly, upon completion of the experimental time points, the slides 
were removed from the flow systems (along with the non-sheared controls), trypsinized, 
and centrifuged at 1000 RPM in a bucket centrifuge.  The supernatant was then 
 Aortic Static Valve Static





Figure 5-1: Schematic of comparison groups for microarray analysis.  Solid line 
indicates “treated” condition.  Dashed line indicates “control” condition. 
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completely drained, the cells disrupted using a GITC-containing buffer, which inactivates 
RNases, and then homogenized by using a QIAshredder column (QIAGEN #79654).  
The resulting lysate was run through an RNeasy mini column (QIAGEN #74104), which 
enriches for mRNA by selectively binding RNA sequences longer than 200 nucleotides.  
The quantity and quality of the RNA was then checked by spectrophotometry and gel 
electrophoresis respectively.  High quality RNA is determined by an absorbance ratio 
A260/A280 of 1.8 – 2.1, with no other appreciable peaks, while the quantity of RNA is 
determined by measuring the absorbance at 260nm (A260).  Acceptable integrity of 
mRNA is alternatively quantified by sharp 28S and 18S bands in gel electrophoresis, 
with the intensity of the 28S band approximately twice that of the 18S band.  The quality 
and quantity of the total RNA samples were determined in these experiments using the 
Agilent Bioanalyzer (Agilent #2100) and UV spectrometry.  Only samples with greater 
than 10 µg total RNA and 28S/18S rRNA ratios between 1.8 and 2.1 were used for 
microarray hybridization.  Preliminary experiments indicated that the amount of total 
RNA per experiment was approximately 5-7 µg, which was too low for optimal 
hybridization (10 µg.).  While techniques exist for amplifying RNA quantities[19], it was 
decided early on to avoid any potential issues with biases that may exist in these 
processes.  To achieve adequate sample quantities, two RNA samples from identical 
experiments were pooled together.  This not only achieves an adequate RNA quantity, 
but also mitigates possible variation between samples. 
 RNA Labeling and Hybridization.  Since no oligonucleotide array is available 
for porcine cells, a cDNA microarray platform was used.  Porcine RNA has been shown 
to hybridize well with human probes in microarray experiments[20].  Total RNA pools 
from two different experimental conditions, each labeled differently, were hybridized 
together to an Agilent Human 1 cDNA microarray slide (Agilent #G4100A), which 
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contains 12,814 unique clones from Incyte’s Unigene 1 and Human Drug Targets DNA 
clone sets.  This is a competitive microarray platform, where two independently 
generated RNA samples are labeled with two different fluorophores (either Cy3 or Cy5) 
and hybridized competitively on a single probe array.  This creates a comparative 
assessment of RNA levels between the two samples based on the color of the spot (red 
for one sample, green for another, and yellow for a mix), as well as an estimate of total 
mRNA levels per gene (intensity level).  Total RNA from experiments and controls at 
identical time points were then directly labeled fluorescently (experimental RNA with 
Cy3, while control pools with Cy5), mixed together, and hybridized overnight to a cDNA 
microarray.    The RNA labeling and hybridization process was performed at the 
Morehouse School of Medicine’s Cardiovascular Research Institute, which had a core 
facility specializing in the Agilent cDNA microarray platform.  It was important to have 
expert technicians handle these steps, as the chips used in these experiments cost over 
$1000 each, and optimized techniques and reagents are critical to the success of the 
experiments. 
 Image Analysis and Feature Extraction.    Three slides were processed for 
each experimental condition, giving 6 arrays in an N = 3 (number of slides), n = 2 
(replicates per slide) arrangement.  High resolution images were taken of each array 
hybridization area using a microarray scanner (Agilent) and these images were analyzed 
to extract fluorescence intensities (Cy3 and Cy5) at each spot.  The processing of these 
images involves several steps[21-23], and a more detailed description of the process 
can be found in Appendix C.  First is the proper identification of spots on the array and 
their separation from the local background.  This is especially important, because 
contaminating fragments can cause artificial spikes in genes, which confound analysis 
with small sample numbers.  Misaligning the microarray in a scanner by as little as 10 
µm can cause the false identification of every spot in the array.  Local background levels, 
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rather than global background levels, must be determined for spot intensity 
normalization, because random differences in the hybridization process cause 
background to vary across the array.  Next all spots which do not contain appreciable 
signal in either of the fluorescence channels, or are saturated, need to be removed from 
post analysis, because their digitized values are likely misleading.  Finally each array 
needs to be analyzed to identify and adjust for any perceived bias in the expression of 
fluorophores[24], and non-specific hybridizations.  Strategies for accomplishing this 
include difference to mean ratio thresholds, duplicate spotting, and anti-sense strand 
spotting[25].  Many array analysis software packages perform these functions, but it is 
important to know how the specific package employed handles these difficulties.  The 
Agilent cDNA microarrays used in these experiments contain duplicate spots, sense and 
anti-sense strands, and a controlled ink jet spotting procedure that ensures consistent 
numbers of immobilized fragments at each location.  In addition, the Feature Extraction 
Software (Agilent) used for these experiments identifies each array spot based on the 
alignment of specific reference spots that frame the array areas.  Each feature is 
identified according to the preset spotting order.  A detailed description of how the 
Agilent Feature Extraction Software was used in these experiments can be found in the 
Appendix C.  
 Statistical Analyses.  Once fluorescent intensity measurements have been 
generated for each feature, representing the hybridization of each sample, statistical 
analyses must then be conducted to determine significant changes in expression 
between treatments.  Because of the variation that is apparent between supposedly 
identical arrays (due to random differences in the spotting process, imperfections in the 
substrate, etc.), it is necessary to conduct multiple microarray hybridizations to achieve 
statistical significance[26].  Many feature extraction software packages have the 
capability to perform rudimentary statistical analyses on arrays, but only on one array at 
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a time.  This is severely limiting for the aforementioned reasons.  For instance, the 
Agilent Feature Extraction Software performs population statistics (Z-Tests) based on 
the green and red channel values of each pixel within a spot [27].  The significance test 
is therefore based on a large degree of freedom due to the over 200 pixels per spot.  
The variation between pixels in a single spot is much less than the variation between 
identical spots in different arrays and the degrees of freedom will be much lower 
between arrays.  Therefore statistics must be conducted on multiple arrays using the 
average fluorescence intensity levels for each channel at a spot as the data points.  
Statistical analyses on data from multiple arrays have been conducted in several ways.  
Many microarray reports in the literature use a “fold expression” cutoff level to determine 
significant genes [28].  While this is a quick and simple method to identify genes of 
interest, there is no statistical basis for this method, and large but wild expression 
differences between samples would be improperly deemed significant, especially if only 
a small number of arrays are processed.  Also, it is possible that many biological 
systems are highly sensitive to small changes in gene expression that would be less 
than a prescribed fold change limit.  Statistical models, which are based on population 
distributions, are therefore much more useful tools for significance determination.  
Agilent microarray slides contain two identical array areas, which facilitate the use of 
highly robust statistical models to determine significant relationships across experimental 
conditions.  Two factor mixed Analysis of Variance (ANOVA) was therefore used to 
determine significant changes in expression with treatment condition.  This method 
isolates the variation associated with the treatment effect, thus dramatically improving 
sensitivity.  A more detailed explanation can be found in Appendix C.  The treatment 
condition (flow or cell type) was identified as the fixed effect, and the microarray slide as 
the random effect.  The data for each array area served as the replicate measurements 
for the ANOVA.  ANOVAS were performed on each comparison group shown in Figure 
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5-1.  Because the statistical analysis requires that the number of measurements for each 
condition be equal, only genes for which an accepted spot was recorded in all six arrays 
were used in this analysis.  The data from each useful feature of each array was 
overlapped to identify genes with measurements in all the arrays in the comparison.  
This reduced the number of comparable genes to approximately 5000 for each group, 
which was still greater than 50% of the genes with identified functions.  To further 
improve statistical sensitivity, the mean squares of a particular gene ANOVA were 
pooled according to the rules of Sokal and Rohlf[29].  Basically, two variance estimators 
can be pooled together if they are not significantly different from each other (and thus 
estimators of the same quantity).  While increasing the absolute value of the error 
variance in the ANOVA, pooling also increases the degrees of freedom for the 
significance test, thus reducing the threshold value needed for significance.  However, 
because the actual population parameters estimated by the mean squares are unknown, 
strict rules must be followed, or incorrect conclusions could be drawn.  Because of the 
improved sensitivity, P<0.005 was used as the significance threshold for these analyses. 
 Clustering and Ontological Characterization.  Subsequent to statistical 
analysis within comparison groups, further characterization of differences between 
comparisons can be done using other software techniques.  One helpful tool is called 
clustering.  This involves grouping genes across arrays that are similarly expressed.  
Genes with upregulated expression in group 1, downregulated expression in group 2, 
etc., appear grouped together in a cluster.  Free software to achieve this is available 
through Stanford University[30].  K-means clustering was performed on the data from all 
arrays together, and organized into 30 groups of similar expression trends.  Because 
each comparison group had many genes that were either uniquely expressed in that 
group, or were significant only in that group, all genes for which readings existed in 
every array with a significant difference existed in at least one comparison, were 
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included in the clustering.  While this method may confound statistically significant trends 
with non significant trends, it is helpful to visualize as many genes as possible to develop 
related cluster groups.  The expression trends of the clusters were then visualized using 
software that bins the fold changes and renders them in a pseudocolor format, called a 
heatmap.  Genes whose expression levels were significantly changed were also 
categorized using the GoMiner database engine[11].  This program links every known 
gene to its ontological hierarchy, creating multiple categories to which the gene is 
associated, an example of which is shown in Figure 5-2.  This is done for every gene, 
and changes in the numbers of genes changing within a gene category can be assessed 
statistically.  GoMiner uses a Fisher’s Exact test to determine significance based on the 
numbers of significantly changed genes and total genes given by the user.  In this 
manner, enrichment or depletion of genes in a category, as well as changes in 
expression of category members, can be assessed.  A significance level of 0.05 was 
Significance testing 
 (Fisher’s Exact) Categorization Gene lists 
Figure 5-2: GoMiner gene categorization software. 
The example above shows significantly changing cell 
adhesion genes. 
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used in the Fisher’s tests. 
 Real Time PCR Confirmation for Selected Genes.  Additional shear flow and 
static experiments were carried out according to the aforementioned comparison 
scheme (Figure 5-1) to confirm the expression of relevant genes as determined by the 
microarray data.  Briefly, 4 µg of total RNA (isolated as previously described) was 
reverse-transcribed by using random primers and a Superscript-II kit (Invitrogen) to 
synthesize first-strand cDNA. The cDNA was purified using a microbiospin 30 column 
(Bio-Rad) in Tris buffer and stored at –20 °C until used.  PCR primers for bone 
morphogenic protein 4 (BMP-4)[31], cytochrome P450 (CYP1A1)[32], and caveolin-1 
(Cav-1)[33] were used to amplify the cDNA using a LightCycler (Roche Applied Science) 
RT-PCR machine. Similar amplification using universal 18S primers (Ambion, 50 nM) 
were used as an internal control for the real-time PCR[31].  Each reaction was 
conducted a capillary (Roche Applied Sciences) containing 50 nM primers, 1 µg total 
RNA, PCR buffer (20 mM Tris-Cl, pH 8.4, at 25 °C, 4mM MgCl2 to which was added 250 
µg/ml bovine serum albumin, 200 µM deoxynucleotides) containing SYBR green 
(1:84,000 dilution), 0.05 unit/µl Taq DNA polymerase (Invitrogen), and Taq Start antibody 
(Clontech, 1:100 dilution).  The mRNA copy numbers were determined based on 
standard curves generated with serial dilutions of the BMP-4, CYP1A1, Cav-1 and 18 S 
templates.  The primers used in these experiments, as well as the cycling temperatures, 
are listed in Table 5-1.  To confirm the specific amplification of the RNA, DNA gel 
electrophoresis was conducted using the amplified samples.  Briefly, 2% agarose gel 
containing 30 µL of ethidium bromide were created, and 20 uL of samples were 
inoculated into separate wells, followed by a well with a standard DNA ladder (100 – 400 
bp).  Gels were run for 1.5 hours at 80V, and imaged under UV light.        
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5’ – 3’ 













BMP-4 +:CTGCGGGACTTCGAGGCGACACTTCT -:TCTTCCTCCTCCTCCTCCCCAGACTG 130 65 72 7 
Cav-1 +:ACAAGCCCAACAACAAGGC -:TTGCCATTCTCTCCTTCCTG 250 68 72 13 
CYP1A1 +:TGGAGAGGCAAGAGTAGTTGG -:GGCACAACGGAGTAGCTCATA-3 
180 
 57 72 8 
 
 PCR - Microarray Comparison Across Microarray Groups.  Expression 
comparison across these cDNA microarray groups requires relating data generated with 
two independent variables: treatment condition and array.  The expression data for all 
four variable combinations (PAVEC shear, PAVEC static, PAEC shear, PAEC static) can 
be extracted from the microarray data.  Because individual sample conditions are 
fluorescently labeled differently (either Cy3 or Cy5), a numerical intensity value 
proportional to copy number can be obtained for each sample pooled in the array.  
Comparisons can be made using each component of the shear-treated arrays (groups 1 
and 2), or cell-treated arrays (groups 3 and 4).  The results of the PCR were compared 
to the absolute expression levels of the hybridized RNA obtained from the microarray 
studies.  For statistical purposes, one way ANOVA was used to determine significance 
within a methodology, and Students-t tests were employed for comparison between 








 Gene Expression Differences between Endothelial Cell Types.  The goal of 
this study was to compare the genetic response of two different types of endothelial cells 
(PAVEC and PAEC) to steady laminar shear stress.  To achieve this goal, the effects of 
steady shear stress were compared within each cell type (Group 1: PAVECs shear vs. 
PAVECs static, and Group 2: PAECs shear vs. PAECs static).  Next, differences in gene 
expression between the two cell types were determined in either statically cultured cells 
(Group 3: PAVEC static vs. PAEC static) or cells under flow (Group 4: PAVEC flow vs. 
PAEC flow).   Adequate quantities of high quality, pure total RNA were needed for the 
hybridizations.  Figure 5-3 shows the results of several RNA isolation samples as 
determined by the Bioanalyzer.  Two clear peaks representing the large amount of rRNA 





























Figure 5-3: Confirmation of high quality pure RNA as evidenced by 
28S/18S rRNA peaks with minimal contamination. 
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validating them as useful samples for hybridizations.  Each sample used for hybridization  
was similarly characterized before use.   The results of the cDNA microarray analysis 
are summarized in Table 5-2.  Over 9000 spots were identified as reliable on each array, 
an example of which is shown in Figure 5-4, and approximately 4,700 genes were 
expressed above local background levels in all 6 arrays processed.  Using the two factor 
mixed ANOVA model, over 1,200 genes in one sample were determined significantly 
changed relative to their co-hybridized sample at P<0.05, and over 400 at P<0.005.  
Further data processing was conducted on genes at P<0.005 because of the high false 
positive generation rate often seen in microarray data.  As an example, microarray 
experiments that generate 200 significantly changed genes at P<0.05 with 1000 total 
genes analyzed, have a 25% chance that any particular gene is a false positive.  The 
Positive Predictive Value (PPV) is an indication of the confidence one can place in the 
hypothesis rejection of one trial in a large number of trials[10].  The PPV for our dataset 
at P<0.005 was approximately 0.95 for each group, indicating a 95% “confidence” that 
Figure 5-4: Example of microarray image generated by Agilent scanner.  
 127
any particular gene in the dataset is a true positive.  In each microarray group, more 
genes were upregulated than downregulated in each group.  This was not due to 
fluorescence bias, as the intensity signals for each array spot were normalized to 
internal dye controls on each array.  The significantly changed genes from each group 
are listed in Appendix F.  The improved sensitivity of the two factor ANOVA in 
comparison to other relevant statistical methods is highlighted in Appendix C. 
 As shown in Table 5-2, the two different endothelial cell types show quite distinct 
gene expression profiles under both static and shear exposed conditions.  Shear 
exposure increased 545 and 324 genes in PAVEC and PAEC, respectively.  Under static 
conditions, 236 genes were upregulated in PAVEC in comparison to PAEC.  In contrast, 
615 genes were upregulated in PAVEC in comparison to PAEC in response to shear 
 
 
Table 5-2:  Comparison of gene expression changes within experimental groups.  
V = Valvular EC, A = aortic EC, F = 20 dynes/cm2 flow, S = static control. 
 Group1Array Set Group 2 Group 3 Group 4




V vs. A 
Flow 
V vs. A 
Total genes included 4297 4801 4786 5404 
No. Significant Genes 
(P<0.05) 1586 1262 1213 2276 
No. Significant Genes 
(P<0.005) 856 481 416 1152 
PPV (P<0.005) 0.975 0.950 0.942 0.977 
No. Upregulated (P<0.005) 545 324 236 615 
No. Downregulated (P<0.005) 311 157 180 537 
GoMiner categories 
enriched (P<0.05) 133 97 36 37 
Gominer categories 
depleted (P<0.05) 66 20 25 12 
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stress. On the other hand, shear exposure downregulated expression of 311 and 157 
genes in PAVEC and PAEC, respectively.  The comparisons between the two cell types 
showed that 180 and 537 genes were downregulated in static and sheared PAVEC, 
respectively, in comparison to that of PAEC.  As an initial comparison between 
experiment groups, the results of one array group were compared against another to 
note similarly and oppositely regulated genes, summarized in Table 5-3.  This shows the 
number of genes that are registered in the compared categories (at P<0.005 significance 
level).  While hundreds of genes were found significantly changed with flow in one cell 
type and unchanged with flow in another (compare groups 1 and 2), very few genes 
were actually oppositely regulated under flow.  Due to the fact that approximately 75% of 
all genes on each microarray registered data, some important genes may be missed. 
 The relationships among changed genes between experimental comparisons 
were further analyzed through clustering, and the results are rendered in a Heatmap 
format (Figure 5-5).  Four groups of columns represent the comparisons, and within in 
each row, six data points represent the results of the three microarrays in duplicate.  The  
pseudo-color indicates a degree of fold change (red for increased expression, green for 
decreased). This schematic is helpful to isolate and highlight clusters of genes of 
interest, such as genes that are regulated differently between aortic and aortic valve 
origin.  Inset A of Figure 5-5 highlights genes that are upregulated in PAVEC with shear, 
but downregulated in PAEC with shear.  In contrast, inset B shows genes that are 
upregulated in PAEC with shear, but downregulated in PAVEC with shear. Inset C 
shows genes similarly regulated by flow in both cell types.  The complete clustered data 
set is given in  Appendix E.  Analyzing the color changes within a group 
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Table 5-3: Numbers of genes regulated by overlapping the expression 
results of two comparison groups, as explained by row subheadings.  
(P<0.005). F=Flow, S=Static, V=Valve EC, A=Aortic EC, NC = No 
significant change. Gene Expression Results for Each Independent Comparison Group 
Group 1: V-F vs. S Group 2: A-F vs. S Group 3: S-V vs. A Group 4: F-V vs. A 
Up 545 Up 327 Up 121 Up 615 
Down 311 Down 157 Down 126 Down 537 
NC 3441 NC 4320 NC 4539 NC 4252 
Comparisons of endothelial gene expression in 
response to flow (Groups 1 and 2) # Genes Up # Genes Down 
Valvular and Aortic EC 119 45 
Valvular EC not Aortic EC  260 184 
Aortic EC not Valvular EC  69 37 
Valvular EC UP Aortic EC DOWN 2 
Valvular EC DOWN Aortic EC UP 0 
Other Paired Group Comparisons from the Gene Data 
1 UP and 4 
UP 172  
1 UP and 
3 UP 42  
4 UP and  3 
UP 101 
1 UP and 4 
DOWN 20  
1 UP and 
3 DOWN 22  
4 UP and 3 
DOWN 1 
1 UP and 4 
NC 258  
1 UP and 
3 NC 350  
4 UP and 3 
NC 337 
1 DOWN and 
4 UP 15  
1 DOWN 
and 3 UP 8  
4 DOWN and 
3 UP 0 
1 DOWN and 




10  4 DOWN and 3 DOWN 85 
1 DOWN and 
4 NC 171  
1 DOWN 
and 3 NC 204  
4 DOWN and 
3 NC 248 
1 NC and 4 
UP 219  
1 NC and 
3 UP 127  
4 NC and 3 
UP 32 
1 NC and 4 
DOWN 239  
1 NC and 
3 DOWN 98  
4 NC and 3 
DOWN 34 
1 NC and 4 
NC 2212  
1 NC and 
3 NC 2238  
4 NC and 3 
NC 2796 
2 UP and 4 
UP 92  
2 UP and 
3 UP 25  
2 NC and 3 
UP 132 
2 UP and 4 
DOWN 11  
2 UP and 
3 DOWN 14  
2 NC and 3 
DOWN 100 
2 UP and 4 
NC 135  
2 UP and 
3 NC 185  
2 NC and 3 
NC 2185 
2 DOWN and 
4 UP 8  
2 DOWN 
and 3 UP 4  
2 NC and 4 
UP 310 
2 DOWN and 




15  2 NC and 4 DOWN 252 
2 DOWN and 
4 NC 66  
2 DOWN 
and 3 NC 70  




   
Grp1   Grp2    Grp3   Grp4
Grp1   Grp2    Grp3   Grp4
A
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Figure 5-5: Heatmap rendition of global gene expression clusters.  Gene 
expression levels were converted into a pseudocolor, with red indicating 
upregulation, and green downregulation.  Insets A and B indicate groups of genes 
that are oppositely regulated by shear in PAVEC and PAEC.  Inset C shows 
genes that are similarly regulated under shear in both cell types.  Panels D and E 
list some of the genes that are included within Insets A and B, respectively. 
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indicates the high reproducibility of the data within each group.  Group 1 (PAVECs) and 
Group 2 (PAECs) show the shear effects in comparison to static controls in each cell 
type.  On the other hand, Group 3 shows the differential gene expression between the 
cell types in static culture (PAVECs vs. PAECs).  Group 4 shows the genes expressed in 
sheared PAVECs vs. PAECs.   
 Categorization of changed genes.  To determine which categories of genes 
change under different flow vs. static condition in the two different cell types, GoMiner 
was used.  GoMiner displays significantly changed genes according to ontological 
hierarchy, as shown in figure 5-2.  The gene categories created by the GoMiner 
database engine were assessed for enrichment and depletion, and the significantly 
changed gene categories were organized according to function, and are shown in Table 
5-4, along with the direction of the change.  As an example, the superoxide metabolism 
category is enriched (more upregulated genes than by chance) in PAECs under flow.  
The changes in gene categories therefore may provide additional mechanistic insights 
and suggest testable hypotheses of functional differences between the cell types[34-36].  
For example, the GoMiner software indicated that valvular endothelial cells were more 
proliferative than vascular endothelium.  To investigate this hypothesis, the effects of 
four different extracellular matrices (tissue culture plastic-TCP, collagen I, gelatin, and 
fibronectin) on endothelial cell proliferation were determined.  While PAEC proliferate 
more than PAVEC on TCP, PAVEC proliferate more than PAEC when cultured on 
collagen I matrix (Figure 5-6).  No differences in cell proliferation were observed with 
fibronectin or gelatin.  A complete list of the changed gene categories for each array 









 Table 5-4: A profile of gene categories that were enriched or depleted within each 
array comparison as determined by GoMiner.  The numbers in each box represent
categories of related genes, a significant proportion (P<0.05) of which are similarly 
regulated under the imposed condition.  V = Valvular EC, A = aortic EC, F = 20 




V-F vs. S 
Group 2: 
A-F vs. S 
Group 3: 
S-V vs. A 
Group 4: 
F-V vs. A 
Up 109,139,155,169,177 8,29,51-53 3 
13,28,41,5
7 Oxioreductase Activity 
Down     














 50,57  Cell Polarity 
Down     
Up  12 1,6,11,17  Cell Migration 
Down  103  31 
Up  1,2,5,9,25,106,131  16,17,26 Extracellular Matrix 
Down  6   
Up 145,238    Membrane 
Channel Activity Down   23,37,38,46,47  
Up  55,102,132,133   Synaptic 
Transmission Down 32,34  32,33  
Up 64 14,67,71   Metal Ion 



































Figure 5-6:  Comparison of cell proliferation between endothelial cell types 
cultured on different matrices.  Cell number assessed at day 0 and day 5.  * 
denotes significant (P<0.05). 
While enrichment or depletion of genes within a category determined by GoMiner can 
provide an overall assessment of cell phenotype, different genes within a category also 
indicate phenotypic differences.  For example, Table 5-5 shows the genes which are 
significantly changed in each comparison that are associated with extracellular proteins, 
whether they are cytokines, growth factors, or matrix proteins.  Some genes are present 
in only one experimental comparison (e.g. CLCA, CYR61 in Group 1), while some are 
present in all comparisons (e.g., BMP-4, SST).  Within this particular category, 
somatostatin (SST) appears to be differentially regulated with flow between valvular and 
aortic endothelial cells.  Extracellular-related proteins are important indicators of cell  
phenotype and biological response, and these results suggest important differences 






















G4: F- V vs. AG3: S- V vs. AG2: A- F vs. SG1: V- F vs. S
Table 5-5: Differentially expressed genes within the 
“extracellular” category as determined by GoMiner.  V = 






 Real Time PCR confirmation of selected flow sensitive genes.  Real time 
PCR was used to confirm some of the Microarray data.  Each sample amplification was 
normalized to amplified 18S rRNA from the same sample.  Figure 5-7 shows a 
comparison of real time PCR BMP-4 expression and 18S expression on an experiment-
wide basis.  The different color boxes indicate separate reverse transcriptions.  Based 
on the trends within each box, it is clear that while BMP-4 expression changes between 
cell type and flow conditions, the 18S expression remains consistent.  There will always 
be some differences between reverse transcriptions, because random factors in the 
reaction process will contribute to slight differences in transcription efficiency.  
Nevertheless, the use of 18S as a control primer for these experiments was confirmed.  
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The expression of BMP-4 across all four conditions as determined by the different 
methods (real time PCR and microarray) is shown in Figure 5-8A.  The real time PCR 
data showed that BMP-4 levels were downregulated in both PAVEC and PAEC and  in 
response to flow.  The PCR data indicates a much stronger expression of BMP-4 in 
statically cultured PAVECs compared to PAECs (9.4 fold greater), and a much stronger 
sensitivity to shear stress (23.5-fold downregulation vs. 5.0 fold downregulation in 
PAECs).  Although the fold stimulation was not identical to that of the microarray result, 
real time PCR data did confirm the trend.  There was no significant differences between 
either rendering of the microarray data (P>0.05).   
 The upregulation of CYP1A1 by flow in PAECs as shown by the microarray data 
was confirmed by real time PCR (Figure 5-8B).  The sensitivity of CYP1A1 to flow was 
more prominent with PCR (12.6-fold) than that of the microarray data (9.4-fold and 2.9-
fold). The absolute expression of CYP1A1 in PAVECs was greater than PAECs in both 
conditions according to PCR (P<0.05), but there was no significant difference in 
sensitivity to shear stress between the two cells (13.2-fold for PAVECs, 12.6-fold for 
PAECs, P>0.05).  The data comparison of Cav-1 is shown in Figure 5-8C.  The PCR 
data indicates a downregulation of Cav-1 with shear in PAECs, while the microarray 
datasets did not indicate a significant change in expression for PAECs.  Both the 
microarray datasets and the PCR data indicated downregulation of Cav-1 in PAVEC with 
shear.  There was a greater expression of Cav-1 in static PAVECs compared to static 
PAECs according to PCR (P<0.05), but no difference in expression between the cells 















































































































































Figure 5-7: Individual sample expression of 18s and BMP-4 as 
determined by real time PCR.  Each color bar represents a 


















































































































































Figure 5-8: Verification of the expression of example genes by 
quantitative real time PCR.  Microarray intensities were 
compared to PCR product normalized to 18S content.  Data 
normalized to PAEC control for comparison.  Inset shows gel 







 It was determined in this study that endothelial cells derived from aortic and 
aortic valvular origins share several similarities, but present notable differences at the 
genomic level.  As reported in Chapter 4, both cell types grow with contact inhibition and 
show a similar cobblestone shape in static culture.  However, in response to shear 
PAVECs align perpendicular to flow whereas PAECs align with the flow direction[37].  
The mechanisms underlying these different morphological responses may have a 
significant implication in understanding how they behave under in vivo hemodynamic 
conditions.  The microarray results showed hundreds of genes that were significantly 
regulated in each comparison group.  The genes that were significantly changed in one 
cell type but not in another and not may therefore provide more clues as to functions not 
present in both cell types.  For example, more than 1,100 genes (615 up and 535 down 
in Group 4, Table 3) were differentially expressed in response to flow in PAVEC when 
compared to PAEC.  At least a part of these differential genes may be responsible for 
the unique mechanoresponses including the morphological responses (Fig. 1) between 
the two cell types.  Further comparison of this subset of genes with Groups 3 and 4 
would then indicate flow regulated genes that are expressed significantly more or less in 
one cell type.  The heat map analysis provides the simplest rendering of the results from 
all four Groups.  Clusters of genes following the aforementioned patterns could be 
identified, and some genes from these groups were highlighted.  While it is inappropriate 
to exhaustively discuss all of the possible combinations revealed by this analysis, the 
complete cluster database is presented in the online supplement.  This cluster analysis 
is by no means complete, however, because any gene for which a spot was not 
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recorded on any of the 24 arrays studied could not be included in this profile.  This 
reduced the number of genes analyzed to just over 1000, which is about 80% less than 
the 5000 that existed in each comparison group and significantly less than the 12,814 
possible features on each array.  While it would be expected that a large percentage of 
genes would not register on these arrays because of low expression in these cell types, 
experimental difficulties common to all microarray hybridization and processing may in 
addition corrupt array regions containing potentially important information.  It is therefore 
critical to review the data from each stage in this analysis (microarray, pairwise 
comparison, K-means clustering, ontological hierarchy) to create a clearer picture of how 
these cells are similar and different.   
  Ontological profiling of the gene changes provided the fastest access to potential 
research hypotheses as to the unique and shared phenotypic properties of these cells, 
some of which have been verified by previous studies.  The GoMiner engine indicated 
enrichment of many cell polarity genes in PAVECs in static and fluid flow environments 
(Table 5-4), and this supports the unique morphology reported for PAVECs.  The 
enrichment of proliferation-related gene categories in PAVECs compared to PAECs and 
depletion of proliferation-related categories under flow also support the data reported in 
this study and others[3, 38, 39].  Many other categories were also enriched and 
depleted, and the database provided by this study in Table 5-4 and in the online 
supplement suggests other readily testable hypotheses of similarities and differences 
between these two cell types.   
 To begin to ascertain some of the similarities and differences between these two 
cell types while confirming the microarray data, real time PCR was conducted on 
selected genes which coded for important regulatory proteins in endothelial physiology 
and pathology.  BMP-4 was one of the most robustly inhibited genes by laminar shear in 
both PAEC and PAVEC.  Consistent with this finding, it has been shown previously that 
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laminar shear stress inhibits and oscillatory shear stimulates BMP-4 production[31].  
BMP-4, induced by the pro-atherogenic oscillatory shear stress, is a potent inflammatory 
cytokine stimulating monocyte adhesion to endothelial cells, a critical early atherogenic 
step.  BMP’s are also critical for normal development of the aortic valve[40].  Given the 
additional importance of BMP-4 in osteogenic differentiation, the dramatically high levels 
of BMP-4 in statically cultured PAVEC suggests possible connections between shear 
environment and the initiation of calcification.  The majority of valvular calcification 
originates on the aortic side of the valve leaflet, which experiences a circulating flow 
pattern with much lower wall shear stresses than the ventricular side.  It is thus possible 
that unstable and low shear stress may initiate some endothelial dysfunctions resulting 
in the initiation of calcification through BMP-4.    CYP1A1 is a mechanosensitive protein 
that is part of the cytochrome P450 family of oxidants.  It is an indicator of oxidative 
stress state, which is induced by pharmacological toxins[32, 41] and shear stress[42].  In 
our experiments, a similar large increase in CYP1A1 expression under steady shear was 
observed in both cell types, but greater expression was observed with PAVECs.  The 
ontological profiling suggested enrichment of oxioreductive gene categories in PAVECs 
in shear and over PAECs, suggesting that PAVECs are more sensitive to oxidative 
stress than PAECs.  Indeed some pharmacological agents that increase oxidative stress 
have been shown to preferentially affect aortic valve function[43, 44].  Cav-1 is another 
mechanosensitive gene hat has been shown to be downregulated by shear stress[33].  
Cav-1 protein was shown to be reorganized into the luminal surface of the plasma 
membrane caveolae in valvular and vascular endothelial cells[45], altering the 
responsiveness of endothelial cells to subsequent shear changes[33].  Cav-1 expression 
was one of the least significant determined in the microarray studies, and only for 
PAVECs.   The expression of this gene therefore would be an appropriate check of the 
sensitivity of the array design.   While real time PCR confirmed Cav-1 downregulation 
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with shear in both cell types, the microarray indicated downregulation in valvular 
endothelial cells only.  The exhaustive literature supporting Cav-1 downregulation under 
flow in vascular endothelial cells coupled with the PCR data that indicates the same lead 
to the conclusion that the microarray was not sensitive to this effect, not that the effect 
does not occur.  These results suggest that both valvular and vascular endothelial cells 
involve caveolae in mechanosensing fluid flow.   
 In summary, we have identified lists of hundreds of genes that are regulated by 
shear stress in aortic and aortic valve endothelial cells.  These two cell types respond to 
shear conditions in similar and different ways, some of which were determined using 
ontological categorization.  The explicit roles of valvular endothelial cells in inflammatory, 
oxidative stress, and mechanotransduction pathways have yet to be elucidated, but this 
data suggests that valvular endothelial cells are important mediators of valvular function, 
and vascular endothelial cells may not adequately mimic these functions in a tissue 
engineering application.  While valvular endothelial cells may not ultimately be useful as 
a cell source for living heart valve replacements, future study with these cells will yield 
more insight into appropriate valvular functions, and help develop targeted therapeutic 
strategies, perhaps identifying valvular pathologies before they progress beyond the limit 
of efficacy of non-surgical interventions. 
 A statistical significance level of P<0.005 was chosen for these studies partly 
because the PPV was approximately 95% for each comparison group, but also because 
it pared the data to a more manageable amount to mine.  The blessing of reams of data 
in microarray experiments is also a curse.  One of the consequences of this more 
stringent significance level is that genes whose expression may in fact be noteworthy 
are deemed non-significant.  It is possible that by relaxing the significance level, many 
other genes now significantly different would be differently regulated between 
comparison groups.  As an example, relaxing the significance level to P<0.05 indicates 8 
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genes upregulated in flow in PAVECs but downregulated in PAECs, and 4 genes 
regulated in the opposite way (as opposed to 2 and 0, respectively).  Simply relaxing the 
significance level is a risky proposition however, and independent techniques should 
always be used to verify any genes of interest before any conclusions can be drawn.  
 The expression levels of example genes of interest were verified in this study 
using real time PCR.  While this method is an independent measurement of transcript 
quantity, it may also have little relevance to protein levels.  Many post-transcriptional 
modifications exist in cells, which regulate how mRNAs are transcribed to proteins, and 
the ratio of transcript to protein likely varies between genes.  Therefore, it is critical to 
assess expression at both the genomic and proteomic levels.  Protein quantification is 
also challenging, due to the many isoforms and cleavage sites that may exist, but a 
general method such as Western blotting should be sufficient.  Other methods of protein 
quantification include protein chips, flow cytometry, and ELISA-based assays. 
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TISSUE ENGINEERED AORTIC VALVE LEAFLET MODEL: 




 Cardiovascular tissues perform many important biological functions while 
maintaining a mechanical integrity that enables blood to flow uninhibited.  These include 
maintenance of vessel tone, preventing blood clot formation, and the transfer of 
mechanical and biochemical signals.  Most cardiovascular pathologies begin biologically 
in nature, and progress to mechanical failure.  A prime example of this is with heart valve 
disease.  The four heart valves work in conjunction with the heart to maintain 
unidirectional blood flow through the heart, and as such must resist highly dynamic strain 
and flexure in addition the hemodynamic pressures.  The aortic valve, situated about the 
right ventricle, is the most highly stressed, and as such is the valve most often replaced 
by prosthetic valves.  Biological destruction of the aortic valve often begins with 
endothelial dysfunction, such as in infective endocarditis[1] or aortic valve sclerosis[2].  
Cells differentiate, die, and eventually the valve loses its ability to repair local tissue 
microdamage, which leads to gross tissue failure.  Homograft or prosthetic valve 
replacement is currently the only clinical solution, and can provide approximately 10-15 
years of function before failing in a number of ways mainly associated with the fact that 
they are nonliving substitutes[3-6].  While tissue engineering shows great promise to 
alleviate the weaknesses of non-viability, attempts to engineer heart valve tissue have 
focused perhaps necessarily on the maintenance of mechanical integrity, and have used 
several matrices to achieve this, including biodegradable synthetic polymers[7, 8], 
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decellularized heart valves[9, 10], and biological matrix molecules[11].  While each 
method holds some promise, they have been met with limited success so far in animal 
trials.  Research by the Mayer group over the last 10 years culminated in the 
development of a biodegradable polymer valve populated with autologous vascular cells 
implanted in the pulmonary position[12].  After 20 weeks implantation in a sheep model, 
these valves exhibited similar tissue structure, cell phenotype, mechanical properties, 
and protein levels of normal valves.  While these results demonstrated feasibility of a 
tissue engineered valvular replacement, the valves were still mildly regurgitant even on 
the low pressure pulmonary side, making their clinical use in the high pressure right 
heart system limited.  The success of heart valve tissue engineering will therefore 
depend ultimately on the ability of the cells populating the device to thrive within the 
dynamic and complex mechanical environment, remodel the tissue to repair 
microdamage, and prevent the loss of critical matrix molecules.      
 Advances in the understanding of valvular cells biology has not kept up with the 
understanding of valve tissue mechanics.  Indeed, most tissue engineering applications 
have used cells isolated from blood vessels[8, 9, 13] or stem cells[14] to populate their 
matrices.  The aortic valve leaflet is populated with interstitial cells and lined with 
endothelial cells.  There is surprisingly little actually known about normal valvular 
endothelial cell function.  Valvular endothelial dysfunction has been implicated as the 
initiator of many clinical sequellae, including inflammatory reactions, calcification, and 
blood clots[1, 15, 16].  Previous work in Chapters 4 has demonstrated that aortic valve 
endothelial cells behave very different from aortic endothelium.  Aortic valve endothelial 
cells align perpendicular to the direction of flow, in contrast to aortic endothelial cells, 
which align parallel, and this morphology change may be associated with unique 
mechanotransduction pathways.  Gene expression is also much different between the 
two cell types, as reported in Chapter 5, and differences in gene regulation in response 
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to shear flow suggests these cells may be phenotypically distinct.  Most research on 
interstitial cells has focused on marker expression and protein synthesis in vitro.  
Comparison to other cell phenotypes indicates that these cells are uniquely suited to 
thrive within the heart valve.  In vivo evidence suggests that valvular interstitial cells are 
highly dynamic producers of protein and glycosaminoglycans, unlike smooth muscle 
cells[17], and express markers that suggest a hybrid myofibroblast like phenotype[18].  
In vitro experiments have largely confirmed these observations.  Interstitial cells express 
α-smooth muscle actin to a variable degree, as well as fibroblast surface antigen, and 
this was not mimicked by cells from other sources.  Taylor and colleagues demonstrated 
that interstitial cells in three dimensional culture in vitro expressed markers similar to 
interstitial cells in vivo, and the relative proportions of specific marker expressing cells 
was maintained[19].  The mechanism for this distribution was unclear, however, because 
no mechanical forces were applied to their constructs.  The results from Chapter 3 
showed that interstitial cells expressed α-smooth muscle actin in vitro to a similar degree 
as smooth muscle cells, desmin to a lesser degree, and that three dimensional culture 
also influences cell phenotype. 
 What has not been addressed by any of the previously mentioned studies is the 
influence that native valvular endothelium may exert on the underlying interstitial cells.  It 
is well known that proper interaction between vascular endothelial and smooth muscle 
cells is paramount to normal vessel function.  Vascular endothelial stimulation of 
underlying smooth muscle cells is critical for the maintenance of vessel tone and 
inhibition of pathological smooth muscle cell differentiation in vivo.  In vitro co-culture 
models have shown that endothelial cells inhibit smooth muscle proliferation under 
flow[20, 21].  Gene expression of endothelial cells and smooth muscle cells are also 
altered when soluble factors are allowed to exchange between the two cells.  It is likely 
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that interactions between valvular endothelial cells and interstitial cells are similarly 
important. 
 The objective of this study therefore was to develop a three dimensional co-
culture system using native aortic valve cells in a biological matrix that can be exposed 
to mechanical forces.  Valvular endothelial-interstitial cell co-cultures were exposed to 
steady laminar shear for up to 96 hours, and the results show that valvular endothelial 
cells modify interstitial cell synthetic response to fluid shear stress, and stimulate 




 Cell Isolation and Culture.  Porcine aortic valve endothelial cells (PAVECs) and 
aortic valve interstitial cells (PAVICs) were isolated, characterized, and cultured as 
described in Chapters 2 and 4.  Briefly, aortic valve leaflets were isolated from porcine 
aortic roots and subjected to short collagenase digestion, at which point the PAVECs 
were removed by gentle scraping.  PAVECs were then plated onto dishes coated with 50 
µg/ml collagen I.  Once denuded, the rest of the tissue was incubated overnight in 
collagenase to isolate PAVICs, which were then plated onto tissue culture plastic.  Both 
cell types were cultured in DMEM supplemented with 10% FBS, 1% Penicillin-
Streptomycin, and 1% L-glutamine, and split 1:3 upon confluence.  For these 
experiments, PAVEC were used at passage 5, while PAVICs were used between 
passage 5 and 8. 
 Co-culture model creation.  Tubular molds were created using glass rods and 
rubber tubing as shown in Figure 6-1 and explained in greater detail in the appendix.  A 
collagen gel suspension containing 1 million PAVICs/ml was created as described 






Figure 6-1: Schematic of valvular co-culture model creation 
tubular molds were then inserted into the tubes, and the constructs were allowed to gel 
for 1 hour.  The molds were then removed from the tubes and placed in a sterile dish 
containing 150 ml of culture media.  The constructs were then allowed to compact for six 
days.  Each construct was then gently removed from the mold and sectioned 
longitudinally.  The surface contacting the glass mandrel was placed face down on a 
glass microscope slide, and any media aspirated from under the tissue to ensure a flat 
profile.  A rectangular polycarbonate mold was placed around the construct, and 6 ml of 
a 3.5% agar solution at 47°C was poured over the construct and immediately sealed with 
another slide.  The agar solidified after 1 minute at room temperature.  The sandwich 
was flipped over and the slide covering the flat surface was removed to expose it to 
media.  The resulting embedded construct was then placed in 35 ml of culture media.  
Some constructs were seeded with 50,000 PAVECs/cm2 by aspirating enough media to 
expose the top surface of the construct, inoculating 200 ml of the concentrated cell 
suspension onto the surface, and allowing the cells to adhere for one hour.  Media was 
then added to the embedded constructs, and the co-culture was allowed an additional 
two days for endothelial monolayer formation.  Non PAVEC constructs followed the 
same procedure, except were not seeded with PAVECs. 
 Shear Stress Experiments.  The embedded constructs were placed into a 
modified version of the flow chamber explained in Chapter 4.  A smaller rubber spacer 
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was used to accommodate the glass coverslip and rectangular mold containing the 
embedded construct.  A larger spacer was used to create the shear flow, to 
accommodate the increased variation in channel height due to any undulations in the 
construct surface.  The lumenal surfaces were then exposed to 20 dynes/cm2 steady 
laminar shear stress for 48 or 96 hours, with static cultures serving as controls.  The 
actual wall shear stress on an aortic valve leaflet is much more complex and challenging 
to measure.  Weston and colleagues estimated a maximum wall shear stress of 79 
dynes/cm2 for leaflet surfaces, but noted that the shear stress varied continuously with 
the valve cycle[22].  While it is important to study physiological levels of mechanical 
forces, those forces are often damaging to engineered tissue in vitro.  The 20 dynes/cm2 
of steady laminar shear stress used in these experiments was an approximation of the 
mean leaflet wall shear stress, and also was the maximum shear stress that could be 
imposed while maintain a reasonably confluent endothelial monolayer critical to the 
power of the study. 
 Endothelial Morphology.  The morphology of the endothelial cells on the 
construct surface was investigated using confocal microscopy using a modification of the 
procedure previously described in Chapter 4.  Upon completion of the experiments, the 
constructs were removed and the agar mold cut away, leaving only a few millimeters of 
agar around the constructs.  Co-cultures were then fixed in 3.7% paraformaldehyde 
overnight, then the constructs were gently peeled from the agar and placed in well of a 
6-well plate in PBS.  The endothelial cells were then permeablized with 0.1% Triton X-
100 for 5 minutes, followed by blocking in 1% neonatal goat serum (NGS) for 1 hour.  
Endothelial cell phenotype was then labeled by incubation with anti-human von 
Willebrand Factor (Sigma F-3520, 1:100, in rabbit) for one hour, followed by rinsing, 
secondary antibody incubation (goat anti-rabbit, FITC, Molecular Probes A-11008, 
1:100, one hour) and additional rinsing.  Cells were then counterstained for f-actin 
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(rhodamine phalloidin, Sigma R-418, 1:400) and cell nuclei (Hoechst, Sigma F-32258, 
1:1000) for 30 minutes, followed by additional rinsing and coverslipping.  Constructs 
were then imaged using confocal microscopy.  The lumenal surface of the constructs 
was placed face down (closest to the objective) on a glass coverslip and five 
representative pictures were taken of each construct.  Morphological parameters were 
assessed as previously described in Chapter 4.  Shape index and orientation angle 
measurements were then compared with the morphology of PAVECs monolayers on 
glass slides presented in Chapter 4.  Two factor ANOVA was used to determine 
significance between cell type and condition with P<0.05 considered significant. 
 Biochemical Assays.  PAVIC only constructs and co-culture models were 
analyzed for cell number, total protein content, and sulfated glycosaminoglycan content 
using the biochemical assays described in Chapter 3.  Constructs were sectioned in half 
widthwise: half of the construct was fixed for histology, half was immediately frozen at -
80°C until analyzed.  Frozen constructs were then lyophilized in a vacuum centrifuge, 
weighed, and then digested with Proteinase-K overnight at 55°C.  For cell number 
quantification, 10 µl of samples were added to 200 µl of buffer containing Hoechst dye at 
1:10000 concentration in a 96 well plate, and plates read on a fluorometer at 385 nm.  
Total protein and sulfated glycosaminoglycan content was quantified using the BCA 
(Pierce) and Blyscan (Biocolor) assays according to the manufacturers’ protocols using 
the proteinase K digested samples.  Cell number was normalized to dry weight to 
account for differences in size of the samples, while matrix production was normalized to 
DNA content to account for slight differences in construct sizes.  Additionally, all 
construct values were normalized by day 0 averages to account for variations between 
batches of constructs.  Statistical significance was determined using Analysis of 
Variance for time duration, and T tests for differences between flow condition and cell 
type.  P<0.05 was considered significant for these tests. 
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 Cell Phenotype Characterization.  PAVIC phenotype was qualitatively 
assessed using immunohistochemistry.  Construct samples fixed overnight in 3.7% 
paraformaldehyde, and placed in 70% ethanol.  Constructs were then paraffin 
embedded and sectioned at 5 µm.  Immunohistochemistry was performed as described 
in greater detail in the appendix.  Briefly, slides were deparaffinized, washed twice in 
PBS, and blocked in 1% bovine serum albumin (BSA) for 30 minutes.  Antibodies to von 
Willebrand Factor (Sigma F-3520, 1:600), vimentin (Cy3 conjugate, Sigma V2228, 
1:200), and α-smooth muscle actin (Cy3 conjugate, Sigma 0-6198, 1:400) were 
incubated singly for one hour.  Before von Willebrand Factor (vWF) incubation, a brief 
gelatinase digestion was conducted to expose antigen.  Slides were then washed, 
followed by incubation in secondary antibody for vWF (Molecular Probes, A-11008, 
1:100) for 40 minutes.  Slides were then washed twice and coverslipped with a DAPI 
counterstain for cell nuclei.  Slides were viewed using a fluorescent microscope (Nikon 




 Co-culture Model Development.  Porcine aortic valve interstitial cells 
compacted the collagen hydrogels over the six day period, with a majority of the 
compaction occurring by day 3 (data not shown), much similar to what was shown in 
Chapter 3.  Figure 6-2 shows an example of the compacted tubular collagen gel, which 
was then sectioned longitudinally to create a thin, flat three dimensional substrate 
entombed with interstitial cells.  Imaging by polarized light showed the collagen fibril 
alignment through the thickness of the construct.  Highly aligned fibers were 
concentrated near the surface of the tissue closest to the glass mandrel, and more 
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Figure 6-2: Co-culture model characterization.  A: Tubular mold; B: sectioned 
construct; C: Confocal microscope image indicating endothelial monolayer; D: 
Three dimensional confocal image indicating cellular arrangement; E: Polarized 
light image indicating matrix alignment (bright field).  Confocal staining – green 
(von Willebrand factor), red (f-actin), blue (cell nuclei).  Scale bar = 1 cm (A,B), 
100 µm (C-E). 
randomly oriented near the opposite surface.  This is somewhat similar to what is seen 
in the native valvular leaflet.  It is likely the developed tissue anisotropy is due to the 
physical constraint placed at this surface.  Cells were homogeneously distributed 
throughout the construct, with only slight alignment near the constrained surface.   
 The surface with highly aligned underlying matrix became the “lumenal” surface 
upon longitudinal sectioning, which was then seeded with PAVECs.  Immunofluorescent 
staining for von Willebrand Factor indicated a reasonably confluent endothelial 
monolayer on the surfaces of the constructs.  The entire surface of the leaflet was not 
completely covered with endothelial cells, but large patches like the image shown 
existed throughout the surface, leading us to estimate the surface approximately 70% 
covered with endothelial cells, with some variation between individual constructs.  Z-
stacked confocal microscopy showed a contact-inhibited endothelial monolayer on top of 
a closely apposed interstitial cell population.  Some close contacts were observed 
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between PAVICs and PAVECs, suggesting that these cells readily interact with each 
other.   
 Endothelial Cell Alignment under Flow.  It was previously shown in Chapter 4 
that PAVECs in two dimensional culture align perpendicular to the direction of fluid flow.  
Figure 6-3 shows that on an aligned three dimensional matrix in co-culture with PAVICs, 
the alignment tendencies were overall not significantly different.  Valvular endothelial 
cells in both conditions decreased their Shape Indexes from approximately 0.8 to 0.6 
under flow, and changed orientation from 45° (random) to 75° (perpendicular to flow).  
The larger standard deviation in orientation angle for PAVECs in co-culture was due to 
the deviations in regional cell orientation.  The PAVICs directly underneath the PAVECs 
gave an indication as to the matrix alignment, and some swirling patterns were observed 
which the endothelial cells also mimicked to a degree in their alignment.  Cell alignment 
under flow was still predominantly perpendicular to the flow direction, and never 
observed to be parallel to flow direction.  PAVEC morphology was different in ways 
undetectable by the Shape Index, however.  In two dimensional culture, filamentous 
extensions protruded from one cell onto another, but PAVECs in three dimensional 
culture appeared more regularly elliptical.  The protrusions increase cell perimeter 
without similar increases in cell area, thus compromising the effectiveness of the Shape 
Index in determining cell elongation.  It is therefore possible that valvular endothelial 
cells in three dimensional co-culture were more elongated than in two dimensional 
culture.    
 Cell Organization and Proliferation.  PAVEC seeded PAVIC constructs and 
non seeded PAVIC constructs were exposed to 20 dynes/cm2 steady shear with static 
cultures of both conditions serving as controls.  Figure 6-4 shows the histologically 
determined cellular arrangement in seeded and non-seeded constructs over time.  
Interstitial cells are randomly oriented within non-EC seeded constructs, with slight  
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Figure 6-3: Endothelial cell alignment on valve leaflet co-culture models.  
A: Static culture; B: 48 hour flow (20 dynes/cm2); C: Shape index 
comparison; D: Cell orientation angle comparison.  Green = von 









Figure 6-4: Hematoxylin and Eosin staining of constructs depicting matrix and 
cellular architecture.  Inset depicts endothelial layer.  Scale bar = 200 µm.  
circumferential alignment near the lumenal surface.  The application of flow enhances 
this alignment somewhat, but only right at the surface.  Co-culture leaflet models had 
cells throughout the construct, but there were preferentially more cells near the lumenal 
surface and opposite edge of the constructs.  This may be due to diffusion constraints 
imposed by the addition of PAVECs, limiting perfusion through the highly porous 
collagen matrix.   Biochemical analysis of cell number (DNA content) across 
experimental conditions is shown in Figure 6-5A.  Interstitial cell only constructs tended 
to increase cell number over time, with shear stress having no effect.  This was in 
contrast to the endothelial seeded co-culture model, which maintained cell number 
during static culture, and decreased cell number under flow.  By day four, cell content in 
PAVIC sheared constructs was significantly higher than sheared co-culture models.  
 Matrix Production.  Figure 6-5B and 6-5C show the matrix production of the 
PAVIC constructs and PAVIC/VEC co-culture models under static and fluid flow  
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Figure 6-6: Cell content (A), Protein content (B), and 
sulfated glycosaminoglycan content (C) of EC and non-
EC seeded constructs.  Data normalized to Day 0 values 
and presented as mean +/- SEM.  * denotes significant 
with respect to different condition (P<0.05), ** denotes 
significant with respect to Day 0 value (P<0.05) 
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conditions.  Protein content was regulated in an opposite manner than cell content.  
PAVIC only constructs tended to have less protein over time, with no effects of shear.  
PAVIC/VEC constructs, on the other hand, tended to maintain protein content in static 
culture, but increase protein content under flow.  At day 4, sheared PAVIC/VEC 
constructs have significantly more protein than PAVIC only constructs.  Sulfated 
glycosaminoglycan (sGAG) content regulation was much different, however.  sGAG 
content was lost in PAVIC constructs over time and with shear.  Both day 2 and day 4 
sheared PAVIC only constructs had significantly less sGAGs than day 0, but no 
significant difference between static sheared constructs at day 4.  In PAVIC/VEC co-
cultures, no significant difference in sGAG content was detected in static culture or 
under flow (P=0.055).  There was significantly more sGAG content in day 4 sheared 
PAVIC/VEC constructs compared to sheared PAVIC only constructs, but no significant 
difference between statically cultured models (P=0.18).   
  Evolution of Interstitial Cell Phenotype.  The evolution of cell phenotype was 
determined through the expression of vimentin, α-smooth muscle actin (α−SMA), and 
smooth muscle myosin.  Figure 6-7 shows the vimentin expression of the PAVIC only 
and co-culture constructs.  Vimentin expression is maintained throughout the time points 
investigated in both models, with little differences between flow and static culture.  The 
cells appear more aligned after four days of flow, with vimentin expression throughout 
the cytoplasm.  Figure 6-8 shows the expression of α-SMA in both culture models and 
flow conditions.  In PAVIC only constructs, only a basal level of expression is observed 
in static culture throughout the time period investigated.  The application of flow, 
however, increases expression of α-SMA, especially near the lumenal surface.  The  
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Figure 6-7: Vimentin expression in PAVIC constructs and PAVEC-Seeded 
co-cultures (TEVL).  Counterstained for cell nuclei (blue).  Bottom left panel 
indicates native leaflet endothelium (von Willebrand factor).  Scale bar = 
100 µm. 
Native PAVL D0 D4 Static D4 Flow
PAVIC
TEVL
Native PAVL D0 D4 Static D4 Flow
PAVIC
TEVL
Figure 6-8: α-smooth muscle actin expression in PAVIC constructs and 
PAVEC-Seeded co-cultures (TEVL).  Counterstained for cell nuclei (blue). 
Bottom left panel indicates TEVL endothelium (von Willebrand factor).  
Scale bar = 100 µm. 
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expression of α-SMA is further regulated with the addition of PAVECs.  At day 0, a basal 
level of expression is noted, but this expression drops off during the culture period.  By 
day 4, virtually no expression is detectable in static culture, and only slightly more with 
the application of flow, again in the cells closest to the lumenal surface.  These results 
suggest that the PAVECs modulate the expression of α-smooth muscle actin in PAVICs 
in static and fluid flow conditions.  No expression of smooth muscle myosin was 
observed in either model under any culture condition (data not shown).  PAVEC 
phenotype on the lumenal surface of the co-culture models was confirmed through von 
Willebrand Factor (vWF) staining, as shown in the panels of figure 8-7 and 8-8.  A 
confluent monolayer of endothelial cells was more difficult to demonstrate through 
immunohistochemistry, as these constructs were extremely fragile, and the handling 
necessary for paraffin processing likely detached some of the cells.  It was interesting to 
note that  a few cells expressing of vWF were detected in the subendothelial layers of 
the constructs, suggesting some migration may have occurred (arrow). 
     
6.3: Discussion 
 
 Previous work presented in Chapters 3 and 4 and done by others have shown 
that valvular endothelial cells and interstitial cells behave differently in several respects 
from vascular cells.  Valvular endothelial cells align perpendicular to fluid flow in two 
dimensional culture, and valvular interstitial cells express contractile markers in a 
different manner than smooth muscle cells.  This study is the first to present a co-culture 
model of a valvular leaflet for in vitro study.  Native aortic valve endothelial cells were 
placed in close proximity to valvular interstitial cells, which were homogeneously 
entombed in an anisotropic biological collagen matrix.  This model could then be 
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incorporated into a steady shear flow system to investigate interactions between fluid 
flow, endothelial cells, and interstitial cells. 
 Numerous studies have demonstrated the importance of appropriate vascular 
endothelial-smooth muscle interactions for maintenance of blood vessel tone, and the 
importance of mechanical forces in regulating cell phenotype.  Surprisingly, almost 
nothing is known about how native valvular endothelial and interstitial cells interact, or 
how mechanical forces influence these interactions.  Rothenburger and colleagues 
created valvular leaflet like tissue with valvular cells co-cultured in a collagen matrix, and 
found that these cells synthesized collagen and proteoglycans, but did not identify any 
particular aspects of endothelial regulation of interstitial cell function[23].  Weston and 
Yoganathan developed an organ culture model of aortic valve leaflets and exposed them 
to shear stress for up to 48 hours[24].  They found a dramatic increase in cell number 
and protein and glycosaminoglycan synthesis with static incubation, but no differences 
with the application of any flow regimes.  These results are similar in some respects and 
different in others in comparison with this work.  Our results indicate an increase in cell 
content, but a decrease in protein and sGAG content for PAVIC only constructs.  Weston 
and Yoganathan reported that their leaflet isolation protocol may have removed all viable 
endothelium from the leaflet surfaces, creating a model more like the PAVIC only 
construct, making a comparison with the co-culture model inappropriate.  The native 
leaflet has other matrix components besides type I collagen (Christie, 1992), so some of 
the differences may be a result of additional matrix signals not present in these models.  
The static culture induced cell proliferation reported in this study may also mimic a 
wound healing response as has been reported by Lester et al, who showed an increase 
in interstitial cell proliferation with endothelial denudation[25].  Valvular interstitial cells 
may therefore be regulated by valvular endothelial cells to maintain cell numbers in vivo, 
which was mimicked by the co-culture model.  In our studies, the presence of endothelial 
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cells caused a maintenance cell number, increase in protein synthesis, and a reduction 
in the loss of sGAGs induced by shear in comparison to controls.  While no in vitro 
studies have explored these phenomena, short term studies in rat aortic valves indicated 
a generally more active production of proteins and GAGs in comparison to other tissues, 
as was reported earlier in Chapter 3.  The experimental time scales were much different 
in our study compared to theirs, but their results suggest that the valvular endothelial – 
interstitial cell interactions reported by our model are somewhat similar to the in vivo 
condition. 
 Valvular endothelial cells were also shown to modulate interstitial cell phenotype 
in three dimensional co-culture.  Contractile phenotype as determined by α-smooth 
muscle actin expression was reduced in co-culture, and only interstitial cells near the 
lumenal surface expressed the marker after four days of steady shear stress.    Rabkin 
and colleagues have defined an “activated” interstitial cell phenotype based on among 
other characteristics increased α-smooth muscle actin expression[26].  This suggests 
that the presence of viable valvular endothelial cells helps to maintain a normal 
interstitial cell phenotype.  In this respect, valvular endothelial cells are similar to 
vascular endothelial cells, which have been shown to enhance underlying cell 
expression of α-smooth muscle actin in a microvessel co-culture model[27].  The 
opposite regulation of α-smooth muscle actin induced by the different endothelial cell 
types suggests that each one is uniquely suited for their respective application.  The 
presence of positive actin expression at day 0 may be due to an artificial interstitial cell 
activation resulting from in vitro culture, tissue handling and embedding.  Previous work 
in Chapter 3 showed high expression of a-smooth muscle actin in two dimensional 
culture, which was dramatically reduced in three dimensional culture, but still positive.  
There were no valvular endothelial cells in those studies, however. 
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   Mechanical forces are also very potent stimulators of cell function, including 
matrix remodeling, strengthening and signal transduction pathway activation.  Vascular 
cells populating engineered valvular conduits implanted into the pulmonary circulation of 
sheep were able to modify their phenotype to resemble that of native interstitial cells by 
20 weeks of implantation[28].  There are many sources of stimulation within animal 
models, including mechanical and biochemical factors, as well as the possibility of host 
cell growth into the conduit and immune response.  It is therefore difficult to attribute 
causation to any specific aspect of this environment on a particular conduit response.  
The valvular leaflet co-culture model presented here enables the investigation of the 
specific effects of fluid shear stress on valvular endothelial-interstitial interactions.  We 
have demonstrated that valvular endothelial cells align perpendicular to flow direction 
while in co-culture with interstitial cells in a collagen matrix, confirming our previous 
results in Chapter 4.  Matrix alignment was predominantly circumferential, however, and 
a subtle influence of matrix alignment was noted.  Similar constructs made with vascular 
endothelial cells and smooth muscle cells aligned parallel to flow regardless of matrix 
alignment[29], suggesting that interstitial cell-matrix alignment may influence valvular cell 
alignment.    The actual wall shear stress on an aortic valve leaflet is much more 
complex and challenging to measure.  Weston and colleagues estimated a maximum 
wall shear stress of 79 dynes/cm2 for leaflet surfaces, but noted that the shear stress 
varied continuously with the valve cycle[22].  While it is important to study physiological 
levels of mechanical forces, those forces are often damaging to engineered tissue in 
vitro.  The 20 dynes/cm2 of steady laminar shear stress used in these experiments was 
an approximation of the mean leaflet wall shear stress, and also was the maximum 
shear stress that could be imposed while maintain a reasonably confluent endothelial 
monolayer critical to the power of the study.  This level of shear stress was identical to 
that imposed on the monolayer studies in Chapter 4, enabling comparisons between the 
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two studies.  The limited response of interstitial cells to steady shear suggests that this 
force is not important to interstitial cell function.  Mechanical stimulation did have some 
effects on Endothelial co-culture, contributing to an increase in protein content and a 
reduction in the loss of glycosaminoglycans.  Glycosaminoglycans perform an important 
lubrication function in valve leaflets, permitting internal shear between the major load 
bearing layers: the ventricularis and fibrosa[30].  Many glutaraldehyde-fixed bioprosthetic 
valve failures can be attributed to a loss of this function[31].  It is clear from these studies 
that fluid shear stress does not stimulate any net synthesis of glycosaminoglycans by 
interstitial cells, and therefore other mechanical forces may be responsible for this 
function. 
 Many serious valvular pathologies begin with the dysfunction and denudation of 
the endothelium, and progress through abnormal interstitial cell behavior[2].  This tissue 
engineered leaflet model provides an ideal system to investigate the effects of fluid 
forces on endothelial-interstitial cell interactions.  Well controlled in vitro studies can 
complement more complex animal model studies to progress understanding of valvular 
cell biology and help develop a clinically successful living valvular replacement. 
 The reduction of interstitial cells within the center of some of the constructs is a 
concern that suggests nutrient diffusion limitations.  Native valve leaflets are on the order 
of 500 µm thick, therefore not requiring supporting vasculature for nourishment.  Only 
one surface of the tissue is exposed to nutrients during the six days of compaction 
before it is embedded in agar.  It is possible that some cell loss due to starvation is 
occurring.  The immunohistochemistry images in Figures 6 and 7 indicated that some of 
the engineered tissues were thinner than the native leaflet, suggesting that the collagen 
matrix could be compacted by the interstitial cells to a density greater than that of the 
native leaflet.   It is interesting to note from Figure 4 that the thickness of the engineered 
tissue appears to be inversely proportional to the number of healthy cells within the 
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matrix.  It is likely that both of the aforementioned factors play some role.  To improve 
upon the diffusion limitations, the glass mandrel used in these experiments can be 
replaced with a porous tubular mandrel, enabling media diffusion from both sides of the 
leaflet.     
 Another limitation in this study was the lack of equal sample numbers for 
statistical analyses and the variability between sample batches.  Each batch of interstitial 
cells produced between 12 and 16 constructs, which were divided into the various 
experimental categories.  Inefficiencies in PAVEC seeding, accidental construct 
aspiration, and unintended leaks in the flow system eliminated constructs from this pool 
creating unequal sample numbers in virtually every round of experiments.    Because a 
maximum of 8 flow loops could be used at one time due to space limitations, it 
sometimes occurred that no data was obtained for one experimental condition.  For 
these reasons all data was pooled together and considered as independent 
experiments.  While this was somewhat reasonable given the many different 
manipulations done independently to each construct, the variability in the data appeared 
to be larger between batches rather than within batches, further complicating data 
analysis.  An improvement for the future would involve averaging data from constructs of 
an experimental condition from the same batch, and then using multiple batches to 
generate enough samples for statistical significance.  A further reduction in variability 
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7.1: Aortic Valve Disease Treatment 
 
 The clinical data presented in Chapter 1 demonstrate the serious global problem 
of aortic valve disease (AVD) and its etiologies.  There is a great divide between 
developed and underdeveloped countries as to the underlying causes of AVD, which 
reflects upon their relative economic status.  In developed countries, great advances in 
medical technologies and expertise have all but eliminated rheumatic causes of AVD, 
yet these countries suffer from degenerative valve disorders that mimic atherosclerotic 
pathologies and “old age” vascular disorders.  Virtually no degenerative pathology is 
acknowledged in these underdeveloped countries, but the eminently preventable 
rheumatic heart disease is severely rampant.  While effective distribution of medical 
information and antibiotic therapy can help bridge the gap, there may be a larger issue 
behind this divide in terms of the direction of medical research.  The cost of medical 
research is tremendous and time consuming, as is the cost of treating these types of 
diseases.  The direct and indirect costs of cardiovascular disease alone were over $200 
billion in the United States in 2002[1].  Many companies strive to develop therapeutic 
devices and drugs to target these diseases that affect over 40 million Americans.  
Unfortunately, it appears that a much larger global population may suffer from disease 
etiologies for which these novel medications and devices may not be suitable, and this 
population cannot afford to develop these cures themselves.  While antibiotics can be 
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relatively inexpensive to obtain, these in general do not treat the underlying causes of 
these pathologies.  Even in the United States, current diagnostic tools for aortic valve 
dysfunction relies on echocardiography, which may show a problem at a stage where it 
is already too late to treat non-invasively[2].  What is needed in both these situations is 
an effective strategy to understand the mechanistic development of these pathologies.  
That way diagnostic tools and targeted therapeutics can be developed for these 
underlying causes, effectively removing the need for any kind of prosthetic valvular 
replacement. 
 Tissue engineering technologies may provide the tools needed to achieve this 
goal.  By combining living cells, a supportive substrate, and appropriate mechanical 
and/or biochemical signals, it is theoretically possible to create a living tissue substitute 
that can grow and remodel according to the bodies needs.  Perhaps even more 
importantly, tissue engineering can provide more physiological models for the in vitro 
study of normal and pathological tissue biology in well defined chemical and mechanical 
environments.  The paradigm for biological research in the 20th century was animal 
research.  While having the advantage of systemic circulation, hormonal cues, and 
immune response, these models are very expensive, require long development times, 
and offer little useful mechanistic data.  While animal studies are critical for the 
evaluation of preclinical safety and efficacy of medical drugs and devices, a significant 
number of animal studies could be reduced with the development of in vitro test beds 
that mimic physiological responses.  Over the last 30 years, experimental research has 
developed along this line, exposing single cell layers to combinations of biochemical and 
mechanical cues to understand their mechanism of action and biological response.  
While these experiments have greatly advanced the understanding of diseases like 
atherosclerosis, they suffer from the potential for artificial responses due to in vitro 
culture.  In vascular research, for example, it has been shown that statically cultured 
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endothelial cells actually represent a pathologically activated phenotype.  With the 
addition of physiological mechanical cues, these cells revert to a more quiescent 
phenotype as is seen in vivo[3], yet still lack fundamental signals owing to a lack of 
neighboring smooth muscle cells and three dimensional tissue matrix.  The research 
paradigm for the 21st century could then be the evolution of three dimensional tissue 
engineered models, capable of exposure to well defined mechanical and biochemical 
cues, so that truly mechanistic data can be obtained and properly interpreted.  In the 
long term (and perhaps even short term), these engineered systems will shorten the time 
to develop promising therapeutic strategies. 
 
7.2: Aortic Valve Biology 
 
 Almost nothing is known about aortic valve cell biology and the effects of 
mechanical and biochemical cues on their behavior.  Techniques to isolate and culture 
these cells have only recently been developed, and to date only static two-dimensional 
culture phenotype has been assessed, and only at a surface level.  In Chapter 2 of this 
work, detailed protocols were developed to isolate pure populations of aortic valve 
endothelial and interstitial cells.  These cells were characterized through cytoskeletal 
marker expression and some functional assays, and the results compared favorably with 
other reports in the literature.  These cells were then used to determine biological 
responses to mechanical forces and the effects of three dimensional culture, the results 
of which were discussed at the end of each chapter.  The purpose of this chapter is then 
to combine some of the results of different chapters to gain more insight into the 
biological responses of valvular endothelial cells and interstitial cells to defined 
environments.  Two prominent themes developed, and they are addressed in the 
following paragraphs. 
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 Valvular Endothelial Mechanotransduction.  Much has been made of the 
influence of mechanical signals on vascular endothelial – smooth muscle cell 
interactions [4-7].  Endothelial cells maintain vascular wall shear stress by maintaining 
vessel tone, and regulate the quiescent smooth muscle cell phenotype.  Numerous 
experiments have been conducted in vitro to determine the mechanism of these effects, 
and both centralized and decentralized hypotheses have been suggested[8].  In Chapter 
4, it was shown that valvular endothelial cells were also sensitive to shear forces, but in 
a different manner than vascular endothelial cells.  Valvular endothelial cells aligned 
perpendicular to flow, while vascular endothelial cells aligned parallel.  The 
perpendicular endothelial alignment is also present in vivo on aortic valve leaflets[9], 
suggesting that the in vitro response is similar to what is seen in vivo.  This 
morphological change was shown to be dependent on cytoskeletal reorganization driven 
by changes in focal adhesion development.  Focal adhesion plaques have been 
implicated as mechanosensors for endothelial cells[10].  It was also discussed that these 
differences may be related to differences in signaling pathways used by the cell.  
Valvular endothelial cell alignment was not disrupted by inhibition of PI 3-kinase activity, 
while vascular endothelial cell alignment was.  Table 7-1 highlights significant gene 
expression differences revealed by microarray analysis that relate to shear stress 
response (Groups 1 and 2) from Chapter 5.  Genes coding for proteases, adhesion 
molecules, signal pathways, and other proteins were found to change in both groups.  
Significant changes in genes involved with rho kinase, PI 3-kinase, and calpain were 
noted in valvular endothelial cells under flow.  The combination of these genetic changes 
and the specific pathway inhibition reported in Chapter 4 strongly suggest unique 
mechanotransduction pathways are involved with each endothelial cell type.   
 A speculative hypothesis for this difference may be related to the differences in 
tissue strains experienced in vivo.  Endothelial cells perhaps have a “memory” of their in 
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vivo tissue and fluid mechanical environment, and their ability to respond to these stimuli 
may persist in vitro.  As described in Chapter 1, valvular cells are exposed to a very 
Table 7-1: Flow regulated genes involved in mechanotransduction in valvular and 
vascular endothelial cells. 
PAVEC Flow vs. PAVEC Static (Group 1)     
Modulatory Adhesion Molecules/Proteases     
Gene Reg Fold Std P < 
ADAM15 Up 1.26 0.12 0.005 
MMP23B Up 1.40 0.23 0.005 
CD36 (thrombospondin receptor) Down 1.30 0.09 0.001 
Thrombospondin Up 1.24 0.25 0.05 
Thrombin inhibitor Up 1.33 0.11 0.005 
Thrombomodulin Down 1.67 0.12 0.001 
Prothrombin Up 1.41 0.35 0.025 
Alpah 5 integrin Up 1.48 0.10 0.001 
Beta 4 integrin binding protein Up 1.59 0.48 0.005 
Alpha 3 integrin Down 1.15 0.05 0.05 
Signal Pathways     
Gene Reg Fold Std P < 
Calpain 4 Up 1.38 0.12 0.005 
Calpain 1 Up 1.61 0.18 0.001 
GTP-binding Rho 7 Up 2.28 0.36 0.001 
Rho GDP dissociation inhibitor (DI) alpha Up 1.41 0.23 0.025 
Rho GDP DI beta Down 1.31 0.06 0.05 
Rho Guanine Nuclear Exchange factor 
(GNEF) 1 
Up 1.40 0.08 0.005 
Rho G Up 1.47 0.55 0.05 
Rac Z Up 1.75 0.17 0.001 
Rho associated coiled-coil protein kinase 1 Down 1.26 0.08 0.005 
PI 3K regulatory subunit 3 Up 1.35 0.25 0.025 
Activated LCAM Down 1.48 0.30 0.005 
PECAM Up 1.30 0.30 0.05 
Junction plakoglobin Up 1.12 0.06 0.001 
Connexin 50 Up 1.44 0.22 0.01 
Connexin 45 Up 1.28 0.12 0.005 
Endothelial Genes     
Gene Reg Fold Std P < 
Human vascular endothelial growth factor 
(VEGF) 
1 1.13 0.08 0.005 
endothelial PAS domain protein 1 1 2.84 0.84 0.001 
nitric oxide synthase 3 (endothelial cell) 1 1.18 0.22 0.050 
platelet/endothelial cell adhesion molecule 
(CD31 antigen) 
1 1.30 0.30 0.050 
endothelin type b receptor-like protein 2 2 1.16 0.15 0.005 
Human kruppel-like zinc finger protein 
(ZNF300) 
1 1.09 0.07 0.005 
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Table 7-1 Continued:     
PAEC Flow vs. PAEC Static (Group 2)     
Modulatory Adhesion Molecules/Proteases     
Gene Reg Fold Std P < 
ADAM17 Up 1.22 0.20 0.05 
MMP10 Down 1.13 0.12 0.05 
MMP2 Up 3.00 0.80 0.001 
Thrombospondin 1 Up 1.15 0.17 0.01 
Thrombospondin 4 Up 1.40 0.46 0.05 
Beta 2 integrin Down 1.18 0.04 0.025 
Alpha 5 integrin Up 2.09 0.70 0.025 
Beta 4 integrin binding protein Up 1.79 0.43 0.025 
Alpha 2B integrin Up 1.47 0.25 0.05 
Thrombomodulin precursor Down 2.52 1.02 0.001 
Thrombomodulin Down 2.00 0.48 0.001 
Prothrombin Up 2.49 0.62 0.005 
Signal Pathways     
Gene Reg Fold Std P < 
Calpain 1 Up 1.64 0.57 0.01 
Rho GDP DI alpha Up 1.68 0.48 0.05 
Rho GNEF 1 Up 1.19 0.12 0.025 
Activated LCAM Down 2.49 0.5 0.001 
PECAM Up 1.84 0.38 0.05 
ICAM3 Up 1.19 0.08 0.025 
Connexin 50 Up 1.37 0.25 0.025 
Cardiac Gap Junction Down 1.31 0.1 0.05 
Connexin 37 Down 1.63 0.44 0.001 
Endothelial Genes     
Gene Reg Fold Std P < 
Human endothelin converting enzyme-1 
(ECE-1) 1 2.20 0.79 0.001 
vascular endothelial growth factor-related 
protein 1 1.73 0.23 0.010 
Human endothelial cell protein C/APC 
receptor (EPCR) 1 1.63 0.45 0.005 
platelet/endothelial cell adhesion molecule 
(CD31 antigen) 1 1.84 0.38 0.050 
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complex and dynamic biaxial tissue strain, in addition to fluid forces, that may also exert 
an influence on the endothelial cells.  It has been reported that endothelial cells exposed 
to uniaxial stretch align perpendicular to the major axis of strain.  Figure 7-1 shows a 
schematic of the directions and relative magnitudes of tissue strains and fluid forces.  
Blood vessels experience primarily circumferential strain, and the endothelial cells align 
perpendicular to this strain axis, which also happens to be parallel to the general flow 
direction.  The major strain axis in valve leaflets, however, is radial, and the valvular 
endothelial cells align perpendicular to this, which is circumferentially along the leaflet.  
This alignment also happens to be perpendicular to the flow direction.  Therefore, it may 
be possible that tissue strain is a stronger stimulus of endothelial cell alignment.  An 
abstract presented at the 2002 EMBS-BMES Conference suggested that a 2% axial 
strain has the same “alignment power” as 80 dynes/cm2 steady shear stress in a 24 hour 
period[11].  Additionally, Sarraf and colleagues presented a bioreactor design capable of 
exposing combinations of shear and strain, and their results suggest a tendency to align 
more with strain than flow[12].  As shown in Chapter 6, aortic valve endothelial cells 
aligned perpendicular to flow when cultured on top of somewhat circumferentially aligned 
valvular interstitial cells in a three dimensional collagen matrix.  The valvular endothelial 
cell alignment in both cases was under the action of shear, without any strain present.  It 
might be that endothelial cells respond to a portion of their mechanical environment (flow 
or strain) as if the entire environment (flow and strain) were present.  As was reported in 
Chapter 4, valvular endothelial cells lose the ability to align to flow in later passages, 
suggesting that this may be a phenotypic function that can be lost with serial in vitro 
passaging.  Data supporting the notion of a “memory” of in vivo mechanical environment 
does not exist currently.  To truly investigate this hypothesis, experiments exposing both 
valvular and vascular endothelial cell responses to combinations of strain and shear 







Aortic Wall Valve Leaflet
Figure 7-1:  Schematic detailing the tissue strains and fluid shear 
stresses on aortic valve leaflets and aortas.  
cells orient with the direction of mechanically aligned matrix and smooth muscle cells in 
static culture, but parallel to the direction of flow under shear regardless of initial 
orientation[7].  Due to the slight matrix effect observed in Chapter 6, it would be 
interesting to see if valvular endothelial cells continue to align perpendicular to flow while 
co-cultured on top of an oppositely (longitudinally) aligned matrix. 
 The more important question however is: what is the purpose for valvular 
endothelial mechanotransduction?  There is evidence that aortic valve leaflet tissue 
exhibits some contractile responses to vasoactive agents, but any evidence of a 
vasoactive response of leaflets in vivo has yet to be reported[13].  If it is found to exist, 
the source of these agents must somehow be the valvular endothelial cells.  In Chapter 
5, the genetic profile of valvular endothelial cells in response to steady laminar shear 
stress was determined in the “group 1” microarray studies.  A list of vasoactive agents 
significantly regulated by shear in valvular endothelial cells is given in Table 7-2.  The 
presence of regulated vasoactive genes suggests that some leaflet vasoactivity may  
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Table 7-2: Genes coding for vasoactive agents that are sensitive to shear stress as 
determined by microarray analysis. 
 
Gene Regulation Magnitude P value 
Nitric oxide Up 1.18+/-0.22 0.0475 
Endothelin receptor B Down 1.16 +/- 0.15 0.0019 
Angiotensin I converting enzyme Up 1.74 +/- 0.34 0.0031 
Angiotensin II receptor Down 1.10 +/- 0.07 0.0131 
Angiotensinase C Down 1.19 +/- 0.10 0.0447 
Angiotensin protease inhibitor Down 1.26 +/- 0.11 0.0018 
Somatostatin Up 1.38 +/- 0.11 0.00004 
occur, although more experiments are needed to investigate these responses.  
Interestingly, the somatostatin gene is upregulated in response to flow in aortic valve 
endothelial cells (1.38, P<0.001), but downregulated in aortic endothelial cells (3.24,  
P<0.001).  In addition to vasoactive properties, somatostatin is an important regulator of 
angiogenesis[14].  The precise role of each of these agents in aortic valve biology is  
unclear, and without additional experiments speculation would be premature.  It is 
certainly an interesting possibility. 
 
 Physiological vs. Pathological Valvular Cell Function.  The existence of 
physiological and pathological phenotypes of cells is well known in vascular biology.  
Normal healthy vessels are characterized by a quiescent endothelial monolayer on top 
of a lamellar sequence of smooth muscle cells and elastic fibers.  In a disease state 
such as in atherosclerosis, endothelial cells become activated by expressing receptors 
that recruit circulating monocytes, which adhere and migrate through the vessel surface 
into the underlying intima.  The inflammatory mediators released by these cells and the 
endothelial cells induce smooth muscle proliferation, migration, and matrix synthesis, 
eventually forming the signature “atherosclerotic plaque” on the vessel[15, 16].  It has 
been shown that some form of atherosclerotic plaque is present on the leaflets of 
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diseased aortic valves, suggesting that there may be a similar pathogenesis in valvular 
endothelial – interstitial cell interactions[17].  Atherosclerotic progression in aortic valve 
leaflets in vivo is associated with the presence of inflammatory mediators, systemic 
endothelial dysfunction, and intra leaflet angiogenesis [18].  It is likely therefore that 
similar physiological and pathological phenotypes of valvular endothelial cells and 
interstitial cells exist.   
 The results from Chapters 2 through 6 suggest some possible aspects of these 
roles, which are listed in Table 7-3.  Shear conditioned endothelial cell monolayers 
provided a picture of a physiological phenotype, while statically cultured cells a 
pathological phenotype.  As shown in Chapter 4, sheared valvular endothelial cells 
maintain a contact inhibited monolayer, but change morphology to align perpendicular to 
the flow direction. It is clear from Chapter 5 that valvular endothelial cells respond to 
shear stress with changes in a large number of genes, a portion of which code for pro 
and anti-inflammatory genes.  Aortic valve endothelial cells in shear appear to  




Table 7-3: Potential similarities and differences between aortic and aortic 
valve endothelial cells 
Aortic vs. Aortic Valve Endothelial Cells 
Similarities 
Maintain non-thrombogenic barrier 
Transmit nutrients and signals to underlying cells 





Regulation of underlying cells 
Bacterial adhesion properties 
Calcification pathways (?) 
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examples of which are given in Table 7-4.   
 Additionally, both vascular and valvular endothelial cells may be important 
mediators of calcification.  Both valvular and vascular endothelial cells downregulate 
BMP-4, a known osteogenic protein, in response to shear stress, as previously 
discussed in Chapter 5.  Calcification is a major issue with biological and prosthetic heart 
Table 7-4: Genes coding for inflammatory regulating proteins in valvular endothelial 
cells that are sensitive to shear stress as determined by microarray analysis.  
valves, as discussed previously, and also affects the vasculature.  Two genes with 
osteogenic properties were also differentially regulated between the two cell types, as 
shown in Table 7-5.  It is interesting to note that one gene (OSF-2) is almost exclusively 
present in the vascular EC, while the other (OB-Cad) was exclusively present in the 
valvular endothelium.  The fact that these genes are downregulated in response to flow 
suggests a calcification-protective endothelial phenotype.  Data linking these genes to 
vascular and/or valvular calcification does not currently exist, but the microarray results 
indicate the intriguing possibility.   
Gene Regulation Magnitude P value 
Interleukin 7 Down 1.27 +/- 0.16 0.0103 
Interleukin 13 Down 1.47 +/- 0.26 0.0036 
Interleukin 18 Down 1.36 +/- 0.09 0.0118 
Prostacyclin synthase Up 1.26 +/- 0.07 0.0007 
Leukocyte Cell Adhesion Molecule Down 1.48 +/- 0.30 0.0015 
    





Table 7-5: Genes coding for bone regulating proteins in endothelial cells that are
sensitive to flow. Gene 
Difference in expression 
between cell types in 
static culture 
Regulation under flow in 
higher expressed cell 
type 
OSF-2 (fasciclin) 444 fold higher in aorta Down 3.13 +/- 1.52 
adherin 11 (OB Cadherin) 113 fold higher in valve Down 1.67 +/- 0.13 
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 In Chapter 3, it was determined that aortic valve interstitial cells have increased 
α-smooth muscle actin in two dimensional culture in comparison to the more 
physiological three dimensional culture.  Probably the best examples of phenotypic and 
pathological phenotypes are the two three dimensional culture models in Chapter 6.  
Here it is shown that aortic valve endothelial cells and interstitial cells act synergistically 
with steady shear stress to present a physiological tissue.  Interstitial cell only constructs 
lack the endothelial mediated factors to maintain a physiological phenotype, thus 
presenting a more pathological phenotype.  It was also interesting to note that non-
endothelial seeded constructs had virtually change in response to flow as determined by 
the tests in Chapter 6, possibly suggesting an inability of interstitial cells to respond to 
this mechanical stimulus.  Physiological valvular endothelial – interstitial cell interactions 
involve (1) maintenance of interstitial cell number under flow, (2) quiescent interstitial cell 
phenotype exhibited by decreased a-smooth muscle actin expression (except maybe 
immediately near the flow surface), (3) active protein synthesis, and (4) maintenance of 
glycosaminoglycans.  Pathological conditions would be the opposite of these.  These 
observations have been confirmed in part from research by others.  Schneider and Deck 
showed that native leaflet cells actively produce proteins and glycosaminoglycans in 
vivo, and further suggested that these properties may be related to the local mechanical 
environments[19].  Pathological interstitial cells have also been shown to express 
catabolic enzymes and proteases that degrade matrix proteins, and become activated in 
terms of increased α-smooth muscle cell actin expression[20].   
 The differences in physiological and pathological valvular and vascular cell 
phenotype suggest a potential fundamental limitation in the use of vascular cells in 
repopulating tissue engineered heart valve substitutes.  Rabkin and colleagues 
demonstrated that vascular cells resembled a physiological interstitial cell phenotype 
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after 20 weeks in the ovine pulmonary circulation in terms of cell phenotype and matrix 
synthesis[21].  One question not addressed by these researchers was whether the donor 
cells persisted through the 20 weeks, or if they were replaced by invading host cells, in 
which case they may in fact be interstitial cells.  What this study does say, however, is 
that mechanical forces are very potent regulators of cell phenotype. 
 All heart valves are additionally susceptible to specific bacterial infections and 
genetic anomalies as detailed in Chapter 1, and it is as yet unclear how the phenotypes 
of cells from different valves vary.  The pulmonary and aortic valves appear to be similar 
in terms of morphology, with the exception of the coronary ostia emanating from the 
aortic sinuses, and pulmonary autografts appear to function normally with the potential 
for growth in the aortic position[22].  The mitral and tricuspid valves are morphologically 
different from these two, however, and are exposed to different regimes of tissue 
stresses and fluid flows.  The pulmonary and aortic valves both arise from the same 
series of endocardial cushions during development[23], in contrast to the atrio-
ventricular valves[24], suggesting that these pairs of valves may share similar 
phenotypic traits.  So far, only one study has assessed any differences between the cells 
from the four valves.  Taylor and colleagues showed that valvular interstitial cells 
exhibited a more similar cytoskeletal profile to themselves than other cell sources, but 
that there were some differences between valves[25].  Functional differences between 
these cells and their consequences will undoubtedly be ascertained by future studies.  
   
7.3: Aortic Valve Tissue Engineering 
 
 The limited success of tissue engineered heart valves to date may reflect a 
consideration of only a few of the many possible requirements of a functional living aortic 
valve replacement.  These studies were primarily concerned with mechanical integrity 
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and matrix synthesis using vascular endothelial cells, and potential cellular functions 
may have been lost with their “the best available” cell source decisions.  As previously 
discussed, the possibility of using isolated mature autologous valvular cells is probably 
severely limited, unless somehow healthy cells could be obtained and cultured from the 
damaged valve without compromising the limited function it still possesses prior to 
replacement.  Nevertheless, because of the extremely limited understanding of valvular 
cell biology and valve physiology, many questions need to be addressed before this field 
can progress.  The next few paragraphs address what is known and what needs to be 
known about valve biology for the purposes of tissue engineering. 
 Cellular Response to Mechanical Signals.  The mechanical data presented in 
Chapter 1 indicated that valve leaflets are highly viscoelastic structures, whose cells 
must thrive under a variety of mechanical forces.  Christie et al determined physiological 
stresses on the order of 400 kPa in peak systole, but the mechanical properties of the 
valve leaflet can withstand much higher stresses[26].  The tissue microstructure is such 
that it exhibits an elastic phase at low modulus, followed by an inelastic phase with a 
much stiffer modulus.  Therefore valve leaflets are specifically designed to be very 
pliable at physiological stresses, but strongly resist increased distension under increased 
load.  This is useful for creep resistance.  Weston and Yoganathan determined that local 
shear stresses near the ventricularis are almost 80 dynes/cm2[27], much higher than any 
vascular shear forces, and yet a confluent functional endothelium is present on the 
leaflet at all times.  What is needed, therefore, is an understanding of how valvular cells 
respond to mechanical forces in a manner that enables them to thrive in this 
environment.  What are the particular biological responses of valvular endothelial and 
interstitial cells to single defined mechanical stimuli?  What are the individual effects of 
uniaxial strain, biaxial strain, pulsatile shear stress, and flexure on aortic valve interstitial 
and endothelial cell biology?  Are there differences when the cells are placed in co-
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culture?  What are the contributing effects of three dimensional matrix?  It is likely that 
different mechanical forces have different biological effects on valvular cells.  Unlike 
blood vessels, however, it seems impossible to develop a device that can expose a 
tissue engineered aortic valve (with annulus or root) to these modes independently.  It 
does appear possible for leaflets, but the clinical utility of a tissue engineered leaflet may 
be limited due to the surgical expertise required for its successful implantation.    
 Interfacial Dynamics of Aortic Wall and Leaflet.  The aortic valve works in 
close cooperation with the aortic annulus and root sinuses in normal valve function.  The 
mechanisms for the development of these unique structures are not known, but their 
functions have been well documented.  Tissue engineered heart valves will need to 
address the accommodation of the native annulus and root, or strategies to mimic these 
in their designs.  In order to do this, an understanding of the specific phenotypes that 
populate the sinus, sinotubular junction, and attachment regions also needs to be 
developed.  It is likely that specific cell types regulate these areas as evidenced by the 
differences in tissue contraction in response to vasoactive agents.  The aforementioned 
mechanical properties and cellular responses may also be different within these tissue 
regions.  Apparent vasoactivity adds another level of phenotypic function that needs to 
be mimicked long term in a tissue engineered valvular root, but maybe just 
accommodated in valve leaflets.     
 Host Cellular Invasion and Remodeling.  It was unclear whether the cells 
populating the engineered tissue valves in the study by Rabkin and colleagues were 
from the host sheep or donor sheep.  Shinoka and colleagues demonstrated that 
autologous cells performed superior to allogeneic cells in a leaflet replacement model, 
suggesting that host response plays a strong role[28].  It is unclear how this could be 
monitored in autologous cell transfers, but Ball and colleagues successfully monitored 
allogeneic donor and host cell engraftment by using female (X chromosome) hosts and 
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Y chromosome donor cells[29].  These results suggest that some signaling exists 
between the donor and recipient tissue that encourages cell ingrowth.  Some studies 
suggest that allogeneic stem cells are less immunogenic than other allogeneic cells[30].  
Perhaps with these cells one can determine which cell source ultimately remains in 
implanted engineered valvular tissue without the risk of early failure.    
 Control of Tissue Remodeling.  The Hoerstrup study showed that while 
engineered leaflets exhibited good mechanical properties and cellularity, the leaflets did 
not coapt properly due to leaflet shrinkage[31].  This leaflet shrinkage may be due to 
uncontrolled matrix compaction by the vascular cells.  Matrix compaction is one of the 
characteristic responses when cells are embedded in engineered tissue, as evidenced 
by the models created in Chapters 3 and 6.  In Chapter 3, valvular interstitial cells and 
smooth muscle cells compacted the tissue to a fixed cell density level.  It is possible that 
this cell density is the maximum supported by engineered tissue in the contexts explored 
in the studies in this work.  It is unclear from the Hoerstrup and Rabkin studies whether 
the engineered valves maintained any steady cell density, or if their constructs 
compacted continuously.  It is therefore of critical importance to understand the matrix 
compaction process and how it is controlled by cells to ensure that the design of initial 
tissue dimensions are adequate.  In this way, the cells will remodel the valve according 
to their own needs, but the resulting tissue will be of the right annular size with 
appropriately coapting leaflets.  
 Immune Competency.  Finally, one critical issue that is particularly important for 
valvular tissue engineering is immunological competency.  All tissue engineering utilizing 
allogeneic cell sources must necessarily find a way to overcome the host immune 
response.  The fact that valvular tissues are particularly susceptible to bacterial infection 
makes this issue more critical.  Even prosthetic valves suffer from bacterial adhesion 
and growth, and the invisibility of these implants to the patient’s immune system makes 
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these infections much harder to treat.  Traditional pharmacological immune suppression, 
although successful, carries many long term side effects that reduce patient quality of 
life.  The ideal tissue engineered valvular substitute would therefore need to 
accommodate an active immune presence without rejection.  This may be achievable 
through the design of substrates to encourage host cell ingrowth, so that the final 
product is devoid of allogeneic cells.  This has been achieved in other applications 
through the use of processed extracellular matrices, which retain growth factors and 
matrix signals necessary for cellular recruitment[32, 33].  It is not yet known how these 
substances would perform in the dynamic mechanical environment of the aortic valve. 
 To be sure, these issues are really just a start, and more data will surely bring 
more questions.  What is clear is that this area of biology is vastly understudied, and its 
functional roles are only beginning to be appreciated.   
 
7.4: Aortic Valve Development – a Window to the Future? 
 
 One final thought about heart valve tissue engineering, and this is that the human 
body has been engineering heart valves out of essentially nothing since the beginning of 
mankind.  The development of the aortic valve and cardiac outflow tract is a complex, 
highly regulated process that occurs in a remarkably short amount of time.  The 
embryonic heart begins as several primitive endocardial tubes that fuse together and 
form a primitive single atrium and ventricle[34].  Soon after the heart tube folds upon 
itself, the cardiac jelly is infiltrated with differentiating mesenchymal and neural crest 
cells, forming cushions[35], which in turn mature into valves[23, 36, 37].  The process of 
cushion tissue maturation is almost completely unknown.  The use of animal models, 
such as the zebrafish[23, 38], chick[39-41], and mouse[42-44] has greatly contributed to 
the understanding of cardiac development, and provide the only means of studying 
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these complex events in real time.  Many experiments using these models have 
identified genes whose expression is critical to heart valve development, but most of 
these studies involve knockout models which develop defects or complete absences of 
valves that are usually not mimicked in humans.  One stimulus that has only recently 
been investigated is mechanical force.  It is known that the cardiac tube can loop while 
cultured in vitro, and at this stage in development it maintains some circulation[45].  
Hove et al. have shown that complete obstruction of blood flow within the developing 
cardiac tube in zebrafish caused complete cessation of tube developing, including 
appropriate looping and valve formation[46].  Hogers et al. ligated vitelline veins in 
developing chick embryos, and were able to repeatedly cause a range of cardiac 
defects, many seen in the clinic[47].  These ligations altered the flow patterns through 
the heart, and specific patterns were related to an increased proportion of certain cardiac 
defects.  While demonstrating an association between fluid flow patterns and valvular 
development, the exact mechanisms are still unclear.  The progression from gelatinous 
acellular matrix to endocardial invasion to mesenchymal differentiation to matrix 
maturation appears to present a perfect model for tissue engineering.  What is needed 
before this strategy can be mimicked in vitro is an understanding of how this process 
occurs in vivo.  Specifically, what are the stimulating factors that contribute to this 
process?  It is likely that mechanical environment plays a very prominent role.  How is 
the matrix composition modified by the cells during development?  Bioreactor schemes 
currently take developmental pressures and flow rates into consideration in stimulating 
tissue engineered heart valves in vitro, but the initial substrate is nothing like the 
substrate appearing in vivo.  It is also possible that extracellular matrix components play 
a large role in cell differentiation.  
 In summary, the study of the specific roles of mechanical forces and extracellular 
matrix cues on valvular cells in both development and in adult animals can lead to the 
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development of an effective protocol for the generation of a clinically applicable tissue 
engineered heart valve, capable of growing and remodeling into the patient’s own 
cardiovascular system.  In the short term, the use of tissue engineering models of 
mature valvular leaflets in experiments can lead to a better understanding of the 
mechanistic roles of mechanical environment and extracellular matrix in physiological 
and pathological valvular biology.  This can lead to the development of targeted 
therapeutic strategies that can heal the valve before disease progresses to the point of 
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 Aortic valve disease (AVD) is a serious clinical problem that affects the entire 
globe.  The etiologies of AVD are different between the developed and underdeveloped 
world, and different research strategies will need to be pursued to meet these needs.  
Tissue engineering can provide an ideal solution for living heart valve replacement, 
including the possibilities for growth and remodeling.  Tissue engineering can also be 
used to develop effective models for in vitro study of valvular biology and the effects of 
biochemical and mechanical signals on valvular cell response.  A more developed 
understanding of valvular cell interactions in physiological conditions will help develop 
targeted diagnostic and therapeutic strategies that may alleviate valvular cell dysfunction 
before it progresses to tissue failure, potentially removing the need for valvular 
replacement entirely. 
 Pure populations of aortic valve endothelial and interstitial cells were isolated 
using the protocols developed in Chapter 2.  Theoretically, these protocols can be 
applied to isolate cells from other valves, but it has yet to be tried.  The cells of the mitral 
and pulmonary valves might be of particular interest to study: the mitral valve because of 
its unique morphology and function, and the pulmonary valve because of its 
morphological similarity to the aortic valve and ability to function well in the left heart.  
Ultimately, these protocols were dependent on large samples of tissue for isolation of 
adequate numbers of valvular endothelial cells.  More powerful studies using cells from 
genetically modified animals, such as mice, will require different techniques to achieve 
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this.  In the future, a more uniformly applicable, less labor intensive protocol should be 
pursued.  Fluorescence Activated Cell Sorting (FACS) was attempted early on in this 
work to achieve this, but it was difficult to maintain cell viability and sterility during the 
sorting process.  One potential technique to be used would be magnetic sorting using 
beads coated with endothelial specific surface markers.  PECAM (CD31) is present in 
valvular endothelial cells, and may serve as a useful marker.   
 In Chapter 3 it was shown that aortic valve interstitial cells were similar to aortic 
smooth muscle cells in terms of contractile properties, but synthesized matrix molecules 
differently while in three dimensional cultures.  The tissue model used in these 
experiments was a stress free type I collagen disk.  Three important components not 
addressed by these studies were the effects of mechanical forces, biochemical signals, 
and different extracellular matrix molecules, all of which are strongly present in vivo.  It is 
likely that additional differences will be observed between valvular and vascular cells in 
these environments. 
 In Chapter 4 it was shown that valvular endothelial cells align perpendicular to 
flow, which was dependent on focal adhesion and cytoskeletal rearrangement.  The fact 
that PI 3-kinase was differentially involved in the regulation of the morphological 
response was intriguing, but this was only demonstrated through a cursory experiment.  
Additional work using genetically modified cells or gene knockdown through siRNA 
technology, followed by restoration of function, would be appropriate to confirm this 
response difference.  If true, the differences in these cells would provide excellent 
models to study endothelial mechanotransduction.  One could also investigate the 
response of endothelial cells from other heart valves to compare their alignment 
response.  An additional question that needs to be addressed is the effects of flow on 
the endothelial cells from different sides of the leaflet.  Each side of the leaflet 
experiences different shear forces, and the endothelial cells from each side may respond 
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differently.  Furthermore, the steady laminar shear used in this model is only an 
approximation of the mean shear force, and does not model the complex pulsatile flow 
the leaflet experiences.  More accurate flow regimes might show additional differences 
between these cells, including altered mechanotransduction. 
 In Chapter 5, microarray analysis determined hundreds of genes that were 
differentially expressed between valvular and vascular endothelial cells in static and fluid 
flow environments.  These genes code for many different proteins, suggesting several 
functional differences between these two cell types.  The results from this chapter can 
be taken in literally hundreds of directions, but careful consideration of each level of 
genomic profiling presented in this work is critical to prevent meandering down the 
wrong path.  Genomic data mining software, like GOMiner, can provide an excellent 
understanding of the connections between genes.  It is also critical to confirm the 
expression of genes of interest using other techniques, preferably at the gene and 
protein level, before conducting additional experiments.  A particularly interesting set of 
genes to investigate would be fasciclin (OSF-2) and cadherin II (Cad11).  These genes 
were differentially expressed over 100 fold in static culture, and shown to be differentially 
regulated under flow.  While these huge expression differences could be purely artificial, 
if proven true they may be a window to understanding differences between vascular and 
valvular calcification, and how these processes are regulated by endothelial cells.   
 In Chapter 6 two models were presented for the study of valvular cell biology: a 
physiological model with both endothelial and interstitial cells in three dimensional co-
culture, and a pathological model without endothelial cells.  These models were exposed 
to steady laminar shear stress, with static cultures serving as controls, and a profile of 
potentially physiological and pathological responses were developed.  Future 
experiments would involve the investigation of pulsatile flow on these models initially, 
followed by other mechanical modes, such as tissue strain and flexure.  The synergistic 
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effects of strain and fluid flow could also be investigated.  New bioreactor systems will 
ultimately need to be developed to apply these forces in an independently controlled 
manner.  Like the tissue models in these studies, it may not be necessary to replicate 
exact leaflet geometries, but rather just have a three dimensional biological matrix that 
can accommodate close contacts between these cells. 
 In summary, many more questions were raised then answered by these studies, 
but the field of valvular biology is ripe for investigation.  The clinical need is surely 
present, and with additional research, hopefully can be addressed in the future. 
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APPENDIX A: RELEVANT PROTOCOLS 
 
 






Antibiotic-Antimycotic Solution    Tissue Culture Rm  Fridge 
 GibcoBRL, Cat. No. 15240-062 
Dulbeccos Phosphate Buffered Saline (DPBS)  Tissue Culture Rm  Fridge 
 Gibco, Cat. No. 14190-144, no Ca or Mg 
Glucose       Laboratory Rm  Shelf 
 SIGMA, Cat. No. G 7021, 95% α, 5% β anomer 
Trypsin-EDTA:      Tissue Culture Rm  Freezr  
Gibco, Cat. No. 25300-054, 0.05% Trypsin, 0.53 mM EDTA 
Collagenase CLS2:      Protein Rm  Fridge 
 Worthington, Cat. No. 4176, ~300 U/mg  
Dulbecco’s Modified Eagle Medium (DMEM) (500mL) Tissue Culture Rm  Fridge  




Porcine Medium (See PJTB002):     Tissue Culture Rm  Fridge 
• Dulbecco’s Modified Eagle Medium (DMEM) (500mL)  
Gibco, Cat. No. 11965-092 
• 1% L-Glutamine added      
Mediatech Cellgro, Cat. No. 25-005-C1 
• 1% HyQ Penicillin added      




Cooler for organ transport 




• Surgical tray(s) 
• Petri dishes precoated with paraffin 
• Surgical needles 
• Swabs 




Preparation of the Tissue Solution – PBS w/ 5x Antibiotic-Antimycotic (527.5 mL) 
 
1. Add 27.5 mL of Antibiotic – Antimycotic solution to 500 mL of DPBS. 
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2. Filter to sterilize. 
 
Preparation of the Collagenase Solution 
 
1. Dissolve 1 mg/mL collagenase solution in DMEM without FBS (base medium). 
2. Prepare 10 mL solution per valve exised. 




Isolation of Heart Valve Leaflets  
 
1. Excise heart with aorta intact aseptically from the animal as soon as possible after 
death. 
2. Thoroughly rinse in cold DPBS, and place in a plastic bag with enough ice cold 
DPBS to submerge the tissue.  Place the bag in the cooler and fill with ice.  
Transport back to the lab. 
3. Upon arrival at the laboratory, place the container with the porcine heart under the 
sterile hood. 
4. Take the heart out of the bag and quickly cut away the aorta and the lower third of 
the ventricles until the leaflets are exposed.  Cut the leaflets about 20 percent of the 
length of the leaflet away from the attachment region, as that area can posess some 
smooth muscle cells and vascularity.  Keep the tissue hydrated throughout this 
process using cold Tissue Solution when necessary. 
5. Place the leaflets in a sterile 15 mL centrifuge tube with cold Tissue Solution.  Use 
one tube per valve.  Let incubate at room temperature for 15 minutes.  
 
Isolation of Endothelial Layer 
 
1. Fill 3 15 mL centrifuge tubes per valve with complete Porcine Medium. 
2. Remove the tissue from the tubes, and place on a sterile (UV light) dish that has 
been previously coated with congealed paraffin beads to provide a surface for pin 
attachment.  
3. Gently lay the tissue concave downwards (ventricular side upwards) on the paraffin 
surface.  Pin the edges of the leaflet to expose the endothelial layer.  All of the 
leaflets from a valve can be placed in the same dish and pooled together.  
4. Place a few drops of cold collagenase on each upwards-facing endothelial surface.  
Incubate the tissue for 10 minutes at 37 C. 
5. Gently swab the endothelial layer by rotating the dry, sterile swab as the endothelial 
surface is scraped.  Place swab into one of the centrifuge tubes and gently rotate to 
dislodge cells.  Dab the swab several times in the collagenase to dislodge cells from 
the fibers.  Repeat this procedure two more times with fresh swabs each time.   
6. Collect the collagenase/cell suspension for each valve into a separate tube. 
7. Centrifuge the tubes at 1000 rpm for 10 minutes to pellet any isolated cells.  Aspirate 
supernatant.   
8. If isolating interstitial cells as well, perform that protocol while cells are centrifuged. 
9. Add 3 mL Porcine Medium to the tubes and centrifuge again.  Aspirate supernatant. 
10. Add 5 mL Porcine Medium to the centrifuge tubes and plate the cells in a T-25 flask.  
Use 1 flask per centrifuge tube. 
11. Culture as normal. 
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Isolation of Interstitial Cells 
 
1. Fill 1 15 mL centrifuge tube with 10 mL collagenase solution per valve exised.  
Complete this step before isolating endothelial cells if that portion of the protocol is 
being followed. 
2. After swabbing the leaflets, immediately place them in the appropriate tube with the 
collagenase solution. 
3. Incubate for an appropriate amount of time (12 to 18 hours).  Agitate gently if 
desired. 
4. Centrifuge the digested tissue fragments and cells for 5 minutes at 1000 rpm, and 
aspirate the supernatant. 
5. Centrifuge the tubes at 1000 rpm for 10 minutes.  Aspirate supernatant. 
6. Add 5 mL of Porcine Medium and again centrifuge tubes.  Aspirate supernatant. 
7. Resuspend pellet in one tube with 5 mL of Porcine Medium and add to a T-175 filled 
with 35 mL Porcine Media. 




• Do not mix leaflets of different valves. 
• Aortic root with leaflets can be isolated directly at the slaughterhouse 
• Inspect endothelial cell cultures for endothelial and other developing morphology.  If 
other cell types develop, trypsinize the cells, centrifuge them at 1000 rpm for 10 
minutes, plate them back down, but change the Medium after 1 hour (can be 
modified based on results).  Endothelial cells tend to adhere quicker than other cell 
types. 
• Endothelial cells can also be enriched from contaminating cells using magnetic 
sorting with PECAM (CD31) antibody. 
 
 201




Dulbecco’s Modified Eagle Medium (DMEM) (500 ml) Tissue Culture Rm  Fridge 
Gibco, Cat. No. 11965-092 
L-Glutamine (L-Glut) (100 ml)    Tissue Culture Rm  Freezr 
Mediatech Cellgro, Cat. No. 25-005-C1 
HyQ Penicillin (PS) (100 ml)     Tissue Culture Rm  
Freezer 
Mediatech Cellgro, Cat. No.  SV30010 
Fetal Bovine Serum (FBS) Heat inactivated (500 ml) Tissue Culture Rm  Freezr 
  Mediatech Cellgro, Cat. No. 35-011-CV 
Sterile Tissue Culture Water (500 ml)   Tissue Culture Rm  Shelf 
 Sigma, Cat. No. W3500 
Collagen, Type 1 (Coll I) (100 mg)    Tissue Culture Rm  Fridge 
  BD Biosciences, Cat. No. 354236  
Trypsin-EDTA (100 ml):     Tissue Culture Rm  Fridge  





Tissue Culture Dishes/Flasks 




Porcine Aortic Endothelial Cells (PAEC) (1 vial)   Liquid Nitrogen Tank 
Porcine Aortic Smooth Muscle Cells (PASMC) (1 vial)   Liquid Nitrogen Tank 
Porcine Aortic Valve Endothelial Cells (PAVEC) (1 vial)   Liquid Nitrogen Tank 






Aliquot of Media materials: 
1. Defrost stock solutions of L-Glut, PS, and FBS 
2. Divide L-Glut into 10 ml aliquots. 
3. Divide PS into 10 ml aliquots (can combine with L-Glut if you want). 
4. Divide FBS into 100 ml aliquots (usually done for you). 
5. Make more aliquots if enough solution exists for more complete aliquots.  
6. Place aliquots in the freezer and store at -20 C. 
 
Dilution of Collagen I for growth substrate 
1. Each bottle has a different concentration of collagen in mg/ml. 
2. Make 150 ml of 50 µg/ml collagen I in Sterile Water. 
 
Preparation of the Porcine Cell Media (1120 ml): 
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1. Place aliquot of L-Glut, PS, FBS, and two bottles of DMEM in the warm water bath 
(37 C) until they have completely thawed and/or warmed. 
2. Place 1000 ml sterile filter and all reagents in the sterile hood. 
3. Activate the filter by attaching the aspirating tube and turning on the vacuum pump. 
4. Pour all the reagents through the sterile filter.   
5. Remove the filter, cap the bottle, and label it. 
 
Coating of Cell Culture Surface (PAVEC only) 
1. Add just enough of the diluted Coll I to completely coat cell culture surface (1-2 ml/ 
25 cm2) 
2. Incubate at 37 C for 1 hour. 
3. Aspirate excess Coll I from dishes. 
 
Defrosting of Cells: 
1. Place the Pre-Prepared Media in the warm water bath until warmed (if needed). 
2. Place the desired number of flasks into the sterile hood (usually indicated on the 
cryovial). 
3. Add 5 ml of media/ 25 cm2 surface area to each flask.  
4. Remove the cryovials containing the appropriate cells from the Liquid Nitrogen Tank. 
5. Quickly thaw the vials as quickly as possible by swirling the vials around in the bath 
while they are completely submerged.  Remove when only a small amount of ice left 
in the vial(s).  The rest will thaw in your hand. 
6. Place an appropriate amount of cell suspension into the designated culture dishes. 
7. Properly label each flask. 




Cells should be fed 24 hours after thawing or isolating, and then every 48 hours 
 
1. Inspect flasks for adherent cells, and any contamination. 
2. Place flasks with cells under sterile hood. 
3. Aspirate out the old media from the opposite wall to which the cells are adhered. 
4. Add 1 ml of the appropriate culture media for every 5 cm2 of cell culture surface. 
5. Place flasks back in incubator. 
 
Splitting of Cells 1:3 according to cell culture surface area: 
 
9. Place the Porcine Medium and the T-EDTA Solution in the warm water (37 C) bath 
until the reagents have completely thawed and warmed. 
10. Place the dishes/flasks containing cells under the sterile hood. 
11. Aspirate the current media from the opposite wall to which the cells are adhered. 
12. Add 1 ml of the T-EDTA Solution for each 25 cm2 of culture surface area to the 
dishes/flasks.  
13. Place cells in the incubator for 3 to 5 minutes. 
14. View the cells under a microscope to ensure they have released from the flask wall.  
If the cells have not released from the wall, lightly tap the side of the dish/flask. 
15. Add 3 ml of Porcine Medium for each 25 cm2 of culture surface area to neutralize the 
Trypsin. 
16. Rince any adherent cells off the wall of the flask by drawing in and expelling the 
media from the pipette.  Don’t take too long though. 
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17. Place the cell suspension in the appropriate centrifuge tube and spin for 5 minutes at 
1000 rpm. 
18. While the cells are spinning add 5 ml of the appropriate media per 25 cm2 of culture 
surface area. 
19. Aspirate the supernatant and resuspend the pellet in a small amount of media (1 ml 
per flask). 
20. Divide this cell suspension and plate evenly onto 3 times the original culture surface 
area. 
21. Close and properly label each flask/dish before placing them in the incubator. 





• DMEM is a standard medium for animal cell culture, the exact constituents can be 
found by consulting Gibco. 
• L-Glutamine is a protein that provides a major energy source to the cells.  It 
degrades rapidly, so the medium is supplemented with it to ensure growth. 
• Penicillin and streptomycin are anti-bacterial agents. 
• The molar ratios within the Porcine Medium are not exact, but it has been the 
standard way of making the medium at the lab. 
• Diluting collagen in sterile water maintains the acidic pH to prevent precipitation. 
• Trypsin is an enzyme that cleaves cell adhesion moecules.  Prolonged exposure to 
the enzyme could disrupt normal cell function. 
• EDTA removes calcium, thereby disrupting cell adhesion. 
• Don’t try to split too many flasks at once.  The Trypsin will kill cells if not neutralized 
after a short amount of time. 
• PAVEC culture medium can be supplemented with 50 U/ml of heparin (Sigma) to 
help mitigate the contamination of the culture by interstitial cells. 
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Dimethyl Sulfoxide (DMSO)     Laboratory Rm  Shelf 
 J. T. Baker, Cat. No. 9224-01 (500 ml) 
Fetal Bovine Serum (FBS) Heat inactivated   Tissue Culture Rm  Freezr 




Porcine Medium SERUM FREE (See PJTB001):   Tissue Culture Rm  Fridge 
• Dulpecco’s Modified Eagle Medium (DMEM) 
Gibco, Cat. No. 11965-092 
• 1% L-Glutamine added     
Mediatech Cellgro, Cat. No. 25-005-C1 
• 1% HyQ Penicillin added      















1. Thaw one (of the aliquotted) bottle of FBS, and divide it into 10 ml aliquots. 
2. Label and freeze for later use. 
 
Creation of the Cryopreservation Medium 
 
1. Make sure all reagents are sterile. 
2. Do not warm reagents, merely thaw them.  Do not place DMSO in refrigerator, it will 
freeze. 
3. Cryopreservation medium is Serum Free DMEM (50%), FBS (40%), and 10% 
DMSO. 
4. Combine the DMEM and FBS in a sterile tube.  Make enough medium for 1.5 ml 
(total, including DMSO) per cryovial.  The DMSO will be added later. 
 
Freezing the Cells 
 
 
1. Trypsinize (PJTB001) the cells to be stored.   
 205
2. Properly label the contents of the appropriate number of cryovials to be used, and 
place them under the sterile hood. 
3. Place the cell solution in the centrifuge, and balance it with an equal amount of water 
in an identical tube on the opposite side of the centrifuge. 
4. Run the centrifuge at 1000 rpm for 5 minutes. 
5. Aspirate the supernatant, being careful not to disturb the pellet, leaving about 100µL 
remaining. 
6. Close the tube, and flick the bottom of the tube to dislodge the pellet. 
7. Add the DMEM/FBS solution to the cell pellet, and bring the cells into suspension.  
Make sure there are no pieces of cell pellet remaining.  
8. SLOWLY add the DMSO to the cell solution, swirling the suspension after every few 
drops. 
9. Place the 1.5 ml of cell solution into each cryovial. 
10. Place the cryovials into the freezer storage container, and place it in the –70 C 
freezer for at least 24 hours, but not more than 3 days. 
11. Remove the storage container from the freezer, and place the cryovials into 
appropriately labeled locations of the designated storage box in the nitrogen tank. 





• DMSO is an agent that inhibits ice crystal formation, but also permeablizes the cell 
membranes, which is cytotoxic. 
• Initial cell storage amounts were based on cell counting (1.5 million cells per 
cryovial), but subsequent storage was based on intended thawed culture.  Typically 
cells were trypsinized from one T-175 flask (for PAVICs) or 1 T-75 flask (for 
PAVECs) and split into three cryovials.  This was easier, more consistent, and 








1 Fluid Reservoir      Laboratory Rm  Shelf 
 Nalgene, Cat. No. DS2127-0250 
1 Filling/Venting Caps: tubing 1/4", caps 53B  Laboratory Rm  Shelf 
 Cole Parmer, Cat. No. UA-06258-10 
1 Pressure Dampener     Laboratory Rm  Shelf 
 Cole-Parmer, Cat. No. 07596-20 
1 Flow Chamber      Laboratory Rm  Shelf 
 Polycarbonate (In House Construction) 
8’ Silicone Tubing       Laboratory Rm  Shelf 
 ¼” O.D. 1/8” I.D. Cole-Parmer, Cat. No. 0641167   
8” “PharMed” (or Norprene) Tubing No. 16    Laboratory Rm  Shelf 
 Masterflex, Cat. No. 06485-16 
Assorted tube fittings.  Value Plastics, Inc.   Laboratory Rm  Shelf 
• 10 MTLL230-20 (A) 
• 4 SFTLL-20 (B) 
• 5 FTLL230-20 (C) 
• 1 FTLLC-6 (D)  
4” Plastic Tie Wraps      Laboratory Rm  Shelf 
  
Teflon Tape       Laboratory Rm  Shelf 
 
1 Flow loop (assembled with FTLLC-6)    Laboratory Rm  Shelf 
 See PJTB0005 
1 Assembled flow block      Laboratory Rm  Shelf 
 See PJTB0005 
1 Flow chamber top plate     Laboratory Rm  Shelf 
 Aluminum (In house construction) 
1 Flow chamber bottom plate     Laboratory Rm  Shelf 
 Aluminum (In house construction) 
1 Silicone rubber gasket       Laboratory Rm  Shelf 
 Stock material   
1 Spacer (thickness important)     Laboratory Rm  Shelf 
 Stock material 
Square non-treated tissue culture dish   Tissue Culture Rm  Shelf 
 
6 8-32 x 2” Standard head screws    Laboratory Rm  Shelf 
  
2 Long tweezers      Laboratory Rm  Shelf 
  
1 Standard glass slide      Laboratory Rm  Shelf 
 Corning, Cat. No. 2947 
2 Cell Scrapers       Tissue Culture Rm  Shelf 
 Fischer Scientific, Cat. No. 08-773-2 
1 Air Filter 





Porcine Medium (See JTB002):     Tissue Culture Rm  Fridge 
• Dulpecco’s Modified Eagle Medium (DMEM) (1000 ml)  
Gibco, Cat. No. 11965-092 
• 1% L-Glutamine added      
Mediatech Cellgro, Cat. No. 25-005-C1 
• 1% HyQ Penicillin added      
MediaTech Cellgro, Cat. No.  SV30010 









Collagen, Type 1 (Coll I) (50 µg/ml) (See PJTB002)  Tissue Culture Rm  Fridge 




Assemble Flow Block 
 
1. Tap the four holes in the flow block with a ¼-28 tap. 
2. Wrap the threads of the (B) fittings with teflon tape, and twist them into the tapped 
holes.  Be careful not to overtighten, they will break inside the holes. 
 
Assemble Pressure Dampener 
 
1. Use the components provided in the dampener box.  Wrap the long needle-head 
nozzle threads with teflon and screw them into the damper holes. 
2. Coat the outside of the nozzles close to the damper with silicone gasket (Pro Seal 
#80006).  Let dry overnight. 
 
Assemble Fluid Reservoir 
 
1. Cut the tubing attached to the reservoir lid into a 3” and a 1” length.  The 3” length 
will serve as the reservoir outflow port, and the other as the inflow. 
 
Cut and Assemble Tubing: 
 
23. Cut the Silicone tubing into 3 longer (24”) pieces, and 6 shorter (6”) pieces. 
24. Cut an 18” piece of the Norprene tubing.  
25. Using a previously constructed Flow Loop (Figure 1) as a guide, attach the 
appropriate fittings to the ends of the different lengths of tubing.  Seal the 
connections by tightly wrapping a tie wrap around the tubing near the connector. 
26. Assemble the flow loop components.  If it is desired to keep the flow chamber 
separate from the loop, attach the free ends of the loop tubing to the FTLLC-6 
























































Figure A-1: Schematic of parallel plate flow loop system. 
Cell Seeding 
 
3. Autoclave glass slide and tweezers. 
4. Place slide into square dish with tweezers. 
5. Coat glass slide with Coll I solution (~1 ml).  Spread evenly with cell scraper. 
6. Incubate for 1 hour. 
7. Trypsinize cells (PJTB002) into solution at a sufficient density to seed slide with 1 ml 
of cell solution.  Typical cell densities range from 10,000 – 20,000 cells/cm2, and are 
application specific.  Inject solution onto slide, and spread evenly with a different cell 
scraper.   
8. Allow 20 minutes to adhere on flat surface inside hood.  Turn slide 180 degrees and 
let adhere for another 20 minutes.  This helps to account for any unevenness of the 
surface. 
9. Add approximately 25 ml of Porcine Medium.  Cover dish. 
10. Place dish into the incubator. 
11. Allow 24 – 48 hours for cells to become confluent. 
 
Autoclave Flow Loop Components 
 
3. Place flow loop into large autoclave bag, unscrew the reservoir lid a few turns to 
provide air access. 
4. Place the flow chamber bottom, flow block, and flow chamber top (in that order) into 
medium sized autoclave bag. 





2. Sterilize the spacer according to particular requirements of that material.  Placing 
under UV light for 45 minutes on each side works well for most materials. 
 
Combine Flow Loop 
 
27. Place autoclaved flow loop components, autoclaved tweezers, sterilized spacer, 
square dish with slide, air filter, and medium under sterile hood. 
28. Open the bag with the flow chamber components and place ONLY the chamer 
bottom onto a tray. 
29. Open the bag just enough to remove the tweezers, and use them to grab the rubber 
gasket, and place it in the space in the chamber.  
30. Use the tweezers to grab the slide, and place it on top of the gasket. 
31. Use the tweezers to grab the spacer, and place it on top of the slide. 
32. Carefully place the tweezers back into its bag to maintain sterility. 
33. Grab the flow block by the tubing loop, being careful not to touch the bottom surface, 
and place it on top of the spacer. 
34. Add the flow loop chamber top, and seal the assembly with the 6 screws.  Be careful 
to tighten uniformly, and not too tightly, so that the slide doesn’t break. 
35. Wipe the bottom of the slide surface showing from the chamber with an alcohol wipe. 
36. Open the bag with the flow loop, and disconnect the FTLLC-6 while holding both 
ends of the tubing.  Place the assembled flow chamber into the flow loop according 
to Figure 1.  Twist the tubing in the opposite direction before connecting them so no 
stress develops in the tubing. 
37. Unscrew the reservoir lid and add 125 ml of medium.  Screw cap tightly. 
38. Add air filter to the remaining tubing on the reservoir lid. 
 
Running Flow Loop 
 
1. Place a clean sheet of adsorbant paper onto one of the shelves of the large 
incubator. 
2. Place calibrated roller pump onto shelf. 
3. Carry tray with assembled flow loop to incubator, and place flow loop inside 
incubator. 
4. Using a bracket supplied with the pump, affix the norprene tubing to the rollers. 
5. Set the pump to the appropriate speed (for shear stress), and turn it on.  Watch to 
make sure that fluid is taken from the reservoir. 
6. Turn the pressure damper on its side, to allow fluid buildup inside. 
7. Once the fluid builds up to the point that both ports are under the liquid line, turn the 
damper over again.  Watch to make sure the fluid flows evenly out of the damper.  
Be careful not to overfill the damper. 
8. Once the fluid travels back into the reservoir, add a hemostat to the loop in the flow 
chamber. This provides back pressure, and ensures that the flow is through the 
channel. 
9. Let flow loop run for desired amount of time.  
 
Removing Slides from Flow Loop System 
 
1. Once the allotted time has passed, remove the flow cartridge from the pump and 
remove the hemostat from the top of the flow chamber.  Disconnect tubing from 
either side of the flow chamber being careful not to unscrew the fittings within the 
flow block.  Take a FTLLC-6 fitting and reconnect the tubing so media does not leak. 
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2. Place the flow chamber in the hood and evenly loosen the screws so the slide does 
not break.   
3. Remove the spacer with tweezers and set aside. 
4. Remove the slide of cells with tweezers and place in a square Petri dish.  Add PBS 
(with calcium) to the dish to rinse off media and keep cells moist. 
5. Thoroughly rinse out tubing and pulse dampener after use.  Add bleach to media 




• Letters on Figure 1 refer to connectors used. 
• When running the Flow Loop, always place the PharMed/Norprene tubing under the 
bracket of the roller pump. 
• The Pharmed/Norprene tubing only lasts a few (~6) trials, after which longitudinal 
cracks will appear, so inspect it after the conclusion of each trial.  
• Size 16 tubing is adequate for low and high shear of monolayers and low shear of 
constructs but size 25 tubing must be used for high shear of constructs due to the 
large spacer thickness.  Construction of flow loops with size 25 tubing requires use of 
a 1/8 to 3/16 connector (Value Plastics part number 3050-6) 
• If the holes in the non-tubular components of the Flow Loop have not already been 
drilled and tapped, do so now.  The drill bits and tap sizes are listed below: 
• Flow Chamber:  # 3 Drill, ¼ - 28 Tap, 4 holes 
• Pressure Damper: “Q” Drill, 1/8 – 27 Tap, 2 holes 
• The Pharmed tubing only lasts a few (~6) trials, after which longitudinal cracks will 
appear, so inspect it after the conclusion of each trial.  
• If block leaks from the top of the bottom chamber plate, tighten (evenly) the screws 
more.  If it leaks from underneath the chamber, the slide has broken, and the loop 
should be removed so that the slide could be used as a contol. 














Formaldehyde, 20% (20 ml)     Protein Rm  Fridge 
 Tousimis, Cat. No. #1008A 
Triton-X 100       Laboratory Rm  Shelf 
 USB, Cat. No. 22686 
Tween-20        Laboratory Rm  Shelf 
 Sigma, Cat. No. P-7949 
Hoechst 33258 (Cell Nuclei)     Protein Rm  Fridge 
 Molecular Probes, Cat. No. H-1398 
Rhodamine Phalloidin (F-actin)    Protein Rm  Freezer 
 Molecular Probes, Cat. No. R-415 
Neonatal Goat Serum (NGS)     Tissue Culture Rm  
Freezer 
Non-Sterile PBS (See PJTB003)    Laboratory Rm  Shelf 
Deionized Water (dH20)     Tissue Culture Rm  Sink 
Mounting Media      Laboratory Rm  Shelf 




Preparation of 0.1% Triton-X 100 
 
39. Add 1 ml of Triton into 1 L of non-sterile PBS. 
40. Vortex for 30 minutes. 
 
Preparation of 1% NGS Blocking Buffer 
 
1. Add 5 ml NGS into 500 ml non-sterile PBS. 
 
Preparation of 3.7% Paraformaldehyde Solution 
 




1. Fix the cells in 3.7% paraformaldehyde for 5 minutes. 
2. Rinse 2 times with PBS. 
3. Permeabilize the cells in cold 0.1% triton-X 100 for 5 minutes. 
4. Rinse 2 times with PBS. 
5. Incubate in 1% NGS Blocking Buffer for 1 hour at 37 C. 
6. Incubate in primary antibody, diluted to the proper concentration with Blocking Buffer, 
for 40 minutes at 37 C. 
7. Rinse 2 times with PBS. 
8. Incubate in secondary antibody diluted to the appropriate concentration in Blocking 
Buffer for 40 minutes at 37 C.  Many fluorophores used in secondary antibodies are 
sensititve to light, so cover them with an opaque container. 
9. Rinse 2 times with PBS. 
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10. Incubate in Hoechst and Rhodamine Phalloidin (counterstains) diluted to the 
appropriate concentrations for 20 minutes at 37 C.  Again, cover the slides during 
this process. 
11. Rinse twice with PBS. 
12. Rinse once in dH20. 
13. Place a drop of Mounting Media on the slide or coverslip to be sealed. 
14. Place a coverslip over the drop, and press firmly but evenly on the coverslip to 
remove the air bubbles.  Be careful not to slide the coverslip across the slide. 
15. Seal the coverslip with nail polish. 
16. Wrap slides in a paper towel, and place in the refridgerator until it is time to image 
slides. 




Table A-1: Antibody sources and dilutions used in experiments. 
 
Primary antibodies and dilutions used with success 
Antibody Host Imm/Fluor. Company Cat. Number Dilution 
Rhod.  Phalloidin N/A Tex Red Conj. Molecular Probes R-415 10 U/ml 
Hoechst 553 N/A Dapi Conj. Molecular Probes H-1398 1:100 
Anti-Vinculin Mouse Mono IgG Upstate Biotech. 05-386 1:100 
Anti-α Actinin Mouse Mono IgM Sigma A5044 1:100 
Anti-α5 integrin Rabbit Poly IgG Chemicon AB1928 1:100 
von Willebrand 
factor 
Rabbit Mono IgG Sigma F-3520 1:100 
Talin Mouse IgG Sigma T-3287 1:100 
Desmin Mouse IgG Sigma D-1033 1:100 
β3 Integrin Rabbit IgG Chemicon AB1932 1:100 
Focal Adhesion 
Kinase 
Rabbit IgG Upstate Biotech 06-543 1:100 
α-Smooth muscle 
actin 
Mouse/Cy 3 Sigma 0-6198 1:100 
 vimentin Mouse/Cy 3 Sigma V2258 1:100 
β1 Integrin Mouse Mono IgG Chemicon MAB2000 1:100 
 
Secondary antibodies used with success 
Antibody Host Imm/Fluor. Company Cat. Number Dilution 
Anti-mouse IgG Goat/FITC Sigma F 0257 1:100 
Anti-Rabbit IgG Sheep/FITC Sigma F7512 1:100 
Anti-Mouse IgM Unknown/FITC Dr. Andres Garcia  1:100 
Anti-Rabbit IgG Goat/AF 488 Molecular Probes A-11008 1:100 
 
Approximate amounts of diluted antibody for various surfaces 
Surface Area, cm2 Fluid volume, µl 
Glass slide 28.5 125 









Porcine Medium (See JTB002):     Tissue Culture Rm  Fridge 
• Dulpecco’s Modified Eagle Medium (DMEM) (1000 ml)  
Gibco, Cat. No. 11965-092 
• 1% L-Glutamine added      
Mediatech Cellgro, Cat. No. 25-005-C1 
• 1% HyQ Penicillin added      
MediaTech Cellgro, Cat. No.  SV30010 
• 10% Fetal Bovine Serum (FBS) added   
 
Collagen, Type 1 (Coll I) (100 mg)    Tissue Culture Rm  Fridge 
  BD Biosciences, Cat. No. 354236  
Trypsin-EDTA (100 ml):     Tissue Culture Rm  Fridge  
Gibco, Cat. No. 25300-054, 0.05% Trypsin, 0.53 mM EDTA 
Fetal Bovine Serum (FBS) Heat inactivated (500 ml) Tissue Culture Rm  
Freezer 
 Mediatech Cellgro, Cat. No. 35-011-CV 
DMEM Powder      Back Wall of 1D  Fridge  




Sodium Bicarbonate      Laboratory Rm  Shelf 
 Sigma, Cat. No. S-6014 
Sodium Hydroxide (NaOH)     Laboratory Rm  Shelf 
 VWR, Cat. No. VW5749-4 (1 N) 
Sulfuric Acid (H2SO4)      Flammable Cab  Shelf 








Note: For disk constructs, the molds to be used are the 35 mm diameter wells of a 6-
well plate (non-tissue culture treated).  For tubular constructs, the mold consists of a test 
tube and inner mandrel assembly (see diagram).  Tubular constructs are molded onto a 
silicone sleeve that is coated with collagen. 
 
 
Preparation of Silicone Sleeves (for tubular constructs only) 
 
1. Cut sleeves into 3.81 cm (1.5”) lengths. 
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2. Under a fume hood and wearing proper protection, transfer approximately 30 mL of 
10 N sulfuric acid to a centrifuge tube.  Put the sleeves in the sulfuric acid in order to 
etch the surface.  Allow the sleeves to sit in the acid for 45-90 min.  Separate sleeves 
from each other so that the entire surface is etched. 
 
3. Carefully remove the sleeves from the sulfuric acid and rinse WELL (6-8 times) with 
fresh distilled water.  The sulfuric acid can be re-used. 
 
4. Autoclave sleeves.  Also autoclave glass mandrels, stoppers, test tubes, caps and 
instruments at the same time. 
 
5. Prepare 50 µg/mL collagen Type I from rat tail in sterile tissue culture water. 
 
6. Transfer ~30 mL of the stock collagen solution to a 50 mL centrifuge tube.  Immerse 
etched and autoclaved silicone sleeves into the ECM and allow to sit for 12-24 h at 4 
˚C. 
 
7. Arrange sleeves in a sterile Petri dish.  Using sterile forceps, slide silicone sleeves 
onto sterile glass mandrels.  It may help to pre-wet the mandrel with the ECM in the 
lumen of the sleeve; this provides lubrication for the sleeve to slide onto the mandrel.  
Place rubber stoppers on mandrels in appropriate positions for preparation of 
constructs (i.e. sleeves will provide 1.5” gap between stoppers). 
 
8. Allow sleeves on mandrels to dry for at least 1 h. 
 
 
Preparation of Collagen Gel Reagents 
 
1. Dilute 1 N NaOH to 0.1 N in dH2O.  Filter to sterilize.  Approximately 50 mL of 0.1 N 
NaOH is sufficient for the creation of 100 constructs. 
2. Prepare 5X concentrated DMEM.  Dissolve powder in 200 mL of dH2O.  Add 3.7g 
sodium bicarbonate.  Filter sterilize.  Separate into 10 ml aliquots and store at -20°C 
until use. 
 
Preparation of Cell-Collagen Suspension 
 
Appropriate volumes of the following reagents should be ready and kept on ice: 
(use attached worksheet to determine appropriate volumes) 
 
 5X concentrated DMEM: (Volume of FBS, NaOH, and Collagen)*0.25 
 Fetal Bovine Serum: (Total Suspension Vol)*0.10 
 Extra DMEM: Added extra to ensure proper total volume 
 0.1 M NaOH: (Collagen Vol.)*(0.02)/(NaOH Conc.) 




1. Use trypsin to detach cells to be used from their culture surface.  Collect cells in an 
appropriate tube and remove a sample for cell counting.  Wash cells once in medium 
and centrifuge for 5 min @ 1000 rpm to obtain a cell pellet. 
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2. Count cell sample using Coulter Counter.  Resuspend pellet of collected cells and 
transfer number of cells required to make constructs to a 50 mL centrifuge tube 
(allows up to 50 mL of cell-collagen suspension to be made). 
3. Centrifuge cell suspension for 5 min @ 1000 rpm to obtain a pellet.  Aspirate 
supernatant and place tube on ice. 
4. To tube containing cell pellet, add required volumes of complete culture medium, 5X 
concentrated DMEM and Fetal Bovine Serum.  Use a pipetor to gently resuspend 
cells. 
 
5. Add required volume of 0.1 M NaOH and mix.  The next steps should be done 
quickly but carefully to avoid prolonged contact of cell with high pH solution, while 
avoiding premature gelation of cell-collagen suspension. 
6. Add required volume of acid-solubilized Type I collagen from rat tail and mix 
thoroughly. Solution is viscous, so mixing is difficult.  Tube can be capped and 
inverted if required, taking car to create as few bubbles into the solution as possible.  
Once collagen component has been added, keep cool to prevent gelling, and pour 
mixed solution into molds as soon as possible. 
7. Use a pipettor to transfer the required volume of cell-collagen suspension to each of 
the molds.  
 For disk constructs  Add 3.0 mL of cell-collagen suspension to 35 mm wells of 
a non-tissue culture treated 6-well plate.  Gently swirl plate to distribute 
suspension evenly in the wells.  Put cover on plate. 
 For tube constructs  First add 5.0 mL of cell-collagen suspension to glass test 
tubes.  Then immediately insert a mandrel-sleeve-stopper assembly into the test 
tube, ensuring that there is no air trapped in the annular space that will form the 
tubular construct.  Cover test tubes with a cap. 
8. Immediately place mold in a cell culture incubator at 37 °C.  Allow to sit undisturbed 
for 30-60 min, until gelation is visibly complete. 
 
9. For disk constructs  leave in cell culture incubator for 24 h. 
10. For tubular constructs  Remove molds from cell culture incubator and place in 
laminar flow hood.  Remove caps and aspirate gelled material from lumen of glass 
mandrels.  Be careful not to aspirate too much material (i.e. do not aspirate part of 
construct, only excess material in lumen of mandrel).  Use ridged forceps to carefully 
remove mandrel assembly and gelled constructs from test tubes, and place in a 150 
mm Petri dish containing ~130 ml of warm culture medium.  Place constructs in cell 
culture incubator at 37 °C. 
 
11. Allow constructs to incubate for 24 h undisturbed.  After this period, release 
constructs from mold to allow further gel compaction. 
 For disk constructs  Use a sterile small spatula or pipette tip to release 
constructs from sides and floor of culture well.  If wells are non-tissue culture 
treated, the construct will not re-adhere and will compact unconstrained. 
 For tube constructs  Use sterile scissors and forceps to cut the construct free 
from the rubber stoppers at the end of the mold.  There will be some excess 







• This protocol is for use with acid solubilized Type I rat tail collagen.  It may need to 
be modified for other collagen types. 
• The attached printout of an Excel spreadsheet shows the information needed to 
prepare 8 standard tubular constructs.  The calculation used to determine the 
amount of 0.1 M NaOH needed to neutralize the collagen solution is based on the 
information given in the manufacturer’s Product Specification sheet. 
• 3.5 mg/mL is minimum collagen concentration that can be used to get a final 
collagen concentration of 2.0 mg/mL.  Higher collagen concentrations (3.8 – 4.5 
mg/mL) are desirable for their improved gelling qualities. 
• Constructs have been made with and without silicone sleeves.  While using sleeves 




PJTB07: Flow Cytometry for Cells in Three Dimensional Constructs 
 
Reagents : 
Glycine       Laboratory Rm  Shelf 
   
Sodium Chloride (NaCl,     Laboratory Rm  Shelf 
          
Normal Goat Serum      Tissue Culture Rm  
Freezer 
 
3.7% Paraformaldehyde (see JTBP05)    Protein Rm  Fridge 
 Tousimis Cat. No. #1008A    
Sucrose       Laboratory Rm  Shelf 
 
Triton X-100       Laboratory Rm  Shelf 
 Sigma X-100    
Trizma Pre-Set Crystals     Laboratory Rm  Shelf 
 Sigma # T-4753   
Tween-20       Laboratory Rm  Shelf 
Collagenase CLS2:      Protein Rm  Fridge 
 Worthington, Cat. No. 4176, ~300 U/mg  




Dulbeccos Phosphate Buffered Saline (DPBS)  Tissue Culture Rm  Fridge 
 Gibco, Cat. No. 14190-144, no Ca or Mg 
Porcine Medium (See PJTB002):     Tissue Culture Rm  Fridge 
• Dulbecco’s Modified Eagle Medium (DMEM) (500mL)  
Gibco, Cat. No. 11965-092 
• 1% L-Glutamine added      
Mediatech Cellgro, Cat. No. 25-005-C1 
• 1% HyQ Penicillin added      




Tween-20 Stock Solution : 0.1 % 
 Tween-20   100 µL 
 
 Add Tween-20 to 100 mL of dH20 and mix well. 
 
Tris-Buffered Saline with Tween (TTBS) 
Trizma Pre-Set Crystals 14.2 g 
NaCl    11.7 g 
Tween-20 Stock  10 mL    
 
Dissolve the Trizma Crystals and NaCl in 990 mL dH20 and add 10 mL of 0.1% 
Tween stock (to give a final concentration of 0.001 % Tween).  Mix well.  Adjust 
pH to ∼8.0 using Tris-Base/Tris-Cl at RT. 
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Glycine : 20 mM 
Add 0.15 g of glycine to 100 mL of TTBS and mix to dissolve.  Adjust pH to 2-3 
for use in protocol. 
 
Blocking buffer : 5% NGS 
Add 5 mL of NGS to 95 mL of TTBS. 
 
Coating buffer : 1% NGS 
Add 1 mL of NGS to 99 mL of TTBS. 
 
Fixation buffer : Paraformaldehyde (for 20 mL final solution) 
 3.7% paraformaldehyde  (dilute from 20%)    
 
Dilute Tousimis formaldehyde (stored under nitrogen) to desired concentration in 
DPBS.  Add appropriate amount of sucrose and allow to dissolve.  Solution can 
be kept up to 1 month at 4 ˚C. 
 
Triton X-100 Stock Solution : 10 % 
 Triton X-100   10 mL 
  
Add Triton X-100 to 90 mL of dH20 and put on stir plate with stir bar.  Will take 
∼30-60 minutes to fully dissolve. 
 
Permeabilization buffer : 
Add 1 mL of Triton X-100 Stock to 99 mL of TTBS (for final concentration of 0.1% 
Triton X-100) and mix well. 





1. Cells should be in a suspension in DMEM to begin protocol.  If cells are from 
monolayer culture they must be trypsinized to bring into suspension (PJTB02).  If 
cells are from 3D construct, the construct must be digested to bring cells into 
suspension (PJTB01). 
a. Incubate constructs in 600 U/ml collagenase in serum free DMEM for 1 hour, 
vortexing frequently. 
b. Once all the collagen is digested, centrifuge the suspension for 5 minutes at 
~200g (1000 rpm). 
2. Wash cells gently once with TTBS (or DPBS).  For each wash, suspend the cells in 
TTBS (or DPBS) and agitate gently, then spin down at 1000 rpm for 3 min and 
aspirate supernatant. 
3. Add 0.5 mL of 3.7% paraformaldehyde (PF) in DPBS and mix well with light 
vortexing.  Let fix for 5 min at room temperature. 
4. Wash cells gently once in TTBS (or DPBS).   
5. Incubate the cells in 20 mM glycine solution solution for 15 min at room temperature.  
This will neutralize the charges caused by PF fixation. 
6. Wash cells gently once in TTBS (or DPBS).  Cells can be stored at 4 °C at this point 
in fresh TTBS (or PBS) if desired. 
7. Permeabilize cells in Permeabilization buffer for 5 min at room temperature. 
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8. Wash cells gently twice in TTBS.  
9. Block nonspecific binding with 5% normal goat serum (diluted in TTBS or PBS) for 1 
hr at 37°C or overnight (12-15 hr) at 4 °C.   
10. Centrifuge at 1000rpm for 3 min and remove blocking medium: do not wash off, 
merely drain. 
11. In order to perform a flow cytometric analysis, three types of samples will be 
necessary : 1] an unstained sample of cells, 2] a sample stained with the appropriate 
isotype control antibody (or secondary only), and 3] a sample stained for the marker 
of interest. 
12. Briefly spin down thawed primary antibody aliquot and isotype control aliquot to bring 
any crystals to bottom of tube.  Add antibody to tubes, vortex gently and incubate at 
37 °C for 60 min. 
13. Wash samples gently 2 times in TTBS or PBS.   
14. Add 100µL of blocking buffer (5% NGS) to each tube prior to adding secondary 
antibody. 
15. Briefly spin down secondary antibody aliquot to bring any crystals to bottom of tube.  
Add secondary antibody to tubes, vortex gently and incubate samples with 
secondary antibody for 30min at 37°C. 
16. Wash samples gently 2 times in TTBS or PBS.  Resuspend in 500 µL PBS for flow 





• use of 1.7 mL non-stick centrifuge tubes is recommended to avoid loss of cells. 
• TTBS has the potential advantage that the low concentration of mild detergent 
(Tween) may keep cells from sticking to each other and to the wash tubes.  Also, 
TBS is reported to be better at maintaining physiological pH during temperature 
changes. 
• Pre-coat centrifuge tubes or plates to be used with 1% NGS to prevent cells from 
sticking to sides of tubes.  This prevents loss of cells during the multiple washing 
steps. 
• pre-coat for 1 h @ 37 ºC, or 4 h @ RT, or overnight @ 4 ºC 








Solutions:        
Agar         Laboratory Rm  Shelf 
 Sigma, Cat. No. A-9915 
Porcine Medium (See JTB002):     Tissue Culture Rm  Fridge 
• Dulpecco’s Modified Eagle Medium (DMEM) (1000 ml)  
Gibco, Cat. No. 11965-092 
• 1% L-Glutamine added      
Mediatech Cellgro, Cat. No. 25-005-C1 
• 1% HyQ Penicillin added      
MediaTech Cellgro, Cat. No.  SV30010 




Instrument tray:      Laboratory Rm 
Mandrel grabbers 
Section lifter (spatula) 
Smooth angled forceps 
Serrated angled forceps 
Flat tweezers 
Angled scissors 
# 4 Scalpel with No.20 blade 
Glass microscope slides 
Embedding molds 
 




Tubular constructs cultured to day 6    Tissue Culture Rm  Incbtr 
 
All procedures should be performed in a biological safety cabinet using aseptic 




Preparation of Materials and Instruments 
 
1. Immediately before embedding constructs, create 3.5% agar solution (w/v in dH2O) 
in a 125 ml bottle.   
2. Autoclave agar solution and 50 ml glass centrifuge tubes to melt agar.   
3. While hot, transfer agar solution to a hot water bath at 48°C to keep liquid. 
4. Prepare tray of instruments on paper towel.  Autoclave new glass slides, used glass 
slides, molds and tray of instruments in advance. 
 
Preparation of Constructs 
 221
Steps can be done for all constructs at once. 
 
1. Place one autoclaved new glass slide in a square cell culture dish and set aside. 
2. Remove dish of constructs from incubator and place in sterile cell culture hood.   
3. Remove rubber stopper from mandrel end and slide constructs on sleeves off the 
mandrel.  Remove mandrels and rubber stoppers from dish. 
4. Holding silicone sleeve with angled forceps slowly cut sleeve and construct along the 
long axis with angled scissors.  Then remove the silicone sleeve from the construct. 
 
Embedding Procedure 
Steps should be done to only two constructs at a time to prevent drying and cell death. 
 
1. Using smooth angled forceps grab one corner of the construct and slide onto spatula 
with the lumen down.  Transfer construct onto new glass slide in square dish keeping 
the lumen down. 
2. Using a scalpel, cut away ragged ends of construct and remove excess material.  
Center the construct on the glass slide with forceps. 
3. Aspirate excess fluid off the slide being careful not to aspirate the construct but 
remove all fluid from around it to ensure a good agar seal. 
4. Place mold over slide with hole over construct.  Quickly remove agar from hot water 
bath and add 7 ml over construct.  Quickly place used glass slide over agar and 
press hard with mandrel grabbers and flat tweezers until the agar solidifies to ensure 
a good seal. 
5. After the agar has cooled, remove excess from the sides of the mold and discard.  
Add 35 ml of flow media to the dish.  Using flat tweezers flip the slide/mold/slide 
combination over and carefully slide off the top slide to expose the lumen. 
6. Place the dishes of embedded construct into the incubator at 37°C and 5% CO2.  
 
Construct Flow Loop Assay 
 
1. Follow steps identical to PJTB04, except use the glass slide/embedded construct 
instead of the glass slide. 
2. For this modification, a thinner rubber substrate is required to accommodate the 
added thickness of the mold.   
3. Use a thicker spacer to create the channel height needed for the appropriate shear 












 Sigma T-4753 
EDTA 
  
Sodium Chloride (NaCl)     Laboratory Rm  Shelf 
 Sigma, Cat. No. S-7653 
Sodium Doecytl Sulfate     Laboratory Rm  Shelf 
 US Biochemicals, Cat. No. 21651 
Hoechst 33258 Dye      Protein Fridge  Shelf 
 Sigma, Cat. No. 33258 
Calf Thymus DNA Standard Solution 





Proteinase K Solution:     For 500 mL 
   - Buffer 1 : 
dH2O    475 mL 
50 mM Tris-HCl  25 mL of 1 M stock 
0.1 M EDTA   18.6 g 
0.2 M NaCl   5.84 g 
   - pH to 7.4 
   - Aliqout out volume required (1 mL per construct) 
   - Add : 
    0.5 mg/mL Proteinase K 
    0.1 mg/mL SDS 
   - dissolve and freeze excess aliquots 
 
Hoechst 33258 Dye Solution : 
   - Buffer 2 : 
    10 mM Tris 
    1 mM EDTA Na2.2H20 
    0.2 M NaCl 
   - pH to 7.4 
   - Add : 
   0.1 µg/mL Hoechst 33258 dye 
    - stock is at 10,000X, shake well before using 
     - stock soln is made up in H2O (Sigma protocol) 
  - PROTECT FROM EXPOSURE TO LIGHT. 
 
DNA Standards : 






Digestion of Constructs : 
 
1. Cut desired amount of material from construct.  Rinse 3X in PBS to remove medium.  
2. Lyophilize constructs using Speed-Vac for 4 – 8 h (until vacuum pressure is 
constant).  Take dry weight of sample (if desired), 
3. Put construct sample in tube with 1 mL of Proteinase K solution per ~1 M cells (keep 
track of precise Proteinase K volume in order to determine absolute amount of DNA 
later).  Vortex to mix thoroughly. 
4. Incubate construct in Proteinase K solution for 12-16 h at 55 ˚C, shaking (vortex) 
occasionally. 
5. At end of incubation, visually inspect sample to ensure that construct is fully 
digested. 
6. Freeze sample once, then use in assay. 
7. For blanks, load 10 µL of Buffer 1 (used for Proteinase K solution) into each of 4 
wells. 
8. For DNA Standards, prepare 4 microcentrifuge tubes containing 200 µL of Buffer 1 
each.   
a. Add 200 µL of DNA Standard Solution (30 µg/mL) to the first tube and mix well to 
yield a 15 µg/mL solution.   
b. Repeat serial dilution to get solutions of 30, 15, 7.5, 3.75, and 1.88 µg/mL.   
c. Load 10 µL of each standard solution into 96-well plate, in duplicate. 
9. For cell standards, prepare 4 microcentrifuge tubes containing 500 µL of Buffer 1 
each.   
a. Add 200 µL of Cell Standard Solution (1000 K cells/mL) to the first tube and mix 
well to yield a 500 K cells/mL. 
b. Repeat serial dilution to get solutions of 1000, 500, 250, 125 and 62.5 K cells/mL. 
c. Load 10 µL of each standard solution into 96-well plate, in duplicate. 
10. Vortex vigorously to ensure that samples are well mixed.  Draw through a 25G 
needle to fully mix and break up debris.  Centrifuge 2 min at 2000 rpm to remove any 
large debris from supernatant. 
11. Load samples into 96-well plate in duplicate.  Aim to have ~0.5 – 1.0 M cells per mL 
of sample solution being analyzed (to be well in linear region of standard curve). 
12. Add 200 µL of Hoechst 33258 Dye solution to every well in plate.  Protect entire plate 
from light in order to minimize fading of fluorochrome. 
13. Incubate for 15 min @ RT in the dark, then read on fluorometer. 
a. Excitation 365 nm, Emission 458 nm. 




• Modified from Jan Stegemann, adapted from Kim B-S, Mooney DJ, “Engineering 
Smooth Muscle Tissue with a Predefined Structure”, J Biomed Mater Res, 41, pp. 
322-332, 1998 and Topher Hunter’s protocol. 
• USE BLACK 96-well plates for best results (though clear ones can also be used). 
• For total protein (Pierce BCA) assay, Proteinase K buffer 1 will need to be diluted 
10:1 in dH2O to lower concentrations of SDS and EDTA under the assay thresholds.  
Then use 5 µl of sample in 50 µl of buffer in the 96 well plate assay. 
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Western Blotting for Focal Adhesion Proteins 
With Optional Immunoprecipitation 
 
 
Day 0:  Prepare stock buffers and gels 
 
Preparing the polyacrylamide gel: 
 
- prepare the following stock solutions 
o A:  50% acrylamide/BIS (29:1) 
 4.3 g acrylamide 
 1.7 g BIS 
OR 
 50 g 29:1 BisAcrylamide 
 bring to 100 ml with water 
 store at 4°C covered with foil (for 2 months) 
o B:  separating gel buffer (1M Tris-HCl pH 8.8) 
 add 30.3 g Tris to about 150 ml water; adjust pH to 8.8 with HCl 
 bring to 250 ml with water 
o C:  10% SDS 
 10 g SDS 
 bring to 100 ml with water 
o D:  stacking gel buffer (0.375 M Tris HCl pH 6.8) 
 add 11.4 g Tris to about 150 ml water; adjust pH to 6.8 with HCl 
 bring to 250 ml with water 
o E:  catalyst (make fresh on the day of use) 
 100 mg ammonium persulfate in 2 ml of water 
o F:  50% sucrose 
 50 g sucrose 
 bring to 100 ml with water 
- prepare the separating gels (2) 
o 7% separating gel 
 A:  3.5 ml 
 B:  9.4 ml 
 C:  250 µl 
 F:  4 ml 
 Water:  7.3 ml 
 E:  625 µl  (add last and mix well 
 TEMED:  6.25 µl  (add last and mix well) 
o fill cassette to the second from top line and overlay with water to the top 
o polymerize for 1 hour 
- prepare the stacking gels (2) 
o 4% stacking gel 
 A:  500 µl 
 D:  2.1 ml 
 C:  62.5 µl 
 Water:  3.15 ml 
 E:  0.5 ml (add last and mix well) 
 TEMED:  2.5 µl (add last and mix well) 
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o pour out the overlay solution completely and fill to the top with the 
stacking gel solution 
o insert the comb and polymerize for 30 min 
 
Preparing 6x Protein Loading Buffer: 
 
- make 4x Tris-HCl SDS buffer, pH 6.8 
o 6.05 g Tris + 40 ml water  pH to 6.8 with HCl 
o bring up to 100 ml with water 
o filter in 0.45 µm filter 
o add 0.4 g SDS 
- make 6x protein loading buffer 
o 7 ml 4x Tris-HCl SDS, 3.8 g glycerol, 1 g SDS, 0.93 g DTT, 1.2 mg 
bromphenol blue 
o bring up to 10ml with water 
 
Preparing 10x Running Buffer: 
 
- make 240 mM Tris (base), 1.92 M glycine, 1% SDS in water 
o 29 g Tris (base), 144 g glycine, 10 g SDS 
o bring up to 1 L with water 
 
Preparing 10x Tris-Glycine (for Transfer Buffer): 
 
- 30.3 g Tris (base), 144.1 g glycine 
- bring up to 1 L with water 
 
Preparing 1M Tris-HCl, pH 7.6 (for TBS-Tween): 
 
- 31.52 g Tris-HCl 
- bring up to 200 ml with water  pH to 7.6 
 
Preparing RIPA Lysis Buffer: 
 
- make 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 150mM 
Tris, pH 7.2 
o 15 ml 1 M Tris-HCl  pH to 7.2 
o 0.88 g NaCl 
o 1 ml Triton X-100 
o 1 ml 10% SDS 
o 1 g deoxycholate (DOC) 
o bring up to 100 ml with water 
 
Day 1:  Preparing Cell Lysate, Immunoprecipitation 
 
Preparing Cell Lysates: 
 
1. After experiments, place one or two glass microscope slides into a square Petri dish. 
2. wash the monolayer once with room temp PBS with Ca, Mg 
3. Prepare cold RIPA lysis buffer containing 1mM Na3VO4 and add fresh protease 
inhibitors 
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a. 100 µl for each slide. 
b. RIPA lysis buffer:  150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, 
150mM Tris, pH 7.2 
c. Add protease inhibitors:  350 µg/ml PMSF, 10 µg/ml leupeptin, 10 µg/ml aprotinin 
i. → 2.5 ml RIPA + 1 mg Na3VO4 + 25 µl PMSF (57 mM) + 25 µl leupeptin + 25 
µl   
(1) aprotinin (both are 1 mg/ml) 
4. incubate at room temp. for 10-20 min (optional: 4°C with occasional rocking) 
5. scrape the cells from the dishes and transfer to a 0.65 ml microcentrifuge tube 
6. pipette up and down ~25 times to shear DNA with the R-100 pipette 
7. spin the tube for 10 min at 10,000g 
8. keep supernatant - transfer to a clean tube (can keep pellet if want to assay it) 




1. Run µ-BCA Assay 





1. Pre-clear with serum, if necessary 
2. add 5 µg (5 µl) anti-FAK (rabbit polyclonal IgG) to 65 µl of the cell lysate (save some 
lysate to load as a positive control) 
3. incubate at 4°C for 60 min, fix tubes to orbital rocker to shake 
4. add 10 µl protein A beads (10% vol/vol in lysis buffer); use the R-20 pipette, trim the 
tip to accommodate the slurry 
5. incubate at 4°C for 60 min, fix tubes to orbital rocker to shake 
6. collect protein A beads by centrifugation at 10,000g for 3 min 
7. aspirate with a pipette tip and save the supernatent (4°C) 
8. wash the beads three times with lysis buffer and aspirate completely with a 23-gauge 
bent needle (insert the needle directly into the beads to remove the remaining wash 
buffer) 
9. resuspend the beads in 20 µl 6x protein loading buffer  
10. boil the samples for 10 min and spin the tubes for 10 min at 10,000g 
11. transfer the supernatant to clean tubes 
 
Day 2:  SDS-PAGE, Transfer 
 
1. prepare protein marker and cell lysate positive control 
2. boil samples for 10 min 
3. make running buffer or dilute 10x running buffer in dH2O (make 500 ml) 
4. assemble the gel box (cassettes face inward) 
a. fill middle channel with running buffer 
b. fill outer channel at least halfway with running buffer 
5. load samples into the gel  
6. run the electrophoresis  
a. 90 V in stacking gel (~30 min) 
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1. prepare the transfer buffer 
a. transfer buffer:  100 ml 10x Tris-glycine, 2.5 ml 10% SDS, 150 ml methanol, 
water up to 1 L 
2. prepare the transfer membrane and filter paper 
a. cut PVDF or nitrocellulose transfer membrane to the dimensions of the gel (do 
not handle, use tweezers) 
b. pre-wet PVDF transfer membrane in methanol for 30 seconds (do NOT pre-wet 
nitrocellulose), rinse in deionized water, soak in 50-100 ml of transfer buffer for 
several minutes 
c. cut filter paper to the dimensions of the gel and soak in transfer buffer briefly prior 
to use 
3. prepare the blotting pads 
a. soak blotting pads in transfer buffer until saturated 
b. remove air pockets and bubbles by squeezing pads while they are submerged in 
buffer 
4. load the blot module assembly 
a. place 2 saturated blotting pads on the electrode of the cathode core (deeper and 
darker gray) 
b. place the filter paper on the top of the blotting pads 
c. place the first gel on top of the filter paper, making sure no air bubbles are 
trapped beneath the gel 
i. make sure that the protein transfers to the membrane in the same orientation 
as it was loaded 
d. wet the surface of the gel with several milliliters of transfer buffer and place the 
transfer membrane on the gel; remove air bubbles 
e. place the filter paper on the top of the membrane; remove air bubbles 
f. repeat for the second gel 
g. place the anode core on the top of the gel/membrane sandwiches 
 
For 2 membranes: 
 














cathode core (-) 
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1. hold the blot module together at the top and slide it into the guide rails on the lower 
buffer chamber 
2. places the wedges 
3. fill the blot module with transfer buffer until the gel/membrane sandwich is covered in 
transfer buffer (approximately 200 ml) 
4. fill the lower buffer chamber with transfer buffer in the gap between the front of the 
blot module and the front of the lower buffer chamber (the water level should be 
approx. 2 cm from the top of the lower buffer chamber) 
5. place the lid on the unit and plug the leads into the power supply 
6. turn the power supply on and set to the appropriate voltage (30 V, 90 min) 
7. prepare blotto/Tween blocking buffer 
a. Blocking buffer:  5% non-fat dry milk in PBS w/o Ca2+/Mg2+ + 0.02% azide + 0.2% 
Tween 20 
i. For 100 ml:  5 g non-fat dry milk, 2 ml azide (1%), 200 l Tween 20, bring to 
100 ml with PBS w/o Ca2+/Mg2+ 
8. dry the transfer membrane on a paper towel for 5 min (protein facing up) 
9. mark the ladder with a pencil 
10. rewet the membrane with methanol 
11. rinse the membrane several times with water 
12. block in blotto/Tween blocking buffer overnight at 4°C 
 




1. cut the membrane in half, if necessary (based on size of the protein) 
2. incubate the primary antibodies at room temp for 1 hour, rocking (use 12 ml per 
membrane) 
3. prepare TBS-Tween for washing 
a. TBS-T:  20 mM Tris-HCL + 137 mM NaCl + 0.1% Tween-20 
i. For 1 L:  20 ml 1M Tris-HCl (pH 7.6), 8 g NaCl, 1 ml Tween-20, bring to 1 L 
with water 
4. wash the membrane twice with TBS-T 
5. rock with TBS-T for 15 min, then rock with TBS-T twice for 5 min each 
6. incubate the secondary antibody at room temp for 1 hour, rocking (use 12 ml per 
membrane) 
a. alkaline phosphatase-conjugated donkey anti-rabbit or mouse IgG, 1:10,000 
dilution 
i. 12 ml blocking buffer + 1.2 µl secondary (per membrane) 
7. wash the membrane twice with TBS-T 




1. ECF substrate is stored in the –80C (stock is 0.6 mg/ml) 
2. use 1 ml ECF per membrane 
3. spread 1 ml ECF evenly on a transparency 
4. allow excess buffer to drip off the membrane 
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5. lay the membrane face down on the ECF, starting with an edge; make sure no 
bubbles are trapped and that the membrane doesn’t move after it touches the ECF 
6. react for 5+ min. 
7. dry the membranes on a paper towel 
8. Fuji Film PhosphoImager: 
a. use the FLA Fluor State 2340 
b. place the membrane face down on the stage in the upper left-hand corner 
c. lay a transparency over the membrane to flatten 
9. Image Reader Software 
a. Sample Mode:  Fluor 473, Filter Y520 
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PJTB11: Immunohistochemistry Assay 
  
Reagents and Solutions 
 
10X PBS 
Boehringer Mannheim #1666789 
 
1%BSA/PBS
Dissolve 1g fraction V BSA (Sigma #A2153 kept on fridge door) in 100ml 1X PBS. 
Mix until fully dissolved. Aliquot into 5ml volumes and store at -20 C. 
 
1% Gelatin/PBS 
Dissolve 1g of gelatin powder in 100ml 1X PBS using gentle heat.  
Aliquot into 5ml volumes and store at –20 C.   
 
Biotinylated Secondary antibody and normal animal serum 
Vector Laboratories, Inc.: 
Biotinylated horse anti-mouse IgG # 
Normal horse serum # 
Biotinylated goat anti-rabbit IgG # 
Normal goat serum # 
 
Avidin D, Fluorochrome conjugated 
Vector Laboratories, Inc.:  
Texas red #A-2006, Fluoroscein #A-2001 
 
Vectashield Mountant with DAPI 
Vector Laboratories #H-1500 
 
Antibodies 
Monoclonal mouse anti-alpha sma-cy3  
 Sigma #C6198 Clone 1A4 (1:400) 
Monoclonal mouse anti-vimentin-cy3 
 Sigma #C9080 Clone V9 (1:200) 
Monoclonal Rabbit anti-von Willebrand Factor 
 Sigma #F3520 (1:600) 
Protease 
Sigma #8083  




1. Fixed paraffin embedded tissue is deparaffinized, and rehydrated in descending 
grades of alcohol.  This can be done using the Leica Autostainer. 
2. Sections are washed in 1X PBS 4min.   
3. Coverslip autofluorescnce control slides with Vector hardset/DAPI mountant (for 
nuclear counterstain).  
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4. Sections that will be stained with vWF require antigen retrieval using 100ug/ml 
protease pretreatment of the tissue for 10 min., rt.  Dilute 50ul of 100mg/ml stock in 
50ml PBS. 
5. Wash slides in 1X PBS twice for 4 min. each, rt. 
6. Block tissue using 1% gelatin/PBS mixture for 20 min. rt.  
7. Prepare primary antibodies in 1%BSA/PBS: 
a. Mouse anti-SMA-Cy3 at 1:400 
b. Mouse anti-VIM-Cy3 at 1:200 
c. Rabbit anti-vWF at 1:600    
d. BSA/PBS only (vWF secondary control) 
8. Blot off the gelatin/PBS and apply the primary antibody.  Incubate sections in a 
humid chamber for 1h at rt in the dark. 
9. Blot off excess antibody and wash slides in 1X PBS twice for 4 min. each, rt in the 
dark.  Coverslip finished slides as per step 1.  
10. Prepare 1:400 working dilution of the biotinylated goat anti-rabbit IgG secondary 
antibody in 1%BSA/ PBS, and add 2% normal goat serum.  Apply antibody and 
incubate 30 min. at rt in a humid chamber in the dark.   
11. Blot off excess antibody and wash slides in 1X PBS twice for 4 min. each, rt in the 
dark. 
12. Incubate sections with a 1:100 dilution of fluorescein conjugated avidin D in 
1%BSA/PBS for 30 minutes in the dark. 
13. Blot off excess solution and wash slides in 1X PBS for 4 minutes, twice in the dark.  
Coverslip slide #3 and 4 as per step 1. 
14. Apply second batch of primary antibodies and incubate for 1 hour at rt in the dark. 
i. Anti-SMA-Cy3 at 1:400 
ii. Anti-VIM-Cy3 at 1:200 
15. Blot off excess antibody and wash slides in 1X PBS twice for 4 min. each at rt in the 
dark. 





The following control slides are subjected to the same experimental conditions including 
blocking solution, washes, etc.  The differences are noted below. 
 
1. No primary antibody aka secondary antibody control:  This primary antibody 
is omitted from this slide.  Incubate this slide with the diluent of the primary 
antibody.  This slide is treated the same as all other slides after this step. 
Purpose:  Determines the specificity of the primary antibody.  Ensure there is 
no nonspecific staining resulting from the secondary antibody. 
 
2. Autofluorescence control:  This slide is subjected to diluents of antibodies and 
reagents only.  It is not exposed to the primary, secondary or avidin solutions. 
Purpose:  Confirms specificity of the primary antibody.  Detection of 
autofluorescence or background fluorescence that may be present in the 






• Positive von Willebrand Factor staining was also demonstrated using goat anti-
rabbit Alexa Fluor 488 (Molecular Probes #A-11008, 1:100) 







PJTB12: Isolation and Quantification of RNA 
Equipment: 
RNEasy kit 
 Qiagen, Cat. No. 74104 
RNAse free DNAse 
 Qiagen, Cat. No. 79254 
Homogenizer (Qiashredder) 
 Qiagen, Cat. No. 79654 
RNAse free sterile tips 
 Fisherbrand: 10 µl, 20 µl, 200 µl, 1000 µl 
UV Cuvettes 
RNA 6000 Nano LabChip Kit 




Dulbecco’s Phosphate Buffered Saline (DPBS) 
 Gibco, with Ca, Mg 
β-Mercaptoethanol (B-ME) 
 Sigma, Cat. No. M-3148 Molecular biology grade 
Ethanol 
 Aldrich, Cat. No. E702-3 Molecular biology grade 
DEPC Water 








1. 10 ml RLT buffer with 100 µl B-ME. 




1. Mix DNAse and Qiagen water from kit, aliquot into 100 µl units, store at 20C. 











NOTE: This process can only be done on a few samples at a time.  RNA changes w/in 1 
hour. 
 
1. For shear experiments, place two slides in a square Petri dish filled with DPBS. 
2. Aspirate DPBS and trypsinze cells with 1mL per slide for 3 mins at rt.  Place in 15 ml 
tube. 
3. Centrifuge at ~200g (1000 rpm) for 5 minutes and COMPLETELY remove 
supernatant. 
4. Add 350 µl lysis buffer to each tube.  Homogenize sample with either a 20 gauge 
needle (5-10 times) or with the Qiashredder (10,000 rpm for 2 minutes).   
 
Samples can be stored at -20C at this point if desired.  Thaw at 37C for 10 minutes 
before continuing. 
 
5. Add 350 µl 70% ethanol to each tube.  Mix well by pipetting.   
6. Transfer the 700 µl solution to an RNEasy Mini column placed in a 2 ml collection 
tube.  Centrifuge at 10,000 rpm for 30 sec. 
7. Pipette supernatant back into top of column, repeat centrifugation and discard 
effluent.  Make sure no fluid remains on top of the column. 
8. Add 350 µl of RW1 solution (from kit) to each RNEasy column.  Centrifuge at 10,000 
rpm for 30 sec. and discard effluent. 
9. Add 80 µl DNAse mix to each column and incubate for 15 min. at rt. 
10. Repeat step 8. 
11. Replace the collection tubes with new ones and add 500 µl RPE buffer to each 
column.  Centrifuge at 10,000 rpm for 30 sec. and discard effluent. 
12. Add 500 µl RPE and centrifuge at MAX rpm for 2 minutes.  Make sure no fluid 
remains at the top of the column. 
13. Label 1.5 ml collection tubes (in kit) and aliquot some RNAse free water into a small 
tube. 
14. Transfer the RNEasy columns to the labeled tubes.  Add 25 µl of RNAse free water 
and incubate for 1 minute.  Centrifuge at MAX speed for 1 minute, and discard the 
RNEasy column.   
15. Place the collection tube on ice 
 
Samples can be stored at -20C for up to 1 month at this point if desired.  Thaw at 37C 
for 10 minutes before using. 
 
RNA Quality Assessment and Quantification 
 
RNA quantity is determined using UV Spectrometry.  
 
1. Label small eppendorf tubes and add 99 µl RNAse free water to each tube (may be 
different for each spectrometer). 
2. Add 1 µl of RNA solution to each tube.  Can use 2 µl (in 98 µl water) if sample is 
dilute. 
3. Place the 100 µl solution in a UV-Vis cuvette. 
4. Follow protocol for particular Spectrometer.  Optimal values for UV-Vis are 1.8-2.1. 
5. Record RNA concentration (ng/µl). 
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RNA quality is assessed using the Agilent RNA 6000 Nano LabChip on the Agilent 
Bioanalyzer. 
 
1. For total RNA, the RNA 6000 Nano Assay quantitative range is 50-500 ng/µl. 
2. Prepare Gel-Dye mix.  Put 400 ml of RNA gel matrix in to spin filter and centrifuge at 
1500 g for 10 min.  Use within 4 weeks. 
3. Mix 130 µl of filtered RNA gel matrix with 2 µl RNA dye in a 1.5 ml RNAse free tube.  
Vortex well and store at 4C for up to 1 week. 
4. Place new RNA chip on the chip priming station. Pipette 9.0 µl of gel-dye mix into 
well marked “G”.  Close priming station and press plunger until held by the clip. 
5. Release the clip after exactly 30 seconds, and inspect the chip for air bubbles. 
6. Pipette 9.0 µl of gel-dye mix in wells marked “G” 
7. Pipette 5.0 µl of RNA 6000 Nano Marker in each of 12 sample wells and ladder well. 
8. Pipette 1.0 µl of an RNA sample into each sample well.  Place 1 µl of RNA 6000 
Nano Marker in each well not used. 
9. Vortex chip for 1 min. at set point of the IKA-Vortexer.   
10. Run the chip in the Agilent 2100 Bioanalyzer for 5 min. 
11. Remove chip and discard.  Clean bioanalyzer with water chip.   





PJTB13: Real Time PCR Quantification of RNA 




Roche Light Cycler 
Light Cycler capillaries 
 Roche, Cat. No. 1909339 
Cold block 
Siliconized tubes 




Invitrogen recombinant Taq kit 
 Invitrogen, Cat. No. 10342-020 
Taq start antibody 
 Clonetech (BD) 
dNTPs (100 mM) 
 Invitrogen, Cat. No. 10216-018, 10219-012, 10218-014, 10217-016 
Agarose 
 Invitrogen, Cat. No. 15510-027  
Ethidium Bromide 
 Fisher Biotech 
DTT 
RNAse OUT 






Reverse Transcription of RNA to cDNA. 
 
1. From UV spectrometer, determine amount of RNA sample (µl) that contains 4 µg 
RNA. 
2. For first strand synthesis of each RNA sample, add the following components at rt: 
a. 1 µl random primers 
b. 4 µg RNA (in µl). 
c. 1 µl of dNTP mix (each 10 mM) 
d. Enough milliQ water to reach 12 µl.  
3. Heat mixture to 65C for 5 min. then chill on ice.  Briefly centrifuge. 
4. Add the following reagents while tube is on ice: 
a. 4 µl of 5X first strand buffer 
b. 2 µl 0.1 M DTT 
c. 1 µl RNAse OUT (40 U/µl) 
5. Mix contents gently and incubate at 42C for 2 min. 
6. Add 1 µl of SuperScript II and mix gently by pipetting. 
7. Incubate for 50 min. at 42C. 
8. Inactivate the reaction by heating at 70C for 15 min. 
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9. Add 1 ml of RNAse H (Ecoli) and incubate at 37C for 20 min to purify the cDNA 
(optional). 
10. Samples can be stored at -20C until used. 
 
Real time PCR Amplification of cDNA 
 
1. Assemble all reagents and samples on ice.   
2. Use a siliconized tube for the master mix (prevents mix loss). 
3. While on ice, add the following reagents (multiplied by number of samples) to a 
different tube. 
a. 0.75 µl Taq Antibody (working dilution) 
b. 0.15 µl Taq polymerase 
4. Let the reaction progress for 5 min. on ice.  Mix by pipetting gently. 
5. While this reaction is occurring, add the following reagents to the siliconized tube as 
fast as possible. 
a. MilliQ water – enough to ensure 14 µl total sample volume per reaction – 
calculate first!) 
b. 1.5 ml 10X PCR buffer – buffer for the PCR reaction 
c. 1.2 µl MgCl2 – activates reaction (50 mM) 
d. 0.5 µl BSA – random blocking agent 
e. 0.3 dNTPs – nucleotide building blocks 
f. 0.3 µl forward primer – designed for RNA of interest 
g. 0.3 µl reverse primer – designed for RNA of interest 
h. 0.16 µl SYBR Green – fluorescent dye for quantification.  Keep covered or in 
dark. 
6. Once the 5 min. have passed, add the Taq – Ab mix to the siliconized tube and 
continue adding reagents until complete. 
7. Mix master mix by vortexing very lightly, then briefly spin down. 
8. Aliquot 14 µl of mix to each capillary tube while tubes are in the cold block. 
9. Add 1 µl of Milli Q water to blank tube and immediately cover. 
10. Add 1 µl of RNA sample to each sample capillary tube.  Pipette several times to 
ensure mixing. 
11. Add 1 µl of standard RNA to each standard tube. 
12. Cover all tubes, place the capillary cassettes in the microcentrifuge, and spin briefly 
(stop once 2000 rpm is reached). 
13. Replace cassettes into the cold block, and transfer the cold block to the Light Cycler. 
14. Adjust settings on the machine for the proper cycling temperatures and times. 
15. Add capillaries to machine and begin cycle.  Retain amplified samples when 
completed. 
 
Confirmation of Specific Amplification through DNA Gel Electrophoresis 
 
1. Make a 2% agarose gel (for small gel, 100 ml TAE buffer and 2 g agarose in glass 
beaker). 
2. Microwave until solution begins to bubble.  Add 7 ml Ethidium Bromide to gel 
solution. 
3. Pour solution into a DNA gel dedicated electrophoresis unit (because of ethidium) 
under the fume hood.  Add sample well mold.  Let solidify at rt. 
4. Uncover and invert capillary sample tubes in labeled 1.5 ml tubes, and centrifuge 
briefly. 
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5. Fill electrophoresis box with TAE buffer. 
6. Once gel has solidified, pre-run (before adding samples) the gel at 100 V for one 
hour. 
7.  Add 20 µl DNA ladder to the first well, followed by 15 µl of samples in subsequent 
wells. 
8. Run the gel at 80 V until ladder separates enabling the distinction of appropriate 
band length. 
9. Stop voltage, remove gel and image using UV camera. 
10. Inspect ladder and sample bands to confirm appropriate band is present without 




APPENDIX B: DERIVATION OF WALL SHEAR STRESS IN PARALLEL PLATE 
FLOW 
 
Navier-Stokes Equations (Cartesian coordinates): 
      ρ(∂u/∂t + u∂u/∂x + v∂u/∂y + w∂u/∂z) = fx – ∂P/∂x + µ(∂2u/∂x2 + ∂d2v/∂dy2 + ∂2w/∂z2) 
Continuity: 
       ∂ρ/∂t + ρ(∂u/∂x + ∂v/∂y + ∂w/∂z) = 0  







Equations reduce to: 
        dP/dx = µ(∂2u/∂y2)  
Parabolic velocity profile   
u(y) = (1/µ)(dP/dx)(y2/2) + c1y + c2  boundary conditions: u(h/2) = u(-h/2
 u(y) = -(1/8µ)(dP/dx)(h2 – 4y2) 
Velocity – Flow rate relationship: 
 Q = V = ∫u·ndA = uaveAcs uave = (-2/3)(h2/8µ)(dP/dx) 
 Q = -(bh3/12µ)(dP/dx)  dP/dx = -12µQ/bh3
Wall shear stress: 
 τw = µ(du/dy)  du/dy = (1/µ)(dP/dx)y 




APPENDIX C: AGILENT MICROARRAY FEATURE EXTRACTION AND 
PROCESSING 
 
 The following is a summary of how the features on the microarrays were 
extracted and processed using the Agilent G2566AA Feature Extraction Software, 
located at the Cardiovascular Research Institute at the Morehouse School of Medicine in 
Atlanta, GA.  The microarrays were processed by technicians at the Institute, with my 
sincere appreciation for their assistance.  More detailed information can be found in the 
software User’s Manual.  Table C-1 shows the Feature Extraction filter criteria used in 




 All data processing is conducted on an extremely high resolution image taken of 
the microarray by the Microarray Scanner.  The extraction software first brackets the 
microarray image by locating bright fields placed at the corners of the arrays, and then 
makes a sweep across the image to locate the intense spots.  Since most of the array 
features should have a high intensity with respect to background, the software can easily 
develop a grid using the found features, across which it then passes once more to 
identify weaker features.  The spots are identified with an ellipse (usually a circle) 
centered over the feature centroid.  Sometimes, spots are located off the originally 
designed grid, which the software can usually find; otherwise they can be selected for 
manually. 




Table C-1: Agilent Feature Extraction Software filter criteria used for the microarray 






ControlType 0 Data point was not a control 
rSurrogateUsed 0 No surrogate value was used 
gSurrogateUsed 0 No surrogate value was used 
gIsFound 1 Green signal is present in spot 
rIsFound 1 Red signal is present in spot 
gIsSaturated 0 <50% pixels above saturation threshold 
rIsSaturated 0 <50% pixels above saturation threshold 
gIsFeatNonUnifOL 0 Green pixel noise not non uniform outlier 
rIsFeatNonUnifOL 0 Red pixel noise not non uniform outlier 
gIsBGNonUnifOL 0 Same with local green background pixel noise  
rIsBGNonUnifOL 0 Same with local red background pixel noise 
gIsFeatPopnOL 0 Green feature not a population outlier (IQR) 
rIsFeatPopnOL 0 Red feature not a population outlier (IQR) 
gIsBGPopnOL 0 Green background not  population outlier (IQR) 
rIsBGPopnOL 0 Red background not population outlier (IQR) 
IsManualFlag 0 Not flagged by user upon manual inspection 
rIsPosAndSignif 1 Red BG subtracted signal > Red BG (T test, P<0.01) 
gIsPosAndSignif 1 Green BG subtracted signal > Green BG (T test, 
P<0.01) 
rIsWellAboveBG 1 Red signal > 2.6*StDev of Red BG signal 
gIsWellAboveBG 1 Green signal > 2.6*StDev of Green BG signal 
rPValFeatEqBG <0.01 Red mean signal significance over red BG 
gPValFeatEqBG <0.01 Green mean signal significance over green BG 
gProcessedSignal Value Processed Red intensity used for statistics 




 The pixels within the ellipse were used to calculate feature data values.  The 
software also calculates a local background in the immediate vicinity of the ellipse.  From 
these pixels, feature mean signal, standard deviation, and number of pixels were 
determined for each color.  The extraction software then performed pixel outlier rejection 
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to eliminate extreme intensity values (high or low) based on population statistics.  The 
final statistics were then calculated for each color of every feature and its local 
background.  The pixel correlation (between the two colors) was also calculated.  Local 
background is determined by placing two sequentially larger ellipses concentric with the 
first one: the space between the first ellipse and the second was an “exclusion zone”, 
while the space between the second and third ellipses was the “background zone”.  
Background for each feature was then determined by measuring the red and green 
channels in the portions of the background zones not overlapped by other exclusion 
zones. 
 Outlier Rejection.  Pixel outlier rejection was determined for every pixel within 
the ellipse after the initial statistics were determined.  Outlier pixels were determined 
based on their intensity values being greater than 1.42 times the interquartile range 
(IQR).  For normally distributed pixel intensities, values outside this range were outside a 
99% confidence interval of the mean (>2.6 times the standard deviation).  If a pixel was 
an outlier in one color, the pixel was removed in both colors.  It is also possible that 
entire features are outliers because the presence of some corruption on the array or a 
contaminating fiber that shows up in the scanner as a highly fluorescent smear.  To 
account for this, a noise model was applied to the entire array to identify feature and 
local background pattern expressions that significantly deviated from a baseline.  The 
model is a polynomial equation made up of three variables:  the intensity dependent 
variance (square of the coefficient of variation percentage), variance due to the Poisson 
distributed noise, and variance due to signal independent background noise (i.e. scanner 
noise).  Additionally, the Agilent Human cDNA 1 microarray has 100 replicate features, 
whose expression levels can be compared to determine a noise distribution within the 
array spots using the same model.  The same level of 1.42*IQR is used to flag the 
feature or local background as outliers.   
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 Feature Saturation.  Pixel saturation was defined as a signal at the maximum 
allowed intensity value as determined by the scanner.  If more than 50% of all pixels 
remaining after outlier rejection are saturated in one color, then the feature is marked as 
saturated.   
 Background Subtraction.  It is very important to subtract background 
measurements from the raw feature signals to account for systematic biases in the data 
arising from sources such as substrate fluorescence, non-specific binding to the 
substrate, or the scanning process.  Background can also vary differently for each color 
channel.  The feature extraction software has a multitude of global background level 
determinations, but local background for each individual feature was subtracted from the 
features in these experiments. 
   Dye Normalization.  After background subtraction, it is common to have a 
green or red color bias at the low end of the signal range.  In a self-self array (same 
target labeled by both red and green channels) one would expect to see a linear plot of 
red vs. green signal.  Bias at the low end will cause the signal to “hook” towards one 
axis.  Agilent’s background adjustment algorithm corrects for this bias in two steps: first it 
finds the central tendency of the data set, and then estimates the best adjustments in the 
red and green channels that would create a linear relationship.  In these microarray 
experiments, the normalization features (features which followed the central tendency) 
were selected using a Rank Consistency Filter, which selects features that fall within 
consistent trends of the red and green channels with no assumption of the underlying 
tendency of the data.  Only the features that passed the previous criteria were 
considered for this normalization.  Once this dataset was determined, the data was 
normalized according to the well known LOWESS method, a locally weighted linear 
regression curve fit.  This method assumes that dye bias is intensity dependent, and 
therefore the background subtracted signal is multiplied by a value that is a function of 
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the feature intensity.  The normalization dataset was used to determine these functions, 
which were then applied to all of the applicable features. 
 Significance Determination.  Once the data have been normalized, significant 
expression can now be determined.  Two factors are important in determining 
significance: the log ratio and the measured error.  The Agilent software calculates error 
based on two models: the propagated error based on pixel statistics, and a Universal 
Error Model.  For these experiments, the most conservative error model (one that results 
in the higher P<value) was used.  Using the available pixels on all applicable spots, 
sample statistics were calculated based on underlying normally distributed populations 
(T tests) to determine significant expression.  Only sample for which each channel was 
significantly expressed above background (P<0.01) were used in subsequent analyses, 
and the processed signal intensity values (red and green) were then used as the data 
points.  
 
Statistics Using Multiple Microarrays 
 
 The Agilent Feature Extraction Software also has the capability to determine 
significantly changed expression by measuring the differences in intensity of the red and 
green channels.  Each pixel is counted as an independent data point, thus creating a 
large sample number as an estimator of the population.  T tests are conducted on this 
data, and usually P<0.01 is considered significant.  While this method is simple and 
accommodated by the software, its utility breaks down when considering multiple 
microarrays.  It appears that the variability between microarray hybridizations is larger 
than the variability within the arrays.  If this were not so, then only a single array would 
be needed for any study, just using multiple spots for each cDNA profiled.  Furthermore, 
differences in sample batches, hybridization efficiencies, and random variations in the 
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entire process can lead to extensive variation in microarray intensities.  An example of 
several genes whose expression varies tremendously between arrays is shown in Figure 
A3-1.  These genes were all significantly expressed within each array (P<0.01), had fold 
changes larger than 2.0 within these arrays, yet between the arrays varied wildly, even 
to the point of significant expression in the opposite direction.   
 Two Factor Analysis of Variance.  It was therefore decided early on to design 
the microarray experiments to accommodate high-powered statistical analyses.  
Multifactor Analysis of Variance is a powerful statistical tool that partitions experimental 
variation into bins, therefore reducing the variance used for a specific test.  As shown in 
Table C-2, the mean squared error associated with the treatment effect (shear or cell 
type) can be separated and used in determining significant expression.  A two factor 
































































Gene Variation Between Arrays
Genes significant within each array
AL035737 AL136699 AJ001531 NM_003399 X04412
Figure C-1: Example genes with significant expression as 
determined by single array feature extraction software (P<0.01) yet 
wildly varying expression between arrays. 
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Table C-2: Mixed ANOVA model (A fixed, B random).  Statistical Model is: 
 
Yijk = µ + αi + βj + (αβ)ij + εijk




Expected Mean Squared Error 
(MSE) 
A (fixed) a-1 σ2 + nσ2AB + [(nb)/(a-1)]Σα2
B (random) b-1 σ2              + naσ2B
AxB (interaction) (a-1)(b-1) σ2 + nσ2AB
Within Subgroups ab(n-1) σ2
Total abn-1  
 
 
this work.  Cell type or shear stress was the treatment effect, while slide number was the 
random effect.  Since each slide contained two identical array areas, each hybridized at 
the same time with the same samples, each spot present in both arrays could be 
considered as replicates.  Three microarray slides were used for each experiment, 
creating an N=3, n=2 arrangement.   
 To highlight the improved sensitivity of the two factor ANOVA, a comparison was 
made between this method and other statistical methods for which assumptions could 
reasonably be made to satisfy their criteria, including non-parametric analyses and 
paired statistical analyses, the results are shown in Figure A3-2.  The mixed ANOVA 
was much more sensitive than other models, with hundreds of genes determined 
significant at the P<0.001 level, in contrast to the single factor ANOVA, where only 4 
genes were deemed significant.  Other methods were not capable of determining 
significance at more conservative P values because the sample numbers required were 
larger than those available from these experiments. 
 While the increased sensitivity improved the Positive Predictive Value in these 
experiments at increasingly more conservative P values, it was unclear whether these 
methods were actually excluding non-significant expression.  Although much less critical 
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2 Way ANOVA (Mixed) SRH ext. KW 1 Way ANOVA (Fixed)
Kruskal-Wallis Paired T Wilcoxon SR
Figure C-2: Comparison of significantly changed genes as determined by relevant 
statistical models based on different underlying assumptions on population and sample 
distributions. 
than equal sample sizes, two factor ANOVA presupposes an underlying normal sample 
distribution.  To compare the potential confounding effects of non-normal distributions 
and very conservative P values, a comparison of “smallest fold accepted” (SFA) genes 
and “largest fold rejected” (LFR) genes at different significance levels.  Figure A3-3 
shows some examples of these.  From these figures it is clear that the large variations in 
intensity levels between arrays pose a problem for using a “fold change” cutoff in 
determining significant gene expression using multiple arrays.  What remains unclear, 
however, is which statistical level is best.  Arguments can be made to use less 
conservative P values based on the LFR method, but more conservative values based 
on the SFA method.  Both methods, however, seem to converge upon P<0.005 as being 
the most reasonable.  Regardless of what level of significance is chosen, it is critical to 




























































































































































































































































LFR: 0.001 < P < 0.005























































































































































































































































































































































































































Figure C-3: Comparison of Largest Fold Rejection (LFR) and Smallest Fold 
Accepted (SFA) genes at different significance levels. 
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Figure 5-8 of this thesis, microarray data does not necessarily compare 1:1 to other 
methods, and further differences may be seen at the protein level.     
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Group 1: PAVEC 20 48 vs. PAVEC C 48 



















1 biosynthesis 567 29 66 95 0.134 1E-04 0 Enrchd
2 cytoskeleton 390 21 51 72 0.128 0 0 Enrchd























10 4 2 6 5E-04 0.164 0.0003 Dpltd 
8 motor activity 82 11 10 21 5E-04 0.076 0.0003 Dpltd 






18 6 2 8 1E-04 0.385 0.0004 Dpltd 










100 8 15 23 0.055 0.006 0.0007 Enrchd
14 intracellular 3499 163 277 440 0.009 0.02 0.0007 Dpltd 




of cell polarity 
(sensu Fungi) 
















5 0 4 4 1 1E-04 0.0008 Enrchd
19 establishment of cell polarity 5 0 4 4 1 1E-04 0.0008 Enrchd
20 
establishment 




5 0 4 4 1 1E-04 0.0008 Enrchd





278 15 34 49 0.177 0.002 0.0012 Enrchd













25 1 8 9 0.654 3E-04 0.0012 Enrchd
26 tRNA ligase activity 25 1 8 9 0.654 3E-04 0.0012 Enrchd






157 23 8 31 0 0.9 0.0016 Dpltd 
29 RNA ligase activity 26 1 8 9 0.668 4E-04 0.0017 Enrchd






6 2 2 4 0.023 0.066 0.0021 Dpltd 
 252






28 1 8 9 0.695 7E-04 0.003 Enrchd
34 synaptic vesicle transport 10 2 3 5 0.062 0.032 0.003 Enrchd






45 4 8 12 0.115 0.015 0.0038 Enrchd
37 M phase 153 16 13 29 5E-04 0.332 0.0041 Dpltd 
38 spindle assembly 15 5 1 6 3E-04 0.682 0.0045 Dpltd 
39 vacuole 95 0 20 20 1 0 0.0048 Enrchd
40 polyamine metabolism 4 1 2 3 0.156 0.029 0.0055 Enrchd
41 tRNA binding 4 0 3 3 1 0.002 0.0055 Enrchd
42 
amino acid and 
derivative 
metabolism 
103 5 16 21 0.425 0.003 0.0058 Enrchd
43 kinesin complex 72 7 9 16 0.029 0.079 0.0065 Dpltd 
44 carboxylic acid metabolism 193 7 27 34 0.696 8E-04 0.0066 Enrchd





26 2 6 8 0.293 0.01 0.0069 Enrchd
47 organic acid metabolism 194 7 27 34 0.701 8E-04 0.0072 Enrchd
48 myosin II 14 1 4 5 0.447 0.016 0.0162 Enrchd
49 actin filament 19 2 4 6 0.185 0.046 0.0163 Enrchd















171 19 10 29 1E-04 0.816 0.0192 Dpltd 
54 lysosome 81 0 16 16 1 2E-04 0.0201 Enrchd
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10 4 0 4 5E-04 1 0.0205 Dpltd 





10 1 3 4 0.345 0.032 0.0205 Enrchd
59 telomere maintenance 10 3 1 4 0.007 0.534 0.0205 Dpltd 





165 19 9 28 0 0.865 0.021 Dpltd 






20 6 0 6 1E-04 1 0.0211 Dpltd 
64 response to temperature 37 0 9 9 1 0.001 0.0212 Enrchd










on the CH-NH 
group of donors 
6 0 3 3 1 0.007 0.0231 Enrchd
68 cortical actin cytoskeleton 6 0 3 3 1 0.007 0.0231 Enrchd






6 2 1 3 0.023 0.367 0.0231 Dpltd 













44 3 7 10 0.274 0.039 0.0246 Enrchd
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74 isomerase activity 70 3 11 14 0.56 0.012 0.0258 Enrchd
75 chromatin 70 10 4 14 5E-04 0.766 0.0258 Dpltd 
76 
S phase of 
mitotic cell 
cycle 
132 20 3 23 0 0.997 0.026 Dpltd 
77 cell 4532 192 348 540 0.28 0.032 0.0265 Enrchd









on the CH-CH 
group of donors 










11 1 3 4 0.372 0.042 0.0293 Enrchd
83 response to heat 33 0 8 8 1 0.002 0.0297 Enrchd
84 carbohydrate metabolism 252 8 31 39 0.829 0.003 0.0302 Enrchd





72 11 3 14 2E-04 0.907 0.0323 Dpltd 
87 extrachromosomal DNA 46 3 7 10 0.297 0.048 0.0329 Enrchd


























of mitotic cell 
cycle 





34 5 3 8 0.012 0.46 0.035 Dpltd 
94 membrane lipid metabolism 53 0 11 11 1 0.001 0.0355 Enrchd










3 0 2 2 1 0.015 0.0365 Enrchd
98 NADPH regeneration 3 0 2 2 1 0.015 0.0365 Enrchd





3 0 2 2 1 0.015 0.0365 Enrchd
101 regulation of catabolism 3 0 2 2 1 0.015 0.0365 Enrchd


























3 2 0 2 0.005 1 0.0365 Dpltd 















3 0 2 2 1 0.015 0.0365 Enrchd
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3 0 2 2 1 0.015 0.0365 Enrchd





















7 0 3 3 1 0.011 0.037 Enrchd










7 0 3 3 1 0.011 0.037 Enrchd










17 0 5 5 1 0.006 0.0375 Enrchd






12 0 4 4 1 0.009 0.0401 Enrchd




of mitotic cell 
cycle 
35 6 2 8 0.003 0.739 0.041 Dpltd 
130 amine metabolism 117 5 15 20 0.537 0.023 0.0432 Enrchd










42 1 8 9 0.832 0.01 0.0454 Enrchd
134 morphogenesis 624 26 59 85 0.52 0.022 0.0459 Enrchd





18 1 4 5 0.534 0.038 0.0472 Enrchd
137 nucleosome 30 4 3 7 0.034 0.38 0.0492 Dpltd 





126 14 7 21 7E-04 0.828 0.0494 Dpltd 




Group 2: PAEC 20 48 vs. PAEC C 48 




















1 extracellular space 479 21 64 85 0.198 0 0 Enrchd 
2 extracellular 557 27 71 98 0.06 1E-04 0 Enrchd 
3 actin cytoskeleton 80 4 18 22 0.329 1E-04 0.0001 Enrchd 





37 4 8 12 0.043 0.01 0.0009 Enrchd 
6 extracellular matrix 101 9 14 23 0.01 0.042 0.0015 Dpltd 
7 nonselective vesicle docking 3 0 3 3 1 6E-04 0.0017 Enrchd 
8 superoxide metabolism 3 0 3 3 1 6E-04 0.0017 Enrchd 
9 collagen fibril organization 3 0 3 3 1 6E-04 0.0017 Enrchd 
10 structural molecule activity 217 13 28 41 0.047 0.013 0.0017 Enrchd 
11 calcium ion binding 179 13 22 35 0.011 0.043 0.002 Dpltd 
12 regulation of cell migration 9 2 3 5 0.04 0.034 0.0021 Enrchd 
13 pigmentation 17 2 5 7 0.124 0.011 0.0023 Enrchd 
14 ferric iron binding 6 0 4 4 1 6E-04 0.0026 Enrchd 
15 membrane 1020 37 110 147 0.531 8E-04 0.0032 Enrchd 
16 actin filament 10 0 5 5 1 7E-04 0.0037 Enrchd 
17 vacuole 54 0 14 14 1 1E-04 0.0037 Enrchd 
18 iron ion binding 10 0 5 5 1 7E-04 0.0037 Enrchd 
19 striated muscle thin filament 7 2 2 4 0.024 0.112 0.0054 Dpltd 
20 cellular process 1732 73 159 232 0.028 0.053 0.0057 Dpltd 


















25 1 7 8 0.604 0.004 0.007 Enrchd 
25 secretion 25 1 7 8 0.604 0.004 0.007 Enrchd 







71 4 12 16 0.255 0.014 0.0087 Enrchd 





































135 3 23 26 0.876 7E-04 0.0091 Enrchd 

















66 4 11 15 0.215 0.02 0.0101 Enrchd 
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27 1 7 8 0.632 0.006 0.0116 Enrchd 





33 1 8 9 0.706 0.005 0.0134 Enrchd 















2 0 2 2 1 0.007 0.0145 Enrchd 
46 anti-apoptosis 28 1 7 8 0.646 0.007 0.0145 Enrchd 























28 1 7 8 0.646 0.007 0.0145 Enrchd 






2 0 2 2 1 0.007 0.0145 Enrchd 
54 dynactin complex 2 0 2 2 1 0.007 0.0145 Enrchd 
55 interleukin-8 receptor binding 2 0 2 2 1 0.007 0.0145 Enrchd 
56 acetate kinase activity 2 0 2 2 1 0.007 0.0145 Enrchd 
57 ferritin complex 2 0 2 2 1 0.007 0.0145 Enrchd 
58 lysosome 45 0 11 11 1 9E-04 0.0153 Enrchd 
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59 muscle fiber 23 3 4 7 0.048 0.123 0.0154 Dpltd 
60 transition metal ion transport 18 1 5 6 0.486 0.014 0.0154 Enrchd 
61 endopeptidase inhibitor activity 51 3 9 12 0.281 0.025 0.0156 Enrchd 
62 protease inhibitor activity 51 3 9 12 0.281 0.025 0.0156 Enrchd 
63 lytic vacuole 51 0 12 12 1 8E-04 0.0156 Enrchd 
64 iron ion transport 9 0 4 4 1 0.004 0.016 Enrchd 
65 glucan biosynthesis 9 0 4 4 1 0.004 0.016 Enrchd 
66 mitotic spindle assembly 9 3 1 4 0.003 0.548 0.016 Dpltd 












34 1 8 9 0.717 0.006 0.0163 Enrchd 
70 carbohydrate metabolism 156 4 24 28 0.827 0.002 0.0177 Enrchd 











36 1 8 9 0.737 0.009 0.0236 Enrchd 





10 2 2 4 0.048 0.204 0.0241 Dpltd 
76 muscle development 54 5 7 12 0.044 0.166 0.0241 Dpltd 
77 kinase inhibitor activity 10 0 4 4 1 0.007 0.0241 Enrchd 











210 7 28 35 0.648 0.009 0.0255 Enrchd 
81 regulation of angiogenesis 6 0 3 3 1 0.01 0.0263 Enrchd 
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6 3 0 3 9E-04 1 0.0263 Dpltd 
84 Golgi membrane 15 3 2 5 0.015 0.365 0.0267 Dpltd 
85 ribonucleotide metabolism 37 1 8 9 0.747 0.01 0.0279 Enrchd 





68 3 11 14 0.45 0.025 0.0292 Enrchd 
88 development 596 31 55 86 0.018 0.243 0.03 Dpltd 
89 polysaccharide metabolism 26 0 7 7 1 0.005 0.03 Enrchd 
90 synaptic vesicle transport 11 0 4 4 1 0.01 0.0344 Enrchd 
91 cell motility 130 11 12 23 0.007 0.417 0.035 Dpltd 













16 0 5 5 1 0.008 0.0351 Enrchd 
95 nucleotide biosynthesis 51 2 9 11 0.558 0.025 0.037 Enrchd 
96 phospholipase D activity 3 0 2 2 1 0.02 0.04 Enrchd 






3 0 2 2 1 0.02 0.04 Enrchd 










3 0 2 2 1 0.02 0.04 Enrchd 





3 2 0 2 0.004 1 0.04 Dpltd 
104 mitotic spindle elongation 3 2 0 2 0.004 1 0.04 Dpltd 
105 hormone secretion 3 0 2 2 1 0.02 0.04 Enrchd 
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7 3 0 3 0.002 1 0.042 Dpltd 





40 1 8 9 0.774 0.016 0.0444 Enrchd 
112 integral to membrane 740 27 76 103 0.519 0.026 0.0445 Enrchd 
113 enzyme regulator activity 190 12 19 31 0.04 0.247 0.0445 Dpltd 
114 ATP metabolism 17 1 4 5 0.467 0.049 0.0449 Enrchd 
115 collagen 17 0 5 5 1 0.011 0.0449 Enrchd 
116 synaptic vesicle 12 0 4 4 1 0.014 0.0468 Enrchd 




Group 3: PAVEC C 48 vs. PAEC C 48 

















1 regulation of cell migration 14 2 6 5 0.039 1E-04 0 Enrchd 





2 0 2 2 1 0.003 0.0025 Enrchd 





2 2 0 2 5E-04 1 0.0025 Dpltd 
6 blood vessel development 49 2 10 8 0.309 3E-04 0.0028 Enrchd 







22 1 6 5 0.399 0.001 0.0041 Enrchd 
9 phosphorylase activity 14 2 4 4 0.039 0.006 0.0043 Enrchd 
10 cadmium ion binding 8 3 0 3 6E-04 1 0.0059 Dpltd 
11 cell motility 263 10 24 23 0.078 0.01 0.0068 Enrchd 
12 cell communication 1660 51 88 103 0.009 0.703 0.0082 Dpltd 
13 structural molecule activity 426 10 35 33 0.513 0.011 0.0084 Enrchd 
14 cellular morphogenesis 59 3 10 8 0.152 0.001 0.009 Enrchd 





790 32 22 54 7E-04 1 0.0111 Dpltd 





10 1 3 3 0.207 0.015 0.0117 Enrchd 
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19 connexon channel activity 10 1 3 3 0.207 0.015 0.0117 Enrchd 





4 2 0 2 0.003 1 0.0143 Dpltd 
22 interleukin-8 receptor binding 4 1 2 2 0.088 0.017 0.0143 Enrchd 
23 acetate kinase activity 4 0 4 2 1 0 0.0143 Enrchd 
24 DNA clamp loader activity 4 0 4 2 1 0 0.0143 Enrchd 
25 drug transporter activity 4 2 0 2 0.003 1 0.0143 Dpltd 
26 RNA-nucleus export 20 0 6 4 1 5E-04 0.0163 Enrchd 
27 chromatin 20 0 4 4 1 0.022 0.0163 Enrchd 
28 RNA transport 20 0 6 4 1 5E-04 0.0163 Enrchd 
29 nucleic acid transport 20 0 6 4 1 5E-04 0.0163 Enrchd 
30 synaptic transmission 119 8 8 12 0.006 0.337 0.0165 Dpltd 
31 transmission of nerve impulse 119 8 8 12 0.006 0.337 0.0165 Dpltd 






12 3 0 3 0.002 1 0.02 Dpltd 
34 alpha-type channel activity 139 7 8 13 0.039 0.506 0.0228 Dpltd 
35 response to metal ion 5 2 0 2 0.005 1 0.023 Dpltd 
36 angiogenesis 45 2 7 6 0.275 0.011 0.0244 Enrchd 
37 chromosome condensation 13 0 6 3 1 0 0.025 Enrchd 
38 imaginal disc metamorphosis 13 2 2 3 0.034 0.159 0.025 Dpltd 
39 cell adhesion 381 12 29 28 0.161 0.048 0.0277 Enrchd 
40 enzyme regulator activity 350 15 21 26 0.013 0.38 0.0296 Dpltd 





24 4 0 4 0.002 1 0.0305 Dpltd 
43 viral life cycle 14 2 1 3 0.039 0.549 0.0307 Dpltd 
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44 viral infectious cycle 14 2 1 3 0.039 0.549 0.0307 Dpltd 
45 regulation of cell shape 14 1 4 3 0.277 0.006 0.0307 Enrchd 
46 response to abiotic stimulus 319 16 8 24 0.002 0.998 0.0314 Dpltd 
47 copper ion homeostasis 6 2 0 2 0.007 1 0.0333 Dpltd 

















6 1 2 2 0.13 0.039 0.0333 Enrchd 
52 establishment of tissue polarity 6 0 3 2 1 0.003 0.0333 Enrchd 
53 sister chromatid cohesion 6 0 4 2 1 1E-04 0.0333 Enrchd 







6 1 2 2 0.13 0.039 0.0333 Enrchd 
56 RNA localization 26 0 6 4 1 0.003 0.0396 Enrchd 





153 10 3 13 0.003 0.992 0.0449 Dpltd 
59 coreceptor activity 7 0 3 2 1 0.005 0.0451 Enrchd 
60 mesoderm cell fate commitment 7 2 0 2 0.01 1 0.0451 Dpltd 




PAVEC 20 48 vs. PAEC 20 48 






























4 0 4 4 1 0 0.0038 Enrchd 
4 calcium ion storage activity 4 3 1 4 0.006 0.43 0.0038 Dpltd 
5 isomerase activity 47 7 13 20 0.301 0.01 0.0055 Enrchd 
6 cytoskeletal protein binding 122 21 22 43 0.039 0.08 0.0057 Dpltd 
7 cell 2716 323 376 699 0.179 0.02 0.0087 Enrchd 
8 carbohydrate metabolism 170 18 38 56 0.702 0 0.0089 Enrchd 
9 nucleolus 40 1 16 17 0.993 0 0.0103 Enrchd 
11 nucleotide-sugar metabolism 12 4 3 7 0.042 0.2 0.0135 Dpltd 
12 chromosome condensation 12 1 6 7 0.773 0 0.0135 Enrchd 
13 NADPH regeneration 5 0 4 4 1 0 0.0151 Enrchd 





5 1 3 4 0.461 0.02 0.0151 Enrchd 
16 collagen type IV 5 1 3 4 0.461 0.02 0.0151 Enrchd 
17 
RNA elongation 
from Pol II 
promoter 










3 2 1 3 0.037 0.35 0.0152 Dpltd 
20 neuron differentiation 3 2 1 3 0.037 0.35 0.0152 Dpltd 
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21 regulation of mitotic cell cycle 3 1 2 3 0.31 0.05 0.0152 Enrchd 
22 
regulation of S 
phase of mitotic 
cell cycle 
3 1 2 3 0.31 0.05 0.0152 Enrchd 
23 cadmium ion binding 3 3 0 3 0.002 1 0.0152 Dpltd 





40 6 10 16 0.317 0.03 0.0238 Enrchd 






37 6 9 15 0.254 0.05 0.0249 Enrchd 
30 nuclear body 8 0 5 5 1 0 0.0263 Enrchd 
31 regulation of cell migration 8 4 1 5 0.009 0.68 0.0263 Dpltd 





19 1 8 9 0.905 0 0.0271 Enrchd 
34 viral capsid 28 2 10 12 0.854 0 0.0273 Enrchd 
35 energy pathways 123 15 25 40 0.462 0.02 0.0306 Enrchd 
36 chromatin 11 1 5 6 0.743 0.01 0.0329 Enrchd 
37 structural molecule activity 225 21 47 68 0.89 0 0.0331 Enrchd 
40 nicotinamide metabolism 6 0 4 4 1 0 0.0365 Enrchd 
41 NADPH metabolism 6 0 4 4 1 0 0.0365 Enrchd 















6 1 3 4 0.523 0.03 0.0365 Enrchd 
46 morphogenesis 433 72 51 123 5E-04 0.84 0.0378 Dpltd 
49 GTPase regulator activity 76 15 11 26 0.026 0.42 0.0405 Dpltd 
52 carbohydrate catabolism 36 4 10 14 0.616 0.02 0.0427 Enrchd 
56 virion 30 2 10 12 0.879 0 0.0473 Enrchd 


















127 16 24 40 0.404 0.04 0.0498 Enrchd 
73 cytoplasm 1235 134 193 327 0.864 0 0.05 Enrchd 
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9443 AJ292757 Human TUBB1 gene for Human beta tubulin 1, class VI. 1.141 1.141 0.672 1.298
12860 D14582 Human mRNA for epimorphin. 0.863 1.030 0.735 1.039
6599 AF195657 Human DNA mismatch repair protein (MLH3) mRNA, complete cds. 1.093 1.419 0.443 0.825
14262 AF243527 Human serine protease gene cluster, complete sequence. 0.787 1.028 0.717 0.941
3648 D83402 Human gene for prostacyclin synthase, exon 10 and complete cds. 1.000 1.033 0.518 0.999
6455 M75110 Human H,K-ATPase beta subunit mRNA, complete cds. 1.010 0.597 0.011 0.767
14372 D13388 Human mRNA for DnaJ protein homolog, complete cds. 1.042 1.371 0.470 1.292
5556 D01038 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 1.004 1.038 0.062 0.994
8386 M36860 Human elastin mRNA, complete cds. 0.894 1.467 0.537 1.157
15945 AL136761 
Human mRNA; cDNA DKFZp434I0515 
(from clone DKFZp434I0515); complete 
cds. 
1.051 1.023 0.663 0.918
12204 AF071771 zinc finger protein 143 (clone pHZ-1) 1.108 1.477 0.433 0.850
3779 AF049090 Human casein kinase I gamma 3L (CSNK1G3L) mRNA, complete cds. 0.927 1.042 0.686 0.969
11470 AB037786 Human mRNA for KIAA1365 protein, partial cds. 0.922 1.168 0.612 0.959
7537 AI962856 Putative prostate cancer tumor suppressor 0.947 1.002 0.653 1.094
7816 AK022927 
Human cDNA FLJ12865 fis, clone 
NT2RP2003643, moderately similar to 
Mouse (Mus musculus) mRNA for CMP-N-
acetylneuraminic acid synthetase. 
1.117 1.002 0.577 1.062
16573 AI299518 ESTs, Highly similar to 2208307A PNG gene [H.sapiens] 0.865 1.523 0.482 1.181
13444 NM_006896 homeo box A7 1.207 1.021 0.645 1.171
9552 M76423 
Human carbonic anhydrase VII (CA VII) 
gene, exons 4,5,6, and 7, and complete 
cds. 
1.024 1.014 0.572 1.034
8972 AI207650 APEX nuclease (multifunctional DNA repair enzyme) 1.058 1.018 0.743 0.806
9864 BC009208 Human, clone MGC:16169 IMAGE:3634845, mRNA, complete cds. 0.849 1.349 0.661 0.832
13458 AI927764 phosphomannomutase 2 0.882 0.696 0.232 1.026
17262 AF195766 Human ZHX1 protein (ZHX1) mRNA, complete cds. 1.063 1.556 0.582 0.652
8626 AL578299 aminoacylase 1 1.097 1.183 0.118 0.951
14383 U45325 Human Kruppel-related 3 (HKR3) gene, exons 4-11, and complete cds. 1.147 1.198 0.687 0.894
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11025 BC003394 
Human, heterogeneous nuclear 
ribonucleoprotein C (C1/C2), clone 
MGC:5418 IMAGE:3447724, mRNA, 
complete cds. 
1.000 1.115 0.530 0.771
10181 AF060568 Human promyelocytic leukemia zinc finger protein (PLZF) gene, complete cds. 0.929 1.179 0.738 0.951
3207 BC000266 
Human, NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 1 (7.5kD, 
MWFE), clone MGC:2066 IMAGE:3352028, 
mRNA, complete cds. 
0.881 1.211 0.605 0.960
6959 AK021796 Human cDNA FLJ11734 fis, clone HEMBA1005443. 0.979 0.678 0.398 0.907
14092 AK026204 Human cDNA: FLJ22551 fis, clone HSI00804. 0.931 1.174 0.635 0.916
9879 M94859 Human calnexin mRNA, complete cds. 1.075 1.211 0.660 1.322
13263 AY014180 Human E3 ubiquitin ligase Smurf2 mRNA, complete cds. 1.076 1.092 0.483 0.964
6267 U03493 Human connexin45 gene, complete cds. 1.273 1.093 0.575 0.653
5440 L12398 Human dopamine D4 receptor (DRD4) mRNA (D4.7) sequence. 0.782 1.323 0.623 0.997
14143 AF060568 Human promyelocytic leukemia zinc finger protein (PLZF) gene, complete cds. 1.013 1.086 0.642 0.923
11004 U03911 Human mutator gene (hMSH2) mRNA, complete cds. 0.960 1.083 0.724 0.957
10532 AI347985 matrix metalloproteinase 23B 1.379 1.285 0.659 0.693
9529 AF124432 Human HOM-TES-103 tumor antigen mRNA, complete sequence. 0.976 1.281 0.701 0.955
14693 AP000577 Human genomic DNA, chromosome 11q, clone:CMB9-51L7. 0.986 1.263 0.746 0.856
9863 BC003564 
Human, ATPase, H+ transporting, 
lysosomal (vacuolar proton pump), member 
J, clone MGC:1970 IMAGE:3546257, 
mRNA, complete cds. 
1.057 1.088 0.709 1.070
15845 AB037831 Human mRNA for KIAA1410 protein, partial cds. 0.995 1.089 0.436 0.741
11488 L12168 Human adenylyl cyclase-associated protein (CAP) mRNA, complete cds. 0.945 1.555 0.503 1.012
4021 AV714317 TGFB inducible early growth response 1.173 0.799 0.317 0.773
12967 L32140 Human afamin mRNA, complete cds. 1.064 0.724 0.195 1.272
3524 AB051544 Human mRNA for KIAA1757 protein, partial cds. 0.951 0.947 0.722 0.899
11128 U11276 Human hNKR-P1a protein (NKR-P1A) mRNA, complete cds. 0.958 0.952 0.355 1.116
12049 AK026690 
Homo sapiens cDNA: FLJ23037 fis, clone 
LNG02036, highly similar to HSU68019 
Homo sapiens mad protein homolog 
(hMAD-3) mRNA 
1.282 0.848 0.547 1.292
3635 AJ003147 
Human complete genomic sequence 
between D16S3070 and D16S3275, 
containing Familial Mediterranean Fever 
gene disease. 
0.972 1.774 0.490 0.924
5969 BE780960 phosphofructokinase, muscle 1.260 0.950 0.721 0.914
11303 D82345 Human mRNA for NB thymosin beta, complete cds. 1.341 0.949 0.602 0.878
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13842 AA489676 BCE-1 protein 0.966 0.899 0.344 0.957
9523 U50871 Human familial Alzheimer's disease (STM2) gene, complete cds. 0.974 0.922 0.252 1.466
5751 L76703 protein phosphatase 2, regulatory subunit B (B56), epsilon isoform 0.824 0.997 0.154 0.902
14689 AF044323 
Human cytochrome c oxidase assembly 
protein COX15 (COX15) mRNA, complete 
cds. 
0.922 0.768 0.243 0.830
10512 U09825 zinc finger protein 173 1.200 0.904 0.294 1.089
8286 U63963 Human CSF-1 receptor (FMS) gene, complete cds, and (SMF) gene, partial cds. 0.959 0.927 0.612 0.812
10392 BI835373 signal sequence receptor, delta (translocon-associated protein delta) 1.122 2.081 0.026 0.910
13340 M84326 Human ADP-ribosylation factor 1 mRNA, complete cds. 1.179 0.955 0.212 0.512
11909 AW965948 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 (6kD, KFYI) 0.808 0.844 0.607 0.973
10360 AW972560 chaperonin containing TCP1, subunit 4 (delta) 1.015 0.920 0.715 0.947
2917 F07456 methionine adenosyltransferase II, alpha 0.950 0.976 0.561 1.099
3876 AB021644 
Human GIOT-4 mRNA for gonadotropin 
inducible transcription repressor-4, 
complete cds. 
0.897 0.977 0.390 0.926
15062 BG495228 low molecular mass ubiquinone-binding protein (9.5kD) 0.988 0.817 0.637 1.273
8500 J03745 Human endonexin II mRNA, complete cds. 0.982 0.822 0.202 1.129
3951 H15124 RAB35, member RAS oncogene family 1.030 0.959 0.431 0.926
10643 BI054765 insulin-like growth factor 1 receptor 0.915 0.836 0.549 0.905
16238 AY008372 Human oxysterol binding protein-related protein 3 (ORP3) mRNA, complete cds. 0.877 0.986 0.340 0.934
18327 AL542973 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.839 0.837 0.493 1.336
3714 AB032957 Human mRNA for KIAA1131 protein, partial cds. 0.815 0.803 0.398 0.801
9551 U09117 Human phospholipase c delta 1 mRNA, complete cds. 1.139 0.970 0.444 1.227
10395 BE168491 major histocompatibility complex, class I, C 1.195 0.963 0.721 1.243
9105 NM_003052 solute carrier family 34 (sodium phosphate), member 1 0.879 0.986 0.614 1.078
16313 M87339 Human replication factor C, 37-kDa subunit mRNA, complete cds. 0.584 0.876 1.601 0.766
17268 D38305 Human mRNA for Tob, complete cds. 0.791 0.913 1.106 0.699
14438 AL132665 
Human mRNA; cDNA DKFZp566E034 
(from clone DKFZp566E034); complete 
cds. 
0.864 0.767 1.561 0.494
11902 BF034561 G-rich RNA sequence binding factor 1 0.750 1.111 1.238 0.875
4179 BC007951 
SRY (sex determining region Y)-box 9 
(campomelic dysplasia, autosomal sex-
reversal) 
0.899 1.101 1.356 0.626
5654 BC005883 hypothetical protein 0.897 0.938 1.343 0.682
16737 AL048242 methylthioadenosine phosphorylase 0.643 0.926 0.956 0.681
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13765 BG618998 CDC28 protein kinase 2 0.476 0.970 1.163 1.046
2920 AI033892 
ESTs, Highly similar to B Chain B, Crystal 
Structure Of The Human Cdk2 Kinase 
Complex With Cell Cycle-Regulatory 
Protein Ckshs1 [H.sapiens] 
0.708 1.020 1.264 0.785
4417 BC000335 nucleoporin 88kD 0.901 0.977 1.545 0.631
14595 AK001696 Human cDNA FLJ10834 fis, clone NT2RP4001207. 0.782 1.014 0.952 0.714
12219 AI536671 hypothetical protein PRO1489 0.606 0.957 1.211 0.426
16245 U15128 
Human beta-1,2-N-
acetylglucosaminyltransferase II (MGAT2) 
gene, complete cds. 
0.930 1.002 1.270 0.686
9416 AK001362 Human cDNA FLJ10500 fis, clone NT2RP2000369. 0.875 0.970 1.086 0.700
14581 U43328 Human link protein mRNA, complete cds. 0.785 1.030 1.139 0.687
12815 AF008915 Human EVI5 homolog mRNA, complete cds. 0.885 1.027 1.033 0.713
9152 BC008328 PAX transcription activation domain interacting protein 1 like 0.803 1.082 1.089 0.744
8749 BG619195 KIAA0528 gene product 0.731 1.077 1.331 0.731
8833 AI051628 v-jun avian sarcoma virus 17 oncogene homolog 0.732 0.932 1.311 0.805
3789 AP000427 Human genomic DNA, chromosome 8q23, clone:KB1171G1. 0.761 1.060 0.838 0.708
4311 BG572762 caspase 4, apoptosis-related cysteine protease 0.738 1.067 1.073 0.819
8282 AB005666 Human mRNA for GTPase-activating protein, complete cds. 0.959 1.039 1.026 0.731
5589 AL531502 serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1 0.716 0.941 1.115 0.644
4265 BG433239 smg GDS-ASSOCIATED PROTEIN 0.748 1.005 1.099 0.917
9117 BF690275 pyruvate kinase, muscle 0.802 0.803 1.303 0.653
13320 BG289736 protein phosphatase 1, catalytic subunit, gamma isoform 0.652 1.163 1.243 0.823
12723 D14497 Human mRNA for proto-oncogene protein, complete cds. 0.899 1.451 1.284 0.661
11894 AL580466 
protein phosphatase 3 (formerly 2B), 
regulatory subunit B (19kD), alpha isoform 
(calcineurin B, type I) 
0.703 1.192 0.853 0.702
13316 AL571008 baculoviral IAP repeat-containing 5 (survivin) 0.577 1.363 1.235 1.027
14254 AF260225 Human TESTIN 2 and TESTIN 3 genes, complete cds, alternatively spliced. 0.698 1.336 1.085 0.810
7368 BG107450 KIAA0256 gene product 0.533 1.335 1.287 0.903
12811 D14134 Human mRNA for RAD51, complete cds. 0.669 1.324 1.005 0.963
6923 M74091 Human cyclin mRNA. 0.680 1.277 1.051 0.812
13441 BE702316 eukaryotic translation initiation factor 4B 0.772 1.309 1.434 0.677
12493 AF132811 Human nectin-like protein 2 (NECL2) mRNA, complete cds. 0.604 1.177 0.983 0.544
16571 BI908492 unc119 (C.elegans) homolog 1.293 1.613 0.609 1.222
6755 D38555 Human mRNA for KIAA0079 gene, complete cds. 1.075 1.564 0.962 0.945
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8676 AI275084 transcription factor AP-2 beta (activating enhancer-binding protein 2 beta) 1.090 1.560 0.875 1.074
16468 AF062332 catenin (cadherin-associated protein), delta 1 1.121 1.704 0.858 0.988
4753 BC011519 
Human, angiotensinogen (serine (or 
cysteine) protease inhibitor, clade A (alpha-
1 antiprotease, antitrypsin), member 8), 
clone MGC:17092 IMAGE:4213559, 
mRNA, complete cds. 
0.797 1.976 0.867 0.978
13485 AL571444 LIS1-interacting protein NUDEL; endooligopeptidase A 1.216 1.527 1.128 1.159
15087 BF793662 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived) 1.085 2.001 0.784 1.031
14288 AL117468 Human mRNA; cDNA DKFZp586N1922 (from clone DKFZp586N1922); partial cds. 1.197 1.525 0.948 1.256
2447 AL529959 eukaryotic translation initiation factor 3, subunit 8 (110kD) 1.130 1.518 0.929 1.401
6364 AK026157 Human cDNA: FLJ22504 fis, clone HRC11430. 1.234 1.516 0.871 0.932
10503 AI619551 nuclear cap binding protein subunit 2, 20kD 0.905 1.514 0.908 1.245
9439 L02547 
Human (clone pZ50-19) cleavage 
stimulation factor 50kDa subunit, complete 
cds. 
1.053 1.735 0.793 1.537
15187 BC004467 KIAA0171 gene product 1.023 1.570 0.857 1.180
4842 BC005968 
Human, ATP binding protein associated 
with cell differentiation, clone MGC:14620 
IMAGE:4073821, mRNA, complete cds. 
0.785 1.607 0.696 0.870
2460 NM_005529 heparan sulfate proteoglycan 2 (perlecan) 1.150 1.878 0.894 1.131
13619 AI698095 KIAA0699 protein 1.066 1.784 0.772 0.870
9731 M94166 Human heregulin-beta1 gene, complete cds. 0.779 1.804 0.948 1.208
16463 BC001832 
Human, eukaryotic translation initiation 
factor 5A, clone MGC:4130 
IMAGE:2961296, mRNA, complete cds. 
1.402 1.603 0.624 1.227
15341 BG675712 calmodulin 2 (phosphorylase kinase, delta) 1.000 1.591 0.940 1.078
8683 L06133 Human putative Cu++-transporting P-type ATPase mRNA, complete cds. 1.083 1.635 1.100 1.583
10516 AV650019 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 2 0.729 1.752 0.786 1.292
16890 BE410539 KIAA0304 gene product 1.047 1.584 1.003 1.559




(PFKFB4) mRNA, complete cds. 
0.988 1.896 0.870 0.980
12103 NM_014214 inositol(myo)-1(or 4)-monophosphatase 2 1.134 1.583 0.809 0.972
8779 L38951 karyopherin (importin) beta 1 0.826 8.971 0.813 1.590
3618 BC004108 Human, clone IMAGE:3687782, mRNA, partial cds. 0.943 2.066 0.971 0.972
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16011 D78130 Human mRNA for squalene epoxidase, complete cds. 1.140 1.507 0.922 1.047
4120 AU135575 villin 2 (ezrin) 1.230 1.504 0.834 1.273
6263 M36711 Human sequence-specific DNA-binding protein (AP-2) mRNA, complete cds. 0.957 2.743 0.673 0.945
2296 BC005133 Human, clone MGC:11134 IMAGE:3836683, mRNA, complete cds. 0.966 2.351 0.919 1.148
9079 BE909056 clathrin, light polypeptide (Lca) 0.927 2.411 0.929 1.191
12274 BG252978 membrane component, chromosome 11, surface marker 1 1.148 2.438 0.863 0.896
10098 AB062981 Macaque brain cDNA clone:QmoA-10634, full insert sequence. 0.954 3.079 0.902 1.050
11864 AW296083 
Homo sapiens cDNA: FLJ21897 fis, clone 
HEP03447, highly similar to AF052178 
Homo sapiens clone 24523 mRNA 
sequence 
0.829 2.302 0.911 1.148
14096 M64925 
Human palmitoylated erythrocyte 
membrane protein (MPP1) mRNA, 
complete cds. 
1.450 3.104 0.270 1.126
9124 NM_003359 UDP-glucose dehydrogenase 1.380 3.147 0.939 0.937
12866 CAA44244 formin, isoform IV 1.041 4.698 0.944 1.511
10200 L06862 
collagen, type VII, alpha 1 (epidermolysis 
bullosa, dystrophic, dominant and 
recessive) 
0.979 2.005 0.929 1.030
7051 BG746580 mitochondrial ribosomal protein S27 1.071 1.284 0.715 1.048
6894 U24166 Human EB1 mRNA, complete cds. 1.606 2.194 0.933 1.016
11589 AJ243972 Human mRNA for 6-phosphogluconolactonase (6PGL gene). 1.008 2.073 0.918 1.004
3366 AB019602 Human IDN3-B mRNA, complete cds. 0.965 1.399 0.720 1.050
8340 AK027542 
Human cDNA FLJ14636 fis, clone 
NT2RP2001233, weakly similar to ZINC 
FINGER PROTEIN 91. 
0.949 1.701 0.863 1.161
17874 AF009802 Human homeodomain protein (BAPX1) gene, complete cds. 1.011 2.072 0.666 1.258
11269 AF025529 Human leucocyte Ig-like receptor-6b (LIR-6) mRNA, complete cds. 1.008 2.087 0.812 1.009
13644 AA582575 intersectin 1 (SH3 domain protein) 0.855 1.655 0.712 1.269
16576 BG569292 angiogenin, ribonuclease, RNase A family, 5 0.882 2.134 0.703 1.003
7590 BG718906 ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens] 0.710 2.125 0.926 0.929
12566 AB033035 Human mRNA for KIAA1209 protein, partial cds. 1.611 0.947 1.044 1.176
6002 AL525317 delta sleep inducing peptide, immunoreactor 1.933 0.903 1.129 1.213
5642 BF340474 hypothetical protein FLJ11560 1.633 0.819 1.042 1.120
16276 L20852 Human leukemia virus receptor 2 (GLVR2) mRNA, complete cds. 1.657 0.915 1.084 1.688
16146 BC000429 
Human, chromosome 14 open reading 
frame 2, clone MGC:8356 IMAGE:2819801, 
mRNA, complete cds. 
1.919 0.883 0.865 1.119
5563 BC012195 
Human, Similar to valosin-containing 
protein, clone MGC:4053 IMAGE:2822943, 
mRNA, complete cds. 
1.621 0.845 0.804 1.093
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10945 BC004967 
Human, putative glialblastoma cell 
differentiation-related, clone MGC:2352 
IMAGE:3535682, mRNA, complete cds. 
1.750 0.978 0.864 1.153
4315 BG831512 
DiGeorge syndrome critical region gene 
DGSI; likely ortholog of mouse expressed 
sequence 2 embryonic lethal 
1.570 0.961 1.183 1.022
8959 AI554560 GTP-binding protein Rho7 2.256 1.099 0.974 1.074
14300 J03746 Human glutathione S-transferase mRNA, complete cds. 1.653 1.312 0.915 1.090
8905 AW303586 transforming growth factor, beta 2 2.815 1.082 0.967 1.368
13749 BF681347 actin, alpha 2, smooth muscle, aorta 1.803 1.265 0.885 1.288
8171 AF252872 Human cystine/glutamate transporter xCT mRNA, complete cds. 4.021 1.251 0.882 1.059
16936 BG498371 clones 23667 and 23775 zinc finger protein 1.513 1.216 1.009 0.952
11403 U76549 Human cytokeratin 8 mRNA, complete cds. 1.352 1.105 0.733 1.246
5961 AF073362 meiotic recombination (S. cerevisiae) 11 homolog A 3.327 1.198 0.984 1.640
16115 AF063594 Human brain my036 protein mRNA, complete cds. 1.553 1.337 1.057 1.198
2757 BG612479 adenine phosphoribosyltransferase 1.670 1.184 0.792 1.105
5727 BF309422 DNA fragmentation factor, 45 kD, alpha polypeptide 1.570 1.120 0.924 1.067
6023 BF795451 tryptophanyl-tRNA synthetase 1.944 1.128 0.831 2.465
2745 BC004390 phosphatidylserine synthase 1 1.678 1.130 0.826 1.050
7047 BF305705 histone deacetylase 5 1.890 1.136 0.916 1.127
12523 AL117413 Human mRNA; cDNA DKFZp566M051 (from clone DKFZp566M051). 1.534 1.330 1.159 1.072
16436 AF024636 serine/threonine kinase 24 (Ste20, yeast homolog) 1.509 1.368 0.858 1.134
8647 BI862079 peroxiredoxin 2 1.588 1.040 1.057 1.422
6647 AB053450 Human mRNA for KIAA1776 protein (fibrillin3), complete cds. 1.780 0.964 1.029 1.244
8820 NM_000157 glucosidase, beta; acid (includes glucosylceramidase) 1.858 0.977 0.978 1.517
2928 K03191 cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1 8.300 0.966 0.920 1.254
8346 U20734 Human transcription factor junB (junB) gene, 5' region and complete cds. 1.704 0.967 0.871 1.187
13837 BF984053 proteasome (prosome, macropain) subunit, beta type, 6 1.346 0.973 0.834 1.525
14767 M10036 Human triosephosphate isomerase mRNA, complete cds. 2.172 0.975 0.920 1.513
4491 AL538660 heterogeneous nuclear ribonucleoprotein R 2.031 0.975 0.892 0.992
5535 BC010693 
Human, Similar to hypothetical protein 
FLJ10883, clone IMAGE:3855861, mRNA, 
partial cds. 
1.466 1.536 1.045 1.303
10171 BI088564 upstream binding transcription factor, RNA polymerase I 1.961 1.140 0.911 1.586
16774 AL543484 Ras association (RalGDS/AF-6) domain family 1 1.898 1.372 1.029 1.234
7286 AU118354 ATP-binding cassette, sub-family G (WHITE), member 2 1.733 1.534 1.236 1.732
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7289 AB007890 KIAA0430 gene product 1.560 1.409 0.919 0.940
18362 BG722759 phytanoyl-CoA hydroxylase (Refsum disease) 1.591 1.398 0.771 1.529
12094 L07956 
glucan (1,4-alpha-), branching enzyme 1 
(glycogen branching enzyme, Andersen 
disease, glycogen storage disease type IV) 
2.548 1.031 0.909 0.964
7441 AW250734 NADH dehydrogenase (ubiquinone) flavoprotein 1 (51kD) 2.005 1.032 1.333 2.063
8059 AAD43813 Na,K-ATPase alpha-4 subunit 1.653 1.168 0.914 0.993
12695 AF220490 Human group III secreted phospholipase A2 mRNA, complete cds. 1.776 1.013 0.853 1.702
16401 BC011741 Human, clone MGC:19671 IMAGE:3352603, mRNA, complete cds. 1.778 0.749 0.916 1.507
10684 AB011173 KIAA0601 protein 0.968 0.687 0.955 1.115
14597 U39657 Human MAP kinase kinase 6 (MKK6) mRNA, complete cds. 0.949 0.571 0.916 0.890
14161 U12535 
Human epidermal growth factor receptor 
kinase substrate (Eps8) mRNA, complete 
cds. 
0.593 0.704 0.816 0.659
16746 AA523974 hypothetical protein MGC14139 0.911 0.597 0.868 0.746
4243 L01042 TATA element modulatory factor 1 0.827 0.589 0.789 1.049
3397 AJ002535 Human mRNA for obscurin (OBSCN gene). 0.827 0.709 0.872 0.756
12085 BG821629 phosphomannomutase 2 0.897 0.710 0.858 1.000
7341 AI952550 MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) 0.680 0.698 1.335 1.084
13215 AB014569 Human mRNA for KIAA0669 protein, complete cds. 0.692 0.711 0.981 1.297
9782 AB023161 Human mRNA for KIAA0944 protein, partial cds. 0.945 0.550 0.937 0.933
3841 BAB47481 KIAA1852 protein 0.826 0.546 0.998 0.948
16743 L33075 IQ motif containing GTPase activating protein 1 0.611 0.545 0.947 1.041
7284 BG390232 reticulocalbin 2, EF-hand calcium binding domain 0.953 0.716 1.048 1.043
12047 AW778997 transforming, acidic coiled-coil containing protein 1 1.058 0.609 0.767 0.965
16707 AA534580 serine/threonine kinase with Dbl- and pleckstrin homology domains 0.865 0.638 0.808 0.828
9596 BC001765 
Human, Similar to stromal antigen 2, clone 
MGC:1282 IMAGE:3352347, mRNA, 
complete cds. 
0.748 0.638 0.864 0.910
18326 AI858946 KIAA0295 protein 0.857 0.530 0.886 1.128
13754 AI299309 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 1.050 0.668 0.849 1.119
15089 U54617 pyruvate dehydrogenase kinase, isoenzyme 4 1.244 0.676 0.660 0.985
11431 AK024923 Human cDNA: FLJ21270 fis, clone COL01749. 0.870 0.679 0.812 1.085
13643 AI050952 activated leucocyte cell adhesion molecule 0.688 0.673 0.841 0.933
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11627 AF279372 
Human inositol 3,4,5,6 tetrakisphosphate 1-
kinase/inositol 1,3,4-trisphosphate 5/6-
kinase mRNA, complete cds. 
1.023 0.767 0.736 0.912
8921 BF310946 ribosomal protein L35 0.805 0.685 1.019 0.866
10378 AI125923 H2B histone family, member B 0.876 0.663 0.935 1.096
14094 AF113127 Human S1R protein (S1R) mRNA, complete cds. 1.170 0.694 0.832 0.799
5716 AI823889 purinergic receptor (family A group 5) 0.952 0.691 0.950 1.122
14398 AF151900 Human CGI-142 protein mRNA, complete cds. 0.665 0.772 0.931 0.839
4938 AF385084 Human heat shock protein mRNA, complete cds. 0.900 0.655 1.055 0.871
8805 D87743 solute carrier family 9 (sodium/hydrogen exchanger), isoform 6 0.976 0.647 0.930 0.819
5489 AI992137 hepatocellular carcinoma-associated antigen 58 0.903 0.772 0.683 1.076
16937 AI885852 H2A histone family, member O 0.676 0.717 0.852 1.350
7112 AL552252 GTP-binding protein homologous to Saccharomyces cerevisiae SEC4 1.042 0.679 0.726 1.438
15183 NM_013416 neutrophil cytosolic factor 4 (40kD) 1.045 0.514 0.795 1.077
14123 AF179896 Human TALE homeobox protein Meis2b mRNA, complete cds. 0.607 0.465 0.925 0.940
14566 AP000504 Human genomic DNA, chromosome 6p21.3, HLA Class I region, section 3/20. 0.926 0.500 0.435 1.075
6496 BAB30461 putative 0.746 0.743 0.743 0.786
13596 U10990 nuclear receptor subfamily 2, group C, member 2 0.820 0.733 0.966 1.095
16452 AA453425 seven transmembrane domain protein 1.017 0.729 1.063 0.769
8526 AF153605 Human androgen induced protein (AIG-1) mRNA, complete cds. 0.982 0.496 0.892 1.156
13210 M36821 Human cytokine (GRO-gamma) mRNA, complete cds. 1.021 0.722 0.787 0.862
10005 M65131 Human methylmalonyl-CoA mutase (MCM) mRNA, complete cds. 0.691 0.421 0.742 1.217
5532 AU119325 protein tyrosine phosphatase, non-receptor type 2 0.797 0.747 0.934 1.138
4104 BG620669 actin related protein 2/3 complex, subunit 3 (21 kD) 1.055 0.738 0.748 1.077
11620 AB016068 Human mRNA for Ste24p, complete cds. 0.922 0.741 0.773 0.895
4271 AA521448 
ESTs, Weakly similar to T22587 
hypothetical protein F53F8.5 - 
Caenorhabditis elegans [C.elegans] 
0.963 0.718 0.783 0.823
16766 AA031914 KIAA0143 protein 0.600 0.736 0.841 0.627
12682 U54996 Human protein ZW10 homolog (HZW10) mRNA, complete cds. 0.959 0.501 0.838 0.906
17531 AF309033 Human tankyrase-2 (TNKS-2) mRNA, complete cds. 1.047 0.924 1.506 1.100
13014 D21205 Human mRNA for estrogen responsive finger protein, complete cds. 0.932 0.981 2.118 1.551
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11163 BC001731 
Human, membrane component, 
chromosome 11, surface marker 1, clone 
MGC:1378 IMAGE:3355481, mRNA, 
complete cds. 
0.905 0.924 2.127 0.873
14447 AK026623 
Human cDNA: FLJ22970 fis, clone 
KAT10766, highly similar to HUMCOXNE 
Human nuclear-encoded mitochondrial 
cytochrome c oxidase Va subunit mRNA. 
0.808 1.268 1.808 1.064
11481 AF073482 Human myotubularin related protein 7 mRNA, partial cds. 0.700 1.308 1.070 1.362
1350 BI962886 U2 small nuclear ribonucleoprotein auxiliary factor (65kD) 0.599 0.955 1.299 1.056
9522 U58334 
Human Bcl2, p53 binding protein 
Bbp/53BP2 (BBP/53BP2) mRNA, complete 
cds. 
0.765 0.823 1.790 1.303





0.604 0.923 1.315 1.477
16428 M62925 Human transglutaminase K enzyme mRNA, complete cds. 1.101 0.967 1.571 1.122
15961 AB011089 Human mRNA for KIAA0517 protein, partial cds. 1.039 1.113 1.507 1.099
16892 BF589570 hypothetical protein FLJ20277 0.833 1.152 1.512 0.988
11924 BG563075 translational inhibitor protein p14.5 0.978 0.894 1.524 1.051
8142 D26361 Human mRNA for KIAA0042 gene, complete cds. 1.002 1.096 1.894 0.902
4123 BC007007 interleukin 18 (interferon-gamma-inducing factor) 0.736 0.761 1.367 1.465
11939 BG740338 acetyl-Coenzyme A acetyltransferase 1 (acetoacetyl Coenzyme A thiolase) 1.016 1.015 1.510 1.439
9377 AF029777 Human histone acetyltransferase (GCN5) mRNA, partial cds. 0.995 1.090 1.283 1.599
3617 BC006285 Human, clone MGC:10315 IMAGE:3960073, mRNA, complete cds. 0.923 0.992 1.617 1.140
15029 F25690 ESTs, Weakly similar to TELT_HUMAN TELETHONIN [H.sapiens] 0.964 1.034 1.786 1.635
7190 NM_001767 CD2 antigen (p50), sheep red blood cell receptor 0.944 0.930 1.824 0.803
10651 R01051 ATP-binding cassette, sub-family A (ABC1), member 1 0.863 1.527 1.293 1.580
6555 CAA73251 Pro-Pol-dUTPase polyprotein 1.035 1.418 1.480 1.613
5360 BC001362 
Human, 2',3'-cyclic nucleotide 3' 
phosphodiesterase, clone MGC:2262 
IMAGE:3051112, mRNA, complete cds. 
1.035 1.005 1.801 1.071
6410 AL080202 Human mRNA; cDNA DKFZp434F172 (from clone DKFZp434F172). 1.024 0.700 1.280 2.109
4112 AL558909 protein tyrosine phosphatase, non-receptor type 18 (brain-derived) 1.070 1.011 1.642 1.127
16738 BF726950 H2A histone family, member L 0.621 1.438 1.485 1.496
15057 AL571972 Fc fragment of IgG, receptor, transporter, alpha 0.932 1.521 1.301 1.126
5023 AB060914 Macaque brain cDNA clone:QtrA-14537, full insert sequence. 0.854 0.831 1.145 1.742
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10975 AF064854 
Human map 17q24; 5.13cR from 
GATA41C05 repeat region, complete 
sequence. 
0.954 1.045 1.522 1.123
5985 D89618 karyopherin alpha 3 (importin alpha 4) 0.856 1.045 1.438 1.544
6888 D28480 Human mRNA for hMCM2, complete cds. 0.666 1.369 1.282 1.189
7523 AV726230 myelin-associated oligodendrocyte basic protein 0.667 0.933 0.925 1.392
13671 R42895 serine dehydratase 1.055 1.020 1.670 1.505
8934 AI417964 calcium channel, voltage-dependent, L type, alpha 1S subunit 0.897 1.011 1.578 1.341
13493 BG469316 H1 histone family, member X 1.200 1.014 1.414 1.713
5965 AA825544 peroxisomal long-chain acyl-coA thioesterase 0.918 0.940 1.505 0.929
12060 U30894 N-sulfoglucosamine sulfohydrolase (sulfamidase) 1.081 0.961 2.275 0.993
8620 BC000833 mitogen-activated protein kinase-activated protein kinase 5 0.900 0.914 1.989 1.044
10068 AK026968 Human cDNA: FLJ23315 fis, clone HEP12021. 1.001 0.961 1.600 1.188
4896 AB070089 Macaque testis cDNA clone:QtsA-13272, full insert sequence. 0.846 0.946 1.978 1.102
2912 M80629 cell division cycle 2-like 5 (cholinesterase-related cell division controller) 0.752 1.014 1.872 0.894
15948 BC011904 
Human, Similar to putative 
sialoglycoprotease type 2, clone 
MGC:20293 IMAGE:4121450, mRNA, 
complete cds. 
1.003 1.072 2.163 0.852
10374 BE935831 microtubule-associated protein 1B 1.244 1.124 5.744 0.904
4955 M32284 Human glucocorticoid receptor gene, partial. 0.902 0.947 1.512 0.988
4118 AL583224 CAT56 protein 1.096 1.002 1.685 1.220
13524 M74547 retinoblastoma-like 1 (p107) 0.765 0.927 2.299 1.407
14396 AF129756 
Human MSH55 gene, partial cds; and 
CLIC1, DDAH, G6b, G6c, G5b, G6d, G6e, 
G6f, BAT5, G5b, CSK2B, BAT4, G4, Apo 
M, BAT3, BAT2, AIF-1, 1C7, LST-1, LTB, 
TNF, and LTA genes, complete cds. 
0.930 0.725 2.950 0.877
6819 AF052224 Human neuronal double zinc finger protein (ZNF231) mRNA, complete cds. 1.438 0.925 1.855 0.879
12095 L04284 myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog) 0.902 1.043 1.686 1.030
4233 AL559849 histone deacetylase 1 1.079 0.923 1.588 1.125
12524 AF062072 Human zinc finger protein 216 (ZNF216) gene, complete cds. 1.332 1.095 
10.36
3 1.266
15992 AJ001612 Human mRNA for L-3-phosphoserine-phosphatase homologue. 1.334 0.936 1.595 0.925
11006 D17530 Human mRNA for drebrin E, complete cds. 1.151 1.081 87.630 1.747
11317 AF132963 Human CGI-29 protein mRNA, complete cds. 0.884 0.978 1.522 1.190
10618 AI915504 KIAA0652 gene product 0.794 0.956 4.167 0.934
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5631 AW082035 keratin 16 (focal non-epidermolytic palmoplantar keratoderma) 1.009 1.076 6.600 1.669
16239 AL133080 Human mRNA; cDNA DKFZp434A0727 (from clone DKFZp434A0727). 1.014 0.738 2.521 0.798
4014 AW409924 chromosome 19 open reading frame 3 1.320 1.126 2.847 1.776
10201 D78333 chaperonin containing TCP1, subunit 6B (zeta 2) 1.071 0.678 1.529 0.982
8468 BC010100 Human, clone MGC:19693 IMAGE:3506451, mRNA, complete cds. 0.899 1.209 1.829 1.421
10036 AF295368 Human G-protein coupled receptor GPR86 (GPR86) mRNA, complete cds. 0.950 0.661 2.048 0.828
13594 BC006103 CDC-like kinase 3 1.067 0.788 1.655 1.005
6454 AJ251026 Human mRNA for putative odorant binding protein b-a (OBPIIb gene). 1.016 0.853 1.534 0.785
4077 AU099021 membrane-bound transcription factor protease, site 2 0.782 0.883 3.807 0.870
18516 AA010378 integral membrane protein 2A 0.664 0.507 3.156 2.764
10073 AB011542 Human mRNA for MEGF9, partial cds. 1.021 0.813 1.679 1.141
7272 AV763549 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, gamma 
polypeptide 1 
1.032 0.791 1.555 0.754
18012 BG033362 adaptor-related protein complex 2, mu 1 subunit 1.543 0.869 1.682 0.790
6046 AI765830 biliverdin reductase A 1.493 0.632 1.651 1.034
5484 AP000529 
Human genomic DNA, chromosome 
22q11.2, Cat Eye Syndrome region, 
clone:c3G11. 
0.867 1.149 1.966 0.875
9106 U49957 LIM domain-containing preferred translocation partner in lipoma 0.844 0.904 1.583 1.193
9055 BG704884 translin-associated factor X 1.116 1.156 2.361 0.904
9846 AK027494 
Human cDNA FLJ14588 fis, clone 
NT2RM4001819, highly similar to Human 
p58/GTA (galactosyltransferase associated 
protein kinase) mRNA. 
1.206 0.667 1.564 0.775
10069 U64998 Human ribonuclease k6 precursor gene, complete cds. 1.030 0.894 1.945 0.796
8899 AI884541 surfeit 5 1.054 0.459 0.928 1.001
10246 BE410528 DNA-damage-inducible transcript 3 1.236 0.458 0.980 1.020
13617 AL109778 phosphodiesterase 8A 1.291 0.722 0.982 0.903
3681 BC001791 Human, clone MGC:2663 IMAGE:3543910, mRNA, complete cds. 1.116 0.474 1.190 1.041
15362 BE620977 electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II) 1.077 0.459 0.943 0.894
4942 D88152 Human mRNA for acetyl-coenzyme A transporter, complete cds. 1.365 0.496 1.350 1.170
2612 NM_025228 hypothetical protein dJ434O14.3 1.109 0.497 1.151 1.055
12206 AL524757 ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha) 1.637 0.319 0.899 0.642
14472 M29474 Human recombination activating protein (RAG-1) gene, complete cds. 1.000 0.424 1.053 1.029
11291 M93651 Human set gene, complete cds. 0.889 0.468 0.898 0.946
15051 NM_005113 golgi autoantigen, golgin subfamily a, 5 1.342 0.474 1.670 2.311
5379 AK025256 Human cDNA: FLJ21603 fis, clone COL07238. 1.000 0.720 1.011 0.986
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4941 AL136699 
Human mRNA; cDNA DKFZp564I1782 
(from clone DKFZp564I1782); complete 
cds. 
1.291 0.426 1.580 1.028
18158 BG387891 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial 1.068 0.730 0.870 1.215
15225 BG261319 transducer of ERBB2, 1 1.145 0.410 1.629 1.057
5222 AF037447 Human ribosomal S6 protein kinase mRNA, complete cds. 1.681 0.349 0.823 0.880
11116 AL136721 
Human mRNA; cDNA DKFZp566K1946 
(from clone DKFZp566K1946); complete 
cds. 
1.156 0.738 0.903 1.010
7199 AL556984 transmembrane 7 superfamily member 2 1.196 0.326 0.546 1.076
11628 S56805 
preproendothelin 1 {alternatively 
transcribed} [Human, placenta, mRNA, 
1251 nt]. 
1.033 0.338 1.384 1.232
11599 AF041432 Human bet3 (BET3) mRNA, complete cds. 1.026 0.345 1.116 0.868
7913 BAB23139 putative 1.188 0.736 1.021 0.906
15238 AB044807 PDZ domain protein (Drosophila inaD-like) 0.982 0.733 0.936 1.037
11338 BAA07650 sulfate transporter 0.787 0.356 0.998 0.895
14594 BC011568 
Human, endoplasmic reticulum chaperone 
SIL1, homolog of Yeast, clone MGC:20202 
IMAGE:4640182, mRNA, complete cds. 
1.220 0.729 0.892 1.086
13435 BG257096 adenosine deaminase 0.903 0.731 1.233 1.187
8615 AK024146 Human cDNA FLJ14084 fis, clone HEMBB1002383. 1.388 0.367 1.247 0.858
16319 AB028971 Human mRNA for KIAA1048 protein, complete cds. 0.973 0.389 0.796 1.374
3625 BAB22250 putative 0.945 0.408 0.930 1.041
17834 AJ293866 Human mRNA for FNK serine/threonine protein kinase. 1.109 0.408 0.765 0.833
2776 U46571 DnaJ (Hsp40) homolog, subfamily C, member 7 1.087 0.500 1.020 2.711
13010 AL137370 Human mRNA; cDNA DKFZp434H2226 (from clone DKFZp434H2226); partial cds. 1.177 0.714 1.108 0.863
9549 M38258 Human retinoic acid receptor gamma 1 mRNA, complete cds. 0.908 0.513 1.242 0.927
14939 AA737180 cofactor required for Sp1 transcriptional activation, subunit 2 (150kD) 0.952 0.519 1.012 2.102
5218 AF182423 Human MDS024 (MDS024) mRNA, complete cds. 0.980 0.695 1.102 0.921
10332 L38935 Homo sapiens GT212 mRNA 1.239 0.639 1.004 0.942
6264 U48296 
Human protein tyrosine phosphatase 
PTPCAAX1 (hPTPCAAX1) mRNA, 
complete cds. 
1.041 0.635 0.906 1.090
13509 BE812844 transcription elongation factor A (SII), 1 0.897 0.637 1.343 1.287
5722 NM_004906 Wilms' tumour 1-associating protein 0.889 0.694 1.169 1.936
9481 AJ302068 Human HSPB9 gene for small heat shock protein B9. 0.954 0.697 1.220 0.887
16001 J03870 Human cystatin SA-I mRNA, complete cds. 1.327 0.694 0.783 1.235
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14555 AAH07256 Unknown (protein for MGC:15514) 1.178 0.647 1.057 0.850
8831 BG258940 phosphotidylinositol transfer protein, beta 1.057 0.628 0.993 1.178
12871 AB022017 Human mRNA for AMP-activated protein kinase alpha-1, complete cds. 0.918 0.663 1.020 0.958
7193 BG768698 homeo box A4 1.053 0.670 1.089 0.940
13763 U22512 conserved helix-loop-helix ubiquitous kinase 1.055 0.692 0.875 1.104
16751 AU121122 suppressor of Ty (S.cerevisiae) 6 homolog 1.321 0.691 0.840 1.243
10102 AB007856 Human KIAA0396 mRNA, partial cds. 1.148 0.652 1.187 0.974
5803 AB044947 NDRG family, member 4 1.210 0.657 0.966 0.911
6728 D30756 Human mRNA for KIAA0049 gene, complete cds. 1.241 0.633 0.966 1.541
5726 AI968278 peroxisome proliferative activated receptor, delta 0.918 0.628 0.972 0.921
3209 AF035606 Human calcium binding protein (ALG-2) mRNA, complete cds. 1.011 0.538 0.899 0.986
4416 AB033823 tektin 2 (testicular) 1.056 0.677 1.079 1.007
7079 NM_014003 pre-mRNA splicing factor similar to S. cerevisiae Prp16 1.226 0.556 1.325 1.076
7518 M58459 ribosomal protein S4, Y-linked 0.938 0.544 1.245 0.870
11109 AF135794 Human AKT3 protein kinase mRNA, complete cds. 1.305 0.554 1.103 0.885
8932 BC001746 protein tyrosine phosphatase, non-receptor type 7 0.819 0.574 1.299 1.145
10471 AW150631 stem-loop (histone) binding protein 1.238 0.542 1.012 1.094
8157 AAF03128 F-box protein FBL2 0.853 0.557 1.197 1.104
7371 AF068266 core-binding factor, runt domain, alpha subunit 2; translocated to, 2 1.177 0.575 0.927 1.172
4249 BG765209 ring finger protein 10 1.044 0.628 1.438 0.750
6349 AB055286 Macaque brain cDNA, clone:QflA-11789. 1.461 0.626 0.904 1.791
14408 AK025398 Human cDNA: FLJ21745 fis, clone COLF5038. 1.160 0.699 1.178 1.346
12814 AB018271 Human mRNA for KIAA0728 protein, partial cds. 1.265 0.613 0.913 1.462
10999 S85655 prohibitin [Human, mRNA, 1043 nt]. 1.261 0.622 1.150 0.999
11619 J03077 Human co-beta glucosidase (proactivator) mRNA, complete cds. 1.199 0.585 1.179 1.135
8606 AI422208 SH3 domain binding glutamic acid-rich protein 1.330 0.601 0.909 1.135
9853 AF007189 Human claudin 3 (CLDN3) gene, complete cds. 1.121 0.669 0.956 1.421
3520 BAB47409 MEGF10 protein (KIAA1780) 1.014 0.180 1.031 0.712
16600 BG236381 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9 (39kD) 0.974 0.747 1.129 1.247
6355 M74099 Human displacement protein (CCAAT) mRNA. 1.182 0.745 0.936 1.125
15684 D67029 Human SEC14L mRNA, complete cds. 1.088 0.748 0.848 1.129
11286 L48722 Human (clone hh18) protein tyrosine phosphatase (ptp-IV1r) gene, 5' end of cds. 0.882 0.749 0.888 1.105
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6711 AL136626 
Human mRNA; cDNA DKFZp564C012 
(from clone DKFZp564C012); complete 
cds. 
1.164 0.743 1.027 1.162
7195 AK027886 CGI-01 protein 1.128 1.771 1.030 1.219
6261 D29641 Human mRNA for KIAA0052 protein, partial cds. 1.192 1.737 1.314 0.838
9869 AF089745 Human FK506-binding protein (FKBP63) mRNA, partial cds. 2.117 1.995 0.804 0.980
4784 BC003698 Human, clone MGC:5601 IMAGE:3461017, mRNA, complete cds. 1.037 1.552 1.084 0.975
5672 BC004151 tyrosyl-tRNA synthetase 1.742 1.518 1.047 1.057
7037 AL570066 fibulin 5 1.766 1.955 0.970 0.731
18004 BC009345 Human, clone MGC:16749 IMAGE:4130844, mRNA, complete cds. 1.198 2.314 1.425 1.311
10486 BG763361 gelsolin (amyloidosis, Finnish type) 1.405 2.608 1.331 0.958
13382 BG697126 calpain 1, (mu/I) large subunit 1.605 1.477 1.146 0.868
7192 BE892211 putative glialblastoma cell differentiation-related 1.564 1.306 0.938 1.045
14267 AJ245599 Human mRNA for putative secreted ligand (fjx1 gene homologue). 1.355 2.292 1.378 0.822
13831 BE730977 
low density lipoprotein-related protein-
associated protein 1 (alpha-2-macroglobulin 
receptor-associated protein 1) 
1.646 1.740 0.995 1.009
11651 CAC28982 
bA243J16.9 (novel protein similar to 
Interferon regulatory factor (transcriptional 
regulator)) 
1.234 1.760 1.095 0.937
16167 AB037799 Human mRNA for KIAA1378 protein, partial cds. 1.039 2.113 1.174 0.959
16759 BI825951 zyxin 1.524 1.459 1.079 1.150
14124 AB056806 Macaque brain cDNA clone:QflA-13812, full insert sequence. 1.512 1.579 0.998 1.057
3213 BC001118 
Human, Similar to seven transmembrane 
domain protein, clone MGC:1936 
IMAGE:2989840, mRNA, complete cds. 
1.124 2.214 1.499 0.880
11918 BC001636 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 1.924 1.672 1.688 0.758
5102 BC002862 
Human, Similar to aldo-keto reductase, 
clone MGC:10612 IMAGE:3941289, 
mRNA, complete cds. 
0.982 1.740 1.120 0.769
3474 BC004821 
Human, diaphorase (NADH) (cytochrome b-
5 reductase), clone MGC:5150 
IMAGE:3450773, mRNA, complete cds. 
1.911 1.766 0.687 0.999
12199 BF868865 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) 1.256 1.673 0.852 1.040
10666 J03210 matrix metalloproteinase 2 (gelatinase A, 72kD gelatinase, 72kD type IV collagenase) 2.297 1.794 1.171 1.145
5827 BF725116 SEX gene 2.238 1.609 0.985 1.142
11424 CAC41174 unnamed protein product 1.069 2.650 1.201 0.900
12235 AB002323 dynein, cytoplasmic, heavy polypeptide 1 2.584 2.663 0.999 1.049
10245 BG260215 KIAA0013 gene product 1.048 1.574 1.016 0.949
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14895 AP000503 Human genomic DNA, chromosome 6p21.3, HLA Class I region, section 2/20. 1.340 1.672 1.166 1.031
5801 BM008239 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 24 1.206 1.695 1.354 0.867
7428 BG431313 stromal cell-derived factor 2 1.560 1.557 1.133 0.912
8161 M12128 Human cytoskeletal tropomyosin isoform (2.5 kb) mRNA, 3' end. 1.381 1.538 1.259 1.151
5596 AB002806 Human OS-9 mRNA, complete cds. 1.880 1.847 1.048 1.060
12061 BG741096 nitric oxide synthase 3 (endothelial cell) 1.166 4.081 1.158 0.895
11460 AP003113 Human genomic DNA, chromosome 8q23, clone:KB1747F8. 1.873 1.861 1.692 0.992
11884 BC003575 mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase 1.334 1.600 1.031 0.906
4414 BI822721 gp25L2 protein 1.657 1.841 0.888 1.098
6037 BE798151 guanine nucleotide binding protein-like 1 1.259 1.814 0.974 1.476
4428 BF671958 malate dehydrogenase 1, NAD (soluble) 1.007 1.713 0.887 1.186
18175 U24576 LIM domain only 4 1.520 1.382 0.907 0.985
10994 BC006313 
Human, musculin (activated B-cell factor-1), 
clone MGC:12624 IMAGE:4123825, 
mRNA, complete cds. 
1.357 1.525 0.886 1.023
14257 BC004868 Human, clone MGC:10702 IMAGE:3833242, mRNA, complete cds. 1.157 1.560 0.933 0.842
10473 BC008813 annexin A8 1.136 1.545 1.010 1.208
14417 AJ007610 Human mRNA for protocadherin alpha 9 (PCDHA9 gene). 0.892 0.432 1.325 0.847
4095 N92498 
Homo sapiens mRNA; cDNA 
DKFZp564H2416 (from clone 
DKFZp564H2416) 
0.657 0.629 0.773 1.249
8181 AB014547 Human mRNA for KIAA0647 protein, partial cds. 0.777 0.677 1.712 0.852
12198 AW968138 seven in absentia (Drosophila) homolog 1 0.897 0.696 1.700 0.904
3485 AB070098 Macaque testis cDNA clone:QtsA-13672, full insert sequence. 0.679 0.647 1.091 0.950
17529 M68956 Human myristoylated alanine-rich C-kinase substrate mRNA, complete cds. 0.587 0.879 1.479 1.155
8638 BG766412 replication factor C (activator 1) 5 (36.5kD) 0.672 0.873 1.169 0.917
7607 BI818571 suppression of tumorigenicity 7 0.733 0.861 1.150 0.923
10204 U13695 Human homolog of Yeast mutL (hPMS1) gene, complete cds. 0.680 0.806 0.910 1.042
14909 NM_003968 ubiquitin-activating enzyme E1C (homologous to yeast UBA3) 1.054 0.633 1.322 0.866
11099 AK027344 
Human cDNA FLJ14438 fis, clone 
HEMBB1000317, weakly similar to 
FIBULIN-1, ISOFORM D PRECURSOR. 
0.694 0.710 1.380 0.966
11957 BG676784 CDK2-associated protein 1 1.187 0.658 1.170 1.134
6914 BC007655 
Human, protein phosphatase 1, regulatory 
(inhibitor) subunit 2, clone MGC:1327 
IMAGE:3346573, mRNA, complete cds. 
1.029 0.700 1.069 1.122
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4107 BG251495 
splicing factor proline/glutamine rich 
(polypyrimidine tract-binding protein-
associated) 
0.889 0.652 1.285 1.011
16781 AI022747 hypothetical protein MGC12904 0.932 0.707 1.065 0.865
14277 AF112219 Human esterase D mRNA, complete cds. 0.709 0.684 1.116 0.935
15342 AA523378 proliferating cell nuclear antigen 0.550 0.687 1.105 0.775
12703 AK001559 
Human cDNA FLJ10697 fis, clone 
NT2RP3000527, weakly similar to ZINC 
FINGER PROTEIN 43. 
0.739 0.626 1.494 1.193
4405 BG333934 replication protein A2 (32kD) 0.771 0.620 0.997 1.130
13419 BG765030 ribosomal protein S16 0.868 0.526 1.126 0.688
14266 AL133047 Human mRNA; cDNA DKFZp434D0215 (from clone DKFZp434D0215); partial cds. 0.695 0.813 1.300 0.900
11907 BG939578 ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) 0.727 0.703 1.225 0.861
9886 J05096 Human Na,K-ATPase subunit alpha 2 (ATP1A2) gene, complete cds. 0.940 0.662 1.249 0.891
16607 U53445 downregulated in ovarian cancer 1 0.720 0.818 1.079 1.127
2517 D90277 carcinoembryonic antigen-related cell adhesion molecule 3 1.034 0.742 1.268 0.744
11798 AK023133 
Human cDNA FLJ13071 fis, clone 
NT2RP3001792, moderately similar to 
HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN M. 
0.802 0.653 1.887 0.627
9555 BC000859 Human, clone IMAGE:3459481, mRNA, partial cds. 0.841 0.735 1.102 0.962
13825 AB011125 KIAA0553 protein 0.783 0.570 1.327 0.937
5019 U37688 Human RATS1 mRNA, complete cds. 0.729 0.782 1.214 1.188
8777 BF797654 chromosome 21 open reading frame 4 1.132 0.569 1.573 1.043
1032 BE253911 H2A histone family, member N 0.647 0.901 1.245 0.950
5562 AK023160 hypothetical protein FLJ10509 0.897 0.587 1.402 0.963
13174 AF309033 Human tankyrase-2 (TNKS-2) mRNA, complete cds. 0.737 0.769 1.240 0.940
16008 M60315 
Human transforming growth factor-beta 
BMP protein (tgf-beta) mRNA, complete 
cds. 
0.747 0.511 1.294 0.643
3933 BC014621 asparagine synthetase 0.742 0.969 1.138 0.984
7440 NM_014725 KIAA0189 gene product 0.917 0.741 1.279 1.070
5025 D10583 Human mRNA for IgE receptor beta subunit, complete cds. 0.979 1.532 0.921 0.858
13674 BG775483 junction plakoglobin 1.116 1.645 1.561 0.772
10013 D25545 Human mRNA for PIMT isozyme I, complete cds. 1.048 1.890 1.230 0.529
12987 AAF51854 CG11367 gene product 1.261 1.490 0.981 0.733
16591 AF006513 chromodomain helicase DNA binding protein 1 0.718 1.393 0.874 0.770
11920 AF241850 ret finger protein 2 0.793 1.779 0.946 0.697
15337 NM_006643 serologically defined colon cancer antigen 3 1.394 1.913 0.885 0.830
11775 L34209 
Human clone DMPC-HFF1-1415B 
prostaglandin synthase-2 (PGHS-2) gene, 
promoter region. 
1.019 1.873 1.008 0.607
15966 AAF47301 BcDNA:GH03108 gene product 1.160 1.364 0.921 0.608
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11246 M93650 Human paired box gene (PAX6) homologue, complete cds. 1.138 2.662 0.917 0.484
10383 BG169146 ribosomal protein S14 1.111 1.716 0.983 0.814
5720 AL574109 
procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), alpha 
polypeptide I 
0.955 1.797 0.668 0.680
10302 AF064087 cullin 3 1.031 1.797 0.914 0.720
13824 BF796127 vacuolar protein sorting 45B (yeast homolog) 1.334 1.253 0.693 0.703
15004 NM_014693 KIAA0604 gene product 0.836 1.528 1.253 0.894
7516 BM009356 general transcription factor IIF, polypeptide 1 (74kD subunit) 0.852 1.589 1.182 0.810
11906 BF808164 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily f, member 1 
1.029 1.525 0.946 0.599
13321 AW969737 basic leucine zipper nuclear factor 1 (JEM-1) 0.950 1.516 1.317 0.703
6026 U15782 cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kD 1.234 1.561 0.898 0.909
11192 AB035207 Human mRNA for Tob2, complete cds. 0.978 1.823 0.935 0.893
7504 D14533 xeroderma pigmentosum, complementation group A 1.240 1.987 0.917 0.782
9789 AF189251 Human cytomegalovirus partial fusion receptor mRNA, partial cds. 0.916 1.588 0.760 0.837
16734 BE644965 
ESTs, Weakly similar to JC5314 
CDC28/cdc2-like kinase associating 
arginine-serine cyclophilin [H.sapiens] 
0.766 1.668 1.004 0.846
16601 AV705674 synaptosomal-associated protein, 23kD 1.039 1.543 1.059 0.791
10060 D28235 Human PTGS2 gene for prostaglandin endoperoxide synthase-2, complete cds. 0.954 2.071 1.088 0.814
43 AAC84147 tuftelin 1.062 1.745 0.863 0.814
4173 BG338004 ubiquinol-cytochrome c reductase (6.4kD) subunit 1.114 3.374 0.948 0.695
14238 AF205075 
Human organic anion transporter 
polypeptide-related protein 4 (OATPRP4) 
mRNA, complete cds. 
1.010 1.508 1.225 0.938
5958 AI110630 
myeloid/lymphoid or mixed-lineage 
leukemia (trithorax (Drosophila) homolog); 
translocated to, 3 
0.881 1.544 1.377 0.792
6892 BC002775 
Human, Similar to CG9602 gene product, 
clone MGC:3733 IMAGE:3619626, mRNA, 
complete cds. 
0.755 1.852 1.121 0.879
15223 AL535015 ubiquinol-cytochrome c reductase core protein II 0.926 1.757 0.936 0.887
8485 AP003480 Human genomic DNA, chromosome 8q23, clone: KB1970H2. 1.172 1.212 1.030 0.734
12032 BI333047 Human D9 splice variant A mRNA, complete cds 0.934 1.548 0.917 0.878
4427 BC005127 adipose differentiation-related protein 0.884 2.161 0.902 0.822
10168 AA122155 kinesin family member 3C 1.341 1.571 0.722 0.594
13615 BE538296 cytochrome c oxidase subunit Va 0.816 1.536 0.890 0.910
11260 U72245 Human phospholemman chloride channel mRNA, complete cds. 1.096 1.807 1.081 0.752
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10100 AL136888 
Human mRNA; cDNA DKFZp434P1672 
(from clone DKFZp434P1672); complete 
cds. 
1.311 1.343 0.779 0.697
8477 M58342 Human iduronate 2-sulfatase mRNA, complete cds. 1.146 1.356 0.915 0.747
13207 AB049054 Human BRAL1 mRNA for brain link protein-1, complete cds. 0.972 1.308 0.891 0.706
8800 BC002390 etoposide-induced mRNA 0.795 2.380 0.893 0.635
12693 AB020880 Human mRNA for squamous cell carcinoma antigen SART-3, complete cds. 0.967 2.311 1.428 0.652
7448 BI911036 tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) 1.164 2.240 0.973 0.654
17838 AF112227 Human TDE homolog mRNA, complete cds. 1.275 1.583 0.954 0.898
14111 AL050144 Human mRNA; cDNA DKFZp586C1620 (from clone DKFZp586C1620); partial cds. 0.769 1.863 0.734 0.755
7595 BG762583 protein tyrosine phosphatase, non-receptor type substrate 1 1.017 1.540 0.875 0.894
11467 BC002466 
Human, v-raf murine sarcoma 3611 viral 
oncogene homolog 1, clone MGC:2356 
IMAGE:3347509, mRNA, complete cds. 
1.254 2.041 0.909 0.862
11745 BF110337 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor 1.610 2.240 1.175 0.854
5329 AF112210 Human heat shock protein hsp70-related protein mRNA, complete cds. 0.748 0.922 0.930 1.088
7842 AP001670 Human genomic DNA, chromosome 21q, section 14/105. 0.703 1.155 0.931 0.994
7398 AW514303 ESTs, Highly similar to I51803 TAXREB107 [H.sapiens] 0.671 0.921 0.992 1.030
16274 BC003554 
Human, ubiquitin-conjugating enzyme E2E 
3 (homologous to Yeast UBC4/5), clone 
MGC:1316 IMAGE:3537280, mRNA, 
complete cds. 
0.626 0.865 0.867 0.835
17241 AK001106 
Human cDNA FLJ10244 fis, clone 
HEMBB1000632, weakly similar to 
GUANINE NUCLEOTIDE RELEASING 
PROTEIN. 
0.648 1.281 1.172 1.088
13315 M86699 TTK protein kinase 0.533 0.903 0.915 1.072
6507 J04111 Human c-jun proto oncogene (JUN), complete cds, clone hCJ-1. 0.555 0.906 0.544 0.985
8791 BG574227 H-2K binding factor-2 0.718 1.080 0.952 0.968
13012 BC004975 Human, cyclin I, clone MGC:3795 IMAGE:2957878, mRNA, complete cds. 0.732 1.145 0.882 1.284
3962 BI492241 
ESTs, Highly similar to TBCA_HUMAN 
TUBULIN-SPECIFIC CHAPERONE A 
[H.sapiens] 
0.692 1.179 0.946 0.916
12801 AF032862 Human intracellular hyaluronic acid binding protein (IHABP) mRNA, complete cds. 0.423 1.144 0.908 0.988
2782 BF795918 topoisomerase (DNA) II alpha (170kD) 0.436 1.119 1.004 1.367
4067 AW779701 aquaporin 7 0.718 1.263 0.972 1.343
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10161 AF199339 
Human lens epithelium-derived growth 
factor gene, alternatively spliced, complete 
cds. 
0.683 1.160 1.197 1.098
13583 NM_014000 vinculin 0.512 1.106 0.828 0.632
15652 AF334735 Human sperm protein 17 mRNA, complete cds. 0.721 1.103 0.946 1.015
16575 AC004969 six transmembrane epithelial antigen of the prostate 0.697 0.820 0.886 1.121
15780 BC000474 
Human, quinone oxidoreductase homolog, 
clone MGC:8642 IMAGE:2961571, mRNA, 
complete cds. 
0.567 0.903 0.815 0.822
17497 AK023115 Human cDNA FLJ13053 fis, clone NT2RP3001459. 0.606 1.116 1.185 0.905
9127 BG198322 brain and reproductive organ-expressed (TNFRSF1A modulator) 0.724 1.260 0.779 0.902
10335 AI478561 dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) 0.698 0.887 0.950 0.920
16922 BE739599 peroxiredoxin 3 0.732 1.038 0.927 1.211
13457 AI042585 S-adenosylmethionine decarboxylase 1 0.662 1.171 1.066 0.871
13835 AY007110 putative human HLA class II associated protein I 0.543 1.029 0.945 0.948
8839 AB014522 CLIP-associating protein 1 0.712 0.992 0.733 1.004
13481 AI687946 PDZ and LIM domain 1 (elfin) 0.436 0.945 0.848 0.931
8368 AK024809 Human cDNA: FLJ21156 fis, clone CAS09878. 0.307 1.171 0.910 1.875
9941 U78027 
Human Bruton's tyrosine kinase (BTK), 
alpha-D-galactosidase A (GLA), L44-like 
ribosomal protein (L44L) and FTP3 (FTP3) 
genes, complete cds. 
0.669 1.030 1.003 1.238
12196 NM_014736 KIAA0101 gene product 0.445 1.574 0.904 1.155
1340 AB011166 KIAA0594 protein 0.659 0.939 0.868 1.051
10397 AI925424 calcium/calmodulin-dependent protein kinase kinase 2, beta 0.652 0.791 1.011 1.140
13776 BC001350 arginase, type II 0.580 1.005 0.859 0.962
10644 BC000418 ectodermal-neural cortex (with BTB-like domain) 0.354 1.026 1.034 0.932
7046 AA738354 cleavage and polyadenylation specific factor 5, 25 kD subunit 0.700 1.012 0.871 1.284
14263 BC000633 
Human, TTK protein kinase, clone 
MGC:865 IMAGE:3343925, mRNA, 
complete cds. 
0.550 0.826 0.886 1.313
181 D00210 Human gene for thrombomodulin precursor, complete cds. 0.600 0.943 0.823 1.077
1197 BF183143 serine/threonine kinase 12 0.692 0.952 0.948 1.036
3798 AF264785 Human hairy (HRY) mRNA, complete cds. 0.746 0.879 0.920 1.204
11934 AL520473 cell division cycle 2, G1 to S and G2 to M 0.380 0.844 0.915 0.929
3946 AU152618 DEK oncogene (DNA binding) 0.537 1.347 0.978 1.649
15222 AA724155 
Homo sapiens cDNA: FLJ23324 fis, clone 
HEP12482, highly similar to HUMMYOHCB 
Human nonmuscle myosin heavy chain-B 
(MYH10) mRNA 
0.604 0.742 0.918 0.910
7362 NM_002188 interleukin 13 0.689 0.932 1.074 0.920
12234 AI636026 leukotriene A4 hydrolase 0.628 0.953 0.801 0.995
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13801 BF977892 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, 
subfamily b, member 1 
0.679 1.076 0.839 1.110
6456 AJ006266 Human mRNA for AND-1 protein. 0.689 0.861 0.879 0.892
6881 AF046001 Human zinc finger transcription factor (ZNF207) mRNA, complete cds. 0.649 0.970 0.918 1.175
9572 AF294842 Human ubiquitin UBF-fl mRNA, complete cds. 0.627 0.982 0.878 1.002
4931 U56387 Human protease PC6 isoform A (PCSK5) mRNA, complete cds. 0.747 1.071 1.076 1.001
10188 AB020863 
Human genomic DNA of 8p21.3-p22 anti-
oncogene of hepatocellular colorectal and 
non-small cell lung cancer , segment 6/11. 
2.398 0.893 1.146 0.974
3460 D90279 Human mRNA for collagen alpha 1(V) chain, complete cds. 1.601 1.006 0.957 0.907
11239 AK000753 Human cDNA FLJ20746 fis, clone HEP06040. 1.560 1.007 0.926 0.767
14871 BG777366 interleukin 8 5.622 1.469 0.851 0.144
6712 BC002735 
Human, dihydrolipoamide S-
succinyltransferase (E2 component of 2-
oxo-glutarate complex), clone MGC:3898 
IMAGE:3627724, mRNA, complete cds. 
1.720 1.013 0.957 0.675
16028 BC007063 Human, peroxiredoxin 1, clone MGC:12514 IMAGE:3961375, mRNA, complete cds. 4.178 1.462 0.819 0.586
16118 M21533 Human MHC class I lymphocyte antigen (HLA-E) (HLA-6.2) gene, complete cds. 2.748 0.989 0.987 0.474
13025 BC000452 
Human, Similar to thioredoxin peroxidase 1, 
clone MGC:8456 IMAGE:2821457, mRNA, 
complete cds. 
1.939 0.767 0.867 0.866
16109 U60644 Human HU-K4 mRNA, complete cds. 1.538 0.788 0.837 0.918
9131 AL567017 
solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 
2 
1.320 0.799 1.032 0.689
15056 BG424817 heat shock 70kD protein 9B (mortalin-2) 1.654 0.774 0.912 0.853
4759 BC000693 
Human, ARP1 (actin-related protein 1, 
Yeast) homolog A (centractin alpha), clone 
MGC:2357 IMAGE:3347881, mRNA, 
complete cds. 
1.715 0.648 0.787 0.965
10522 BG699149 myosin, heavy polypeptide 9, non-muscle 2.108 0.980 0.901 0.726
9121 AL552738 tumor differentially expressed 1 1.813 1.148 0.907 0.894
7279 BC012746 mesoderm development candidate 2 1.387 0.721 0.959 0.714
12033 BI908045 integrin beta 4 binding protein 1.519 1.242 0.922 0.905
10525 AU132321 
guanine nucleotide binding protein (G 
protein), alpha inhibiting activity polypeptide 
1 
1.681 1.002 1.021 0.953
4078 BI553471 isocitrate dehydrogenase 3 (NAD+) beta 1.502 0.994 1.002 0.792
4258 BG708735 ras homolog gene family, member C 2.286 0.753 1.030 1.017
16178 AF068863 Human oligodendrocyte-specific protein (OSP) mRNA, complete cds. 2.415 1.078 0.881 0.694
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10514 U76368 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 2.460 1.056 1.159 0.879
9557 M94345 Human macrophage capping protein mRNA, complete cds. 2.100 0.915 0.969 0.801
13597 AB007851 phosphoribosyl pyrophosphate synthetase-associated protein 2 1.677 0.916 1.269 0.815
16116 AB032261 Human Scd mRNA for stearoyl-CoA desaturase, complete cds. 1.777 0.934 0.958 0.643
7345 AU139931 core promoter element binding protein 2.195 0.660 1.053 0.887
3392 L35263 Human CSaids binding protein (CSBP1) mRNA, complete cds. 1.593 0.807 0.921 0.909
14759 AAC25584 aortic carboxypeptidase-like protein ACLP 2.591 1.190 0.911 0.473
12202 BF981829 myosin, light polypeptide 1, alkali; skeletal, fast 1.969 0.763 0.970 0.945
11913 BC006169 SH3-domain binding protein 5 (BTK-associated) 1.647 1.330 0.744 0.845
15052 BE790900 palmitoyl-protein thioesterase 2 1.576 1.087 1.139 0.879
6905 AF225896 Human tensin mRNA, complete cds. 1.420 1.072 0.874 0.650
14079 AK027263 
Human cDNA FLJ14357 fis, clone 
HEMBA1000005, highly similar to DNAJ 
PROTEIN HOMOLOG MTJ1. 
1.546 0.928 0.978 0.746
16764 AL530764 RAB4, member RAS oncogene family 1.399 0.935 0.900 0.746
14580 BC009384 
Human, Similar to chromogranin A 
(parathyroid secretory protein 1), clone 
IMAGE:4127895, mRNA, partial cds. 
1.624 1.039 0.955 0.956
6281 AB002313 Human mRNA for KIAA0315 gene, partial cds. 1.895 1.121 1.211 0.781
10336 AB014606 kinesin family member 1C 1.660 0.754 0.841 0.724
15392 BF689926 electron-transfer-flavoprotein, beta polypeptide 1.684 0.867 1.202 0.882
11800 AU121423 serine threonine protein kinase 2.592 0.939 0.674 0.937
4327 NM_000543 sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase) 1.514 1.208 0.829 0.711
3321 AB054881 Human mRNA for Soluble-type polypeptide FZD4S, complete cds. 1.839 1.111 1.006 0.950
14743 AF061970 Human paired related homeobox protein (PRX2) mRNA, complete cds. 1.589 0.763 0.934 0.940
11749 BI596354 heme oxygenase (decycling) 1 2.851 1.250 0.728 0.917
7355 BC002502 putative breast adenocarcinoma marker (32kD) 1.526 0.927 0.921 0.818
12666 U29460 Human cytochrome b561 gene, exon 1. 1.405 0.912 0.725 0.926
1975 BC006247 
Human, Similar to KRAB-zinc finger protein 
SZF1-1, clone IMAGE:3945618, mRNA, 
partial cds. 
1.396 0.708 0.919 0.862
4002 AB006713 dihydropyrimidinase-like 4 1.551 0.936 1.011 0.750
6956 AF100759 Human transmembrane 4 superfamily protein mRNA, complete cds. 1.293 0.940 0.951 0.726
13295 M58018 Human beta-myosin heavy chain (MYH7) mRNA, complete cds. 1.355 1.657 1.983 0.916
12680 U28281 Human secretin receptor mRNA, complete cds. 0.971 1.258 1.688 1.119
16614 BG385746 pyrroline-5-carboxylate reductase 1 1.217 1.186 1.536 0.909
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10622 AL574829 1.049 1.598 1.266 1.729farnesyltransferase, CAAX box, alpha 
9136 NM_003605 




1.296 1.265 1.514 0.989
9727 D31885 Human mRNA for KIAA0069 gene, partial cds. 1.139 1.399 2.125 1.248
5422 D14710 Human mRNA for ATP synthase alpha subunit, complete cds. 1.039 1.715 1.412 1.047
16730 BG255394 prefoldin 4 0.781 1.388 1.602 0.942
7131 C06042 carcinoembryonic antigen-related cell adhesion molecule 7 0.982 1.955 1.497 1.303
11472 AP000009 Human genomic DNA of 21q22.2 Down Syndrome region, segment 2/13. 1.070 2.039 1.726 0.961
13667 AV756387 ribosomal protein L3 1.197 1.900 1.497 1.544
8829 BE926667 thousand and one amino acid protein kinase 1.026 1.574 1.327 1.075
12042 AL549846 TGFB-induced factor (TALE family homeobox) 1.263 1.509 1.760 0.945
12180 BG169279 G protein pathway suppressor 1 1.348 2.387 2.727 1.425
12977 AF286904 Human enhancer of polycomb 1 (EPC1) mRNA, complete cds. 1.177 1.929 1.866 0.983
14745 U77085 Human epithelial membrane protein (CL-20) mRNA, complete cds. 0.787 1.222 1.593 1.438
11871 BG575020 thyroid hormone receptor interactor 10 1.415 1.320 1.881 1.597
15988 CAA30534 cytokeratin 4 (408 AA) 0.930 1.751 1.488 1.022
13755 AL598805 Homo sapiens, clone MGC:12401 IMAGE:3933998, mRNA, complete cds 1.332 1.122 1.677 1.173
11474 AK001159 Human cDNA FLJ10297 fis, clone NT2RM1001074. 1.215 1.268 2.147 0.884
10961 BC009001 
Human, 3-oxoacid CoA transferase, clone 
MGC:17088 IMAGE:4148643, mRNA, 
complete cds. 
0.976 1.264 1.193 1.587
9888 AF061832 Human M4 protein deletion mutant mRNA, complete cds. 0.945 0.777 1.107 1.607
5725 BG779717 Homo sapiens cDNA: FLJ21814 fis, clone HEP01068 1.105 0.848 1.271 1.579
2624 AW025893 lymphotoxin beta (TNF superfamily, member 3) 0.929 1.437 1.151 1.817
13634 AL557298 serine hydroxymethyltransferase 2 (mitochondrial) 1.372 1.411 0.965 1.877
7496 BG183465 proteasome (prosome, macropain) subunit, alpha type, 1 0.883 1.248 1.080 2.256
10034 BC001380 
Human, succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp), clone 
MGC:1484 IMAGE:3051442, mRNA, 
complete cds. 
1.012 1.407 0.773 2.145
13775 NM_002470 myosin, heavy polypeptide 3, skeletal muscle, embryonic 1.203 0.858 1.099 1.790
6422 AB027233 Human mRNA for membrane protein FOAP-12, complete cds. 1.060 0.871 1.353 1.816
10324 BG745129 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 1.151 0.856 0.861 1.835
8297 AL137687 Human mRNA; cDNA DKFZp434M152 (from clone DKFZp434M152). 0.567 1.279 1.179 2.174
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11768 BC011978 
Human, Similar to RIKEN cDNA 
1110018J12 gene, clone IMAGE:3865164, 
mRNA, partial cds. 
1.518 1.293 1.624 2.068
8007 AL136919 
Human mRNA; cDNA DKFZp586J1119 
(from clone DKFZp586J1119); complete 
cds. 
1.012 0.877 1.067 1.679
3766 U03272 Human fibrillin-2 mRNA, complete cds. 1.167 1.596 0.975 1.800
10370 AL544102 chromosome 11 open reading frame 13 1.052 1.122 1.002 1.567
6035 BE619835 growth arrest-specific 1 1.092 1.242 0.854 1.523
17697 AP000501 Human genomic DNA, chromosome 8p11.2, clone:91h23 to 9-41. 1.007 1.215 1.066 1.606
10183 BE266628 BCL2-antagonist of cell death 1.074 1.039 1.121 1.917
9847 AL117607 Human mRNA; cDNA DKFZp564N0763 (from clone DKFZp564N0763). 1.156 0.803 1.015 2.043
14276 AF003924 Human zinc finger protein ANC_2H01 mRNA, complete cds. 0.713 0.720 1.242 1.669
10981 L47345 Human elongin A mRNA, complete cds. 0.817 1.027 1.102 1.569
10472 AL519675 arsA (bacterial) arsenite transporter, ATP-binding, homolog 1 1.432 0.936 1.181 1.866
10682 BI870489 nidogen (enactin) 1.116 0.935 1.745 2.573
17233 M77171 Human zinc finger protein gene, partial cds. 1.225 1.010 1.136 1.629
13683 NM_005414 SKI-like 1.433 1.054 1.173 1.535
14158 AK000160 
Human cDNA FLJ20153 fis, clone 
COL08656, highly similar to AJ001381 
Human incomplete cDNA for a mutated 
allele. 
1.111 1.086 1.122 1.684
8909 AL536237 tubulin, beta, 5 1.154 0.924 1.409 1.567
11936 AU131934 origin recognition complex, subunit 4 (yeast homolog)-like 0.904 0.761 1.377 1.818
9068 BE741277 
protein with polyglutamine repeat; calcium 
(ca2+) homeostasis endoplasmic reticulum 
protein 
1.009 1.013 1.238 1.538
3399 AF308285 Human serologically defined breast cancer antigen NY-BR-16 mRNA, complete cds. 1.375 1.006 1.148 1.623
3704 BC001348 
Human, heterogeneous nuclear 
ribonucleoprotein H1 (H), clone MGC:8619 
IMAGE:2961378, mRNA, complete cds. 
0.949 0.836 1.398 1.593
4490 D76444 zinc finger protein homologous to Zfp103 in mouse 1.180 0.956 0.957 2.323
8023 U33635 Human colon carcinoma kinase-4 (CCK4) mRNA, complete cds. 1.231 0.968 0.959 1.636
8448 U23851 Human atrophin-1 mRNA, complete cds. 1.123 0.962 1.147 2.405
15312 BG163551 cerebral cavernous malformations 1 0.720 0.787 1.390 1.895
2742 AK027480 zinc finger protein 266 1.175 0.977 1.121 1.836
14847 NM_001393 extracellular matrix protein 2, female organ and adipocyte specific 1.295 0.980 1.148 1.603
12077 AW469468 palmitoyl-protein thioesterase 2 0.995 1.005 1.148 2.728
16590 NM_000097 coproporphyrinogen oxidase (coproporphyria, harderoporphyria) 0.644 0.790 1.480 3.169
7285 AI088306 hypothetical protein FLJ23306 1.747 0.955 1.025 2.475
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9528 AP000350 Human genomic DNA, chromosome 22q11.2, clone KB1125A3. 0.989 0.951 1.563 2.752
4464 NM_014459 protocadherin 17 0.940 0.950 1.504 1.841
11598 D86967 Human mRNA for KIAA0212 gene, complete cds. 1.071 0.912 1.027 2.864
4246 AB011085 KIAA0513 gene product 1.137 0.785 1.212 1.606
6032 BG825129 glypican 1 1.241 1.760 0.889 2.122
8968 BC015345 homeo box B7 1.117 1.149 1.123 1.892
13362 NM_016614 TRAF and TNF receptor-associated protein 1.245 1.698 1.140 2.304
17683 D85429 Human gene for heat shock protein 40, complete cds. 1.221 1.164 1.248 1.592
2924 BG506029 translocase of inner mitochondrial membrane 17 (yeast) homolog A 1.707 1.700 1.128 4.045
5719 BE217961 ets variant gene 6 (TEL oncogene) 0.836 1.127 1.199 2.005
17693 L00974 Human SP40,40 gene, exons 5-9. 1.270 0.892 1.217 1.729
14090 AB043587 Human gcp60 mRNA for golgi resident protein GCP60, complete cds. 0.764 1.201 1.308 1.618
16138 BC000612 
Human, Similar to katanin p60 (ATPase-
containing) subunit A 1, clone MGC:2599 
IMAGE:3347282, mRNA, complete cds. 
1.254 0.946 1.527 0.533
14750 M31211 Human myosin light chain 1 slow a (MLC1sa) mRNA, complete cds. 2.050 1.035 1.564 0.453
1355 AL532086 group-specific component (vitamin D binding protein) 1.204 1.460 1.116 0.592
16180 AK000852 Human cDNA FLJ20845 fis, clone ADKA01901. 1.528 1.153 1.449 0.829
3365 AF068755 Human sec7 domain family member (GBF1) mRNA, complete cds. 1.149 1.438 1.491 0.632
18032 AA641722 protein kinase C, alpha binding protein 0.996 1.019 1.204 0.668
13652 BE791502 clathrin, light polypeptide (Lcb) 1.769 1.267 1.065 0.782
882 BG824361 putative protein similar to nessy (Drosophila) 1.489 0.711 0.966 0.683
14237 BC001691 
Human, holocytochrome c synthase 
(cytochrome c heme-lyase), clone 
MGC:1443 IMAGE:3030501, mRNA, 
complete cds. 
1.794 1.156 1.405 0.876
10685 AW960243 neural precursor cell expressed, developmentally down-regulated 8 1.372 1.043 1.220 0.749
15398 BE856759 KIAA0138 gene product 1.559 1.173 1.327 0.804
13373 AL556109 mitogen-activated protein kinase kinase kinase 11 1.261 0.836 1.235 0.609
18461 D88674 ornithine decarboxylase antizyme inhibitor 1.375 0.965 1.527 0.899
12994 BC010155 
Human, Similar to RIKEN cDNA 
B230118G17 gene, clone MGC:19604 
IMAGE:3622817, mRNA, complete cds. 
1.657 1.202 1.677 0.726
2826 AJ004832 neuropathy target esterase 1.356 0.975 0.970 0.596
7292 AL521557 p53-induced protein 1.220 1.188 0.897 0.693
14426 BC001900 
Human, Similar to branched chain 
aminotransferase 2, mitochondrial, clone 
MGC:2082 IMAGE:3537603, mRNA, 
complete cds. 
1.101 1.198 1.001 0.726
18485 AL546458 serine protease inhibitor, Kunitz type, 2 1.251 1.207 1.126 0.648
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5797 NM_000702 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 1.795 0.992 1.143 0.447
16611 BG674956 selenophosphate synthetase 2 1.245 1.001 1.390 0.740
6817 L06237 Human microtubule-associated protein 1B (MAP1B) gene, complete cds. 1.265 1.505 1.344 0.698
9945 AK000826 Human cDNA FLJ20819 fis, clone ADSE00511. 1.156 0.935 0.877 0.748
14941 AL548337 Homo sapiens cDNA FLJ10229 fis, clone HEMBB1000136 1.567 1.434 1.115 0.467
9902 AF265208 Human SWI-SNF complex protein p270 mRNA, partial cds. 1.540 0.815 1.202 0.707
10629 AL544994 
myeloid/lymphoid or mixed-lineage 
leukemia (trithorax (Drosophila) homolog); 
translocated to, 7 
1.679 1.360 1.181 0.748
5990 AL553335 N-ethylmaleimide-sensitive factor attachment protein, alpha 1.418 1.067 2.000 0.761
16309 BC000819 
Human, Similar to CG6950 gene product, 
clone MGC:5114 IMAGE:3453829, mRNA, 
complete cds. 
1.092 1.060 0.852 0.743
3141 AB014773 Human mRNA for MOP-4, complete cds. 2.039 1.296 1.055 0.630
11746 NM_019848 Protein P3 1.315 1.076 1.759 0.811
1195 BG283735 hypothetical protein 1.183 1.271 1.292 0.707
18009 AAA28530 fat protein 1.044 1.049 1.804 0.735
8985 BI713774 somatostatin 1.381 1.365 1.271 0.574
5570 L04284 Human germline HRX mRNA, complete cds. 0.854 1.751 1.084 0.881
11752 AL537232 hypothetical protein A-211C6.1 0.697 2.865 0.961 1.692
14382 D31883 Human mRNA for KIAA0059 gene, complete cds. 1.105 1.657 1.064 1.437
15227 AI924594 tetraspan 2 0.799 1.609 0.823 1.005
4017 BI859947 protein kinase, AMP-activated, gamma 1 non-catalytic subunit 0.931 2.441 1.100 0.837
9370 AB032957 Human mRNA for KIAA1131 protein, partial cds. 0.823 2.532 1.338 0.902
5959 AI656717 ESTs, Weakly similar to ubiquitous TPR motif, Y isoform [H.sapiens] 0.899 1.516 0.895 1.046
10467 BG165773 succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 0.803 1.798 1.511 0.819
10186 BI496977 protein phosphatase 2, regulatory subunit B (B56), epsilon isoform 0.757 2.424 1.075 1.085
18311 AK001450 exostoses (multiple)-like 2 0.744 1.525 1.034 0.846
17875 U65090 Human carboxypeptidase D mRNA, complete cds. 0.846 2.384 1.081 0.968
7183 U67733 phosphodiesterase 2A, cGMP-stimulated 0.705 1.763 1.323 0.962
11277 AB058599 Human arpp mRNA for ankyrin-repeat protein, complete cds. 0.676 1.793 0.848 0.919
13778 AL558308 CD3E antigen, epsilon polypeptide (TiT3 complex) 0.893 3.488 1.019 0.792
9834 BC009200 
Human, Rho GDP dissociation inhibitor 
(GDI) beta, clone MGC:15348 
IMAGE:3621138, mRNA, complete cds. 
0.767 4.369 1.148 0.934
4377 NM_021724 nuclear receptor subfamily 1, group D, member 1 0.760 1.669 0.957 1.011
7070 AL571412 RNA helicase-related protein 0.898 1.768 1.260 0.812
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11183 AAC52262 neural cell adhesion protein BIG-2 precursor 0.885 1.768 0.919 0.971
3237 D38550 Human mRNA for KIAA0075 gene, partial cds. 0.868 1.538 1.009 1.014
10711 BI761480 laminin, alpha 2 (merosin, congenital muscular dystrophy) 0.864 2.955 1.370 0.822
8167 M27394 Human B-lymphocyte cell-surface antigen B1 (CD20). 1.038 1.675 0.970 1.127
8652 BF943707 RNA binding motif protein 14 0.767 1.665 1.320 0.978
3788 M28372 Human sterol regulatory element-binding protein (CNBP) mRNA, complete cds. 0.975 1.701 1.029 1.189
5561 AV649527 aldehyde dehydrogenase 1 family, member A1 0.856 1.802 0.996 1.310
12051 BG032793 ribosomal protein L37 0.744 2.165 1.036 1.059
18520 AL526053 cAMP responsive element modulator 0.710 2.166 0.941 1.078
7348 BC007831 phosphodiesterase 6D, cGMP-specific, rod, delta 0.617 1.329 1.290 1.155
10665 AL122062 chromosome 2 open reading frame 6 0.703 1.403 1.124 1.050
10343 AL079635 
RNA polymerase II transcriptional 
regulation mediator (Med6, S. cerevisiae, 
homolog of) 
0.767 1.580 0.930 0.938
6356 L23320 Human replication factor C large subunit mRNA, complete cds. 0.681 1.866 1.073 1.393
11959 BF676785 S-adenosylmethionine decarboxylase 1 0.747 2.042 1.129 0.889
11590 AF080157 Human IkB kinase-a (IKK-alpha) mRNA, complete cds. 0.952 1.904 1.015 1.103
3372 BC000697 
Human, Similar to Male-specific RNA 84Dd, 
clone MGC:3092 IMAGE:3349383, mRNA, 
complete cds. 
0.699 1.815 1.336 1.123
4419 BC012063 retinoid X receptor, gamma 0.783 1.964 0.976 0.950
8769 BG483858 actin related protein 2/3 complex, subunit 3 (21 kD) 1.007 1.945 1.243 1.034
7370 BI602406 3-hydroxyanthranilate 3,4-dioxygenase 1.034 1.942 0.913 1.446
16316 U67615 Human beige protein homolog (chs) mRNA, complete cds. 0.816 1.599 1.223 1.252
7555 BI756567 phosphodiesterase 3B, cGMP-inhibited 0.516 1.651 1.156 0.861
5812 L13858 son of sevenless (Drosophilia) homolog 2 0.926 1.710 0.970 1.203
5162 AF279370 Human DZIP3 mRNA, partial cds. 0.745 1.333 0.891 0.862
16422 D26350 
Human mRNA for inositol 1,4,5-
trisphosphate receptor type 2, complete 
cds. 
1.005 2.133 1.245 1.775
2780 BF439351 hypothetical gene CG018 0.955 1.813 1.029 1.407
15831 BC005330 
Human, tissue factor pathway inhibitor 2, 
clone MGC:12416 IMAGE:3929933, 
mRNA, complete cds. 
0.948 1.501 1.225 1.355
12832 U76713 Human apobec-1 binding protein 1 mRNA, complete cds. 0.850 1.504 1.170 0.906
12838 BC001178 
Human, ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit F6, 
clone MGC:2243 IMAGE:3357779, mRNA, 
complete cds. 
0.803 1.614 1.255 1.282
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17567 AF264014 
Human scavenger receptor cysteine-rich 
type 1 protein M160 precursor, mRNA, 
complete cds, alternatively spliced. 
0.899 0.824 0.811 0.718
3945 AI884353 mitochondrial translational release factor 1 0.855 0.807 0.963 0.728
13187 AF092905 
Human protein phosphatase type-1 
catalytic subunit delta isoform (PPCS1D) 
mRNA, complete cds. 
0.877 0.802 0.922 0.573
8930 AF053755 solute carrier family 4, sodium bicarbonate cotransporter, member 7 0.807 0.816 1.144 0.678
8000 U17714 Human putative tumor suppressor ST13 (ST13) mRNA, complete cds. 0.874 0.536 0.951 0.240
11110 AK001364 
Human cDNA FLJ10502 fis, clone 
NT2RP2000414, highly similar to Human 
HnRNP F protein mRNA. 
0.766 0.788 0.890 0.645
13052 AF193612 Human fringe protein mRNA, partial cds. 1.046 0.804 0.867 0.681
12252 AI922645 origin recognition complex, subunit 2 (yeast homolog)-like 0.931 0.781 0.928 0.735
7583 M17754 BN51 (BHK21) temperature sensitivity complementing 0.915 0.833 0.883 0.638
11098 BAB22284 putative 1.026 0.825 1.036 0.343
6891 AL137751 Human mRNA; cDNA DKFZp434I0812 (from clone DKFZp434I0812); partial cds. 1.132 0.780 0.928 0.692
3774 AF117233 Human znf-xp protein mRNA, complete cds. 0.917 0.878 0.849 0.643
5050 AF251295 Human DC22 mRNA, complete cds. 1.024 1.026 0.957 0.538
11866 BC007506 checkpoint suppressor 1 0.895 1.187 0.998 0.550
3147 AJ278314 Human mRNA for phospholipase C-beta-1b (PLCB1 gene). 1.070 0.785 0.915 0.659
15690 AK024054 
Human cDNA FLJ13992 fis, clone 
Y79AA1002139, weakly similar to DNAJ 
PROTEIN HOMOLOG 1. 
0.965 1.028 1.044 0.620
16406 BG575502 phosphorylase, glycogen; brain 1.257 1.027 1.067 0.631
10502 U52828 
catenin (cadherin-associated protein), delta 
2 (neural plakophilin-related arm-repeat 
protein) 
1.001 0.981 0.911 0.737
10222 U72518 Human destrin-2 pseudogene mRNA, complete cds. 1.081 0.883 0.804 0.736
6648 M13003 Human metallothionein (MT)I-F gene, complete cds. 1.001 1.202 0.919 0.742
5377 BAB01579 unnamed protein product 0.872 1.069 0.904 0.705
9560 L33881 Human protein kinase C iota isoform, complete cds. 0.752 1.170 1.195 0.197
16773 AB005659 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1.045 1.097 0.886 0.680
14120 BC000905 
Human, RAB1, member RAS oncogene 
family, clone MGC:5233 IMAGE:2900705, 
mRNA, complete cds. 
1.213 1.210 0.864 0.660
14245 AF103796 
Human placenta-specific ATP-binding 
cassette transporter (ABCP) mRNA, 
complete cds. 
1.247 1.230 1.069 0.226
12672 AK001148 
Human cDNA FLJ10286 fis, clone 
HEMBB1001384, highly similar to Human 
COP9 complex subunit 4 mRNA. 
0.834 1.021 0.924 0.489
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9108 BE566830 sperm associated antigen 9 1.126 1.250 1.067 0.730
12251 BG829032 eukaryotic translation initiation factor 3, subunit 7 (zeta, 66/67kD) 1.328 1.172 0.925 0.555
10941 L44140 
Human chromosome X region from filamin 
(FLN) gene to glucose-6-phosphate 
dehydrogenase (G6PD) gene, complete 
cds's. 
1.284 0.986 1.063 0.553
10511 BE466436 KIAA1340 protein 1.170 0.966 0.857 0.539
7213 BG211331 gamma-aminobutyric acid (GABA) A receptor, alpha 6 0.808 1.129 0.988 0.453
6358 M57892 Human carbonic anhydrase isozyme VI (CA6) mRNA, complete cds. 0.857 1.047 0.952 0.587
16477 AB020650 Human mRNA for KIAA0843 protein, complete cds. 1.062 1.043 1.280 0.463
17836 AJ278245 Human mRNA for LanC-like protein 2 (lancl2 gene). 0.993 0.908 0.903 0.732
9696 BC007947 Human, clone IMAGE:4299555, mRNA, partial cds. 1.150 1.127 0.914 0.584
7365 AA479280 Sjogren syndrome antigen B (autoantigen La) 0.725 0.906 0.908 0.741
17202 BC000382 
Human, interleukin enhancer binding factor 
2, 45kD, clone MGC:8391 IMAGE:2820505, 
mRNA, complete cds. 
0.868 1.135 0.792 0.373
15982 M21389 Human keratin type II (58 kD) mRNA, complete cds. 1.147 0.990 0.970 0.378
5260 M23077 Human pepsinogen gene, exon 9, clone PCG401. 0.955 0.902 0.865 0.613
11935 BE463542 phosphatidylinositol glycan, class H 0.999 1.059 1.078 0.397
6612 BC005145 
Human, GDP dissociation inhibitor 2, clone 
MGC:2027 IMAGE:3504736, mRNA, 
complete cds. 
1.162 1.148 1.141 0.704
4183 AI989900 glioblastoma amplified sequence 0.818 0.903 0.921 0.727
14848 AW249865 
ATPase, H+ transporting, lysosomal 
(vacuolar proton pump) membrane sector 
associated protein M8-9 
1.010 1.151 0.943 0.679
6886 BC010457 Human, clone IMAGE:4156419, mRNA, partial cds. 0.749 1.152 1.134 0.740
14787 BC009490 Human, clone IMAGE:3936863, mRNA, partial cds. 0.815 1.250 0.995 0.576
11106 U20759 Human parathyroid cell calcium-sensing receptor mRNA, complete cds. 0.898 1.263 0.879 0.532
11890 AI741847 KIAA0076 gene product 0.873 1.052 0.768 0.747
14440 AF142571 
Tamarin (Saguinus oedipus) intracellular 
vitamin D binding protein 1 (IDBP1) mRNA, 
complete cds. 
1.004 0.988 1.123 0.486
9453 AF094481 
Human trinucleotide repeat DNA binding 
protein p20-CGGBP (CGGBP) gene, 
complete cds. 
1.151 0.855 0.762 0.695
9716 AB037788 Human mRNA for KIAA1367 protein, partial cds. 0.957 0.854 0.927 0.738
14711 AB018290 Human mRNA for KIAA0747 protein, partial cds. 1.035 0.987 0.852 0.718
11636 M64347 Human novel growth factor receptor mRNA, 3' cds. 1.013 0.854 1.145 0.699
8765 D87075 solute carrier family 23 (nucleobase transporters), member 1 0.920 0.772 0.774 0.623
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7914 U13879 Human neuron-restrictive silencer factor mRNA, partial cds. 0.941 0.773 1.075 0.241
15381 AI802091 deoxyribonuclease I 0.874 0.948 1.011 0.467
11630 BC003019 
Human, peroxisomal short-chain alcohol 
dehydrogenase, clone MGC:4052 
IMAGE:2822884, mRNA, complete cds. 
1.048 0.971 0.853 0.361
17975 AF043906 Human T245 protein (T245) mRNA, complete cds. 0.906 1.077 1.267 0.515
11563 L03411 Human RD protein (RD) mRNA, complete cds. 1.068 0.843 1.159 0.611
17842 AK002022 
Human cDNA FLJ11160 fis, clone 
PLACE1007014, weakly similar to 36 KD 
NUCLEOLAR PROTEIN HNP36. 
0.853 1.000 0.941 0.216
6756 U09368 Human zinc finger protein ZNF140. 1.045 0.992 1.141 0.733
5262 BAB08217 embryonic serine protease-2 0.900 0.929 1.029 0.625
3176 AF218313 Human putative helicase RUVBL mRNA, complete cds. 0.801 0.924 0.893 0.718
3178 AK001393 Human cDNA FLJ10531 fis, clone NT2RP2001036. 0.923 1.062 1.099 0.592
9588 AB049842 Macaque brain cDNA, clone:QnpA-17571. 0.911 1.047 0.990 0.615
13774 AV740966 ESTs, Highly similar to R5HU7 ribosomal protein L7, cytosolic [H.sapiens] 0.692 0.866 0.929 0.649
16561 AA130458 lectin, galactoside-binding, soluble, 4 (galectin 4) 1.314 0.989 0.761 0.661
16604 BG258011 S-adenosylhomocysteine hydrolase 0.801 1.266 0.751 0.625
9097 AI632238 peanut (Drosophila)-like 2 1.208 1.091 0.920 0.523
5583 BI711468 integral membrane protein 2B 1.240 0.992 0.898 0.500
11422 BC001380 
Human, succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp), clone 
MGC:1484 IMAGE:3051442, mRNA, 
complete cds. 
1.176 1.091 0.983 0.107
16243 BC001971 
Human, Similar to cyclin-dependent kinase 
inhibitor 1B (p27, Kip1), clone MGC:5304 
IMAGE:3458141, mRNA, complete cds. 
1.099 0.960 1.015 0.712
11315 AB016243 
Human gene for regulatory factor 2 of 
sodium/hydrogen exchanger isoform A3, 
complete cds. 
0.952 0.948 0.753 0.693
9419 AK000679 
Human cDNA FLJ20672 fis, clone 
KAIA4492, highly similar to M95549 Human 
sodium/glucose cotransporter-like protein. 
0.989 0.962 0.910 0.419
11240 D63486 Human mRNA for KIAA0152 gene, complete cds. 0.886 0.987 0.720 0.440
16731 BG775549 ESTs, Highly similar to A31233 ribosomal protein RS.40K, cytosolic [H.sapiens] 0.994 0.976 1.037 0.603
13439 AJ009610 
autoimmune regulator (automimmune 
polyendocrinopathy candidiasis ectodermal 
dystrophy) 
1.006 1.337 0.760 0.541
16263 AY029486 Human G-protein gamma subunit 13 mRNA, complete cds. 0.989 0.961 0.904 0.641
1273 M10058 asialoglycoprotein receptor 1 0.717 0.482 1.049 2.386
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10099 L14754 Human DNA-binding protein (SMBP2) mRNA, complete cds. 1.065 0.990 0.894 2.043
5277 AF109135 Human archvillin (SVIL) mRNA, complete cds. 0.940 0.997 0.874 1.768
14295 M25629 Human kallikrein mRNA, complete cds, clone clone phKK25. 0.802 1.058 0.908 1.636
14297 AJ238520 Human mRNA for putative transcription factor-like nuclear regulator (TFNR gene). 0.684 1.033 0.908 3.361
8212 D83664 Human mRNA for CAAF1 (calcium-binding protein in amniotic fluid 1), complete cds. 0.948 0.797 0.785 1.554
6042 AW245149 
siah binding protein 1; FBP interacting 
repressor; pyrimidine tract binding splicing 
factor; Ro ribonucleoprotein-binding protein 
1 
1.032 0.992 0.873 1.683
7360 M74047 
steroid-5-alpha-reductase, alpha 
polypeptide 2 (3-oxo-5 alpha-steroid delta 
4-dehydrogenase alpha 2) 
1.147 1.001 0.970 1.641
16736 BG537655 ribosomal protein S4, X-linked 0.939 1.006 0.750 1.362
10063 AF260728 Human lipocalin-interacting protein mRNA, complete cds. 1.074 0.946 0.901 1.706
2611 AI193222 hypothetical protein LOC55565 1.010 0.998 0.863 1.602
18359 AA487463 HYA22 protein 0.675 1.009 0.870 1.431
7128 AU159460 LIM and SH3 protein 1 0.753 0.945 0.753 1.538
5491 AB022659 KIAA0470 gene product 0.709 1.030 1.161 1.968
8916 BG761337 carbamoyl-phosphate synthetase 1, mitochondrial 0.897 0.804 1.085 1.506
11157 BC006286 
Human, dual specificity phosphatase 12, 
clone MGC:10337 IMAGE:3958403, 
mRNA, complete cds. 
1.027 1.030 0.963 2.634
10067 BC007065 
Human, glutathione S-transferase theta 1, 
clone MGC:12516 IMAGE:3995846, 
mRNA, complete cds. 
0.973 0.716 0.777 3.213
8502 AF373036 Human ZNFPHEX133 protein (ZNFPHEX133) mRNA, complete cds. 0.997 1.020 0.955 1.703
13517 N62961 synaptosomal-associated protein, 91 kDa (mouse) homolog 0.813 0.781 0.974 1.539
7113 BC005861 
integrin, beta 2 (antigen CD18 (p95), 
lymphocyte function-associated antigen 1; 
macrophage antigen 1 (mac-1) beta 
subunit) 
1.031 1.016 0.952 1.638
2913 BG033340 similar to ubiquitin binding protein 0.940 1.064 1.338 1.787
11159 BAB23372 putative 1.024 0.912 0.837 1.541
15233 BE729850 enhancer of zeste (Drosophila) homolog 2 0.618 1.069 0.899 1.593
4487 AL046515 vimentin 0.844 1.069 1.071 1.589
6879 U05040 Human FUSE binding protein mRNA, complete cds. 0.662 0.877 0.892 1.545
17217 AAC59868 MAM domain protein 1.028 1.272 0.701 1.689
12796 AB058685 Human mRNA for KIAA1782 protein, partial cds. 0.877 1.265 0.952 1.734
6874 BC000692 
Human, Similar to 
hyaluronoglucosaminidase 2, clone 
MGC:1922 IMAGE:3347760, mRNA, 
complete cds. 
1.154 1.265 0.750 1.701
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6420 AF002715 Human MAP kinase kinase kinase (MTK1) mRNA, complete cds. 1.030 0.868 0.977 2.247
11439 AF322916 Human uveal autoantigen mRNA, complete cds. 0.602 0.729 0.932 1.636
5251 U62631 
Human B-cell receptor CD22-B isoform and 
alternatively spliced B-cell receptor CD22-A 
isoform (CD22) gene, complete cds. 
1.182 1.273 0.991 1.930
13214 L25270 Human XE169 mRNA, complete cds. 0.957 1.366 0.739 1.499
4444 AW327435 
ESTs, Highly similar to SR72_HUMAN 
SIGNAL RECOGNITION PARTICLE 72 KD 
PROTEIN [H.sapiens] 
0.857 0.882 0.910 1.522
9883 AJ250915 
Human p10 gene for chaperonin 10 (Hsp10 
protein) and p60 gene for chaperonin 60 
(Hsp60 protein). 
0.721 0.854 0.767 1.765
5553 AW439814 Homo sapiens cDNA FLJ13092 fis, clone NT2RP3002147 0.989 0.847 1.135 1.569
17532 BAB26282 putative 1.005 0.786 0.835 1.587
6576 AB029488 Human C11orf21 mRNA, complete cds. 1.049 0.840 0.961 1.649
10174 BF229298 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 5 1.193 0.857 0.886 2.047
3959 BI259169 KIAA0052 protein 0.790 0.857 1.092 1.860
14531 AB051551 Human mRNA for KIAA1764 protein, partial cds. 0.772 0.757 1.128 1.593
5800 AV713821 
S100 calcium-binding protein A4 (calcium 
protein, calvasculin, metastasin, murine 
placental homolog) 
0.884 0.780 0.838 1.666
2385 AL560352 STIP1 homology and U-Box containing protein 1 1.521 0.659 1.011 2.391
16242 AK001355 Human cDNA FLJ10493 fis, clone NT2RP2000274. 0.915 0.739 1.156 1.829
6962 BAA91104 unnamed protein product 1.141 1.096 0.889 1.914
10944 BC000508 
Human, proteasome (prosome, macropain) 
subunit, beta type, 1, clone MGC:8505 
IMAGE:2822268, mRNA, complete cds. 
1.173 0.816 0.979 2.849
14908 BF224187 
natriuretic peptide receptor C/guanylate 
cyclase C (atrionatriuretic peptide receptor 
C) 
0.652 1.091 0.682 2.614
10365 AL533518 UDP-glucose pyrophosphorylase 2 0.842 1.095 0.824 1.617
4429 U46024 myotubular myopathy 1 0.847 0.913 0.939 2.215
8794 BC006297 chromosome 1 open reading frame 2 1.214 1.086 0.833 1.835
7215 AA404652 interferon-stimulated transcription factor 3, gamma (48kD) 0.866 0.984 0.848 2.210
10079 BC000113 Human, clone IMAGE:3352566, mRNA, partial cds. 1.248 1.116 0.839 1.633
3633 AB021663 Human mRNA for leucine-zipper protein, complete cds. 0.964 0.891 0.721 2.396
13342 K00842 Human beta-tubulin pseudogene, clone 7-beta. 0.705 1.163 0.981 1.540
2904 S46622 
protein phosphatase 3 (formerly 2B), 
catalytic subunit, gamma isoform 
(calcineurin A gamma) 
1.115 1.706 0.502 2.411
16114 AF177198 Human talin mRNA, complete cds. 0.896 0.833 1.155 1.514
6898 AF098534 Human RAD17 isoform 4 (RAD17) mRNA, complete cds. 0.869 1.147 0.707 1.506
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7369 N94350 Thy-1 cell surface antigen 0.641 1.119 0.826 1.688
17211 U78181 Human sodium channel 2 (hBNaC2) mRNA, complete cds. 0.875 0.952 0.785 1.525
7350 BF913759 uroporphyrinogen III synthase (congenital erythropoietic porphyria) 1.234 0.847 0.619 2.150
8907 AF009674 axin 1.558 0.794 0.956 1.133
14600 AK001111 
Human cDNA FLJ10249 fis, clone 
HEMBB1000725, highly similar to Rattus 
norvegicus GTPase Rab8b mRNA. 
1.306 0.971 0.918 1.848
15787 AAH11294 ectonucleotide pyrophosphatase/phosphodiesterase 5 2.108 0.992 1.408 2.084
15782 AB037819 Human mRNA for KIAA1398 protein, partial cds. 1.750 0.983 0.817 1.021
13056 U31501 
Human fragile X mental retardation 
syndrome related protein (FXR2) mRNA, 
complete cds. 
1.656 0.777 1.115 1.235
12246 BG211824 malic enzyme 1, NADP(+)-dependent, cytosolic 1.979 1.090 1.185 1.013
14623 AB017169 Human mRNA for Slit-3 protein, complete cds. 1.943 0.997 1.110 1.003
5494 BE271496 anchor attachment protein 1 (Gaa1p, yeast) homolog 1.870 0.861 0.986 1.137
11493 BC008881 
Human, kinesin 2 (60-70kD), clone 
MGC:15245 IMAGE:4301579, mRNA, 
complete cds. 
1.753 0.889 1.176 1.173
2588 AA314436 chaperonin containing TCP1, subunit 7 (eta) 1.965 1.249 1.116 1.442
2673 AL545741 solute carrier family 1 (neutral amino acid transporter), member 5 2.014 1.321 1.138 1.403
9623 D31767 Human mRNA for KIAA0058 gene, complete cds. 1.360 0.866 1.316 1.856
10567 BG674024 heat shock 70kD protein 1A 2.221 0.861 1.450 1.483
12896 CAB05006 
contains similarity to Pfam domain: 
PF00207 (Alpha-2-macroglobulin family), 
Score=377.3, E-value=1.1e-113, N=1; 
PF01835 (Alpha-2-macroglobulin family N-
terminal region), Score=157.5, E-
value=2.1e-46, N=2~cDNA EST yk41d7.3 
comes fr 
1.804 1.111 1.170 0.967
5537 BC006332 
Human, clathrin, light polypeptide (Lcb), 
clone MGC:12930 IMAGE:4299637, 
mRNA, complete cds. 
1.799 1.398 1.108 1.524
13029 AB002347 Human mRNA for KIAA0349 gene, partial cds. 1.597 0.620 0.995 1.013
4310 U62966 solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 1.605 0.826 1.188 0.898
14844 M80899 Human novel protein AHNAK mRNA, partial sequence. 1.339 0.839 1.103 1.521
13165 BC001778 
Human, Similar to uroporphyrinogen 
decarboxylase, clone MGC:1856 
IMAGE:3542421, mRNA, complete cds. 
1.729 1.134 1.066 1.352
6751 J04988 Human 90 kD heat shock protein gene, complete cds. 1.777 1.105 1.241 1.022
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14626 AF196481 Human RING finger protein (FXY2) mRNA, complete cds. 1.890 0.999 1.310 1.170
16887 AA528133 Homo sapiens 14q32 Jagged2 gene, complete cds; and unknown gene 1.574 1.026 0.893 1.355
3927 NM_004785 solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulatory factor 2 1.798 1.006 1.590 1.330
5559 BF726634 crystallin, alpha B 1.633 0.800 1.174 0.981
12183 BE876028 tropomyosin 2 (beta) 1.842 1.009 0.951 0.995
11592 BC012085 
Human, Similar to serine/threonine protein 
kinase, clone MGC:20014 IMAGE:4554884, 
mRNA, complete cds. 
1.958 0.944 1.276 1.155
5488 BF968460 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble) 2.379 0.936 1.350 1.168
17702 D88674 Human mRNA for antizyme inhibitor, complete cds. 1.556 0.777 0.978 1.284
15839 AK026573 
Human cDNA: FLJ22920 fis, clone 
KAT06686, highly similar to HSU29175 
Human transcriptional activator (BRG1) 
mRNA. 
1.635 0.934 1.210 0.934
5715 AL545227 synaptogyrin 2 1.584 1.062 1.046 1.193
4091 BE787478 thioredoxin reductase 1 3.381 0.757 1.048 1.172
16765 D87071 KIAA0233 gene product 1.686 0.760 1.188 1.155
9067 NM_002222 inositol 1,4,5-triphosphate receptor, type 1 1.528 0.967 0.979 0.952
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Genes Significantly (P<0.005) Upregulated By Shear Stress in PAVEC 
 Group 1 Up 
 
Agilent  Count 545 
Feature # Gene Name/Description Gene ID Fold AVE Fold STD 
2928 cytochrome P450, subfamily I (aromatic 
compound-inducible), polypeptide 1 
K03191 8.38 1.27 
2518 carboxylesterase 1 (monocyte/macrophage 
serine esterase 1) 
L07765 6.66 2.59 
14871 interleukin 8 BG777366 5.85 1.77 
8171 Human cystine/glutamate transporter xCT 
mRNA, complete cds. 
AF252872 4.46 2.29 
2435 aldo-keto reductase family 1, member C1 
(dihydrodiol dehydrogenase 1; 20-alpha (3-
alpha)-hydroxysteroid dehydrogenase) 
BI759009 4.36 1.65 
16028 Human, peroxiredoxin 1, clone MGC:12514 
IMAGE:3961375, mRNA, complete cds. 
BC007063 4.23 0.70 
4091 thioredoxin reductase 1 BE787478 3.52 1.00 
15436 secretory leukocyte protease inhibitor 
(antileukoproteinase) 
BG533465 3.42 0.48 
5961 meiotic recombination (S. cerevisiae) 11 
homolog A 
AF073362 3.39 0.71 
6425 Human E2IG1 (E2IG1) mRNA, complete cds. AF191017 3.22 0.86 
7857 Human full length insert cDNA YH92E12. AF074995 3.15 1.65 
11212 Human, Similar to ubiquitin carboxy-terminal 
hydrolase L1, clone MGC:8524 
IMAGE:2822541, mRNA, complete cds. 
BC000332 3.05 0.65 
6011 procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), beta 
polypeptide (protein disulfide isomerase; 
thyroid hormone binding protein p55) 
BG744516 2.88 0.75 
11749 heme oxygenase (decycling) 1 BI596354 2.86 0.18 
4415 endothelial PAS domain protein 1 AW377189 2.84 0.84 
16118 Human MHC class I lymphocyte antigen 
(HLA-E) (HLA-6.2) gene, complete cds. 
M21533 2.83 0.78 
8905 transforming growth factor, beta 2 AW303586 2.83 0.32 
18356 FOS-like antigen 2 X16706 2.82 1.25 
12235 dynein, cytoplasmic, heavy polypeptide 1 AB002323 2.73 0.91 
16878 2,3-bisphosphoglycerate mutase X04327 2.70 0.40 
10233 enolase 2, (gamma, neuronal) BG169625 2.68 0.65 
10220 Human mRNA for fibrillin. X63556 2.67 0.45 
12094 glucan (1,4-alpha-), branching enzyme 1 
(glycogen branching enzyme, Andersen 
disease, glycogen storage disease type IV) 
L07956 2.66 0.85 
15034 cysteine-rich protein 2 AL515731 2.65 0.54 
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16417 voltage-dependent anion channel 3 AI492354 2.62 1.77 
11800 serine threonine protein kinase AU121423 2.61 0.32 
14759 aortic carboxypeptidase-like protein ACLP AAC25584 2.60 0.25 
11977 FK506-binding protein 9 (63 kD) AL555732 2.56 0.45 
5488 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 1 (soluble) 
BF968460 2.54 1.08 
16899 solute carrier family 6 (neurotransmitter 
transporter, L-proline), member 7 
NM_014228 2.54 0.63 
10115 Human SP-40,40 mRNA for complement-
associated protein SP-40,40 alpha-1 and 
beta-1 chain. 
X14723 2.53 0.55 
12902 Human HK2 mRNA for hexokinase II. Z46376 2.50 0.72 
10514 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 2 
U76368 2.50 0.49 
16413 G protein-coupled receptor 3 U18550 2.47 0.59 
15033 dickkopf (Xenopus laevis) homolog 3 AB034203 2.45 0.54 
16475 potassium inwardly-rectifying 
channel,subfamily J, member 13 
AJ006128 2.45 0.57 
16178 Human oligodendrocyte-specific protein 
(OSP) mRNA, complete cds. 
AF068863 2.44 0.36 
15024 HCGII-7 protein X81001 2.42 0.56 
10188 Human genomic DNA of 8p21.3-p22 anti-
oncogene of hepatocellular colorectal and 
non-small cell lung cancer , segment 6/11. 
AB020863 2.41 0.28 
5827 SEX gene BF725116 2.39 0.87 
12595 Human mRNA for Tec protein-tyrosine 
kinase, complete cds. 
D29767 2.39 0.85 
13782 chitinase 3-like 1 (cartilage glycoprotein-39) AL035737 2.39 0.57 
8279 Human MHC class I HLA-B13 chain gene 
(Aw68.2,30; B13,51), complete cds. 
M24041 2.38 0.51 
15787 ectonucleotide 
pyrophosphatase/phosphodiesterase 5 
AAH11294 2.37 1.29 
11748 Human, clone IMAGE:2905327, mRNA, 
partial cds. 
BC002991 2.34 0.43 
4266 hexosaminidase A (alpha polypeptide) BG686397 2.31 0.51 
4258 ras homolog gene family, member C BG708735 2.30 0.30 
9787 Human proto-oncogene Bcd orf1 and orf2 
mRNA, complete cds. 
U51869 2.29 0.44 
3624 Human mitochondrial glutathione reductase 
(GRD1) mRNA, complete cds; nuclear gene 
for mitochondrial product. 
AF228704 2.28 0.27 
8959 GTP-binding protein Rho7 AI554560 2.28 0.36 
18203 hexabrachion (tenascin C, cytotactin) BG679767 2.27 0.53 
14484 Human, CDC37 (cell division cycle 37, S. 
cerevisiae, homolog), clone MGC:3241 
IMAGE:3505011, mRNA, complete cds. 
BC000083 2.25 0.42 
6470 Human, ATPase, H+ transporting, lysosomal 
(vacuolar proton pump) 21kD, clone 
MGC:4498 IMAGE:2964510, mRNA, 
complete cds. 
BC005876 2.25 0.50 
10567 heat shock 70kD protein 1A BG674024 2.24 0.33 
14767 Human triosephosphate isomerase mRNA, 
complete cds. 
M10036 2.23 0.56 
10522 myosin, heavy polypeptide 9, non-muscle BG699149 2.23 0.73 
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7345 core promoter element binding protein AU139931 2.22 0.35 
6642 Human, 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 1 (soluble), clone 
MGC:8344 IMAGE:2819708, mRNA, 
complete cds. 
BC000297 2.21 0.73 
9557 Human macrophage capping protein mRNA, 
complete cds. 
M94345 2.17 0.66 
959 phosphorylase, glycogen; muscle (McArdle 
syndrome, glycogen storage disease type V) 
BI759873 2.16 0.66 
9869 Human FK506-binding protein (FKBP63) 
mRNA, partial cds. 
AF089745 2.15 0.44 
16969 heat shock 70kD protein 8 BG504802 2.14 0.48 
5906 CD151 antigen BE787930 2.12 0.49 
14750 Human myosin light chain 1 slow a (MLC1sa) 
mRNA, complete cds. 
M31211 2.09 0.48 
2925 ATPase, H+ transporting, lysosomal 
(vacuolar proton pump) 21kD 
BG108730 2.08 0.32 
8380 Human triosephosphate isomerase mRNA, 
complete cds. 
M10036 2.08 0.48 
4491 heterogeneous nuclear ribonucleoprotein R AL538660 2.08 0.45 
3141 Human mRNA for MOP-4, complete cds. AB014773 2.06 0.34 
7572 protein tyrosine phosphatase, receptor type, 
U 
U73727 2.06 0.16 
16148 Human mRNA for diacylglycerol kinase. X62535 2.06 0.14 
14791 Human cathepsin B mRNA, 3' UTR with a 
stem-loop structure providing mRNA stability. 
L22569 2.03 0.73 
2588 chaperonin containing TCP1, subunit 7 (eta) AA314436 2.02 0.53 
16267 Human follistatin gene, exons 1-5. M19480 2.02 0.62 
6440 Human hepatocellular carcinoma associated 
protein (JCL-1) mRNA, complete cds. 
U92544 2.02 0.39 
7441 NADH dehydrogenase (ubiquinone) 
flavoprotein 1 (51kD) 
AW250734 2.02 0.30 
16671 ubiquitin-conjugating enzyme E2H 
(homologous to yeast UBC8) 
AW206129 2.02 0.55 
10615 ALL1-fused gene from chromosome 1q BG498770 2.02 0.37 
2673 solute carrier family 1 (neutral amino acid 
transporter), member 5 
AL545741 2.02 0.14 
8692 plexin B2 BC004542 1.99 0.52 
10171 upstream binding transcription factor, RNA 
polymerase I 
BI088564 1.98 0.34 
12202 myosin, light polypeptide 1, alkali; skeletal, 
fast 
BF981829 1.98 0.25 
12246 malic enzyme 1, NADP(+)-dependent, 
cytosolic 
BG211824 1.98 0.12 
10555 calcium channel, voltage-dependent, beta 3 
subunit 
AL565681 1.98 0.26 
11592 Human, Similar to serine/threonine protein 
kinase, clone MGC:20014 IMAGE:4554884, 
mRNA, complete cds. 
BC012085 1.97 0.25 
13025 Human, Similar to thioredoxin peroxidase 1, 
clone MGC:8456 IMAGE:2821457, mRNA, 
complete cds. 
BC000452 1.96 0.35 
7592 collagen, type IV, alpha 1 NM_001845 1.96 0.46 
16146 Human, chromosome 14 open reading frame 
2, clone MGC:8356 IMAGE:2819801, mRNA, 
complete cds. 
BC000429 1.96 0.43 
6023 tryptophanyl-tRNA synthetase BF795451 1.96 0.22 
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11918 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 1 
BC001636 1.95 0.33 
3474 Human, diaphorase (NADH) (cytochrome b-5 
reductase), clone MGC:5150 
IMAGE:3450773, mRNA, complete cds. 
BC004821 1.94 0.41 
6002 delta sleep inducing peptide, immunoreactor AL525317 1.94 0.19 
14882 hexokinase 2 BI257175 1.94 0.18 
6281 Human mRNA for KIAA0315 gene, partial 
cds. 
AB002313 1.93 0.40 
18327 cyclin-dependent kinase inhibitor 1A (p21, 
Cip1) 
AL542973 1.93 0.68 
11460 Human genomic DNA, chromosome 8q23, 
clone:KB1747F8. 
AP003113 1.93 0.51 
3321 Human mRNA for Soluble-type polypeptide 
FZD4S, complete cds. 
AB054881 1.93 0.64 
13169 Human mRNA for plasma gelsolin. X04412 1.92 0.67 
16774 Ras association (RalGDS/AF-6) domain 
family 1 
AL543484 1.92 0.33 
14626 Human RING finger protein (FXY2) mRNA, 
complete cds. 
AF196481 1.92 0.39 
10426 KIAA0088 protein BI760656 1.92 0.38 
8820 glucosidase, beta; acid (includes 
glucosylceramidase) 
NM_000157 1.92 0.54 
12553 Human, pleckstrin 2 (Mouse) homolog, clone 
MGC:4867 IMAGE:3457876, mRNA, 
complete cds. 
BC001226 1.91 0.37 
5494 anchor attachment protein 1 (Gaa1p, yeast) 
homolog 
BE271496 1.91 0.40 
5596 Human OS-9 mRNA, complete cds. AB002806 1.90 0.31 
7047 histone deacetylase 5 BF305705 1.90 0.22 
17843 Human cathepsin L (CTSL) gene, exon 1, 
intron 1, and exon 2 including 5' end of cds. 
L06426 1.89 0.24 
4263 tyrosine kinase with immunoglobulin and 
epidermal growth factor homology domains 
X60957 1.88 0.39 
12183 tropomyosin 2 (beta) BE876028 1.88 0.41 
12906 Human T-cell receptor zeta-chain mRNA, 
complete cds. 
J04132 1.88 0.41 
5852 protein tyrosine phosphatase, receptor type, 
T 
NM_007050 1.88 0.16 
9126 creatine kinase, mitochondrial 1 (ubiquitous) BG680747 1.88 0.35 
12896 contains similarity to Pfam domain: PF00207 
(Alpha-2-macroglobulin family), Score=377.3, 
E-value=1.1e-113, N=1; PF01835 (Alpha-2-
macroglobulin family N-terminal region), 
Score=157.5, E-value=2.1e-46, N=2~cDNA 
EST yk41d7.3 comes fr 
CAB05006 1.87 0.56 
10745 lectin, galactoside-binding, soluble, 1 
(galectin 1) 
BF979102 1.85 0.28 
13749 actin, alpha 2, smooth muscle, aorta BF681347 1.85 0.46 
5537 Human, clathrin, light polypeptide (Lcb), 
clone MGC:12930 IMAGE:4299637, mRNA, 
complete cds. 
BC006332 1.83 0.37 
3927 solute carrier family 9 (sodium/hydrogen 
exchanger), isoform 3 regulatory factor 2 
NM_004785 1.83 0.33 
15877 Human MAP1 light chain 3-like protein 1 
mRNA, complete cds. 
AF276658 1.82 0.36 
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9121 tumor differentially expressed 1 AL552738 1.82 0.21 
16656 excision repair cross-complementing rodent 
repair deficiency, complementation group 4 
NM_005236 1.82 0.26 
15338 protease, cysteine, 1 (legumain) Y09862 1.82 0.49 
11493 Human, kinesin 2 (60-70kD), clone 
MGC:15245 IMAGE:4301579, mRNA, 
complete cds. 
BC008881 1.82 0.52 
4880 Human cDNA: FLJ22163 fis, clone 
HRC00430. 
AK025816 1.82 0.33 
5797 ATPase, Na+/K+ transporting, alpha 2 (+) 
polypeptide 
NM_000702 1.81 0.29 
15343 cystinosis, nephropathic BG392867 1.81 0.14 
16401 Human, clone MGC:19671 IMAGE:3352603, 
mRNA, complete cds. 
BC011741 1.81 0.36 
6751 Human 90 kD heat shock protein gene, 
complete cds. 
J04988 1.81 0.35 
16116 Human Scd mRNA for stearoyl-CoA 
desaturase, complete cds. 
AB032261 1.81 0.36 
10945 Human, putative glialblastoma cell 
differentiation-related, clone MGC:2352 
IMAGE:3535682, mRNA, complete cds. 
BC004967 1.80 0.46 
6647 Human mRNA for KIAA1776 protein 
(fibrillin3), complete cds. 
AB053450 1.80 0.31 
14237 Human, holocytochrome c synthase 
(cytochrome c heme-lyase), clone MGC:1443 
IMAGE:3030501, mRNA, complete cds. 
BC001691 1.80 0.16 
7285 hypothetical protein FLJ23306 AI088306 1.80 0.50 
13652 clathrin, light polypeptide (Lcb) BE791502 1.80 0.34 
15108 syntaxin 6 AI339089 1.79 0.40 
10727 stress-induced-phosphoprotein 1 
(Hsp70/Hsp90-organizing protein) 
BG721124 1.79 0.14 
12695 Human group III secreted phospholipase A2 
mRNA, complete cds. 
AF220490 1.79 0.20 
7286 ATP-binding cassette, sub-family G (WHITE), 
member 2 
AU118354 1.78 0.44 
18376 cyclin D3 AI803460 1.78 0.48 
5933 microsomal glutathione S-transferase 1 BF037095 1.78 0.12 
14752 Human plasma membrane calcium ATPase 
(hPMCA4) mRNA, complete cds. 
M25874 1.77 0.22 
16672 bridging integrator 1 BG250172 1.77 0.13 
7037 fibulin 5 AL570066 1.77 0.15 
15782 Human mRNA for KIAA1398 protein, partial 
cds. 
AB037819 1.77 0.29 
5672 tyrosyl-tRNA synthetase BC004151 1.77 0.34 
6916 Human cDNA: FLJ20866 fis, clone 
ADKA02201. 
AK024519 1.77 0.34 
13788 hematopoietic cell-specific Lyn substrate 1 X16663 1.76 0.36 
9006 nucleoside phosphorylase BE266250 1.76 0.40 
10754 KIAA0202 protein AL532971 1.76 0.25 
9969 Human, tubulin, beta polypeptide, clone 
MGC:8685 IMAGE:2964590, mRNA, 
complete cds. 
BC001352 1.75 0.40 
12289 ras-related C3 botulinum toxin substrate 2 
(rho family, small GTP binding protein Rac2) 
BG684065 1.75 0.17 
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18360 v-Ha-ras Harvey rat sarcoma viral oncogene 
homolog 
BG419155 1.75 0.24 
4964 Human Bmx mRNA for cytoplasmic tyrosine 
kinase. 
X83107 1.75 0.13 
4759 Human, ARP1 (actin-related protein 1, Yeast) 
homolog A (centractin alpha), clone 
MGC:2357 IMAGE:3347881, mRNA, 
complete cds. 
BC000693 1.74 0.35 
18361 peptidylprolyl isomerase B (cyclophilin B) BE868117 1.74 0.21 
499 Human, transmembrane 4 superfamily 
member (tetraspan NET-7), clone MGC:4120 
IMAGE:2958221, mRNA, complete cds. 
BC003157 1.74 0.34 
10561 adenylate cyclase 7 D25538 1.74 0.19 
13200 Human gamma-filamin (FLNC) gene, 
complete cds. 
AF252549 1.74 0.23 
6712 Human, dihydrolipoamide S-
succinyltransferase (E2 component of 2-oxo-
glutarate complex), clone MGC:3898 
IMAGE:3627724, mRNA, complete cds. 
BC002735 1.73 0.23 
2924 translocase of inner mitochondrial membrane 
17 (yeast) homolog A 
BG506029 1.73 0.32 
16765 KIAA0233 gene product D87071 1.73 0.41 
15410 spectrin, beta, non-erythrocytic 1 BI758140 1.73 0.46 
16663 phosphofructokinase, platelet BE378739 1.73 0.42 
10629 myeloid/lymphoid or mixed-lineage leukemia 
(trithorax (Drosophila) homolog); translocated 
to, 7 
AL544994 1.72 0.43 
16791 microtubule-associated protein 1A NM_002373 1.72 0.26 
9881 Human mRNA for enteric smooth muscle 
gamma-actin. 
X16940 1.72 0.40 
10525 guanine nucleotide binding protein (G 
protein), alpha inhibiting activity polypeptide 1 
AU132321 1.72 0.39 
8346 Human transcription factor junB (junB) gene, 
5' region and complete cds. 
U20734 1.72 0.22 
8992 phospholipase C, delta 1 BI489731 1.71 0.27 
7335 myosin, light polypeptide 6, alkali, smooth 
muscle and non-muscle 
AV716792 1.71 0.29 
12994 Human, Similar to RIKEN cDNA 
B230118G17 gene, clone MGC:19604 
IMAGE:3622817, mRNA, complete cds. 
BC010155 1.70 0.43 
10090 Human RLIP76 protein mRNA, complete cds. L42542 1.70 0.21 
9162 hypothetical protein FLJ20277 BE501346 1.70 0.15 
14743 Human paired related homeobox protein 
(PRX2) mRNA, complete cds. 
AF061970 1.70 0.61 
2745 phosphatidylserine synthase 1 BC004390 1.70 0.28 
16410 hematopoietic PBX-interacting protein BI754234 1.70 0.11 
11913 SH3-domain binding protein 5 (BTK-
associated) 
BC006169 1.69 0.41 
15038 KIAA0562 gene product AB011134 1.69 0.30 
2757 adenine phosphoribosyltransferase BG612479 1.69 0.28 
3939 collagen, type IV, alpha 4 Y17397 1.69 0.18 
5222 Human ribosomal S6 protein kinase mRNA, 
complete cds. 
AF037447 1.69 0.15 
12983 Human cAMP-specific phosphodiesterase 8B 
(PDE8B) mRNA, partial cds. 
AF079529 1.69 0.34 
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8618 discs, large (Drosophila) homolog 5 NM_004747 1.68 0.14 
5438 Human mRNA for glutathione peroxidase, 
complete cds. 
D00632 1.68 0.66 
13597 phosphoribosyl pyrophosphate synthetase-
associated protein 2 
AB007851 1.68 0.11 
13552 actin related protein 2/3 complex, subunit 5 
(16 kD) 
AL560125 1.68 0.37 
4414 gp25L2 protein BI822721 1.68 0.27 
12829 Human mRNA; cDNA DKFZp762G216 (from 
clone DKFZp762G216). 
AL512709 1.68 0.30 
10088 Human testis-specific PGK-2 gene for 
phosphoglycerate kinase (ATP:3-phospho-D-
glycerate 1-phosphotransferase, EC 2.7.2.3). 
X05246 1.67 0.19 
15056 heat shock 70kD protein 9B (mortalin-2) BG424817 1.67 0.28 
16970 calumenin AW614911 1.67 0.32 
13655 P450 (cytochrome) oxidoreductase AF258341 1.67 0.24 
16276 Human leukemia virus receptor 2 (GLVR2) 
mRNA, complete cds. 
L20852 1.67 0.22 
12913 Human carnitine octanoyltransferase mRNA, 
complete cds. 
AF073770 1.67 0.16 
10336 kinesin family member 1C AB014606 1.67 0.17 
14156 Human cDNA FLJ11937 fis, clone 
HEMBB1000556, weakly similar to Human 
mRNA for KIAA0750 protein. 
AK021999 1.67 0.18 
8059 Na,K-ATPase alpha-4 subunit AAD43813 1.66 0.20 
13056 Human fragile X mental retardation syndrome 
related protein (FXR2) mRNA, complete cds. 
U31501 1.66 0.16 
14300 Human glutathione S-transferase mRNA, 
complete cds. 
J03746 1.66 0.17 
14617 Human, clone MGC:15351 IMAGE:4126712, 
mRNA, complete cds. 
BC008861 1.66 0.36 
11972 Niemann-Pick disease, type C2 gene BG397837 1.65 0.25 
5559 crystallin, alpha B BF726634 1.65 0.27 
3460 Human mRNA for collagen alpha 1(V) chain, 
complete cds. 
D90279 1.65 0.42 
7501 phosphatidylinositol 4-kinase, catalytic, beta 
polypeptide 
BG025389 1.65 0.27 
16652 coronin, actin-binding protein, 1A BG758313 1.65 0.27 
18073 Human, Similar to biliverdin reductase A, 
clone MGC:14491 IMAGE:4282476, mRNA, 
complete cds. 
BC005902 1.65 0.35 
5642 hypothetical protein FLJ11560 BF340474 1.65 0.23 
951 oxygen regulated protein (150kD) AW450554 1.64 0.20 
12206 ARP1 (actin-related protein 1, yeast) 
homolog A (centractin alpha) 
AL524757 1.64 0.16 
5715 synaptogyrin 2 AL545227 1.64 0.51 
4310 solute carrier family 28 (sodium-coupled 
nucleoside transporter), member 1 
U62966 1.64 0.35 
10712 hypothetical protein ET AL545372 1.64 0.22 
13445 protein C (inactivator of coagulation factors 
Va and VIIIa) 
M11228 1.63 0.35 
337 Human myelodysplasia/myeloid leukemia 
factor 2 (MLF2) mRNA, complete cds. 
U57342 1.63 0.27 
12492 Human isopeptidase T-3 (ISOT-3) mRNA, 
complete cds. 
U75362 1.63 0.19 
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5563 Human, Similar to valosin-containing protein, 
clone MGC:4053 IMAGE:2822943, mRNA, 
complete cds. 
BC012195 1.62 0.12 
12566 Human mRNA for KIAA1209 protein, partial 
cds. 
AB033035 1.62 0.21 
11270 Human, clone MGC:2827 IMAGE:2964565, 
mRNA, complete cds. 
BC001087 1.62 0.45 
6894 Human EB1 mRNA, complete cds. U24166 1.62 0.21 
271 Human tie mRNA for putative receptor 
tyrosine kinase. 
X60957 1.62 0.47 
8154 Human choroideremia mRNA. X78121 1.62 0.33 
3392 Human CSaids binding protein (CSBP1) 
mRNA, complete cds. 
L35263 1.62 0.29 
8647 peroxiredoxin 2 BI862079 1.62 0.31 
10268 dual specificity phosphatase 3 (vaccinia virus 
phosphatase VH1-related) 
AL555009 1.62 0.22 
9007 spectrin, alpha, non-erythrocytic 1 (alpha-
fodrin) 
U83867 1.61 0.34 
13382 calpain 1, (mu/I) large subunit BG697126 1.61 0.18 
9902 Human SWI-SNF complex protein p270 
mRNA, partial cds. 
AF265208 1.61 0.54 
13029 Human mRNA for KIAA0349 gene, partial 
cds. 
AB002347 1.61 0.20 
9947 Human LPS-Induced TNF-Alpha Factor 
(LITAF) mRNA, complete cds. 
U77396 1.61 0.23 
12071 procollagen-lysine, 2-oxoglutarate 5-
dioxygenase (lysine hydroxylase) 2 
U84573 1.60 0.10 
18362 phytanoyl-CoA hydroxylase (Refsum 
disease) 
BG722759 1.60 0.22 
14546 Human MHC class I HLA-C-alpha-2 chain 
and alternative mRNA, complete cds, clones 
4 and 10. 
M24097 1.60 0.21 
9410 Human HOK-2 mRNA for zinc finger protein. X82125 1.60 0.23 
16317 Human mRNA for KIAA0834 protein, 
complete cds. 
AB020641 1.60 0.36 
8786 latent transforming growth factor beta binding 
protein 1 
M34057 1.60 0.56 
7192 putative glialblastoma cell differentiation-
related 
BE892211 1.60 0.34 
16759 zyxin BI825951 1.59 0.54 
422 Human cDNA FLJ14781 fis, clone 
NT2RP4000455, weakly similar to TRANS-
ACTING TRANSCRIPTIONAL PROTEIN 
ICP0. 
AK027687 1.59 0.44 
4315 DiGeorge syndrome critical region gene 
DGSI; likely ortholog of mouse expressed 
sequence 2 embryonic lethal 
BG831512 1.59 0.27 
12033 integrin beta 4 binding protein BI908045 1.59 0.48 
16887 Homo sapiens 14q32 Jagged2 gene, 
complete cds; and unknown gene 
AA528133 1.59 0.22 
9660 Human 6-O-methylguanine-DNA 
methyltransferase (MGMT) mRNA, complete 
cds. 
M29971 1.59 0.59 
7428 stromal cell-derived factor 2 BG431313 1.58 0.29 
5727 DNA fragmentation factor, 45 kD, alpha 
polypeptide 
BF309422 1.58 0.21 
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13065 Human, ubiquitin B, clone MGC:8385 
IMAGE:2820408, mRNA, complete cds. 
BC000379 1.58 0.16 
15052 palmitoyl-protein thioesterase 2 BE790900 1.58 0.08 
13795 glutaminyl-tRNA synthetase BG179717 1.58 0.23 
14941 Homo sapiens cDNA FLJ10229 fis, clone 
HEMBB1000136 
AL548337 1.58 0.18 
13233 CG3104 gene product AAF51192 1.58 0.20 
12523 Human mRNA; cDNA DKFZp566M051 (from 
clone DKFZp566M051). 
AL117413 1.58 0.42 
7361 desmoglein 2 AU124258 1.57 0.39 
17702 Human mRNA for antizyme inhibitor, 
complete cds. 
D88674 1.57 0.24 
10229 KIAA0130 gene product D50920 1.57 0.28 
15398 KIAA0138 gene product BE856759 1.57 0.20 
16367 Human serum response factor (SRF) mRNA, 
complete cds. 
J03161 1.57 0.16 
11729 calcitonin/calcitonin-related polypeptide, 
alpha 
X03662 1.57 0.20 
5850 aconitase 2, mitochondrial BC014092 1.57 0.19 
7289 KIAA0430 gene product AB007890 1.57 0.16 
14079 Human cDNA FLJ14357 fis, clone 
HEMBA1000005, highly similar to DNAJ 
PROTEIN HOMOLOG MTJ1. 
AK027263 1.57 0.26 
4002 dihydropyrimidinase-like 4 AB006713 1.57 0.24 
8907 axin AF009674 1.56 0.15 
11239 Human cDNA FLJ20746 fis, clone 
HEP06040. 
AK000753 1.56 0.10 
11827 Human, RNA binding motif protein 4, clone 
MGC:8418 IMAGE:2820928, mRNA, 
complete cds. 
BC000307 1.56 0.15 
4325 integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide) 
M13918 1.56 0.18 
8803 squalene epoxidase AF098865 1.56 0.38 
6019 cysteine-rich protein 1 (intestinal) BI222747 1.56 0.21 
16115 Human brain my036 protein mRNA, complete 
cds. 
AF063594 1.56 0.13 
6784 Human mRNA for KIAA1206 protein, partial 
cds. 
AB033032 1.56 0.30 
16356 Human ADP-ribosylation factor 1 mRNA, 
complete cds. 
M84326 1.56 0.25 
4103 amphiregulin (schwannoma-derived growth 
factor) 
AL546917 1.55 0.30 
7355 putative breast adenocarcinoma marker 
(32kD) 
BC002502 1.55 0.30 
15959 Human phosphatidylinositol polyphosphate 5-
phosphatase type IV mRNA, complete cds. 
AF187891 1.55 0.20 
18012 adaptor-related protein complex 2, mu 1 
subunit 
BG033362 1.55 0.13 
15252 Homo sapiens cDNA: FLJ21339 fis, clone 
COL02601, highly similar to AF007152 Homo 
sapiens clone 23649 and 23755 unknown 
mRNA 
AF007152 1.55 0.10 
740 Human cytosolic inhibitor of NRF2 (INRF2) 
mRNA, complete cds. 
AF361886 1.55 0.21 
4327 sphingomyelin phosphodiesterase 1, acid 
lysosomal (acid sphingomyelinase) 
NM_000543 1.54 0.33 
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15031 procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 3 
AL544817 1.54 0.13 
15809 Human eukaryotic initiation factor 2B-epsilon 
mRNA, partial cds. 
U23028 1.54 0.15 
12026 lipase A, lysosomal acid, cholesterol esterase 
(Wolman disease) 
AU141268 1.54 0.42 
9778 Human RET ligand 2 (RETL2) mRNA, 
complete cds. 
U97145 1.54 0.33 
9067 inositol 1,4,5-triphosphate receptor, type 1 NM_002222 1.53 0.14 
16180 Human cDNA FLJ20845 fis, clone 
ADKA01901. 
AK000852 1.53 0.10 
13807 GTP-binding protein overexpressed in 
skeletal muscle 
AW297828 1.53 0.29 
18175 LIM domain only 4 U24576 1.53 0.20 
12291 carnitine acetyltransferase X78706 1.53 0.27 
16936 clones 23667 and 23775 zinc finger protein BG498371 1.53 0.21 
7534 chloride intracellular channel 1 AA291390 1.53 0.27 
12135 LIM and senescent cell antigen-like domains 
1 
U09284 1.52 0.15 
14768 Human mRNA PLSTIRE for serine/threonine 
protein kinase. 
X66365 1.52 0.39 
10722 nucleoporin 62kD BG822825 1.52 0.26 
11768 Human, Similar to RIKEN cDNA 1110018J12 
gene, clone IMAGE:3865164, mRNA, partial 
cds. 
BC011978 1.52 0.12 
4078 isocitrate dehydrogenase 3 (NAD+) beta BI553471 1.52 0.26 
3999 guanylate cyclase 1, soluble, beta 3 X66533 1.52 0.17 
14124 Macaque brain cDNA clone:QflA-13812, full 
insert sequence. 
AB056806 1.52 0.16 
17690 Human, LIM domain only 4, clone MGC:872 
IMAGE:3355972, mRNA, complete cds. 
BC003600 1.52 0.23 
10982 Human mRNA for NOTCH4, partial cds. D63395 1.51 0.44 
15858 Human ALK-1 mRNA. Z22533 1.51 0.42 
13616 similar to vaccinia virus HindIII K4L ORF BE743194 1.51 0.31 
13442 glutamate receptor, metabotropic 4 NM_000841 1.51 0.23 
9376 Human mRNA for apolipoprotein E receptor 
2, complete cds. 
D50678 1.51 0.20 
9010 keratin 15 AU122673 1.51 0.19 
8034 Human, clone MGC:13090 IMAGE:3938680, 
mRNA, complete cds. 
BC006143 1.51 0.27 
13732 lysosomal-associated membrane protein 2 BI549272 1.50 0.14 
882 putative protein similar to nessy (Drosophila) BG824361 1.50 0.22 
6044 absent in melanoma 1 AU139521 1.50 0.35 
9896 Human cDNA FLJ14871 fis, clone 
PLACE1002591, moderately similar to 
CORONIN-LIKE PROTEIN P57. 
AK027777 1.50 0.29 
10678 glutathione S-transferase A4 BI597618 1.50 0.27 
9386 Human mRNA for phenylalkylamine binding 
protein. 
Z37986 1.50 0.43 
2156 Human DNA for apoER2, complete cds, and 
exon 19. 
D86407 1.50 0.18 
9402 Human myosin heavy chain 12 (MYO5A) 
mRNA, complete cds. 
U90942 1.50 0.24 
6349 Macaque brain cDNA, clone:QflA-11789. AB055286 1.50 0.35 
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16173 Human mRNA for putative phospholipase, 
complete cds. 
AB019435 1.49 0.17 
9772 Human caldesmon mRNA, complete cds. M64110 1.49 0.30 
6666 Human cDNA FLJ14937 fis, clone 
PLACE1010231, weakly similar to CELL 
SURFACE GLYCOPROTEIN EMR1 
PRECURSOR. 
AK027843 1.49 0.17 
12230 ELL-RELATED RNA POLYMERASE II, 
ELONGATION FACTOR 
U88629 1.49 0.54 
6978 Human beta-glucuronidase mRNA, complete 
cds. 
M15182 1.49 0.20 
570 Human, secretory carrier membrane protein 
2, clone MGC:1284 IMAGE:3050527, mRNA, 
complete cds. 
BC001376 1.49 0.18 
16197 Human mRNA for zinc finger protein (clone 
647). 
X16282 1.48 0.10 
13184 Human mRNA for Mel-18 protein, complete 
cds. 
D13969 1.48 0.45 
3403 Human, integrin, alpha 5 (fibronectin 
receptor, alpha polypeptide), clone 
MGC:3697 IMAGE:3629647, mRNA, 
complete cds. 
BC008786 1.48 0.10 
15234 ATPase, H+ transporting, lysosomal 
(vacuolar proton pump) 9kD 
BG779549 1.48 0.21 
86 Human pyruvate dehydrogenase kinase 
isoenzyme 1 (PDK1) mRNA, complete cds. 
L42450 1.48 0.40 
4422 nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 2 (p49/p100) 
BC002844 1.47 0.19 
5535 Human, Similar to hypothetical protein 
FLJ10883, clone IMAGE:3855861, mRNA, 
partial cds. 
BC010693 1.47 0.13 
4445 RAE1 (RNA export 1, S.pombe) homolog BG107329 1.47 0.11 
7099 hypothetical protein BG180936 1.47 0.24 
14537 Human elongation factor G1 (EFG1) mRNA, 
complete cds; nuclear gene for mitochondrial 
product. 
AF367998 1.47 0.19 
6785 Human centrosomal Nek2-associated protein 
1 (C-NAP1) mRNA, complete cds. 
AF049105 1.47 0.16 
4965 Human mRNA for cathepsin C. X87212 1.46 0.14 
9873 Human mRNA for EDF-1 protein. AJ005259 1.46 0.14 
16285 Human mRNA for KIAA0356 protein, partial 
cds. 
AB002354 1.46 0.26 
14096 Human palmitoylated erythrocyte membrane 
protein (MPP1) mRNA, complete cds. 
M64925 1.46 0.17 
13683 SKI-like NM_005414 1.45 0.28 
9535 Human cDNA: FLJ23436 fis, clone 
HRC12692. 
AK027089 1.45 0.30 
6502 Human, fatty acid desaturase 3, clone 
MGC:4158 IMAGE:3532219, mRNA, 
complete cds. 
BC004901 1.45 0.24 
6819 Human neuronal double zinc finger protein 
(ZNF231) mRNA, complete cds. 
AF052224 1.45 0.21 
13861 mitogen-activated protein kinase 3 BC013992 1.45 0.13 
5113 Human mRNA for HKR1, partial cds. AB013897 1.45 0.37 
12819 Human mRNA for copine VI protein. AJ133798 1.45 0.25 
13709 electron-transferring-flavoprotein 
dehydrogenase 
AL551954 1.45 0.30 
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4399 3'-phosphoadenosine 5'-phosphosulfate 
synthase 1 
AF016496 1.45 0.17 
196 Human, Similar to CG5057 gene product, 
clone MGC:5309 IMAGE:2899986, mRNA, 
complete cds. 
BC003353 1.45 0.16 
15218 tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta 
polypeptide 
BI458375 1.44 0.12 
5738 HS1 binding protein BI261559 1.44 0.24 
11087 Human mRNA for lysosomal 
sialoglycoprotein, complete cds. 
D12676 1.44 0.32 
13048 Human mRNA for KIAA0093 gene, partial 
cds. 
D42055 1.44 0.26 
5990 N-ethylmaleimide-sensitive factor attachment 
protein, alpha 
AL553335 1.44 0.31 
4858 epithelial protein lost in neoplasm alpha AAF23756 1.44 0.30 
2608 fibrillin 1 (Marfan syndrome) NM_000138 1.44 0.09 
9943 type II cytokeratin BAA85657 1.44 0.17 
7883 Human liver glycogen phosphorylase mRNA, 
complete cds. 
M14636 1.44 0.19 
7274 protein phosphatase 2, regulatory subunit B 
(B56), beta isoform 
AV708790 1.44 0.18 
12591 Human mitochondrial outer membrane 
protein (TOM40) mRNA, nuclear gene 
encoding mitochondrial protein, complete 
cds. 
AF043250 1.43 0.25 
3935 Human mRNA for KIAA1285 protein, partial 
cds. 
AB033111 1.43 0.29 
9381 Human PRM1, PRM2, PRM3, TNP2 and 
SOCS-1 genes. 
Z46940 1.43 0.40 
9758 cystathionine gamma-lyase [Human, liver, 
mRNA, 1326 nt]. 
S52784 1.43 0.31 
5013 Human cDNA FLJ14456 fis, clone 
HEMBB1001915, moderately similar to 
UBIQUITIN CARBOXYL-TERMINAL 
HYDROLASE 64E (EC 3.1.2.15). 
AK027362 1.43 0.23 
18174 protein tyrosine phosphatase, non-receptor 
type 9 
BC010863 1.43 0.20 
5733 Homo sapiens clone 23763 unknown mRNA, 
partial cds 
BG743005 1.43 0.17 
2821 COP9 homolog BG540353 1.43 0.23 
5639 KIAA0121 gene product D50911 1.42 0.19 
16205 Human tuberin (TSC2) gene, intron 36. AF020094 1.42 0.13 
12210 KIAA0326 protein AB002324 1.42 0.17 
12539 Human PWP1-interacting protein 4 mRNA, 
complete cds. 
AF277317 1.42 0.13 
16612 adaptor-related protein complex 4, mu 1 
subunit 
AW170559 1.42 0.14 
8981 cysteine-rich, angiogenic inducer, 61 AL549837 1.42 0.26 
10626 ubiquitin B BG546472 1.42 0.09 
3926 annexin A7 NM_004034 1.42 0.11 
13840 ilvB (bacterial acetolactate synthase)-like AC003956 1.42 0.18 
10650 cathepsin H BI752945 1.42 0.11 
18382 RAE1 (RNA export 1, S.pombe) homolog AW590594 1.42 0.15 
16947 cysteinyl-tRNA synthetase BF000138 1.41 0.28 
16764 RAB4, member RAS oncogene family AL530764 1.41 0.18 
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16325 Human mRNA for KIAA0272 gene, partial 
cds. 
D87462 1.41 0.13 
17910 Human clone IMAGE:2141030, mRNA 
sequence. 
AF339792 1.41 0.19 
4480 EphB3 X75208 1.41 0.21 
16951 nuclear receptor subfamily 1, group H, 
member 3 
BF570118 1.41 0.11 
16159 Human, heterogeneous nuclear 
ribonucleoprotein U (scaffold attachment 
factor A), clone MGC:1992 IMAGE:2966453, 
mRNA, complete cds. 
BC003621 1.41 0.14 
11885 phosphorylase, glycogen; liver (Hers disease, 
glycogen storage disease type VI) 
BE884737 1.40 0.11 
1975 Human, Similar to KRAB-zinc finger protein 
SZF1-1, clone IMAGE:3945618, mRNA, 
partial cds. 
BC006247 1.40 0.16 
16463 Human, eukaryotic translation initiation factor 
5A, clone MGC:4130 IMAGE:2961296, 
mRNA, complete cds. 
BC001832 1.40 0.07 
7881 putative BAB24631 1.40 0.21 
15353 tubulin, beta polypeptide BE729764 1.40 0.30 
10470 protein tyrosine kinase 9-like (A6-related 
protein) 
BF220316 1.40 0.14 
9157 heat shock 70kD protein 5 (glucose-regulated 
protein, 78kD) 
BI560455 1.40 0.26 
7279 mesoderm development candidate 2 BC012746 1.40 0.19 
15093 Rho guanine nucleotide exchange factor 
(GEF) 1 
BE397399 1.40 0.08 
5512 low density lipoprotein-related protein 1 
(alpha-2-macroglobulin receptor) 
BE838269 1.40 0.23 
13869 BRCA1 associated protein-1 (ubiquitin 
carboxy-terminal hydrolase) 
BG109611 1.40 0.21 
8302 Human sno oncogene mRNA for snoN 
protein, ski-related. 
X15219 1.40 0.27 
9929 Human calmodulin-I (CALM1) mRNA, 3'UTR, 
partial sequence. 
U16850 1.40 0.14 
10532 matrix metalloproteinase 23B AI347985 1.40 0.23 
16940 transformer-2 alpha (htra-2 alpha) BG250879 1.39 0.04 
12766 Human septin 2-like cell division control 
protein mRNA, complete cds. 
AF146760 1.39 0.21 
13526 dystrobrevin, beta AL562339 1.39 0.16 
15361 hydroxysteroid (17-beta) dehydrogenase 4 AU125131 1.39 0.20 
13158 Human, Similar to KIAA0174 gene product, 
clone MGC:3110 IMAGE:3350789, mRNA, 
complete cds. 
BC000116 1.39 0.10 
15355 heat shock protein 75 BE901723 1.39 0.18 
16061 Human mRNA for NuMA protein. Z11583 1.39 0.11 
5588 acetyl-Coenzyme A transporter D88152 1.39 0.08 
8985 somatostatin BI713774 1.38 0.11 
9124 UDP-glucose dehydrogenase NM_003359 1.38 0.10 
17619 Human, calpain 4, small subunit (30K), clone 
MGC:1790 IMAGE:3347146, mRNA, 
complete cds. 
BC000592 1.38 0.12 
2443 Human Fanconi anaemia group A gene, 
exons 39, 40, 41, 42 and 43. 
Z83095 1.38 0.19 
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13546 protective protein for beta-galactosidase 
(galactosialidosis) 
AL562902 1.38 0.39 
554 Human mRNA; cDNA DKFZp434H0923 
(from clone DKFZp434H0923). 
AL137712 1.38 0.14 
13634 serine hydroxymethyltransferase 2 
(mitochondrial) 
AL557298 1.38 0.10 
12711 Human CGI-10 protein mRNA, complete cds. AF132944 1.37 0.15 
10082 Human clone 24863 mRNA sequence. AF131806 1.37 0.46 
4942 Human mRNA for acetyl-coenzyme A 
transporter, complete cds. 
D88152 1.37 0.15 
16931 keratin 6A BG681462 1.37 0.29 
5883 phospholipase D1, phophatidylcholine-
specific 
U38545 1.37 0.24 
4430 galactosidase, alpha X16889 1.36 0.02 
13295 Human beta-myosin heavy chain (MYH7) 
mRNA, complete cds. 
M58018 1.36 0.18 
14769 Human C4-sterol methyl oxidase homolog 
(DESP4) mRNA, complete cds. 
U93162 1.36 0.22 
2450 Human glia-derived nexin (GDN) mRNA, 5' 
end. 
M17783 1.36 0.40 
6038 ATPase, Class I, type 8B, member 1 NM_005603 1.36 0.18 
8911 golgi SNAP receptor complex member 2 BE729362 1.36 0.17 
12180 G protein pathway suppressor 1 BG169279 1.36 0.18 
7121 aldehyde dehydrogenase 3 family, member 
B1 
U10868 1.36 0.10 
8606 SH3 domain binding glutamic acid-rich 
protein 
AI422208 1.36 0.30 
5511 Homo sapiens cDNA FLJ13847 fis, clone 
THYRO1000852, highly similar to Human 
branched-chain amino acid aminotransferase 
(ECA40) mRNA 
AL558311 1.36 0.16 
10339 kinesin family member 1C AB014606 1.35 0.15 
13837 proteasome (prosome, macropain) subunit, 
beta type, 6 
BF984053 1.35 0.16 
10190 similar to S. cerevisiae Sec6p and R. 
norvegicus rsec6 
AF055006 1.35 0.17 
16907 ribophorin I BE780549 1.35 0.09 
18230 myosin, light polypeptide 5, regulatory L03785 1.35 0.19 
17872 Human cDNA: FLJ23249 fis, clone 
COL04196. 
AK026902 1.35 0.19 
14844 Human novel protein AHNAK mRNA, partial 
sequence. 
M80899 1.35 0.22 
17575 Human mRNA for peptide transporter 3, 
complete cds. 
AB020598 1.35 0.25 
5178 Human DNA topoisomerase III mRNA, 
complete cds. 
U43431 1.35 0.17 
7854 Human SWI/SNF complex 170 KDa subunit 
(BAF170) mRNA, complete cds. 
U66616 1.35 0.19 
1968 Human mRNA for ring-IBR-ring domain 
containing protein Dorfin, complete cds. 
AB029316 1.35 0.12 
15051 golgi autoantigen, golgin subfamily a, 5 NM_005113 1.35 0.12 
12251 eukaryotic translation initiation factor 3, 
subunit 7 (zeta, 66/67kD) 
BG829032 1.35 0.23 
13824 vacuolar protein sorting 45B (yeast homolog) BF796127 1.35 0.20 
5834 ATPase, Na+/K+ transporting, beta 3 
polypeptide 
AU151263 1.35 0.08 
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17232 Human, Similar to RIKEN cDNA 2300002L21 
gene, clone MGC:17528 IMAGE:3458906, 
mRNA, complete cds. 
BC010541 1.34 0.07 
4014 chromosome 19 open reading frame 3 AW409924 1.34 0.27 
14895 Human genomic DNA, chromosome 6p21.3, 
HLA Class I region, section 2/20. 
AP000503 1.34 0.13 
13346 Human urokinase-type plasminogen receptor, 
exon 7. 
U09937 1.34 0.15 
11559 Human mRNA for rat HREV107-like protein. X92814 1.34 0.08 
11335 Human cDNA FLJ11848 fis, clone 
HEMBA1006708, weakly similar to 
HYPOTHETICAL 46.4 KD TRP-ASP 
REPEATS CONTAINING PROTEIN IN 
PMC1-TFG2 INTERGENIC REGION. 
AK021910 1.34 0.18 
2605 tumor necrosis factor receptor superfamily, 
member 21 
NM_014452 1.34 0.16 
5510 phenylalanine-tRNA synthetase-like AD000092 1.34 0.12 
5977 D123 gene product BE792735 1.34 0.19 
6564 Novel Human mRNA from chromosome 20, 
similar to SW:GOLI_DROME Q06003 
GOLIATH PROTEIN. 
AL096778 1.33 0.34 
11007 Human DiGeorge syndrome critical region, 
centromeric end. 
L77570 1.33 0.22 
6441 Human cDNA: FLJ23330 fis, clone 
HEP12654. 
AK026983 1.33 0.09 
10559 neuronal PAS domain protein 2 U77970 1.33 0.19 
2820 CD44 antigen (homing function and Indian 
blood group system) 
BG822701 1.33 0.32 
14955 putative mitochondrial outer membrane 
protein import receptor 
BF509900 1.33 0.14 
13080 thrombin inhibitor BAA19875 1.33 0.11 
2448 KIAA0515 protein AB011087 1.33 0.22 
948 heat shock transcription factor 1 BG473635 1.32 0.08 
16968 dynactin 2 (p50) U50733 1.32 0.17 
4941 Human mRNA; cDNA DKFZp564I1782 (from 
clone DKFZp564I1782); complete cds. 
AL136699 1.32 0.29 
11746 Protein P3 NM_019848 1.32 0.06 
4410 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 1 
AU118540 1.32 0.03 
14559 Human, 3 beta-hydroxy-delta 5-C27-steroid 
oxidoreductase, clone MGC:10497 
IMAGE:3626629, mRNA, complete cds. 
BC004929 1.31 0.15 
4307 cytochrome c oxidase subunit IV BF726186 1.31 0.16 
16809 myosin, light polypeptide kinase AW951177 1.31 0.15 
6940 Human cDNA: FLJ23306 fis, clone 
HEP11541. 
AK026959 1.31 0.11 
10236 mitogen-activated protein kinase 4 AV707392 1.31 0.17 
14906 Human keratin 18 (KRT18) gene, complete 
cds. 
AF179904 1.31 0.20 
14600 Human cDNA FLJ10249 fis, clone 
HEMBB1000725, highly similar to Rattus 
norvegicus GTPase Rab8b mRNA. 
AK001111 1.31 0.10 
12657 Human voltage-gated chloride ion channel 
CLCN5. 
X91906 1.31 0.11 
6973 Human mRNA for putative ATPase, partial. AJ006268 1.31 0.16 
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5809 ATP-binding cassette, sub-family B 
(MDR/TAP), member 10 
AW949716 1.31 0.17 
14847 extracellular matrix protein 2, female organ 
and adipocyte specific 
NM_001393 1.30 0.17 
13191 Human, Similar to ribophorin I, clone 
MGC:5072 IMAGE:3461167, mRNA, 
complete cds. 
BC010839 1.30 0.11 
4015 Human mRNA; cDNA DKFZp761F0324 (from 
clone DKFZp761F0324). 
AL136595 1.30 0.17 




NM_003605 1.30 0.12 
14584 Human mitochondrial benzodiazepine 
receptor (MBR) gene, complete cds. 
U12421 1.30 0.19 
5724 diptheria toxin resistance protein required for 
diphthamide biosynthesis (Saccharomyces)-
like 2 
BI521245 1.30 0.15 
14582 Human ERK3 mRNA. X80692 1.30 0.08 
8294 Human, RIKEN cDNA 2610511F20 gene, 
clone MGC:15482 IMAGE:2987858, mRNA, 
complete cds. 
BC007557 1.30 0.17 
15960 Human mRNA; cDNA DKFZp761E129 (from 
clone DKFZp761E129); partial cds. 
AL137453 1.30 0.16 
10941 Human chromosome X region from filamin 
(FLN) gene to glucose-6-phosphate 
dehydrogenase (G6PD) gene, complete 
cds's. 
L44140 1.29 0.11 
7818 Human cDNA FLJ10762 fis, clone 
NT2RP4000008, moderately similar to 
CHLORINE CHANNEL PROTEIN P64. 
AK001624 1.29 0.10 
14616 Human, nucleobindin 1, clone MGC:8479 
IMAGE:2821805, mRNA, complete cds. 
BC002356 1.29 0.04 
7251 sushi-repeat-containing protein, X 
chromosome 
U78093 1.29 0.08 
15203 cystatin B (stefin B) BG283058 1.29 0.37 
9968 Human mRNA for KIAA0996 protein, 
complete cds. 
AB023213 1.28 0.18 
8688 cytoplasmic FMRP interacting protein 1 BI522540 1.28 0.13 
7206 immunoglobulin heavy constant mu BM008087 1.28 0.11 
1668 Human, MpV17 transgene, murine homolog, 
glomerulosclerosis, clone MGC:1703 
IMAGE:2967261, mRNA, complete cds. 
BC001115 1.28 0.28 
12868 Human mRNA; cDNA DKFZp761P2414 (from 
clone DKFZp761P2414); complete cds. 
AL161976 1.28 0.07 
6267 Human connexin45 gene, complete cds. U03493 1.28 0.12 
3708 Human, tubulin alpha 1, clone MGC:16616 
IMAGE:4111591, mRNA, complete cds. 
BC009314 1.28 0.21 
5405 Human gene encoding retina-specific 
guanylyl cyclase. 
AJ222657 1.27 0.11 
13733 zinc finger protein 263 AC004232 1.27 0.13 
4237 zinc finger protein 151 (pHZ-67) BG326594 1.27 0.20 
13366 hypothetical protein 24432 AI379916 1.27 0.17 
10084 Human bcr mRNA (break point cluster gene). Y00661 1.27 0.12 
6817 Human microtubule-associated protein 1B 
(MAP1B) gene, complete cds. 
L06237 1.27 0.09 
10687 eukaryotic translation initiation factor 2B, 
subunit 5 (epsilon, 82kD) 
U23028 1.27 0.06 
15843 Human nuclear orphan receptor LXR-alpha 
mRNA, complete cds. 
U22662 1.27 0.10 
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11458 Human protein phosphatase 2C alpha 2 
mRNA, complete cds. 
AF070670 1.27 0.10 
3953 insulin-like growth factor binding protein-2 
[Human, placenta, Genomic, 1342 nt, 
segment 4 of 4]. 
S37730 1.26 0.20 
11964 prostaglandin I2 (prostacyclin) synthase D38145 1.26 0.07 
13818 tissue specific transplantation antigen P35B BG750166 1.26 0.35 
2513 a disintegrin and metalloproteinase domain 
15 (metargidin) 
BG766668 1.26 0.12 
9115 ELK3, ETS-domain protein (SRF accessory 
protein 2) 
BI767724 1.26 0.14 
13218 Human preprothyrotropin-releasing hormone 
gene, exon 3 and thyrotropin-releasing 
hormone, complete cds. 
M63582 1.26 0.08 
13362 TRAF and TNF receptor-associated protein NM_016614 1.26 0.18 
6807 Human CpG island DNA genomic Mse1 
fragment, clone 186c1, reverse read 
cpg186c1.rt1b. 
Z55026 1.25 0.06 
16772 NBR2 U88573 1.25 0.15 
10374 microtubule-associated protein 1B BE935831 1.25 0.10 
8359 Human mRNA; cDNA DKFZp564K2478 (from 
clone DKFZp564K2478); complete cds. 
AL136690 1.25 0.10 
16611 selenophosphate synthetase 2 BG674956 1.25 0.05 
9134 transmembrane 9 superfamily member 2 AU131084 1.24 0.07 
10246 DNA-damage-inducible transcript 3 BE410528 1.24 0.09 
15404 COP9 (constitutive photomorphogenic, 
Arabidopsis, homolog) subunit 3 
AA287305 1.24 0.11 
11001 Human mRNA for KIAA0820 protein, partial 
cds. 
AB020627 1.23 0.11 
7418 catenin (cadherin-associated protein), alpha 
1 (102kD) 
AW250105 1.23 0.10 
7292 p53-induced protein AL521557 1.22 0.09 
12846 bA346K17.2 (A novel protein similar to the 
cell division control protein 91 (CDC91, 
YLR459W or L9122.2) from Yeast) 
CAC14080 1.22 0.10 
7110 heat shock 70kD protein 9B (mortalin-2) BG427082 1.22 0.14 
13855 for protein disulfide isomerase-related D49490 1.22 0.10 
12136 guanine nucleotide binding protein (G 
protein), alpha inhibiting activity polypeptide 2 
BC014627 1.22 0.09 
14799 Human HALPHA44 gene for alpha-tubulin, 
exons 1-3. 
X06956 1.21 0.24 
13865 prostate tumor over expressed gene 1 BG764153 1.21 0.09 
7424 tight junction protein 2 (zona occludens 2) L27476 1.21 0.15 
15824 Human encoding vasodilator-stimulated 
phosphoprotein (VASP). 
Z46389 1.21 0.19 
6950 Human, Similar to UDP-galactose transporter 
related, clone MGC:20043 IMAGE:3832062, 
mRNA, complete cds. 
BC011888 1.21 0.08 
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11405 Human DMAHP gene. X84813 1.21 0.09 
13075 Human oncomodulin gene, exon 5. L20348 1.20 0.09 
14288 Human mRNA; cDNA DKFZp586N1922 
(from clone DKFZp586N1922); partial cds. 
AL117468 1.20 0.08 
44 Human mRNA for KET protein. Y16961 1.20 0.36 
14751 Human esophageal cancer related gene 4 
protein (ECRG4) mRNA, complete cds. 
AF325503 1.20 0.08 
1809 Human mRNA for ubiquitin-like protein, 
complete cds. 
D23662 1.19 0.12 
10405 PTD008 protein AA315771 1.19 0.15 
7913 putative BAB23139 1.19 0.08 
5560 galactose-1-phosphate uridylyltransferase BG741575 1.18 0.06 
8672 radixin BF194976 1.17 0.07 
7122 Rac/Cdc42 guanine exchange factor (GEF) 6 D13631 1.17 0.09 
4253 KIAA0670 protein/acinus AF124727 1.17 0.12 
12109 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 7 (18kD, B18) 
BI835169 1.16 0.14 
16011 Human mRNA for squalene epoxidase, 
complete cds. 
D78130 1.15 0.20 
15081 myosin, light polypeptide, regulatory, non-
sarcomeric (20kD) 
AA345289 1.15 0.12 
16785 karyopherin (importin) beta 2 U72069 1.14 0.08 
2447 eukaryotic translation initiation factor 3, 
subunit 8 (110kD) 
AL529959 1.13 0.07 
6951 Human, clone MGC:15765 IMAGE:3501642, 
mRNA, complete cds. 
BC009434 1.13 0.24 
6789 Human vascular endothelial growth factor 
(VEGF) mRNA, 3'UTR. 
AF024710 1.13 0.08 
13674 junction plakoglobin BG775483 1.12 0.06 
14611 Human kruppel-like zinc finger protein 
(ZNF300) mRNA, complete cds. 
AF395541 1.09 0.07 
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Genes Significantly (P<0.005) Downregulated By Shear Stress in PAVEC 
Group 1 Down 
Agilent  Count 311  
Feature # Gene Name/Description Gene ID Fold AVE Fold STD 
8368 Human cDNA: FLJ21156 fis, clone CAS09878. AK024809 4.16 3.27 
16488 kinesin-like 4 NM_007317 3.02 1.99 
10644 ectodermal-neural cortex (with BTB-like domain) BC000418 2.95 0.96 
11934 cell division cycle 2, G1 to S and G2 to M AL520473 2.65 0.34 
14388 
Human cDNA FLJ12587 fis, clone 
NT2RM4001217, moderately similar to Mouse 
(Mus musculus) actin-binding protein (ENC-1) 
mRNA. 
AK022649 2.62 0.66 
11654 Human cyclin-selective ubiquitin carrier protein mRNA, complete cds. U73379 2.57 0.30 
8825 caveolin 1, caveolae protein, 22kD NM_001753 2.55 0.79 
9932 Human caveolin 1 (CAV1) gene, exon 3 and partial cds. AF125348 2.52 0.79 
9622 Human cell cycle control gene CDC2. Y00272 2.51 0.35 
13481 PDZ and LIM domain 1 (elfin) AI687946 2.33 0.46 
2782 topoisomerase (DNA) II alpha (170kD) BF795918 2.31 0.28 
12196 KIAA0101 gene product NM_014736 2.26 0.24 
11882 polymerase (DNA directed), epsilon 2 AF036899 2.20 0.34 
10544 kinesin-like 1 X85137 2.19 0.28 
14857 v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived BF313082 2.12 0.92 
11506 Human BRCA1, Rho7 and vatI genes, complete cds, and ipf35 gene, partial cds. L78833 2.10 0.21 
13765 CDC28 protein kinase 2 BG618998 2.10 0.13 
5847 thymopoietin U09088 2.10 0.25 
9094 amylase, alpha 2B; pancreatic NM_020978 2.09 0.69 
11142 Human mRNA encoding the c-myc oncogene. V00568 2.05 0.37 
17894 
Human, Similar to cyclin B1, related sequence 1, 
clone MGC:2548 IMAGE:2963100, mRNA, 
complete cds. 
BC006510 2.03 0.18 
16273 Human nuclear factor I-B2 (NFIB2) mRNA, complete cds. U85193 2.02 0.16 
9541 Human, PDZ and LIM domain 1 (elfin), clone MGC:5344 IMAGE:2985229, mRNA, complete cds. BC000915 2.01 0.36 
13503 chromosome condensation-related SMC-associated protein 1 BE793681 2.00 0.43 
4408 ESTs, Highly similar to A38712 fibrillarin [H.sapiens] AI199605 2.00 0.50 
8941 highly expressed in cancer, rich in leucine heptad repeats AA878068 1.99 0.38 
7555 phosphodiesterase 3B, cGMP-inhibited BI756567 1.98 0.44 
6942 Human dek mRNA. X64229 1.95 0.20 
2619 paternally expressed 10 AF038197 1.95 0.36 
 323
3348 Human histone acetyltransferase 1 mRNA, complete cds. AF030424 1.93 0.21 
251 Human ubiquitin-specific protease (UBP) mRNA, complete cds. AF117386 1.91 0.30 
13815 glia maturation factor, gamma AA279067 1.89 0.12 
2292 Human mRNA for KIAA0949 protein, partial cds. AB023166 1.89 0.19 
7368 KIAA0256 gene product BG107450 1.89 0.27 
13315 TTK protein kinase M86699 1.88 0.17 
3946 DEK oncogene (DNA binding) AU152618 1.87 0.20 
10641 kinesin-like 5 (mitotic kinesin-like protein 1) BM014478 1.87 0.16 
16260 Human cDNA FLJ10633 fis, clone NT2RP2005640. AK001495 1.87 0.64 
8531 similar to mouse olfactory receptor 13; similar to P34984 (PID:g464305) AAD05193 1.87 0.25 
2515 CHK1 (checkpoint, S.pombe) homolog AF016582 1.86 0.24 
203 Human replication protein A 14kDa subunit (RPA) mRNA, complete cds. L07493 1.85 0.86 
1345 serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1 BI915951 1.85 0.16 
13835 putative human HLA class II associated protein I AY007110 1.85 0.12 
15342 proliferating cell nuclear antigen AA523378 1.83 0.19 
6507 Human c-jun proto oncogene (JUN), complete cds, clone hCJ-1. J04111 1.81 0.15 
8297 Human mRNA; cDNA DKFZp434M152 (from clone DKFZp434M152). AL137687 1.80 0.39 
13316 baculoviral IAP repeat-containing 5 (survivin) AL571008 1.79 0.50 
5465 vaccinia related kinase 1 AA312869 1.78 0.16 
3167 
Human, Similar to gene rich cluster, C8 gene, 
clone MGC:2577 IMAGE:3138951, mRNA, 
complete cds. 
BC002551 1.77 0.36 
15978 
Human cDNA: FLJ21715 fis, clone COL10287, 
highly similar to AF071569 Human multifunctional 
calcium/calmodulin-dependent protein kinase II 
delta2 isoform mRNA. 
AK025368 1.77 0.19 
13776 arginase, type II BC001350 1.75 0.31 
12827 Human early B-cell transcription factor (EBF) mRNA, partial cds. AF208502 1.72 0.17 
16313 Human replication factor C, 37-kDa subunit mRNA, complete cds. M87339 1.72 0.09 
8842 fasciculation and elongation protein zeta 2 (zygin II) AF113124 1.70 0.12 
11439 Human uveal autoantigen mRNA, complete cds. AF322916 1.69 0.33 
12219 hypothetical protein PRO1489 AI536671 1.68 0.36 
1350 U2 small nuclear ribonucleoprotein auxiliary factor (65kD) BI962886 1.68 0.20 
12551 Human mRNA for transferrin receptor. X01060 1.67 0.47 
181 Human gene for thrombomodulin precursor, complete cds. D00210 1.67 0.12 
13806 cadherin 11, type 2, OB-cadherin (osteoblast) BI766088 1.67 0.13 
8740 dCMP deaminase AA101974 1.67 0.17 
5976 serum-inducible kinase BG677879 1.67 0.60 
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3326 Human cDNA FLJ10470 fis, clone NT2RP2000032, weakly similar to RAS SUPPRESSOR PROTEIN 1. AK001332 1.66 0.60 
12882 
Human, CDC20 (cell division cycle 20, S. 
cerevisiae, homolog), clone MGC:15276 
IMAGE:2959596, mRNA, complete cds. 
BC009426 1.66 0.28 
5652 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase D89976 1.66 0.17 
16895 BRCA1 associated RING domain 1 AW002440 1.66 0.22 
15222 
Homo sapiens cDNA: FLJ23324 fis, clone 
HEP12482, highly similar to HUMMYOHCB Human 
nonmuscle myosin heavy chain-B (MYH10) mRNA 
AA724155 1.66 0.10 
9014 EphA4 L36645 1.66 0.56 
14123 Human TALE homeobox protein Meis2b mRNA, complete cds. AF179896 1.66 0.20 
7348 phosphodiesterase 6D, cGMP-specific, rod, delta BC007831 1.65 0.34 
10501 exonuclease 1 AC004783 1.64 0.36 
16640 hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) AU154668 1.63 0.11 
11671 Human H1.2 gene for histone H1. X57129 1.63 0.48 
15233 enhancer of zeste (Drosophila) homolog 2 BE729850 1.62 0.13 
1985 Human Trio isoform mRNA, complete cds. AF091395 1.62 0.19 
15044 inhibitor of growth family, member 3 BG574907 1.61 0.22 
4446 KIAA0603 gene product BI906891 1.60 0.22 
16274 
Human, ubiquitin-conjugating enzyme E2E 3 
(homologous to Yeast UBC4/5), clone MGC:1316 
IMAGE:3537280, mRNA, complete cds. 
BC003554 1.60 0.17 
4421 insulin-like growth factor 1 (somatomedin C) M11568 1.60 0.20 
6008 
Homo sapiens cDNA: FLJ21930 fis, clone 
HEP04301, highly similar to HSU90916 Human 
clone 23815 mRNA sequence 
U90916 1.60 0.29 
12707 Human TRIP7-like protein mRNA, complete cds. AY043282 1.60 0.14 
11255 Human mRNA; cDNA DKFZp761C121 (from clone DKFZp761C121); complete cds. AL136560 1.59 0.35 
7533 ataxia telangiectasia and Rad3 related U49844 1.59 0.40 
14908 natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C) BF224187 1.59 0.48 
8747 ribosomal protein L23a AA857067 1.59 0.31 
13679 myosin, heavy polypeptide 8, skeletal muscle, perinatal Z38133 1.59 0.16 
2462 hypothetical protein AI792005 1.58 0.10 
3373 Human, hypothetical protein, clone MGC:3375 IMAGE:3609357, mRNA, complete cds. BC002677 1.58 0.32 
1032 H2A histone family, member N BE253911 1.58 0.37 
12532 Human PBX3 mRNA. X59841 1.57 0.17 
17241 
Human cDNA FLJ10244 fis, clone 
HEMBB1000632, weakly similar to GUANINE 
NUCLEOTIDE RELEASING PROTEIN. 
AK001106 1.57 0.32 
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11284 
Human (clones HGPCD2 and HGPCD15) pterin-
4a-carbinolamine dehydratase (PCBD) gene, 
complete cds. 
L41560 1.57 0.26 
10588 minichromosome maintenance deficient (S. cerevisiae) 7 AI285101 1.57 0.28 
7369 Thy-1 cell surface antigen N94350 1.57 0.13 
16737 methylthioadenosine phosphorylase AL048242 1.56 0.16 
16590 coproporphyrinogen oxidase (coproporphyria, harderoporphyria) NM_000097 1.56 0.12 
7065 heterogeneous nuclear ribonucleoprotein H3 (2H9) BG574659 1.56 0.32 
14618 Human, Similar to advillin, clone MGC:1461 IMAGE:2961396, mRNA, complete cds. BC004134 1.56 0.58 
4719 Human 1-8D gene from interferon-inducible gene family. X57351 1.55 0.36 
10275 hypothetical protein MGC19556 BG830088 1.55 0.18 
9113 primase, polypeptide 2A (58kD) X74331 1.55 0.38 
16328 Human H2B.2 and H2A.1 genes for Histone H2A and H2B. X57138 1.55 0.34 
6881 Human zinc finger transcription factor (ZNF207) mRNA, complete cds. AF046001 1.54 0.10 
8053 Human mRNA for MEMD protein. Y10183 1.54 0.21 
185 
Human, Similar to heterogeneous nuclear 
ribonucleoprotein A3, clone MGC:20045 
IMAGE:4661041, mRNA, complete cds. 
BC012090 1.54 0.25 
10397 calcium/calmodulin-dependent protein kinase kinase 2, beta AI925424 1.54 0.15 
56 Human hypoxanthine phosphoribosyltransferase (HPRT) mRNA, complete cds. M31642 1.54 0.27 
16799 ovo (Drosophila) homolog-like 1 AF016045 1.53 0.10 
13320 protein phosphatase 1, catalytic subunit, gamma isoform BG289736 1.53 0.08 
9169 neurogranin (protein kinase C substrate, RC3) BF948983 1.53 0.29 
4994 Human zinc finger protein 277 (ZNF277) mRNA, complete cds. AF209198 1.53 0.25 
7578 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1 AA527110 1.53 0.13 
6888 Human mRNA for hMCM2, complete cds. D28480 1.53 0.32 
5129 bA149I18.1 (novel protein) CAC16127 1.53 0.42 
10462 mal, T-cell differentiation protein NM_022439 1.53 0.25 
4242 interferon induced transmembrane protein 1 (9-27) BG506643 1.53 0.31 
4095 Homo sapiens mRNA; cDNA DKFZp564H2416 (from clone DKFZp564H2416) N92498 1.53 0.14 
746 Human CAAX box protein TIMAP mRNA, complete cds. AF362910 1.52 0.35 
13543 ESTs, Highly similar to JC4662 ribosomal protein S3a, cytosolic [H.sapiens] BF663467 1.52 0.28 
6879 Human FUSE binding protein mRNA, complete cds. U05040 1.52 0.13 
13457 S-adenosylmethionine decarboxylase 1 AI042585 1.51 0.07 
5267 Human cDNA FLJ13287 fis, clone OVARC1001161. AK023349 1.51 0.30 
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15022 interferon induced transmembrane protein 3 (1-8U) BE886918 1.51 0.25 
14398 Human CGI-142 protein mRNA, complete cds. AF151900 1.51 0.15 
11359 Human putative transcriptional regulator ENX-1 mRNA, complete cds. U52965 1.51 0.06 
13166 Human mRNA for KIAA1226 protein, partial cds. AB033052 1.50 0.25 
7398 ESTs, Highly similar to I51803 TAXREB107 [H.sapiens] AW514303 1.50 0.23 
10005 Human methylmalonyl-CoA mutase (MCM) mRNA, complete cds. M65131 1.50 0.41 
4703 Human mRNA for SET-binding protein (SEB), complete cds. AB022660 1.50 0.16 
3485 Macaque testis cDNA clone:QtsA-13672, full insert sequence. AB070098 1.50 0.30 
14705 Human genomic DNA, chromosome 21q22.1, D21S226-AML region, clone:T604. AP000303 1.49 0.14 
18359 HYA22 protein AA487463 1.49 0.20 
2903 methylmalonyl Coenzyme A mutase AA702733 1.49 0.40 
11277 Human arpp mRNA for ankyrin-repeat protein, complete cds. AB058599 1.49 0.23 
900 polymerase (DNA directed), delta 3 D26018 1.49 0.07 
8510 Human 5T4 oncofetal trophoblast glycoprotein gene. AJ012159 1.49 0.14 
3753 Human mRNA for protein kinase PAK5, complete cds. AB040812 1.49 0.18 
10204 Human homolog of Yeast mutL (hPMS1) gene, complete cds. U13695 1.49 0.25 
1675 Human CUG-binding protein LYLQ isoform mRNA, complete cds. AF267533 1.48 0.08 
15656 Human Ste-20 related kinase SPAK mRNA, complete cds. AF099989 1.48 0.14 
3797 
Human, secretory granule, neuroendocrine protein 
1 (7B2 protein), clone MGC:12446 
IMAGE:3949961, mRNA, complete cds. 
BC005349 1.48 0.12 
13643 activated leucocyte cell adhesion molecule AI050952 1.48 0.30 
8915 hypothetical protein FLJ11149 BI752967 1.48 0.31 
10307 A kinase (PRKA) anchor protein (yotiao) 9 NM_005751 1.48 0.15 
13801 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily b, 
member 1 
BF977892 1.47 0.09 
10161 Human lens epithelium-derived growth factor gene, alternatively spliced, complete cds. AF199339 1.47 0.18 
6356 Human replication factor C large subunit mRNA, complete cds. L23320 1.47 0.11 
7362 interleukin 13 NM_002188 1.47 0.26 
14297 Human mRNA for putative transcription factor-like nuclear regulator (TFNR gene). AJ238520 1.46 0.11 
14266 Human mRNA; cDNA DKFZp434D0215 (from clone DKFZp434D0215); partial cds. AL133047 1.46 0.24 
13774 ESTs, Highly similar to R5HU7 ribosomal protein L7, cytosolic [H.sapiens] AV740966 1.45 0.17 
13174 Human tankyrase-2 (TNKS-2) mRNA, complete cds. AF309033 1.45 0.59 
8978 centaurin, beta 2 BC014843 1.45 0.28 
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14406 Human NADH-ubiquinone oxidoreductase subunit CI-SGDH mRNA, complete cds. AF047181 1.45 0.31 
3962 ESTs, Highly similar to TBCA_HUMAN TUBULIN-SPECIFIC CHAPERONE A [H.sapiens] BI492241 1.45 0.07 
14254 Human TESTIN 2 and TESTIN 3 genes, complete cds, alternatively spliced. AF260225 1.44 0.18 
16950 HIV-1 rev binding protein 2 AW974533 1.43 0.16 
8857 H2B histone family, member A AV759568 1.43 0.21 
8535 Human mRNA; cDNA DKFZp564J2222 (from clone DKFZp564J2222); complete cds. AL136608 1.43 0.10 
7046 cleavage and polyadenylation specific factor 5, 25 kD subunit AA738354 1.43 0.06 
7183 phosphodiesterase 2A, cGMP-stimulated U67733 1.43 0.19 
10665 chromosome 2 open reading frame 6 AL122062 1.43 0.12 
7842 Human genomic DNA, chromosome 21q, section 14/105. AP001670 1.42 0.08 
5503 RAS p21 protein activator (GTPase activating protein) 1 NM_022650 1.42 0.11 
13197 
Human myocyte-specific enhancer factor 2A 
(MEF2A) gene, last coding exon, and complete 
cds. 
U49020 1.42 0.06 
5420 Human nuclear antigen H731-like protein mRNA, complete cds. U96628 1.42 0.06 
8839 CLIP-associating protein 1 AB014522 1.42 0.22 
13342 Human beta-tubulin pseudogene, clone 7-beta. K00842 1.42 0.07 
2920 
ESTs, Highly similar to B Chain B, Crystal 
Structure Of The Human Cdk2 Kinase Complex 
With Cell Cycle-Regulatory Protein Ckshs1 
[H.sapiens] 
AI033892 1.42 0.14 
14276 Human zinc finger protein ANC_2H01 mRNA, complete cds. AF003924 1.41 0.19 
14277 Human esterase D mRNA, complete cds. AF112219 1.41 0.10 
5491 KIAA0470 gene product AB022659 1.41 0.09 
10299 Homo sapiens clone 24711 mRNA sequence AF055029 1.41 0.17 
15813 Human death associated protein 4 (DAP4) mRNA, complete cds. AF081567 1.41 0.13 
7590 ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens] BG718906 1.41 0.07 
7967 thymosin beta-10 [Human, metastatic melanoma cell line, mRNA, 453 nt]. S54005 1.40 0.20 
1368 membrane-bound transcription factor protease, site 1 AL133583 1.40 0.15 
16591 chromodomain helicase DNA binding protein 1 AF006513 1.40 0.18 
15091 putative DNA binding protein BC010013 1.40 0.05 
14744 Human mRNA for p cadherin. X63629 1.40 0.17 
5589 serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1 AL531502 1.40 0.13 
16726 retinoblastoma-binding protein 4 BC015123 1.40 0.16 
8791 H-2K binding factor-2 BG574227 1.40 0.14 
15312 cerebral cavernous malformations 1 BG163551 1.40 0.17 
14704 Human programmed cell death 9 (PDCD9) mRNA, complete cds. AF146192 1.40 0.11 
4272 hypothetical protein W74196 1.40 0.15 
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497 
Human, tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, epsilon 
polypeptide, clone MGC:1250 IMAGE:3139004, 
mRNA, complete cds. 
BC001440 1.40 0.15 
12287 zinc finger protein 197 NM_006991 1.39 0.37 
15652 Human sperm protein 17 mRNA, complete cds. AF334735 1.39 0.16 
16607 downregulated in ovarian cancer 1 U53445 1.39 0.09 
6885 Human monocytic leukaemia zinc finger protein (MOZ) mRNA, complete cds. U47742 1.39 0.07 
13347 Human cDNA FLJ10655 fis, clone NT2RP2005933, weakly similar to NUCLEOPORIN NUP57. AK001517 1.39 0.08 
16462 
Human apolipoprotein AI regulatory protein-
1/chicken ovalbumin upstream promoter 
transcription factor II (TFCOUP2) gene, complete 
cds. 
U60477 1.38 0.05 
9127 brain and reproductive organ-expressed (TNFRSF1A modulator) BG198322 1.38 0.09 
13216 Human mRNA for KIAA1296 protein, partial cds. AB037717 1.38 0.09 
11940 RAP1A, member of RAS oncogene family BI856433 1.38 0.12 
2816 KIAA0301 protein N24059 1.38 0.16 
7365 Sjogren syndrome antigen B (autoantigen La) AA479280 1.38 0.06 
8749 KIAA0528 gene product BG619195 1.38 0.19 
254 Human cDNA FLJ20403 fis, clone KAT01539. AK000410 1.38 0.22 
5874 interferon-induced protein with tetratricopeptide repeats 1 M24594 1.38 0.55 
3798 Human hairy (HRY) mRNA, complete cds. AF264785 1.37 0.34 
7607 suppression of tumorigenicity 7 BI818571 1.37 0.16 
10327 dUTP pyrophosphatase AW276291 1.37 0.12 
8833 v-jun avian sarcoma virus 17 oncogene homolog AI051628 1.37 0.09 
8588 Human cDNA FLJ11341 fis, clone PLACE1010786. AK002203 1.36 0.15 
3933 asparagine synthetase BC014621 1.36 0.22 
6631 Human mRNA for KIAA0636 protein, complete cds. AB014536 1.36 0.11 
11969 pleckstrin homology, Sec7 and coiled/coil domains 1(cytohesin 1) NM_017456 1.36 0.10 
2591 
Homo sapiens, Similar to RNA binding motif 
protein, X chromosome, clone MGC:9398 
IMAGE:3875565, mRNA, complete cds 
BG167309 1.35 0.06 
11902 G-rich RNA sequence binding factor 1 BF034561 1.35 0.23 
12051 ribosomal protein L37 BG032793 1.35 0.11 
11185 Human mRNA for myb-related gene A-myb 5'-region. X13294 1.35 0.10 
8443 Human, ribosomal protein S24, clone MGC:3989 IMAGE:2958303, mRNA, complete cds. BC003149 1.35 0.15 
11959 S-adenosylmethionine decarboxylase 1 BF676785 1.34 0.14 
4265 smg GDS-ASSOCIATED PROTEIN BG433239 1.34 0.16 
10697 nuclear receptor subfamily 3, group C, member 1 X03225 1.34 0.26 
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9596 Human, Similar to stromal antigen 2, clone MGC:1282 IMAGE:3352347, mRNA, complete cds. BC001765 1.34 0.12 
9560 Human protein kinase C iota isoform, complete cds. L33881 1.34 0.19 
5329 Human heat shock protein hsp70-related protein mRNA, complete cds. AF112210 1.34 0.10 
13785 
ESTs, Highly similar to ROA3_HUMAN 
HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN A3 [H.sapiens] 
AW976907 1.34 0.08 
13139 
Human, Williams-Beuren syndrome chromosome 
region 1 homolog (Human), clone MGC:19645 
IMAGE:2960402, mRNA, complete cds. 
BC010021 1.34 0.06 
3455 Human cDNA FLJ12082 fis, clone HEMBB1002492. AK022144 1.34 0.11 
8838 ADP-ribosyltransferase 3 AI201027 1.34 0.13 
6886 Human, clone IMAGE:4156419, mRNA, partial cds. BC010457 1.34 0.05 
1969 
Human Bruton's tyrosine kinase (BTK), alpha-D-
galactosidase A (GLA), L44-like ribosomal protein 
(L44L) and FTP3 (FTP3) genes, complete cds. 
U78027 1.33 0.17 
6892 Human, Similar to CG9602 gene product, clone MGC:3733 IMAGE:3619626, mRNA, complete cds. BC002775 1.33 0.16 
738 Human protocadherin-beta15 (PCDHB15) mRNA, complete cds. AF217742 1.33 0.06 
13305 M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein) X98494 1.33 0.29 
10186 protein phosphatase 2, regulatory subunit B (B56), epsilon isoform BI496977 1.33 0.13 
5413 
Human, Similar to RIKEN cDNA 1200013F24 
gene, clone MGC:12197 IMAGE:3997840, mRNA, 
complete cds. 
BC006982 1.32 0.05 
14090 Human gcp60 mRNA for golgi resident protein GCP60, complete cds. AB043587 1.32 0.16 
9522 Human Bcl2, p53 binding protein Bbp/53BP2 (BBP/53BP2) mRNA, complete cds. U58334 1.31 0.14 
12702 Macaque brain cDNA clone:QmoA-10711, full insert sequence. AB062987 1.31 0.12 
13524 retinoblastoma-like 1 (p107) M74547 1.31 0.13 
16734 
ESTs, Weakly similar to JC5314 CDC28/cdc2-like 
kinase associating arginine-serine cyclophilin 
[H.sapiens] 
BE644965 1.31 0.13 
8652 RNA binding motif protein 14 BF943707 1.31 0.13 
10343 RNA polymerase II transcriptional regulation mediator (Med6, S. cerevisiae, homolog of) AL079635 1.31 0.11 
5970 proliferation-associated 2G4, 38kD BI088072 1.31 0.13 
4419 retinoid X receptor, gamma BC012063 1.31 0.31 
425 Human, Similar to caspase 2, clone MGC:2181 IMAGE:3346279, mRNA, complete cds. BC002427 1.30 0.20 
15186 pre-mRNA splicing factor 17 NM_015891 1.30 0.06 
15359 SFRS protein kinase 1 AW958364 1.30 0.08 
4461 guanine nucleotide binding protein 11 BF115554 1.30 0.03 
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10015 Human mRNA; cDNA DKFZp434F1016 (from clone DKFZp434F1016); partial cds. AL137287 1.30 0.23 
8677 
Human cDNA FLJ11367 fis, clone 
HEMBA1000303, highly similar to Mouse (Mus 
musculus) Plenty of SH3s (POSH) mRNA. 
AK021429 1.30 0.09 
15628 
Human, activated RNA polymerase II transcription 
cofactor 4, clone MGC:17295 IMAGE:3457167, 
mRNA, complete cds. 
BC010537 1.30 0.07 
7574 
CD36 antigen (collagen type I receptor, 
thrombospondin receptor)-like 2 (lysosomal integral 
membrane protein II) 
D12676 1.30 0.09 
6027 complement component 3a receptor 1 NM_004054 1.29 0.19 
8789 cullin 5 X81882 1.29 0.20 
9077 splicing factor, arginine/serine-rich (transformer 2 Drosophila homolog) 10 BC000160 1.29 0.10 
7132 activator of S phase kinase AI289307 1.29 0.06 
116 
Human cDNA FLJ20268 fis, clone HEP01005, 
highly similar to U48251 Human protein kinase C-
binding protein RACK7. 
AK000275 1.29 0.16 
14581 Human link protein mRNA, complete cds. U43328 1.28 0.16 
13286 REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta AL096744 1.28 0.16 
16654 apolipoprotein C-III X01388 1.28 0.06 
8439 Human mRNA (clone p5) for archain. X81198 1.28 0.11 
8336 Human cDNA FLJ20342 fis, clone HEP13572. AK000349 1.28 0.05 
11899 ribosomal protein L12 BG471683 1.28 0.20 
16830 polymerase (RNA) II (DNA directed) polypeptide D AA598900 1.27 0.17 
12573 
Human, heterogeneous nuclear ribonucleoprotein 
R, clone MGC:2039 IMAGE:3139052, mRNA, 
complete cds. 
BC001449 1.27 0.28 
8372 Human, clone MGC:16644 IMAGE:4123062, mRNA, complete cds. BC009294 1.27 0.13 
647 Human protocadherin 43 gene, exon 1. AF052683 1.27 0.07 
12863 Human mRNA for KIAA0551 protein, partial cds. AB011123 1.26 0.17 
16642 Kell blood group precursor (McLeod phenotype) NM_021083 1.26 0.05 
10074 Human PR-domain zinc-finger protein PFM1 mRNA, complete cds. AF144757 1.26 0.25 
15323 Rho-associated, coiled-coil containing protein kinase 1 U43195 1.26 0.08 
4753 
Human, angiotensinogen (serine (or cysteine) 
protease inhibitor, clade A (alpha-1 antiprotease, 
antitrypsin), member 8), clone MGC:17092 
IMAGE:4213559, mRNA, complete cds. 
BC011519 1.26 0.11 
16251 Human mRNA for KIAA1225 protein, partial cds. AB033051 1.26 0.06 
16310 Human histone acetyltransferase (HBOa) mRNA, complete cds. AF140360 1.25 0.09 
7536 mitogen-activated protein kinase kinase kinase 7 BE080188 1.25 0.15 
7416 vascular cell adhesion molecule 1 AL037831 1.25 0.24 
7278 KIAA0710 gene product BE177965 1.25 0.12 
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6004 NM_001812 1.25 0.13 centromere protein C 1 
PAX transcription activation domain interacting 
protein 1 like 9152 BC008328 1.25 0.05 
Human mRNA for annexin A13 (ANXA13 gene), 
isoform b. 14294 AJ306450 1.25 0.22 
Human mRNA; cDNA DKFZp586H1719 (from 
clone DKFZp586H1719); complete cds. 6330 AL136918 1.24 0.06 
12677 
Human, synaptosomal-associated protein, 23kD, 
clone MGC:5155 IMAGE:3461227, mRNA, 
complete cds. 
BC003686 1.24 0.16 
15075 methyl-CpG binding domain protein 4 AI634868 1.24 0.17 
16156 Human mRNA; cDNA DKFZp434F1016 (from clone DKFZp434F1016); partial cds. AL137287 1.24 0.30 
15803 Human mRNA; cDNA DKFZp761F0324 (from clone DKFZp761F0324). AL136595 1.23 0.06 
9581 Human mRNA for hSNF2H, complete cds. AB010882 1.23 0.06 
16305 Human signal transducing adaptor molecule STAM mRNA, complete cds. U43899 1.23 0.10 
8514 Human, Similar to GATA-binding protein 2, clone MGC:2306 IMAGE:3139044, mRNA, complete cds. BC002557 1.23 0.10 
6976 
Human chondroitin sulfate proteoglycan versican 
V0 splice-variant precursor peptide mRNA, 
complete cds. 
U16306 1.23 0.10 
18033 KIAA0903 protein AI022927 1.22 0.17 
5539 immunoglobulin (CD79A) binding protein 1 Y08915 1.22 0.09 
3836 Human, regulator of G-protein signalling 4, clone MGC:2124 IMAGE:3510260, mRNA, complete cds. BC000737 1.22 0.08 
10252 katanin p60 (ATPase-containing) subunit A 1 AI220473 1.21 0.08 
13188 Human mRNA; cDNA DKFZp434H0413 (from clone DKFZp434H0413); partial cds. AL137261 1.21 0.33 
232 Human mRNA for KIAA0259 gene, partial cds. D87448 1.21 0.08 
135 
Human DNA for 3-ketoacyl-CoA thiolase beta-
subunit of mitochondrial trifunctional protein, 
complete cds, exon 16, partial sequence. 
D86850 1.20 0.07 
2744 transcription factor-like 1 AL534715 1.20 0.06 
46 
Human, menage a trois 1 (CAK assembly factor), 
clone MGC:5154 IMAGE:3453943, mRNA, 
complete cds. 
BC000820 1.20 0.06 
14613 Human PTS gene for 6-pyruvoyltetrahydropterin synthase, complete cds. AB042297 1.20 0.06 
5719 ets variant gene 6 (TEL oncogene) BE217961 1.20 0.07 
8501 Human HT032 mRNA, complete cds. AF261138 1.20 0.05 
4429 myotubular myopathy 1 U46024 1.19 0.21 
10365 UDP-glucose pyrophosphorylase 2 AL533518 1.19 0.13 
9570 Human B-cell receptor-associated protein BAP37 mRNA, complete cds. AF126021 1.19 0.15 
11741 Human mRNA for KIAA0827 protein, complete cds. AB020634 1.19 0.11 
12064 kinectin 1 (kinesin receptor) Z22551 1.19 0.10 
8505 Human, cyclin L ania-6a, clone MGC:14615 IMAGE:4066376, mRNA, complete cds. BC007081 1.19 0.11 
15867 Human mRNA for protein phosphatase 6. X92972 1.18 0.04 
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10553 ubiquitin-conjugating enzyme E2I (homologous to yeast UBC9) AW365112 1.18 0.08 
6658 Human, clone MGC:5302 IMAGE:3456869, mRNA, complete cds. BC001297 1.17 0.14 
3945 mitochondrial translational release factor 1 AI884353 1.17 0.07 
7178 endothelin type b receptor-like protein 2 NM_004767 1.16 0.15 
739 Human mRNA; cDNA DKFZp586I1918 (from clone DKFZp586I1918); complete cds. AL136911 1.16 0.02 
5108 Human AF5q31 protein (AF5q31) mRNA, complete cds. AF197927 1.16 0.06 
13213 
Human sodium-hydrogen exchanger 6 (NHE-6) 
mRNA, nuclear gene encoding mitochondrial 
protein, complete cds. 




Genes Significantly (P<0.005) Upregulated By Shear Stress in PAEC 
Group 2 Up 
Agilent  Count 324  
Feature # Gene Name/Description Gene ID Fold AVE Fold STD 
2928 cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1 K03191 9.33 2.87 
2409 Human mRNA for interleukin-1 precursor (pre IL-1). X02851 6.45 3.79 
11749 heme oxygenase (decycling) 1 BI596354 5.45 3.29 
14871 interleukin 8 BG777366 5.29 2.87 
2450 Human glia-derived nexin (GDN) mRNA, 5' end. M17783 5.06 2.22 
16028 Human, peroxiredoxin 1, clone MGC:12514 IMAGE:3961375, mRNA, complete cds. BC007063 4.51 1.04 
4091 thioredoxin reductase 1 BE787478 4.38 1.44 
8171 Human cystine/glutamate transporter xCT mRNA, complete cds. AF252872 4.31 1.73 
1123 peroxiredoxin 1 BG432135 4.26 1.16 
9047 
serine (or cysteine) proteinase inhibitor, clade E 
(nexin, plasminogen activator inhibitor type 1), 
member 1 
BG829624 4.03 2.07 
4290 major histocompatibility complex, class I, B AL537877 3.82 1.60 
471 
Macaque dd-4 gene for 3(20)alpha-
hydroxysteroid/dihydrodiol dehydrogenase, 
complete cds. 
AB070211 3.78 1.58 
16118 Human MHC class I lymphocyte antigen (HLA-E) (HLA-6.2) gene, complete cds. M21533 3.54 1.36 
8279 Human MHC class I HLA-B13 chain gene (Aw68.2,30; B13,51), complete cds. M24041 3.41 1.41 
9557 Human macrophage capping protein mRNA, complete cds. M94345 3.37 1.30 
10133 Human, phosphogluconate dehydrogenase, clone MGC:8331 IMAGE:2819330, mRNA, complete cds. BC000368 3.25 0.80 
12173 superoxide dismutase 2, mitochondrial BG773219 3.23 1.38 
15034 cysteine-rich protein 2 AL515731 3.19 1.40 
4137 capping protein (actin filament), gelsolin-like BF978545 3.18 1.19 
4165 amphiregulin (schwannoma-derived growth factor) AL546917 3.09 0.78 
5908 immediate early response 3 AI911657 3.08 1.46 
10666 matrix metalloproteinase 2 (gelatinase A, 72kD gelatinase, 72kD type IV collagenase) J03210 3.00 0.80 
11212 
Human, Similar to ubiquitin carboxy-terminal 
hydrolase L1, clone MGC:8524 IMAGE:2822541, 
mRNA, complete cds. 
BC000332 2.91 0.63 
12235 dynein, cytoplasmic, heavy polypeptide 1 AB002323 2.90 1.15 
12094 
glucan (1,4-alpha-), branching enzyme 1 (glycogen 
branching enzyme, Andersen disease, glycogen 
storage disease type IV) 
L07956 2.81 0.94 
1067 accessory proteins BAP31/BAP29 BI756994 2.73 0.70 
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9508 Human partial ARNT gene for aryl hydrocarbon receptor nuclear translocator, exons 14-22. AJ251863 2.71 0.96 
10171 upstream binding transcription factor, RNA polymerase I BI088564 2.67 1.10 
12902 Human HK2 mRNA for hexokinase II. Z46376 2.65 0.97 
10514 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 U76368 2.64 0.94 
16774 Ras association (RalGDS/AF-6) domain family 1 AL543484 2.60 0.89 
15152 cytidine deaminase AV649252 2.60 1.09 
4258 ras homolog gene family, member C BG708735 2.59 0.93 
16116 Human Scd mRNA for stearoyl-CoA desaturase, complete cds. AB032261 2.54 0.27 
5827 SEX gene BF725116 2.54 0.70 
12553 Human, pleckstrin 2 (Mouse) homolog, clone MGC:4867 IMAGE:3457876, mRNA, complete cds. BC001226 2.53 0.95 
15338 protease, cysteine, 1 (legumain) Y09862 2.53 0.66 
3342 Human abnormal beta-hexosaminidase alpha chain (HEXA) mRNA, partial cds. J04178 2.51 0.41 
9006 nucleoside phosphorylase BE266250 2.49 1.24 
9536 Human mRNA encoding prothrombin. V00595 2.49 0.62 
10188 
Human genomic DNA of 8p21.3-p22 anti-oncogene 
of hepatocellular colorectal and non-small cell lung 
cancer , segment 6/11. 
AB020863 2.48 0.97 
13025 Human, Similar to thioredoxin peroxidase 1, clone MGC:8456 IMAGE:2821457, mRNA, complete cds. BC000452 2.45 0.64 
10295 desmuslin AB002351 2.44 1.00 
16961 ferritin, light polypeptide BE394443 2.43 0.30 
441 
Human, ras homolog gene family, member C, 
clone MGC:15462 IMAGE:2966676, mRNA, 
complete cds. 
BC007245 2.42 0.74 
10745 lectin, galactoside-binding, soluble, 1 (galectin 1) BF979102 2.41 0.57 
2156 Human DNA for apoER2, complete cds, and exon 19. D86407 2.41 0.89 
16413 G protein-coupled receptor 3 U18550 2.40 0.36 
523 Human, clone MGC:3977 IMAGE:2821990, mRNA, complete cds. BC003000 2.38 0.39 
14998 cathepsin C AV717480 2.36 0.34 
16899 solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 NM_014228 2.36 0.32 
2588 chaperonin containing TCP1, subunit 7 (eta) AA314436 2.35 0.90 
13466 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) S36219 2.35 0.92 
16475 potassium inwardly-rectifying channel,subfamily J, member 13 AJ006128 2.32 0.38 
16146 
Human, chromosome 14 open reading frame 2, 
clone MGC:8356 IMAGE:2819801, mRNA, 
complete cds. 
BC000429 2.31 0.68 
15024 HCGII-7 protein X81001 2.29 0.33 
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4325 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) M13918 2.28 0.90 
2758 transaldolase 1 BE538166 2.28 0.43 
5672 tyrosyl-tRNA synthetase BC004151 2.25 0.69 
14981 membrane protein of cholinergic synaptic vesicles BG760616 2.24 0.74 
2164 Human heparin-binding EGF-like growth factor mRNA, complete cds. M60278 2.24 0.74 
882 putative protein similar to nessy (Drosophila) BG824361 2.23 0.21 
5792 holocytochrome c synthase (cytochrome c heme-lyase) AL561481 2.22 0.79 
15358 cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile) BG939664 2.21 0.78 
11745 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor BF110337 2.21 0.48 
13655 P450 (cytochrome) oxidoreductase AF258341 2.20 0.65 
3345 Human endothelin converting enzyme-1 (ECE-1) gene, exon 19, partial cds. AF018034 2.20 0.79 
13640 growth arrest-specific 11 AL561072 2.19 0.83 
11748 Human, clone IMAGE:2905327, mRNA, partial cds. BC002991 2.17 0.27 
11587 Human dioxin-inducible cytochrome P450 (CYP1B1) mRNA, complete cds. U03688 2.17 0.69 
11460 Human genomic DNA, chromosome 8q23, clone:KB1747F8. AP003113 2.17 0.83 
827 
Human, dimethylarginine dimethylaminohydrolase 
2, clone MGC:1351 IMAGE:3138832, mRNA, 
complete cds. 
BC001435 2.15 0.57 
1128 glutathione-S-transferase like; glutathione transferase omega BI858997 2.15 0.28 
13609 guanine nucleotide binding protein (G protein), beta polypeptide 2 BG251149 2.13 0.76 
14060 Human GP36b glycoprotein mRNA, complete cds. U10362 2.13 0.71 
14580 
Human, Similar to chromogranin A (parathyroid 
secretory protein 1), clone IMAGE:4127895, 
mRNA, partial cds. 
BC009384 2.12 0.84 
13029 Human mRNA for KIAA0349 gene, partial cds. AB002347 2.12 0.33 
15396 annexin A1 AU139496 2.12 0.46 
8647 peroxiredoxin 2 BI862079 2.11 0.44 
4263 tyrosine kinase with immunoglobulin and epidermal growth factor homology domains X60957 2.10 0.49 
8613 phosphoglycerate mutase 2 (muscle) BE264368 2.10 0.70 
9386 Human mRNA for phenylalkylamine binding protein. Z37986 2.10 0.42 
13652 clathrin, light polypeptide (Lcb) BE791502 2.10 0.48 
13113 Human lactate dehydrogenase A mRNA, complete cds. AY009108 2.09 0.52 
14880 stanniocalcin 2 BC013958 2.09 1.00 
16765 KIAA0233 gene product D87071 2.05 0.45 
15383 thiosulfate sulfurtransferase (rhodanese) BI820468 2.05 0.51 
1156 actin, gamma 2, smooth muscle, enteric X16940 2.04 1.01 
8672 radixin BF194976 2.04 0.26 
1227 ferritin, heavy polypeptide 1 BE878314 2.03 0.38 
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9881 Human mRNA for enteric smooth muscle gamma-actin. X16940 2.02 1.03 
3321 Human mRNA for Soluble-type polypeptide FZD4S, complete cds. AB054881 2.02 1.10 
7086 BTG family, member 2 BG750101 2.01 0.53 
2540 melanoma-associated antigen recognised by cytotoxic T lymphocytes BC000507 2.01 0.67 
4327 sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase) NM_000543 1.99 0.57 
563 
Human mitochondrial inner membrane preprotein 
translocase Tim17a mRNA, nuclear gene encoding 
mitochondrial protein, complete cds. 
AF106622 1.98 0.59 
15033 dickkopf (Xenopus laevis) homolog 3 AB034203 1.98 0.83 
602 Human alpha-2 type XI collagen mRNA (COL11A2). J04974 1.98 0.71 
7155 calcium channel, voltage-dependent, alpha 2/delta subunit 2 NM_006030 1.97 0.55 
4120 villin 2 (ezrin) AU135575 1.97 0.55 
10470 protein tyrosine kinase 9-like (A6-related protein) BF220316 1.96 0.54 
14546 Human MHC class I HLA-C-alpha-2 chain and alternative mRNA, complete cds, clones 4 and 10. M24097 1.96 0.43 
15353 tubulin, beta polypeptide BE729764 1.96 0.80 
13597 phosphoribosyl pyrophosphate synthetase-associated protein 2 AB007851 1.95 0.55 
2925 ATPase, H+ transporting, lysosomal (vacuolar proton pump) 21kD BG108730 1.95 0.17 
12206 ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha) AL524757 1.95 0.75 
12896 
contains similarity to Pfam domain: PF00207 
(Alpha-2-macroglobulin family), Score=377.3, E-
value=1.1e-113, N=1; PF01835 (Alpha-2-
macroglobulin family N-terminal region), 
Score=157.5, E-value=2.1e-46, N=2~cDNA EST 
yk41d7.3 comes fr 
CAB05006 1.95 0.30 
16869 HNK-1 sulfotransferase AW956276 1.95 0.87 
91 Human Bcl-2-interacting protein beclin mRNA, complete cds. AF077301 1.94 0.38 
3474 
Human, diaphorase (NADH) (cytochrome b-5 
reductase), clone MGC:5150 IMAGE:3450773, 
mRNA, complete cds. 
BC004821 1.94 0.79 
12994 
Human, Similar to RIKEN cDNA B230118G17 
gene, clone MGC:19604 IMAGE:3622817, mRNA, 
complete cds. 
BC010155 1.93 0.39 
9846 
Human cDNA FLJ14588 fis, clone 
NT2RM4001819, highly similar to Human p58/GTA 
(galactosyltransferase associated protein kinase) 
mRNA. 
AK027494 1.92 0.49 
837 sperm associated antigen 7 BI858087 1.92 0.38 
8964 tumor necrosis factor receptor superfamily, member 5 X60592 1.92 0.74 
3338 Human putative tRNA synthetase-like protein mRNA, complete cds. U07424 1.91 0.49 
1053 calpain, small subunit 1 BG831069 1.91 0.50 
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14617 Human, clone MGC:15351 IMAGE:4126712, mRNA, complete cds. BC008861 1.90 0.40 
10336 kinesin family member 1C AB014606 1.90 0.52 
12174 cytochrome b-245, alpha polypeptide BG751568 1.89 0.84 
8820 glucosidase, beta; acid (includes glucosylceramidase) NM_000157 1.89 0.28 
2385 STIP1 homology and U-Box containing protein 1 AL560352 1.89 0.39 
570 
Human, secretory carrier membrane protein 2, 
clone MGC:1284 IMAGE:3050527, mRNA, 
complete cds. 
BC001376 1.89 0.28 
1135 hyaluronoglucosaminidase 2 AU137033 1.89 0.27 
2867 macrophage stimulating 1 receptor (c-met-related tyrosine kinase) X70040 1.88 0.26 
13028 Human lymphocyte activation antigen 4F2 large subunit mRNA, complete cds. J03569 1.87 0.17 
13786 protease, serine, 15 BC000235 1.87 0.48 
14759 aortic carboxypeptidase-like protein ACLP AAC25584 1.87 0.62 
14769 Human C4-sterol methyl oxidase homolog (DESP4) mRNA, complete cds. U93162 1.86 0.35 
11918 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 BC001636 1.86 0.15 
1309 pM5 protein X57398 1.85 0.36 
2237 Human tenascin-X (XA) mRNA, complete cds. U24488 1.84 0.40 
13749 actin, alpha 2, smooth muscle, aorta BF681347 1.84 0.92 
14905 hypothetical protein FLJ10305 BM012099 1.84 0.60 
12946 Human cDNA: FLJ20986 fis, clone CAE01156. AK024639 1.84 0.29 
1103 dual specificity phosphatase 4 BC002671 1.84 0.47 
3973 colony stimulating factor 2 (granulocyte-macrophage) BE669962 1.83 0.82 
12695 Human group III secreted phospholipase A2 mRNA, complete cds. AF220490 1.83 0.43 
1386 ubiquitin specific protease 5 (isopeptidase T) BE019497 1.82 0.52 
14750 Human myosin light chain 1 slow a (MLC1sa) mRNA, complete cds. M31211 1.81 0.51 
8959 GTP-binding protein Rho7 AI554560 1.81 0.30 
8346 Human transcription factor junB (junB) gene, 5' region and complete cds. U20734 1.80 0.41 
1622 Human sky mRNA for Sky, complete cds. D17517 1.80 0.30 
10982 Human mRNA for NOTCH4, partial cds. D63395 1.80 0.15 
6002 delta sleep inducing peptide, immunoreactor AL525317 1.80 0.53 
2235 Human mRNA; cDNA DKFZp586O0222 (from clone DKFZp586O0222); complete cds. AL136935 1.79 0.31 
12202 myosin, light polypeptide 1, alkali; skeletal, fast BF981829 1.79 0.54 
13788 hematopoietic cell-specific Lyn substrate 1 X16663 1.78 0.39 
1276 xeroderma pigmentosum, complementation group C X65024 1.78 0.52 
15052 palmitoyl-protein thioesterase 2 BE790900 1.78 0.48 
14941 Homo sapiens cDNA FLJ10229 fis, clone HEMBB1000136 AL548337 1.77 0.15 
11410 Human cDNA: FLJ21665 fis, clone COL08913. AK025318 1.77 0.74 
13169 Human mRNA for plasma gelsolin. X04412 1.77 0.73 
2246 Human mRNA for p115, complete cds. D86326 1.77 0.34 
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14745 Human epithelial membrane protein (CL-20) mRNA, complete cds. U77085 1.76 0.56 
13056 Human fragile X mental retardation syndrome related protein (FXR2) mRNA, complete cds. U31501 1.75 0.60 
337 Human myelodysplasia/myeloid leukemia factor 2 (MLF2) mRNA, complete cds. U57342 1.75 0.51 
8618 discs, large (Drosophila) homolog 5 NM_004747 1.74 0.38 
2233 Human ETL protein (ETL) mRNA, complete cds. AF192403 1.74 0.49 
15218 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide BI458375 1.74 0.38 
10176 Human 180 kDa bullous pemphigoid antigen 2/type XVII collagen (BPAG2/COL17A1) gene, exon 23. U76585 1.74 0.65 
15031 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 AL544817 1.73 0.46 
10655 activated p21cdc42Hs kinase BG742978 1.733 0.37 
13795 glutaminyl-tRNA synthetase BG179717 1.73 0.34 
10220 Human mRNA for fibrillin. X63556 1.73 0.88 
6299 Human ASM-2 mRNA for sphingomyelin phosphodiesterase (EC 3.1.4.12). X52679 1.73 0.23 
2757 adenine phosphoribosyltransferase BG612479 1.72 0.61 
12722 Human receptor protein-tyrosine kinase (TEK) mRNA, complete cds. L06139 1.72 0.16 
7286 ATP-binding cassette, sub-family G (WHITE), member 2 AU118354 1.71 0.26 
1132 TNF receptor-associated factor 3 U19260 1.70 0.27 
15179 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6 AL527028 1.70 0.40 
5727 DNA fragmentation factor, 45 kD, alpha polypeptide BF309422 1.69 0.36 
14844 Human novel protein AHNAK mRNA, partial sequence. M80899 1.69 0.51 
12233 cAMP responsive element binding protein-like 1 U89337 1.69 0.65 
13288 LIM domain only 6 AI017508 1.69 0.34 
14906 Human keratin 18 (KRT18) gene, complete cds. AF179904 1.68 0.48 
13743 
cartilage oligomeric matrix protein 
(pseudoachondroplasia, epiphyseal dysplasia 1, 
multiple) 
L32137 1.68 0.63 
15203 cystatin B (stefin B) BG283058 1.68 0.35 
740 Human cytosolic inhibitor of NRF2 (INRF2) mRNA, complete cds. AF361886 1.68 0.27 
15241 class I cytokine receptor AF265242 1.67 0.48 
11885 phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI) BE884737 1.67 0.49 
11913 SH3-domain binding protein 5 (BTK-associated) BC006169 1.66 0.59 
4343 nucleobindin 1 BG288969 1.65 0.45 
14910 keratin 8 BI255878 1.65 0.41 
4487 vimentin AL046515 1.65 0.50 
15038 KIAA0562 gene product AB011134 1.63 0.21 
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6906 Human, Similar to keratin 7, clone MGC:3625 IMAGE:3610347, mRNA, complete cds. BC002700 1.63 0.35 
3512 Human endothelial cell protein C/APC receptor (EPCR) mRNA, complete cds. L35545 1.63 0.45 
915 myosin, light polypeptide 4, alkali; atrial, embryonic BI832777 1.62 0.40 
13319 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6 BG196819 1.62 0.42 
6046 biliverdin reductase A AI765830 1.62 0.20 
4003 Human HES-related repressor protein 2 HERP2 mRNA, complete cds. AF232239 1.62 0.43 
7129 Human, clone IMAGE:3446372, mRNA, partial cds. BC000987 1.62 0.23 
8646 troponin T2, cardiac BC002653 1.62 0.41 
9410 Human HOK-2 mRNA for zinc finger protein. X82125 1.61 0.28 
9402 Human myosin heavy chain 12 (MYO5A) mRNA, complete cds. U90942 1.60 0.64 
6956 Human transmembrane 4 superfamily protein mRNA, complete cds. AF100759 1.60 0.23 
5684 interferon gamma receptor 2 (interferon gamma transducer 1) U05877 1.59 0.35 
422 
Human cDNA FLJ14781 fis, clone NT2RP4000455, 
weakly similar to TRANS-ACTING 
TRANSCRIPTIONAL PROTEIN ICP0. 
AK027687 1.59 0.22 
14584 Human mitochondrial benzodiazepine receptor (MBR) gene, complete cds. U12421 1.59 0.24 
1824 Human collagen type XII alpha-1 precursor (COL12A1) mRNA. U73778 1.59 0.59 
14589 
Human genes for S100E calcium binding protein, 
CAPL, and S100D calcium binding protein EF-
Hand (partial). 
Z18950 1.58 0.39 
8633 
Human basic transcription factor 2 p44 (btf2p44) 
gene, partial cds, neuronal apoptosis inhibitory 
protein (naip) and survival motor neuron protein 
(smn) genes, complete cds. 
U80017 1.58 0.27 
2743 tenascin XB NM_019105 1.57 0.20 
11916 S100 calcium-binding protein A5 AW090645 1.57 0.36 
13299 actin, beta BG481840 1.57 0.67 
12541 
Human ASCL3 gene, CEGP1 gene, C11orf14 
gene, C11orf15 gene, C11orf16 gene and 
C11orf17 gene. 
AJ400877 1.56 0.33 
2572 Homer, neuronal immediate early gene, 3 AL162099 1.55 0.38 
7486 amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) BG699532 1.55 0.41 
3223 Human chloride channel ABP mRNA, complete cds. AF034607 1.54 0.30 
1826 Human hXBP-1 transcription factor DNA. L13850 1.54 0.25 
744 CG14353 gene product AAF49284 1.53 0.26 
2571 mitogen-activated protein kinase 11 AI394426 1.53 0.25 
3699 Human osteonectin gene, exon 7. M25743 1.53 0.36 
13184 Human mRNA for Mel-18 protein, complete cds. D13969 1.53 0.28 
1080 KIAA0853 protein NM_015070 1.53 0.34 
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14096 Human palmitoylated erythrocyte membrane protein (MPP1) mRNA, complete cds. M64925 1.53 0.34 
14375 Human, clone MGC:14836 IMAGE:4286914, mRNA, complete cds. BC008500 1.53 0.14 
14925 KIAA0225 protein D86978 1.52 0.23 
4315 
DiGeorge syndrome critical region gene DGSI; 
likely ortholog of mouse expressed sequence 2 
embryonic lethal 
BG831512 1.52 0.44 
1975 Human, Similar to KRAB-zinc finger protein SZF1-1, clone IMAGE:3945618, mRNA, partial cds. BC006247 1.52 0.24 
820 T-cell, immune regulator 1 NM_006053 1.52 0.22 
1062 iduronate 2-sulfatase (Hunter syndrome) AI042325 1.51 0.60 
499 
Human, transmembrane 4 superfamily member 
(tetraspan NET-7), clone MGC:4120 
IMAGE:2958221, mRNA, complete cds. 
BC003157 1.51 0.16 
13616 similar to vaccinia virus HindIII K4L ORF BE743194 1.50 0.47 
16134 Human leucocyte Ig-like receptor-3 (LIR-3) mRNA, complete cds. AF025533 1.50 0.14 
1115 autocrine motility factor receptor AA582146 1.50 0.09 
2910 Down syndrome critical region gene 1 BG287042 1.50 0.30 
12199 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) BF868865 1.49 0.18 
2723 keratin 7 BI094014 1.49 0.38 
6666 
Human cDNA FLJ14937 fis, clone PLACE1010231, 
weakly similar to CELL SURFACE 
GLYCOPROTEIN EMR1 PRECURSOR. 
AK027843 1.49 0.25 
13515 HLA-G histocompatibility antigen, class I, G AF071019 1.48 0.17 
12996 Human chromosome 21 segment HS21C052. AL163252 1.48 0.28 
12633 Human cell cycle-regulated factor p78 mRNA, complete cds. AF068007 1.48 0.38 
12237 collagen, type VIII, alpha 1 BC013581 1.48 0.73 
15303 heat shock transcription factor 4 AI741735 1.48 0.14 
5113 Human mRNA for HKR1, partial cds. AB013897 1.48 0.20 
12074 zinc finger protein 239 BF972810 1.47 0.18 
7390 cerebellar degeneration-related protein (62kD) BI869500 1.47 0.20 
12833 Human ets homologous factor (EHF) mRNA, complete cds. AF170583 1.47 0.23 
12856 Human guanine nucleotide-binding protein (Gi) alpha subunit mRNA, complete cds. M27543 1.46 0.32 
3987 Human genomic DNA, chromosome 8q23, clone:KB1107E3. AP000426 1.46 0.29 
508 Human chromosome 21 segment HS21C004. AL163204 1.46 0.09 
3201 Human mRNA for KIAA0671 protein, complete cds. AB014571 1.46 0.46 
13562 non-metastatic cells 3, protein expressed in BC000250 1.46 0.44 
13840 ilvB (bacterial acetolactate synthase)-like AC003956 1.45 0.24 
13324 
Human cDNA FLJ12298 fis, clone 
MAMMA1001837, weakly similar to ZINC FINGER 
PROTEIN 29. 
AK022360 1.45 0.30 
2565 ATPase, H+ transporting, lysosomal (vacuolar proton pump), subunit 1 BE252259 1.45 0.23 
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669 Human, hypothetical protein, clone MGC:816 IMAGE:3357388, mRNA, complete cds. BC000244 1.45 0.13 
11419 Human zinc finger protein ZNF133. U09366 1.45 0.13 
10190 similar to S. cerevisiae Sec6p and R. norvegicus rsec6 AF055006 1.45 0.10 
5591 Human, Similar to claudin 15, clone MGC:19536 IMAGE:3677931, mRNA, complete cds. BC010160 1.44 0.19 
14612 Human mRNA for TTF-I. X83973 1.44 0.12 
11422 
Human, succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp), clone MGC:1484 
IMAGE:3051442, mRNA, complete cds. 
BC001380 1.44 0.22 
2558 KIAA0435 gene product AB007895 1.44 0.30 
13478 thymidine kinase 1, soluble AL520356 1.43 0.48 
15036 non-metastatic cells 2, protein (NM23B) expressed in BI599403 1.43 0.15 
14992 2',3'-cyclic nucleotide 3' phosphodiesterase NM_033133 1.42 0.38 
13493 H1 histone family, member X BG469316 1.42 0.44 
14616 Human, nucleobindin 1, clone MGC:8479 IMAGE:2821805, mRNA, complete cds. BC002356 1.42 0.34 
6603 Human, KIAA1049 protein, clone MGC:19865 IMAGE:3678670, mRNA, complete cds. BC011884 1.41 0.39 
1763 Human alkali myosin light chain 1 mRNA, complete cds. M20642 1.41 0.29 
12210 KIAA0326 protein AB002324 1.41 0.26 
8328 Human cDNA: FLJ22528 fis, clone HRC12825. AK026181 1.41 0.18 
1201 mannosidase, alpha, class 1A, member 1 NM_005907 1.41 0.32 
13464 NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH-coenzyme Q reductase) AV698517 1.40 0.18 
12542 aortic carboxypeptidase-like protein ACLP AAC25584 1.40 0.29 
515 Human phospholipid transfer protein mRNA, complete cds. L26232 1.40 0.28 
2295 Human copper chaperone for superoxide dismutase (CCS) mRNA, complete cds. AF002210 1.40 0.14 
8689 Human spinster-like protein mRNA, complete cds. AF212371 1.39 0.19 
6979 
Human ASCL3 gene, CEGP1 gene, C11orf14 
gene, C11orf15 gene, C11orf16 gene and 
C11orf17 gene. 
AJ400877 1.39 0.17 
4013 Notch (Drosophila) homolog 4 D63395 1.39 0.04 
987 sulfotransferase, estrogen-preferring NM_005420 1.39 0.14 
14682 Human PRR2 mRNA. X80038 1.39 0.26 
10218 pvt-1 (murine) oncogene homolog, MYC activator AI498125 1.38 0.22 
13087 
Human cDNA: FLJ22950 fis, clone KAT09618, 
highly similar to HUMCDA24A Human CD24 signal 
transducer mRNA. 
AK026603 1.38 0.11 
16180 Human cDNA FLJ20845 fis, clone ADKA01901. AK000852 1.38 0.15 
677 Human mRNA for ribonuclease/angiogenin inhibitor (RAI). X13973 1.37 0.15 
807 protein phosphatase 4, regulatory subunit 1 AW865929 1.37 0.13 
13614 IMP (inosine monophosphate) dehydrogenase 1 AL525547 1.37 0.40 
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13373 mitogen-activated protein kinase kinase kinase 11 AL556109 1.37 0.32 
13775 myosin, heavy polypeptide 3, skeletal muscle, embryonic NM_002470 1.37 0.20 
12097 KIAA0339 gene product AB002337 1.37 0.32 
2069 Human phosphomannomutase mRNA, complete cds. U86070 1.36 0.14 
4141 erythropoietin receptor S45332 1.36 0.18 
764 Human prostaglandin transporter hPGT mRNA, complete cds. U70867 1.36 0.17 
6612 Human, GDP dissociation inhibitor 2, clone MGC:2027 IMAGE:3504736, mRNA, complete cds. BC005145 1.35 0.11 
11274 Human NF-kappa-B transcription factor p65 subunit mRNA, complete cds. L19067 1.34 0.36 
904 testican 3 BC000460 1.34 0.19 
8802 immediate early protein BG255669 1.34 0.10 
11597 
Human ALAS1 (ALASH) mRNA for delta-
aminolevulinate synthase (housekeeping) (EC 
2.3.1.37). 
X56351 1.34 0.08 
2561 TAR (HIV) RNA-binding protein 2 BC005860 1.33 0.09 
1358 Ts translation elongation factor, mitochondrial AU143121 1.33 0.17 
12079 karyopherin beta 2b, transportin AF019039 1.33 0.28 
1577 
Human, Similar to vesicle-associated membrane 
protein 3, clone MGC:2110 IMAGE:3544610, 
mRNA, complete cds. 
BC003570 1.33 0.09 
6758 Human mRNA for KIAA1092 protein, partial cds. AB029015 1.32 0.29 
1230 phosphofructokinase, liver AL041002 1.32 0.14 
14594 
Human, endoplasmic reticulum chaperone SIL1, 
homolog of Yeast, clone MGC:20202 
IMAGE:4640182, mRNA, complete cds. 
BC011568 1.32 0.13 
7548 Nef-associated factor 1 NM_006058 1.32 0.07 
10339 kinesin family member 1C AB014606 1.32 0.25 
554 Human mRNA; cDNA DKFZp434H0923 (from clone DKFZp434H0923). AL137712 1.32 0.11 
2410 
Human multiple endocrine neoplasia type 1 
candidate protein number 18 (HSPF2) mRNA, 
complete cds. 
AF036874 1.30 0.23 
366 Human TLH29 protein precursor (TLH29) mRNA, complete cds. AF208232 1.30 0.19 
12812 unnamed protein product CAC51188 1.30 0.09 
5397 Human mRNA for DREAM protein. AJ131730 1.29 0.13 
14711 Human mRNA for KIAA0747 protein, partial cds. AB018290 1.29 0.20 
4015 Human mRNA; cDNA DKFZp761F0324 (from clone DKFZp761F0324). AL136595 1.29 0.14 
604 
Human, Similar to RIKEN cDNA 4930500C14 
gene, clone MGC:9341 IMAGE:3456620, mRNA, 
complete cds. 
BC008981 1.29 0.11 
11619 Human co-beta glucosidase (proactivator) mRNA, complete cds. J03077 1.28 0.06 
897 tissue factor pathway inhibitor 2 BG621010 1.28 0.10 
11435 GTPase activating protein SynGAP-c AAC40082 1.28 0.15 
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14574 Human, clone MGC:10520 IMAGE:3938462, mRNA, complete cds. BC004480 1.28 0.09 
7237 ATP-binding cassette, sub-family B (MDR/TAP), member 4 X06181 1.27 0.19 
924 Human activin beta-A subunit (exon 2). X57579 1.27 0.36 
10200 collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) L06862 1.26 0.11 
13142 embryonic poly(A) binding protein AAK29408 1.24 0.17 
11428 
Human, distal-less homeo box 5, clone 
MGC:10672 IMAGE:3941691, mRNA, complete 
cds. 
BC006226 1.23 0.18 
10350 dynamin 2 BE277949 1.23 0.08 
10348 CD34 antigen BG696256 1.23 0.20 
10212 interleukin 2 receptor, beta M26062 1.22 0.06 
7844 Human transcription factor IL-4 Stat mRNA, complete cds. U16031 1.22 0.11 
3229 Human CpG island DNA genomic Mse1 fragment, clone 71f4, forward read cpg71f4.ft1a. Z55905 1.20 0.16 
11629 Human cDNA: FLJ21512 fis, clone COL05769. AK025165 1.18 0.11 
711 
Human mitochondrial carrier homolog 1 isoform b 
(MTCH1) mRNA, partial cds; nuclear gene for 
mitochondrial product. 
AF192559 1.16 0.11 




Genes Significantly (P<0.005) Downregulated By Shear Stress in PAEC 
Group 2 
Agilent  Count 157  
Feature # Gene Name/Description Gene ID Fold AVE Fold STD 
15769 Macaque somatostatin I mRNA, complete cds. M19318 6.91 3.10 
3508 Human, matrix Gla protein, clone MGC:12316 IMAGE:3930143, mRNA, complete cds. BC005272 5.86 2.47 
2397 matrix Gla protein AW999947 5.75 1.82 
10644 ectodermal-neural cortex (with BTB-like domain) BC000418 3.56 1.10 
2692 reelin NM_005045 3.41 1.66 
13133 Human reelin (RELN) mRNA, complete cds. U79716 3.35 1.32 
8297 Human mRNA; cDNA DKFZp434M152 (from clone DKFZp434M152). AL137687 3.27 1.01 
8985 somatostatin BI713774 3.24 1.05 
12801 Human intracellular hyaluronic acid binding protein (IHABP) mRNA, complete cds. AF032862 3.18 1.56 
1232 stathmin-like 2 AL535825 3.15 0.74 
11934 cell division cycle 2, G1 to S and G2 to M AL520473 3.15 1.88 
1196 osteoblast specific factor 2 (fasciclin I-like) AW608422 3.13 1.52 
2619 paternally expressed 10 AF038197 3.11 1.34 
8368 Human cDNA: FLJ21156 fis, clone CAS09878. AK024809 3.08 1.66 
12631 Human butyrylcholinesterase, mRNA, complete cds. M16541 3.07 1.54 
79 Human FZD8 mRNA for seven-transmembrane receptor Frizzled-8, complete cds. AB043703 2.95 1.35 
14388 
Human cDNA FLJ12587 fis, clone 
NT2RM4001217, moderately similar to Mouse 
(Mus musculus) actin-binding protein (ENC-1) 
mRNA. 
AK022649 2.84 0.89 
11100 Human mRNA for KIAA1057 protein, partial cds. AB028980 2.70 0.94 
2782 topoisomerase (DNA) II alpha (170kD) BF795918 2.67 1.26 
16390 pituitary tumor-transforming 1 AW957275 2.66 1.16 
14302 Human factor I (C3b/C4b inactivator) mRNA, complete cds. J02770 2.64 0.62 
4121 lumican AU137979 2.62 0.54 
10641 kinesin-like 5 (mitotic kinesin-like protein 1) BM014478 2.62 0.59 
1214 neuro-oncological ventral antigen 1 NM_006489 2.59 1.11 
2374 inositol polyphosphate-4-phosphatase, type II, 105kD U96922 2.59 1.15 
868 KIAA0022 gene product D14664 2.53 1.20 
181 Human gene for thrombomodulin precursor, complete cds. D00210 2.52 1.02 
2219 Human mRNA for caldesmon, 3' UTR. AJ223812 2.50 0.49 
13643 activated leucocyte cell adhesion molecule AI050952 2.49 0.50 
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15978 
Human cDNA: FLJ21715 fis, clone COL10287, 
highly similar to AF071569 Human multifunctional 
calcium/calmodulin-dependent protein kinase II 
delta2 isoform mRNA. 
AK025368 2.48 0.60 
3322 Human mRNA for mitotic kinesin-like protein-1 (MKLP-1 gene). X67155 2.47 0.61 
8053 Human mRNA for MEMD protein. Y10183 2.44 0.38 
13583 vinculin NM_014000 2.39 0.34 
78 Human mRNA; cDNA DKFZp564F1016 (from clone DKFZp564F1016). AL110174 2.36 0.31 
11089 Human mRNA for Slit-2 protein, complete cds. AB017168 2.34 0.41 
8941 highly expressed in cancer, rich in leucine heptad repeats AA878068 2.32 1.15 
2878 
dystrophin (muscular dystrophy, Duchenne and 
Becker types), includes DXS142, DXS164, 
DXS206, DXS230, DXS239, DXS268, DXS269, 
DXS270, DXS272 
AA889832 2.30 0.88 
5248 Human CpG island DNA genomic Mse1 fragment, clone 25c6, reverse read cpg25c6.rt1b. Z65191 2.29 0.91 
5517 homeo box B6 NM_018952 2.28 0.32 
13481 PDZ and LIM domain 1 (elfin) AI687946 2.24 0.54 
203 Human replication protein A 14kDa subunit (RPA) mRNA, complete cds. L07493 2.18 0.74 
11119 Human protein kinase (SGK3) mRNA, complete cds. AF169035 2.17 0.30 
299 Human cDNA FLJ20271 fis, clone HEP01715. AK000278 2.16 0.35 
331 Human mRNA for lipophilin B. AJ224172 2.15 0.45 
15082 interferon-induced, hepatitis C-associated microtubular aggregate protein (44kD) NM_006417 2.12 0.79 
12035 EphA5 L36644 2.10 0.66 
12259 bone morphogenetic protein 4 NM_001202 2.07 0.91 
13316 baculoviral IAP repeat-containing 5 (survivin) AL571008 2.05 0.47 
5526 secretogranin II (chromogranin C) NM_003469 2.04 0.41 
463 Human adapter protein CMS mRNA, complete cds. AF146277 2.02 0.19 
14161 Human epidermal growth factor receptor kinase substrate (Eps8) mRNA, complete cds. U12535 2.01 0.25 
14263 Human, TTK protein kinase, clone MGC:865 IMAGE:3343925, mRNA, complete cds. BC000633 2.01 0.59 
9192 thrombomodulin M16552 2.00 0.48 
2460 heparan sulfate proteoglycan 2 (perlecan) NM_005529 2.00 0.66 
17270 Human interferon-inducible protein 9-27 mRNA, complete cds. J04164 1.98 0.70 
12532 Human PBX3 mRNA. X59841 1.94 0.50 
13800 KIAA0483 protein AI690717 1.91 0.25 
14266 Human mRNA; cDNA DKFZp434D0215 (from clone DKFZp434D0215); partial cds. AL133047 1.91 0.28 
2292 Human mRNA for KIAA0949 protein, partial cds. AB023166 1.88 0.46 
4931 Human protease PC6 isoform A (PCSK5) mRNA, complete cds. U56387 1.87 0.47 
15022 interferon induced transmembrane protein 3 (1-8U) BE886918 1.85 0.58 
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14847 extracellular matrix protein 2, female organ and adipocyte specific NM_001393 1.82 0.33 
15146 ribosomal protein S29 AA827393 1.82 0.29 
12863 Human mRNA for KIAA0551 protein, partial cds. AB011123 1.81 0.48 
12707 Human TRIP7-like protein mRNA, complete cds. AY043282 1.81 0.45 
4446 KIAA0603 gene product BI906891 1.79 0.33 
13754 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein AI299309 1.78 0.35 
4001 phospholipid scramblase 1 NM_021105 1.77 0.39 
11141 Human, clone MGC:5585 IMAGE:3459639, mRNA, complete cds. BC000861 1.76 0.28 
12703 
Human cDNA FLJ10697 fis, clone 
NT2RP3000527, weakly similar to ZINC FINGER 
PROTEIN 43. 
AK001559 1.75 0.48 
10759 mannose receptor, C type 1 X55635 1.75 0.50 
3221 
Human, ATPase, Na+/K+ transporting, beta 1 
polypeptide, clone MGC:1798 IMAGE:3506311, 
mRNA, complete cds. 
BC000006 1.74 0.56 
12882 
Human, CDC20 (cell division cycle 20, S. 
cerevisiae, homolog), clone MGC:15276 
IMAGE:2959596, mRNA, complete cds. 
BC009426 1.74 0.77 
4133 ribosomal protein S15a BG285655 1.74 0.36 
11155 Human alpha-catenin-like protein mRNA, complete cds. U97067 1.72 0.35 
16461 Human lysyl oxidase-like 3 protein (LOXL3) mRNA, complete cds. AF311313 1.72 0.34 
710 Human, Similar to plastin 3 (T isoform), clone IMAGE:3447893, mRNA, partial cds. BC008588 1.68 0.19 
13850 fibromodulin AI249821 1.67 0.19 
512 Human KIAA0405 mRNA, complete cds. AB007865 1.65 0.63 
7859 Human connexin 37 (GJA4) mRNA, complete cds. M96789 1.63 0.44 
13247 Human lysyl hydroxylase isoform 2 (PLOD2) mRNA, complete cds. U84573 1.60 0.38 
7590 ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens] BG718906 1.59 0.20 
1233 neuropeptide Y K01911 1.59 0.32 
15342 proliferating cell nuclear antigen AA523378 1.59 0.31 
12509 Human, ring finger protein 13, clone MGC:13487 IMAGE:3683407, mRNA, complete cds. BC009781 1.59 0.32 
11593 Human mRNA for KIAA1309 protein, partial cds. AB037730 1.59 0.58 
3190 Human mRNA for fibroblast tropomyosin TM30 (pl). X05276 1.59 0.16 
741 Human putative secretory protein precursor, mRNA, complete cds. AF142573 1.58 0.46 
1144 cyclin G1 BC000196 1.58 0.37 
4944 
Human cDNA FLJ11756 fis, clone 
HEMBA1005595, weakly similar to DYNEIN 
HEAVY CHAIN, CYTOSOLIC. 
AK021818 1.58 0.23 
12702 Macaque brain cDNA clone:QmoA-10711, full insert sequence. AB062987 1.58 0.35 
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8147 Unknown (protein for MGC:15514) AAH07256 1.57 0.32 
3379 Human striated muscle contraction regulatory protein (Id2B) mRNA, complete cds. M96843 1.57 0.28 
106 Human mRNA for PDGF receptor beta-like tumor suppressor (PRLTS), complete cds. D37965 1.56 0.26 
5597 Human homolog of Yeast mutL (hPMS1) gene, complete cds. U13695 1.55 0.35 
14090 Human gcp60 mRNA for golgi resident protein GCP60, complete cds. AB043587 1.53 0.19 
12787 Human genomic DNA, chromosome 1q22-q23, CD1 region, section 2/4. AP002533 1.52 0.17 
1350 U2 small nuclear ribonucleoprotein auxiliary factor (65kD) BI962886 1.52 0.36 
9412 Human mRNA for UDP-N-acetylglucosamine transporter, complete cds. AB021981 1.51 0.14 
12931 Human cDNA: FLJ22903 fis, clone KAT05624. AK026556 1.51 0.22 
1383 CGG triplet repeat binding protein 1 AA225329 1.50 0.18 
1059 anti-Mullerian hormone receptor, type II AF172932 1.49 0.41 
14744 Human mRNA for p cadherin. X63629 1.49 0.26 
14276 Human zinc finger protein ANC_2H01 mRNA, complete cds. AF003924 1.49 0.21 
7220 acid-inducible phosphoprotein AK027723 1.47 0.35 
3355 Human 3-methylcrotonyl-CoA carboxylase biotin-containing subunit (MCCA) mRNA, complete cds. AF297332 1.46 0.51 
2462 hypothetical protein AI792005 1.46 0.27 
9106 LIM domain-containing preferred translocation partner in lipoma U49957 1.44 0.12 
13801 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily b, 
member 1 
BF977892 1.43 0.37 
14256 laminin A-chain AAA39406 1.43 0.21 
12007 Rho-associated, coiled-coil containing protein kinase 2 D87931 1.43 0.20 
2300 Human HNOEL-iso (HNOEL-iso) mRNA, complete cds. AF201945 1.40 0.32 
1000 CDC45 (cell division cycle 45, S.cerevisiae, homolog)-like BC010022 1.39 0.31 
1197 serine/threonine kinase 12 BF183143 1.39 0.41 
9122 reproduction 8 AW474066 1.39 0.25 
13255 Human neuronatin alpha and neuronatin beta genes, complete cds. U31767 1.38 0.25 
12788 Human regulator of G-protein signaling 7 (RGS7) mRNA, complete cds. AF090116 1.37 0.28 
4004 Human mRNA; cDNA DKFZp761K102 (from clone DKFZp761K102); complete cds. AL136593 1.37 0.39 
1357 KIAA0355 gene product AB002353 1.37 0.31 
4932 Human mRNA; cDNA DKFZp586A1519 (from clone DKFZp586A1519); partial cds. AL050095 1.36 0.16 
14294 Human mRNA for annexin A13 (ANXA13 gene), isoform b. AJ306450 1.36 0.09 
1680 Human atrial natriuretic peptide clearance receptor (ANP C receptor) mRNA, complete cds. M59305 1.35 0.19 
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3164 Human genomic DNA of 21q22.2 Down Syndrome region, segment 11/13. AP000020 1.35 0.17 
13342 Human beta-tubulin pseudogene, clone 7-beta. K00842 1.34 0.22 
1032 H2A histone family, member N BE253911 1.33 0.20 
3256 similar to wee1-like protein kinase; similar to P30291 (PID:g1351419) AAD04726 1.33 0.15 
8003 Human two pore domain K+ channel (TASK-2) mRNA, complete cds. AF084830 1.33 0.20 
14522 
Human cDNA FLJ13812 fis, clone 
THYRO1000327, highly similar to Human 
autocrine motility factor receptor (AMFR) mRNA. 
AK023874 1.32 0.20 
3543 Human cDNA FLJ20073 fis, clone COL02320. AK000080 1.32 0.12 
1667 Human mRNA for Sec23A isoform, 2748bp. X97064 1.32 0.21 
4011 myotubularin related protein 8 AW601612 1.31 0.26 
11624 Human mRNA; cDNA DKFZp564M182 (from clone DKFZp564M182); partial cds. AL049999 1.31 0.13 
1845 
Human chromosome 3, olfactory receptor 
pseudogene cluster 1, complete sequence, and 
myosin light chain kinase (MLCK) pseudogene, 
partial sequence. 
AF042089 1.31 0.10 
12090 adenylate cyclase 2 (brain) AI160340 1.30 0.06 
4036 
Human, S-adenosylhomocysteine hydrolase-like 
1, clone MGC:15558 IMAGE:3139729, mRNA, 
complete cds. 
BC007576 1.30 0.18 
4272 hypothetical protein W74196 1.30 0.15 
913 ubiquitin carboxyl extension protein [Human, mRNA, 540 nt]. S79522 1.29 0.20 
746 Human CAAX box protein TIMAP mRNA, complete cds. AF362910 1.28 0.05 
5440 Human dopamine D4 receptor (DRD4) mRNA (D4.7) sequence. L12398 1.28 0.12 
6027 complement component 3a receptor 1 NM_004054 1.27 0.25 
900 polymerase (DNA directed), delta 3 D26018 1.27 0.19 
7132 activator of S phase kinase AI289307 1.23 0.11 
13785 
ESTs, Highly similar to ROA3_HUMAN 
HETEROGENEOUS NUCLEAR 
RIBONUCLEOPROTEIN A3 [H.sapiens] 
AW976907 1.22 0.04 
6031 KIAA0328 protein AB002326 1.22 0.08 
1308 cytochrome c oxidase subunit VIII AW009404 1.21 0.24 
12556 Human type-I T-cell cytokine receptor mRNA, complete cds. AF265242 1.20 0.15 
6976 
Human chondroitin sulfate proteoglycan versican 
V0 splice-variant precursor peptide mRNA, 
complete cds. 
U16306 1.20 0.07 
304 Human glutathione S-transferase A4-4 (GSTA4) mRNA, complete cds. AF025887 1.20 0.14 
104 Human alpha mannosidase II mRNA, complete cds. U31520 1.19 0.10 
13644 intersectin 1 (SH3 domain protein) AA582575 1.19 0.08 
10665 chromosome 2 open reading frame 6 AL122062 1.18 0.13 
4786 Human sorting nexin 8 (SNX8) mRNA, complete cds. AF121858 1.18 0.15 
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2239 Human pancreatic phospholipase A-2 (PLA-2) gene, exons 1 to 3. M22970 1.17 0.10 
2301 Human, serum amyloid A1, clone MGC:12369 IMAGE:4071612, mRNA, complete cds. BC007022 1.16 0.12 
14406 Human NADH-ubiquinone oxidoreductase subunit CI-SGDH mRNA, complete cds. AF047181 1.16 0.11 
13146 Human mRNA; cDNA DKFZp434N1235 (from clone DKFZp434N1235); complete cds. AL136857 1.15 0.07 




Genes Significantly (P<0.005) Abundant In PAVEC 
In comparison to PAEC in static culture 
Group 3 
Agilent  Count 236  
Feature # Gene Name/Description Gene ID Fold AVE Fold STD 
13806 cadherin 11, type 2, OB-cadherin (osteoblast) BI766088 113.16 66.59 
16271 Human short form transcription factor C-MAF (c-maf) mRNA, complete cds. AF055376 10.77 3.23 
18283 adducin 3 (gamma) AU134494 7.11 2.67 
10719 HIV-1 rev binding protein 2 BE380146 5.89 1.42 
15139 neural cell adhesion molecule 1 BI493304 4.51 0.96 
12201 fibrinogen-like 2 AI796353 4.24 0.88 
7859 Human connexin 37 (GJA4) mRNA, complete cds. M96789 3.95 1.14 
7437 transmembrane 4 superfamily member 2 AL568153 3.85 0.60 
13220 Human (clone CCG-B7) mRNA sequence. L10373 3.49 1.14 
2290 Human chondroadherin mRNA, complete cds. AF371328 3.47 1.71 
6891 Human mRNA; cDNA DKFZp434I0812 (from clone DKFZp434I0812); partial cds. AL137751 3.35 0.52 
5567 P311 protein AF119859 3.30 1.54 
18516 integral membrane protein 2A AA010378 3.21 0.60 
8672 radixin BF194976 3.04 0.46 
12595 Human mRNA for Tec protein-tyrosine kinase, complete cds. D29767 2.98 2.11 
5800 
S100 calcium-binding protein A4 (calcium 
protein, calvasculin, metastasin, murine 
placental homolog) 
AV713821 2.96 0.92 
13133 Human reelin (RELN) mRNA, complete cds. U79716 2.93 0.92 
16178 Human oligodendrocyte-specific protein (OSP) mRNA, complete cds. AF068863 2.86 1.42 
14857 v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived BF313082 2.85 0.95 
7592 collagen, type IV, alpha 1 NM_001845 2.82 1.39 
14791 Human cathepsin B mRNA, 3' UTR with a stem-loop structure providing mRNA stability. L22569 2.60 1.75 
16548 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog X06182 2.59 0.51 
17356 Human mRNA for purine nucleoside phosphorylase (PNP; EC 2.4.2.1). X00737 2.53 1.15 
2407 Rho GDP dissociation inhibitor (GDI) beta BG388517 2.45 0.68 
14723 
Human ARTS protein (PNUTL2) mRNA, 
complete cds; nuclear gene for mitochondrial 
product. 
AF176379 2.39 0.74 
9115 ELK3, ETS-domain protein (SRF accessory protein 2) BI767724 2.38 1.17 
2450 Human glia-derived nexin (GDN) mRNA, 5' end. M17783 2.37 0.60 
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10654 sialyltransferase 8 (alpha-2, 8-polysialytransferase) D L41680 2.33 0.50 
18517 glutathione peroxidase 1 BI908630 2.32 0.92 
4120 villin 2 (ezrin) AU135575 2.31 0.79 
3862 Human mRNA; cDNA DKFZp564E227 (from clone DKFZp564E227); complete cds. AL136693 2.30 1.50 
14553 Human, clone IMAGE:4183312, mRNA, partial cds. BC008099 2.29 0.80 
9834 
Human, Rho GDP dissociation inhibitor (GDI) 
beta, clone MGC:15348 IMAGE:3621138, 
mRNA, complete cds. 
BC009200 2.28 0.73 
2376 Human mRNA for KIAA1095 protein, partial cds. AB029018 2.27 0.57 
12906 Human T-cell receptor zeta-chain mRNA, complete cds. J04132 2.25 1.15 
4179 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) BC007951 2.21 1.10 
4263 tyrosine kinase with immunoglobulin and epidermal growth factor homology domains X60957 2.21 1.18 
12722 Human receptor protein-tyrosine kinase (TEK) mRNA, complete cds. L06139 2.20 0.63 
6782 
Human cDNA FLJ11312 fis, clone 
PLACE1010105, weakly similar to RING CANAL 
PROTEIN. 
AK002174 2.20 1.11 
17977 CD3Z antigen, zeta polypeptide (TiT3 complex) AL557555 2.20 1.00 
13158 
Human, Similar to KIAA0174 gene product, 
clone MGC:3110 IMAGE:3350789, mRNA, 
complete cds. 
BC000116 2.17 0.95 
3414 
Human vascular endothelial cell growth factor 
165 receptor/neuropilin (VEGF165) mRNA, 
complete cds. 
AF016050 2.13 0.42 
1367 myosin, heavy polypeptide 11, smooth muscle NM_002474 2.12 1.28 
13589 5'-nucleotidase (purine), cytosolic type B D38524 2.10 1.11 
14254 Human TESTIN 2 and TESTIN 3 genes, complete cds, alternatively spliced. AF260225 2.08 0.38 
1803 Human mRNA; cDNA DKFZp586F2423 (from clone DKFZp586F2423). AL080209 2.07 0.87 
7303 heterogeneous nuclear ribonucleoprotein H1 (H) BE296051 2.06 0.91 
8682 sialyltransferase U14550 2.04 0.71 
11814 adaptor-related protein complex 4, mu 1 subunit BG831341 2.03 1.02 
14060 Human GP36b glycoprotein mRNA, complete cds. U10362 2.03 0.96 
3363 Human mRNA for KIAA1816 protein, partial cds. AB058719 2.03 0.46 
14096 Human palmitoylated erythrocyte membrane protein (MPP1) mRNA, complete cds. M64925 2.03 0.94 
6968 fat protein AAA28530 2.02 0.72 
5797 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide NM_000702 2.01 0.95 
13216 Human mRNA for KIAA1296 protein, partial cds. AB037717 1.97 0.74 
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5672 tyrosyl-tRNA synthetase BC004151 1.96 1.06 
8506 Human transcriptional coactivator ALY mRNA, partial cds. AF047002 1.96 0.66 
12704 Human c-kit proto-oncogene mRNA. X06182 1.96 0.32 
14281 Human, clone IMAGE:3604332, mRNA, partial cds. BC003659 1.96 0.94 
5498 flap structure-specific endonuclease 1 BG773958 1.94 1.03 
18464 Sec23 (S. cerevisiae) homolog B BI460300 1.93 1.34 
9557 Human macrophage capping protein mRNA, complete cds. M94345 1.89 0.87 
6002 delta sleep inducing peptide, immunoreactor AL525317 1.89 0.70 
10655 activated p21cdc42Hs kinase BG742978 1.881 0.73 
14100 antiquitin=26g turgor protein homolog [Human, kidney, mRNA, 1809 nt]. S74728 1.88 0.76 
5193 Human genomic DNA, chromosome 6p21.3, HLA Class I region, section 2/20. AP000503 1.87 0.82 
16612 adaptor-related protein complex 4, mu 1 subunit AW170559 1.87 0.80 
11972 Niemann-Pick disease, type C2 gene BG397837 1.83 1.08 
7857 Human full length insert cDNA YH92E12. AF074995 1.82 1.12 
13348 non-POU-domain-containing, octamer-binding BI254716 1.81 0.49 
10166 tubulin, alpha 1 (testis specific) BE742772 1.81 0.66 
10555 calcium channel, voltage-dependent, beta 3 subunit AL565681 1.80 0.69 
16772 NBR2 U88573 1.80 0.64 
3708 Human, tubulin alpha 1, clone MGC:16616 IMAGE:4111591, mRNA, complete cds. BC009314 1.80 0.77 
6467 
Human, Similar to gene rich cluster, C10 gene, 
clone MGC:4750 IMAGE:3537206, mRNA, 
complete cds. 
BC009925 1.79 0.21 
16165 Human protein kinase HIPK2 mRNA, complete cds. AF208291 1.77 0.97 
4137 capping protein (actin filament), gelsolin-like BF978545 1.76 0.79 
10684 KIAA0601 protein AB011173 1.75 0.44 
3392 Human CSaids binding protein (CSBP1) mRNA, complete cds. L35263 1.75 1.01 
15333 receptor (calcitonin) activity modifying protein 2 AL548945 1.72 0.40 
9580 Human transforming growth factor-beta 1 binding protein mRNA, complete cds. M34057 1.72 0.23 
15398 KIAA0138 gene product BE856759 1.72 0.69 
1642 Human ornithine aminotransferase (OAT) gene, exon 6 and partial cds. M88760 1.71 0.41 
6302 
Human, Similar to threonyl-tRNA synthetase, 
clone MGC:3031 IMAGE:3163506, mRNA, 
complete cds. 
BC000541 1.71 0.32 
14854 KIAA0172 protein D79994 1.71 0.31 
12042 TGFB-induced factor (TALE family homeobox) AL549846 1.71 0.36 
9112 Friend leukemia virus integration 1 X67001 1.71 0.67 
16731 ESTs, Highly similar to A31233 ribosomal protein RS.40K, cytosolic [H.sapiens] BG775549 1.71 0.89 
7047 histone deacetylase 5 BF305705 1.70 0.76 
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18361 peptidylprolyl isomerase B (cyclophilin B) BE868117 1.68 0.80 
16714 adenylosuccinate lyase AL022238 1.67 0.61 
11800 serine threonine protein kinase AU121423 1.67 0.68 
11262 Human EF-1delta gene encoding Human elongation factor-1-delta. Z21507 1.67 0.42 
13200 Human gamma-filamin (FLNC) gene, complete cds. AF252549 1.66 0.81 
13743 
cartilage oligomeric matrix protein 
(pseudoachondroplasia, epiphyseal dysplasia 1, 
multiple) 
L32137 1.66 0.89 
13026 
Human, Similar to S-adenosylhomocysteine 
hydrolase, clone MGC:2319 IMAGE:3139231, 
mRNA, complete cds. 
BC011606 1.66 0.74 
9410 Human HOK-2 mRNA for zinc finger protein. X82125 1.65 0.51 
16737 methylthioadenosine phosphorylase AL048242 1.65 0.20 
13855 for protein disulfide isomerase-related D49490 1.65 0.89 
11040 Human cytoplasmic protein mRNA, complete cds. AF177377 1.64 0.79 
8631 catenin (cadherin-associated protein), alpha-like 1 BF793401 1.64 0.21 
5965 peroxisomal long-chain acyl-coA thioesterase AA825544 1.64 0.40 
2432 cathepsin Z AI913006 1.63 0.37 
9709 Human mRNA for smooth muscle myosin. X69292 1.63 0.56 
8059 Na,K-ATPase alpha-4 subunit AAD43813 1.63 0.68 
9882 Human mitochondrial 2,4-dienoyl-CoA reductase mRNA, complete cds. L26050 1.62 0.45 
11626 Human mRNA for stabilin-1 (stab1 gene). AJ275213 1.62 0.40 
15962 Human mRNA; cDNA DKFZp564C053 (from clone DKFZp564C053). AL049246 1.61 0.83 
11303 Human mRNA for NB thymosin beta, complete cds. D82345 1.61 0.25 
18009 fat protein AAA28530 1.60 0.58 
1975 
Human, Similar to KRAB-zinc finger protein 
SZF1-1, clone IMAGE:3945618, mRNA, partial 
cds. 
BC006247 1.60 0.45 
11336 Human mRNA for HKR1, partial cds. AB013897 1.59 0.33 
5251 
Human B-cell receptor CD22-B isoform and 
alternatively spliced B-cell receptor CD22-A 
isoform (CD22) gene, complete cds. 
U62631 1.58 0.67 
17233 Human zinc finger protein gene, partial cds. M77171 1.58 0.46 
16557 thymosin, beta, identified in neuroblastoma cells BG531641 1.57 0.20 
5572 U2(RNU2) small nuclear RNA auxillary factor 1 (non-standard symbol) BF968650 1.57 0.33 
11450 Human mitogen inducible gene mig-2, complete cds. Z24725 1.56 0.17 
7294 signal sequence receptor, beta (translocon-associated protein beta) BE887942 1.56 0.86 
9535 Human cDNA: FLJ23436 fis, clone HRC12692. AK027089 1.56 0.64 
3700 Human PHD-finger protein (GRC5) mRNA, complete cds. AF043725 1.55 0.67 
17966 KIAA1796 protein AB058699 1.54 0.38 
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9846 
Human cDNA FLJ14588 fis, clone 
NT2RM4001819, highly similar to Human 
p58/GTA (galactosyltransferase associated 
protein kinase) mRNA. 
AK027494 1.54 0.23 
7830 Human can mRNA. X64228 1.53 0.68 
7976 Human SH2-containing protein Nsp3 mRNA, complete cds. AF124251 1.53 0.16 
13733 zinc finger protein 263 AC004232 1.52 0.51 
5802 dihydropyrimidinase-like 3 AU133750 1.52 0.21 
14743 Human paired related homeobox protein (PRX2) mRNA, complete cds. AF061970 1.52 0.30 
6398 Human hCENP-B gene for centromere autoantigen B (CENP-B). X55039 1.51 0.25 
1799 Human mRNA for ADP ribosylation factor-like protein, complete cds. AB016811 1.51 0.66 
9608 Human nonclathrin coat protein gamma2-COP mRNA, complete cds. AF157833 1.51 0.35 
4250 ESTs, Highly similar to I59087 ISG-K54 [H.sapiens] AI609624 1.50 0.47 
6035 growth arrest-specific 1 BE619835 1.50 0.10 
13519 replication factor C (activator 1) 2 (40kD) BE295474 1.49 0.29 
12530 
Human, hydroxymethylbilane synthase, clone 
MGC:8561 IMAGE:2822949, mRNA, complete 
cds. 
BC000520 1.49 0.17 
16785 karyopherin (importin) beta 2 U72069 1.49 0.62 
16738 H2A histone family, member L BF726950 1.49 0.12 
12848 Human histone H2A.1 (H2A) gene, complete cds. M60752 1.48 0.17 
7438 T54 protein AL580887 1.48 0.14 
9453 Human trinucleotide repeat DNA binding protein p20-CGGBP (CGGBP) gene, complete cds. AF094481 1.48 0.43 
6888 Human mRNA for hMCM2, complete cds. D28480 1.47 0.37 
16937 H2A histone family, member O AI885852 1.47 0.17 
16468 catenin (cadherin-associated protein), delta 1 AF062332 1.46 0.64 
9406 Human mRNA for DB1, complete cds. D28118 1.46 0.40 
15218 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta 
polypeptide 
BI458375 1.46 0.48 
2742 zinc finger protein 266 AK027480 1.46 0.31 
6806 Human cDNA FLJ11321 fis, clone PLACE1010324. AK002183 1.46 0.46 
15306 serine palmitoyltransferase, long chain base subunit 2 AF111168 1.46 0.35 
13617 phosphodiesterase 8A AL109778 1.45 0.36 
14711 Human mRNA for KIAA0747 protein, partial cds. AB018290 1.45 0.31 
14388 
Human cDNA FLJ12587 fis, clone 
NT2RM4001217, moderately similar to Mouse 
(Mus musculus) actin-binding protein (ENC-1) 
mRNA. 
AK022649 1.45 0.18 
16936 clones 23667 and 23775 zinc finger protein BG498371 1.45 0.58 
6890 Human gas1 gene, complete cds. L13698 1.44 0.23 
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12977 Human enhancer of polycomb 1 (EPC1) mRNA, complete cds. AF286904 1.44 0.38 
1377 zinc finger protein 184 (Kruppel-like) BG254958 1.44 0.30 
14574 Human, clone MGC:10520 IMAGE:3938462, mRNA, complete cds. BC004480 1.44 0.34 
14611 Human kruppel-like zinc finger protein (ZNF300) mRNA, complete cds. AF395541 1.44 0.34 
15308 Bcl-2 binding component 3 BG258126 1.44 0.23 
1195 hypothetical protein BG283735 1.44 0.13 
14906 Human keratin 18 (KRT18) gene, complete cds. AF179904 1.44 0.63 
7557 RAD54 (S.cerevisiae)-like BG763599 1.44 0.31 
10493 cyclin D1 (PRAD1: parathyroid adenomatosis 1) X59798 1.43 0.27 
3631 
Human, nuclear RNA export factor 1, clone 
MGC:4612 IMAGE:3504065, mRNA, complete 
cds. 
BC004904 1.43 0.12 
5972 immature colon carcinoma transcript 1 BC015335 1.43 0.13 
14257 Human, clone MGC:10702 IMAGE:3833242, mRNA, complete cds. BC004868 1.41 0.39 
15198 ATPase, Ca++ transporting, plasma membrane 4 AI885833 1.41 0.34 
14717 Human zinc finger protein mRNA. M80583 1.41 0.50 
16782 pumilio (Drosophila) homolog 1 BC013398 1.41 0.57 
15100 moesin NM_002444 1.41 0.57 
14514 Human zinc finger protein zfp31 (zf31) mRNA, partial cds. U71600 1.40 0.27 
10506 catalase BG287806 1.40 0.21 
6261 Human mRNA for KIAA0052 protein, partial cds. D29641 1.40 0.42 
10503 nuclear cap binding protein subunit 2, 20kD AI619551 1.40 0.32 
14436 Human translation initiation factor eIF-2 gamma subunit mRNA, complete cds. L19161 1.39 0.50 
6019 cysteine-rich protein 1 (intestinal) BI222747 1.38 0.22 
12033 integrin beta 4 binding protein BI908045 1.38 0.48 
5068 
p59fyn(T)=OKT3-induced calcium influx 
regulator [Human, Jurkat J6 T-cell line, mRNA 
Partial, 1605 nt]. 
S74774 1.38 0.13 
16727 zinc finger protein 184 (Kruppel-like) N80080 1.38 0.41 
12654 Human, clone IMAGE:2989556, mRNA, partial cds. BC001699 1.38 0.13 
16289 
Human, ATP synthase, H+ transporting, 
mitochondrial F1 complex, gamma polypeptide 
1, clone MGC:5380 IMAGE:3445817, mRNA, 
complete cds. 
BC000931 1.37 0.37 
7521 MAX protein BC003525 1.37 0.31 
8229 
Human cDNA FLJ13300 fis, clone 
OVARC1001342, highly similar to 40S 
RIBOSOMAL PROTEIN S8. 
AK023362 1.37 0.15 
8330 Human guanylate cyclase activating protein (GCAP) gene exons 1-4, complete cds. L36861 1.36 0.18 
8638 replication factor C (activator 1) 5 (36.5kD) BG766412 1.36 0.23 
9100 KIAA1688 protein AW207595 1.36 0.39 
1032 H2A histone family, member N BE253911 1.36 0.22 
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10490 cell division cycle 25B BF976307 1.36 0.30 
14382 Human mRNA for KIAA0059 gene, complete cds. D31883 1.35 0.35 
6756 Human zinc finger protein ZNF140. U09368 1.35 0.26 
10309 vesicle-associated membrane protein 3 (cellubrevin) BE379661 1.35 0.27 
11099 
Human cDNA FLJ14438 fis, clone 
HEMBB1000317, weakly similar to FIBULIN-1, 
ISOFORM D PRECURSOR. 
AK027344 1.35 0.15 
5997 acidic 82 kDa protein mRNA BG697006 1.34 0.23 
6874 
Human, Similar to hyaluronoglucosaminidase 2, 
clone MGC:1922 IMAGE:3347760, mRNA, 
complete cds. 
BC000692 1.34 0.35 
3223 Human chloride channel ABP mRNA, complete cds. AF034607 1.34 0.46 
6037 guanine nucleotide binding protein-like 1 BE798151 1.34 0.31 
6333 
Human, nucleolar protein 1 (120kD), clone 
MGC:3093 IMAGE:3349415, mRNA, complete 
cds. 
BC000656 1.33 0.17 
15330 ribosomal protein S15 BG477036 1.33 0.30 
3681 Human, clone MGC:2663 IMAGE:3543910, mRNA, complete cds. BC001791 1.33 0.28 
13502 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 18 (Myc-regulated) BG613100 1.33 0.15 
15192 Homo sapiens PAK2 mRNA, complete cds AF092132 1.32 0.40 
15982 Human keratin type II (58 kD) mRNA, complete cds. M21389 1.32 0.25 
14681 
Human, BCS1 (Yeast homolog)-like, clone 
MGC:8631 IMAGE:2961496, mRNA, complete 
cds. 
BC000416 1.32 0.21 
4161 KIAA0246 protein NM_015136 1.32 0.11 
12693 Human mRNA for squamous cell carcinoma antigen SART-3, complete cds. AB020880 1.31 0.26 
14519 Human mRNA for KIAA1338 protein, partial cds. AB037759 1.31 0.21 
9888 Human M4 protein deletion mutant mRNA, complete cds. AF061832 1.31 0.10 
10999 prohibitin [Human, mRNA, 1043 nt]. S85655 1.30 0.16 
9848 Human, keratin 8, clone MGC:1711 IMAGE:3349233, mRNA, complete cds. BC000654 1.30 0.04 
16104 Human cDNA: FLJ23506 fis, clone LNG03055. AK027159 1.30 0.08 
11584 Human mRNA for CHD5 protein. Y12478 1.30 0.22 
10974 Human mRNA for frizzled-2, complete cds. AB017364 1.30 0.24 
9081 tumor necrosis factor (TNF superfamily, member 2) NM_000594 1.30 0.36 
17357 
Human, aldo-keto reductase family 1, member 
A1 (aldehyde reductase), clone MGC:12529 
IMAGE:4051944, mRNA, complete cds. 
BC005394 1.29 0.09 
16424 Mouse Mammary Turmor Virus Receptor homolog AI280835 1.29 0.18 
7233 nuclear matrix protein p84 AV713026 1.29 0.15 
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8039 
Human, laminin receptor 1 (67kD, ribosomal 
protein SA), clone MGC:12521 IMAGE:3997019, 
mRNA, complete cds. 
BC005391 1.28 0.23 
14057 
Human cDNA FLJ11018 fis, clone 
PLACE1003602, highly similar to Human mRNA 
expressed in placenta. 
AK001880 1.28 0.22 
13499 minichromosome maintenance deficient (S. cerevisiae) 3 AU124152 1.28 0.14 
15361 hydroxysteroid (17-beta) dehydrogenase 4 AU125131 1.28 0.33 
12666 Human cytochrome b561 gene, exon 1. U29460 1.28 0.09 
14925 KIAA0225 protein D86978 1.27 0.35 
2108 
Human general transcription factor 2-I (GTF2I) 
mRNA, alternatively spliced product, complete 
cds. 
AF038968 1.27 0.11 
10063 Human lipocalin-interacting protein mRNA, complete cds. AF260728 1.27 0.18 
11481 Human myotubularin related protein 7 mRNA, partial cds. AF073482 1.26 0.13 
14753 Human protein phosphatase 2A beta subunit mRNA, complete cds. M64930 1.26 0.30 
14719 Human Nit protein 2 (NIT2) mRNA, complete cds. AF284574 1.24 0.42 
15326 vesicle-associated membrane protein 8 (endobrevin) AV716151 1.23 0.23 
9554 
Human, eukaryotic translation initiation factor 4E 
binding protein 2, clone MGC:12944 
IMAGE:2823322, mRNA, complete cds. 
BC005057 1.23 0.25 
14994 synaptojanin 1 BF677649 1.22 0.13 
5052 Human gene for ribosomal protein S2, partial cds. AB007147 1.21 0.27 
2273 
Human cDNA: FLJ21675 fis, clone COL09090, 
highly similar to AF119857 Human PRO1855 
mRNA. 
AK025328 1.21 0.11 
6625 Human acidic ribosomal phosphoprotein P2 mRNA, complete cds. M17887 1.18 0.11 
11422 
Human, succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp), clone MGC:1484 
IMAGE:3051442, mRNA, complete cds. 
BC001380 1.16 0.19 
7390 cerebellar degeneration-related protein (62kD) BI869500 1.15 0.22 
4156 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 BE745439 1.13 0.06 
7450 peroxisomal farnesylated protein AL571857 1.13 0.10 




Genes Significantly (P<0.005) Abundant In PAEC 
In comparison to PAVEC in static culture 
Group 3 
Agilent  Count 180  
Feature # Gene Name/Description Gene ID Fold AVE Fold STD 
1196 osteoblast specific factor 2 (fasciclin I-like) AW608422 444.02 294.72 
15769 Macaque somatostatin I mRNA, complete cds. M19318 107.50 50.03 
14871 interleukin 8 BG777366 40.93 18.28 
8985 somatostatin BI713774 16.45 3.27 
4103 amphiregulin (schwannoma-derived growth factor) AL546917 9.57 5.48 
504 Human metallothionein-I-A gene, complete coding sequence. K01383 7.26 3.24 
4183 glioblastoma amplified sequence AI989900 6.84 2.20 
14728 Human mRNA for pro-alpha-1 type 3 collagen. X14420 6.70 3.93 
17499 Human mRNA for metallothionein isoform 1R. X97261 6.45 2.95 
9935 Human cDNA FLJ20129 fis, clone COL06190. AK000136 6.09 3.58 
18197 metallothionein 1E (functional) H72532 5.66 2.38 
10676 interferon-stimulated protein, 15 kDa AI739106 5.61 1.71 
2397 matrix Gla protein AW999947 5.48 0.96 
11616 Human mRNA for phospholipase C, complete cds. D42108 5.22 1.95 
5874 interferon-induced protein with tetratricopeptide repeats 1 M24594 4.85 1.35 
10569 growth arrest and DNA-damage-inducible, alpha AI814872 4.58 1.58 
3456 Human CD39L3 (CD39L3) mRNA, complete cds. AF039917 4.28 1.23 
17864 Human mRNA for cardiac gap junction protein. X52947 4.19 1.64 
3221 
Human, ATPase, Na+/K+ transporting, beta 1 
polypeptide, clone MGC:1798 IMAGE:3506311, 
mRNA, complete cds. 
BC000006 4.17 1.88 
1214 neuro-oncological ventral antigen 1 NM_006489 4.10 2.49 
6648 Human metallothionein (MT)I-F gene, complete cds. M13003 3.92 1.34 
5561 aldehyde dehydrogenase 1 family, member A1 AV649527 3.91 1.69 
18467 gap junction protein, alpha 1, 43kD (connexin 43) X52947 3.83 1.22 
11122 KIAA0412 BAA24842 3.48 1.74 
13850 fibromodulin AI249821 3.36 1.55 
17217 MAM domain protein AAC59868 3.32 0.91 
10465 neuronatin AI638471 3.30 1.53 
10091 Human leukemogenic homolog protein (MEIS1) mRNA, complete cds. U85707 3.12 1.06 
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17584 Human mRNA for soluble guanylyl cyclase. Y15723 3.07 1.09 
10982 Human mRNA for NOTCH4, partial cds. D63395 3.05 0.44 
10539 myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) AA477235 2.99 0.85 
4964 Human Bmx mRNA for cytoplasmic tyrosine kinase. X83107 2.97 0.64 
13807 GTP-binding protein overexpressed in skeletal muscle AW297828 2.94 0.18 
13444 homeo box A7 NM_006896 2.91 0.84 
16809 myosin, light polypeptide kinase AW951177 2.85 0.75 
9994 Human Apo-2 ligand mRNA, complete cds. U57059 2.83 0.33 
4311 caspase 4, apoptosis-related cysteine protease BG572762 2.78 0.60 
14759 aortic carboxypeptidase-like protein ACLP AAC25584 2.72 2.37 
16296 Human mRNA for cyclin-E binding protein 1, complete cds. AB027289 2.69 1.07 
4796 Human mRNA for KIAA0762 protein, partial cds. AB018305 2.68 0.96 
11439 Human uveal autoantigen mRNA, complete cds. AF322916 2.65 0.83 
2768 very low density lipoprotein receptor BG028841 2.65 0.80 
5958 
myeloid/lymphoid or mixed-lineage leukemia 
(trithorax (Drosophila) homolog); translocated 
to, 3 
AI110630 2.61 0.34 
2460 heparan sulfate proteoglycan 2 (perlecan) NM_005529 2.58 1.49 
9416 Human cDNA FLJ10500 fis, clone NT2RP2000369. AK001362 2.56 0.55 
6842 Human mRNA; cDNA DKFZp586B1817 (from clone DKFZp586B1817). AL050088 2.56 0.51 
18061 ATP-binding cassette, sub-family G (WHITE), member 2 BI497116 2.54 0.35 
18492 PTH-responsive osteosarcoma B1 protein AA002033 2.51 0.16 
12071 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 U84573 2.49 0.62 
8681 glycogen synthase 1 (muscle) AL556228 2.39 0.69 
16426 tetraspan 5 AF065389 2.34 0.41 
17663 Human mRNA for neurexin I-alpha protein, complete cds. AB035356 2.31 0.30 
17241 
Human cDNA FLJ10244 fis, clone 
HEMBB1000632, weakly similar to GUANINE 
NUCLEOTIDE RELEASING PROTEIN. 
AK001106 2.26 0.47 
7286 ATP-binding cassette, sub-family G (WHITE), member 2 AU118354 2.25 0.37 
8983 immunoglobulin superfamily containing leucine-rich repeat AB003184 2.22 0.47 
13537 Human (clone CTG-A4) mRNA sequence AL530945 2.19 0.59 
11598 Human mRNA for KIAA0212 gene, complete cds. D86967 2.13 0.76 
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8037 Human mRNA; cDNA DKFZp667P184 (from clone DKFZp667P184). AL512742 2.11 0.69 
14079 
Human cDNA FLJ14357 fis, clone 
HEMBA1000005, highly similar to DNAJ 
PROTEIN HOMOLOG MTJ1. 
AK027263 2.09 0.66 
11486 Human mRNA for KIAA0705 protein, complete cds. AB014605 2.08 0.43 
6781 Human G-protein gamma-10 subunit mRNA, complete cds. U31383 2.08 0.55 
4753 
Human, angiotensinogen (serine (or cysteine) 
protease inhibitor, clade A (alpha-1 
antiprotease, antitrypsin), member 8), clone 
MGC:17092 IMAGE:4213559, mRNA, 
complete cds. 
BC011519 2.07 0.86 
15227 tetraspan 2 AI924594 2.06 0.28 
18357 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 1 
NM_003069 2.05 0.53 
13215 Human mRNA for KIAA0669 protein, complete cds. AB014569 2.02 0.19 
9695 
Human, glutathione S-transferase M3 (brain), 
clone MGC:3310 IMAGE:3509784, mRNA, 
complete cds. 
BC000088 1.98 0.17 
7886 Human mRNA for NADP dependent leukotriene b4 12-hydroxydehydrogenase, partial cds. D49387 1.96 0.69 
4013 Notch (Drosophila) homolog 4 D63395 1.93 0.26 
5589 serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1 AL531502 1.92 0.63 
15978 
Human cDNA: FLJ21715 fis, clone COL10287, 
highly similar to AF071569 Human 
multifunctional calcium/calmodulin-dependent 
protein kinase II delta2 isoform mRNA. 
AK025368 1.90 0.54 
7499 ESTs AA233775 1.90 0.81 
3543 Human cDNA FLJ20073 fis, clone COL02320. AK000080 1.89 0.77 
16461 Human lysyl oxidase-like 3 protein (LOXL3) mRNA, complete cds. AF311313 1.87 0.37 
7810 Human mRNA for HLA class-I (HLA-A26) heavy chain, complete cds (clone cMIY-1). D32129 1.84 0.50 
14372 Human mRNA for DnaJ protein homolog, complete cds. D13388 1.83 0.84 
14589 
Human genes for S100E calcium binding 
protein, CAPL, and S100D calcium binding 
protein EF-Hand (partial). 
Z18950 1.81 0.31 
8361 Human mRNA for KIAK0002 gene, complete cds. D13639 1.81 0.86 
11916 S100 calcium-binding protein A5 AW090645 1.81 0.19 
14522 
Human cDNA FLJ13812 fis, clone 
THYRO1000327, highly similar to Human 
autocrine motility factor receptor (AMFR) 
mRNA. 
AK023874 1.79 0.55 
16905 KIAA0368 protein AB002366 1.79 0.39 
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11907 ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) BG939578 1.78 0.73 
16267 Human follistatin gene, exons 1-5. M19480 1.77 0.32 
6038 ATPase, Class I, type 8B, member 1 NM_005603 1.77 0.35 
12230 ELL-RELATED RNA POLYMERASE II, ELONGATION FACTOR U88629 1.77 0.45 
3496 Human nectin 3 mRNA, complete cds. AF282874 1.76 0.70 
13583 vinculin NM_014000 1.74 0.50 
5682 retinoblastoma 1 (including osteosarcoma) BI092056 1.73 0.63 
12259 bone morphogenetic protein 4 NM_001202 1.73 0.34 
10395 major histocompatibility complex, class I, C BE168491 1.73 0.28 
15097 cholinergic receptor, nicotinic, delta polypeptide BF306695 1.72 0.59 
4719 Human 1-8D gene from interferon-inducible gene family. X57351 1.70 0.39 
4310 solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 U62966 1.70 0.27 
4296 KIAA0212 gene product D86967 1.69 0.55 
11431 Human cDNA: FLJ21270 fis, clone COL01749. AK024923 1.68 0.73 
11260 Human phospholemman chloride channel mRNA, complete cds. U72245 1.66 0.43 
16607 downregulated in ovarian cancer 1 U53445 1.66 0.28 
7075 neuronatin AW161393 1.66 0.19 
13676 glutaminase BI764185 1.65 0.59 
8826 troponin I, skeletal, slow AL596761 1.65 0.12 
7362 interleukin 13 NM_002188 1.64 0.38 
8671 GRO1 oncogene (melanoma growth stimulating activity, alpha) BG753792 1.63 0.26 
3859 Human angiopoietin-like protein PP1158 mRNA, complete cds. AF202636 1.62 0.33 
17539 Human partial mRNA for putative nuclear factor. AJ276691 1.61 0.54 
17560 Human transcription factor ISGF-3 mRNA, complete cds. M97935 1.60 0.46 
14546 
Human MHC class I HLA-C-alpha-2 chain and 
alternative mRNA, complete cds, clones 4 and 
10. 
M24097 1.60 0.70 
5686 ras-like protein AA043151 1.58 0.16 
6972 Human mRNA for TL132. AJ012755 1.58 0.54 
8497 Human hepatocellular carcinoma-associated antigen 67 (HCA67) mRNA, complete cds. AF243495 1.56 0.19 
5971 Homo sapiens clone DT1P1B6 mRNA, CAG repeat region BI868318 1.55 0.44 
9058 ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42kD N75606 1.55 0.47 
7590 ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens] BG718906 1.53 0.60 
11788 metaxin 2 AW237281 1.53 0.64 
16283 Human RAR-responsive (TIG1) mRNA, complete cds. U27185 1.53 0.35 
 362
5973 receptor-interacting serine-threonine kinase 2 BG170405 1.53 0.40 
15961 Human mRNA for KIAA0517 protein, partial cds. AB011089 1.52 0.39 
6040 ESTs AI869879 1.50 0.36 
9863 
Human, ATPase, H+ transporting, lysosomal 
(vacuolar proton pump), member J, clone 
MGC:1970 IMAGE:3546257, mRNA, complete 
cds. 
BC003564 1.49 0.43 
7408 RAS protein activator like 2 NM_004841 1.49 0.23 
8219 Human forkhead-related transcription factor FREAC-10 (FKHL18) mRNA, partial cds. AF042831 1.49 0.33 
9788 LPRP=pHL E1F1 [Human, lacrimal gland, mRNA Partial, 507 nt]. S79048 1.48 0.41 
3825 Human SH2-containing protein Nsp2 mRNA, complete cds. AF124250 1.46 0.60 
14288 Human mRNA; cDNA DKFZp586N1922 (from clone DKFZp586N1922); partial cds. AL117468 1.46 0.14 
13178 C33 antigen=type III integral membrane protein [human, T cell line MOLT-4, Peptide, 267 aa] AAB23825 1.45 0.29 
8168 Human mRNA for KIAA0769 protein, complete cds. AB018312 1.44 0.42 
4003 Human HES-related repressor protein 2 HERP2 mRNA, complete cds. AF232239 1.44 0.22 
10232 collagen, type V, alpha 2 AU117484 1.42 0.18 
11893 LIM domain kinase 2 NM_016733 1.42 0.15 
1337 ceruloplasmin (ferroxidase) M13699 1.41 0.45 
15843 Human nuclear orphan receptor LXR-alpha mRNA, complete cds. U22662 1.38 0.27 
10416 KIAA0573 protein AB011145 1.38 0.26 
17186 Human homeobox 1.4 protein mRNA, complete cds. M74297 1.38 0.24 
11565 Human 10kD protein (BC10) mRNA, complete cds. AF053470 1.38 0.25 
11752 hypothetical protein A-211C6.1 AL537232 1.37 0.51 
9549 Human retinoic acid receptor gamma 1 mRNA, complete cds. M38258 1.37 0.17 
7366 ubiquitin-conjugating enzyme E2L 6 AW976741 1.36 0.25 
9069 
serine (or cysteine) proteinase inhibitor, clade F 
(alpha-2 antiplasmin, pigment epithelium 
derived factor), member 1 
AL541945 1.36 0.14 
15386 protein tyrosine phosphatase, receptor type, C-associated protein BG397566 1.34 0.38 
15378 phospholipase A2, group IVA (cytosolic, calcium-dependent) AI627464 1.34 0.37 
16773 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 AB005659 1.34 0.32 
16556 phosphotriesterase related BG170397 1.34 0.13 
10532 matrix metalloproteinase 23B AI347985 1.33 0.07 
14888 Human nGAP mRNA, complete cds. AF047711 1.33 0.17 
9912 Human mRNA for NADP+-dependent malic enzyme. X79440 1.33 0.31 
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14126 Human genomic DNA, chromosome 21q, section 96/105. AP001752 1.33 0.10 
13446 alpha2,8-sialyltransferase U91641 1.33 0.38 
13622 nerve growth factor, beta polypeptide X52599 1.33 0.18 
4173 ubiquinol-cytochrome c reductase (6.4kD) subunit BG338004 1.32 0.16 
1818 Human, crystallin, alpha B, clone MGC:12326 IMAGE:3933748, mRNA, complete cds. BC007008 1.32 0.16 
15024 HCGII-7 protein X81001 1.31 0.24 
5720 
procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), alpha 
polypeptide I 
AL574109 1.31 0.22 
6914 
Human, protein phosphatase 1, regulatory 
(inhibitor) subunit 2, clone MGC:1327 
IMAGE:3346573, mRNA, complete cds. 
BC007655 1.31 0.18 
5998 gene with multiple splice variants near HD locus on 4p16.3 AB000460 1.30 0.09 
16422 Human mRNA for inositol 1,4,5-trisphosphate receptor type 2, complete cds. D26350 1.30 0.17 
16961 ferritin, light polypeptide BE394443 1.29 0.16 
2733 transducer of ERBB2, 2 AI554661 1.28 0.31 
16899 solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 NM_014228 1.28 0.16 
14068 Human mRNA for KIAA1249 protein, partial cds. AB033075 1.28 0.32 
3968 Human mRNA for alpha-actinin, partial cds. X55187 1.26 0.14 
17500 Human factor XIII subunit a mRNA, 3' end. M14539 1.25 0.08 
14543 Human RNA polymerase II elongation factor SIII, p15 subunit mRNA, complete cds. L34587 1.24 0.25 
11890 KIAA0076 gene product AI741847 1.23 0.21 
14594 
Human, endoplasmic reticulum chaperone 
SIL1, homolog of Yeast, clone MGC:20202 
IMAGE:4640182, mRNA, complete cds. 
BC011568 1.23 0.16 
12689 Human mRNA for KIAA0085 gene, partial cds. D42042 1.23 0.16 
5487 f-box and leucine-rich repeat protein 5 AA768000 1.22 0.15 
6460 Human, clone MGC:14993 IMAGE:3613406, mRNA, complete cds. BC010420 1.22 0.15 
15851 Human P2X4 purinoreceptor mRNA, complete cds. U83993 1.21 0.38 
12110 GRO3 oncogene X53800 1.21 0.19 
8621 
Human, melanoma inhibitory activity, clone 
MGC:14503 IMAGE:4333499, mRNA, 
complete cds. 
BC005910 1.21 0.16 
15057 Fc fragment of IgG, receptor, transporter, alpha AL571972 1.20 0.20 
14584 Human mitochondrial benzodiazepine receptor (MBR) gene, complete cds. U12421 1.20 0.15 
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14890 
bM106N23.1 (novel protein kinase (ortholog of 
human dJ272L16.1 and rat Ca2+/calmodulin 
dependent protein kinase)) 
CAC41379 1.19 0.10 
13023 Human mRNA for SURF-2. Z35094 1.19 0.10 
6493 Human DC10 (DC10) mRNA, complete cds. AF201932 1.18 0.12 
3800 pN44=prostate secretory protein [Human, prostate tissue, mRNA, 475 nt]. S67815 1.17 0.20 
3882 Human Kruppel-like zinc finger protein GLIS2 mRNA, complete cds. AF325914 1.17 0.19 
17661 Human P2x1 receptor mRNA, complete cds. U45448 1.15 0.11 
12988 
Human testis 6-phosphofructo-2-
kinase/fructose 2,6-bisphosphatase (PFKFB4) 
mRNA, complete cds. 
AF108765 1.15 0.09 
15799 Human mRNA; cDNA DKFZp586A181 (from clone DKFZp586A181); partial cds. AL050391 1.11 0.09 
13752 guanylate cyclase 2D, membrane (retina-specific) NM_000180 1.11 0.11 




Genes Significantly (P<0.005) Abundant In PAVEC 
In comparison to PAEC in shear 
Group 4 
  
Agilent  Count 424  
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9463 Human fatty acid binding protein homologue (PA-FABP) mRNA, complete cds. M94856 25.36 11.71 
16178 Human oligodendrocyte-specific protein (OSP) mRNA, complete cds. AF068863 5.33 2.70 
12201 fibrinogen-like 2 AI796353 5.08 0.72 
8954 gap junction protein, alpha 4, 37kD (connexin 37) AL574266 4.61 0.74 
8756 X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound NM_003399 4.24 2.22 
10719 HIV-1 rev binding protein 2 BE380146 4.07 0.52 
15139 neural cell adhesion molecule 1 BI493304 3.47 0.29 
4250 ESTs, Highly similar to I59087 ISG-K54 [H.sapiens] AI609624 3.45 0.81 
16906 HLA class II region expressed gene KE4 BC000645 3.41 1.29 
16557 thymosin, beta, identified in neuroblastoma cells BG531641 3.28 1.25 
10522 myosin, heavy polypeptide 9, non-muscle BG699149 3.23 1.53 
7009 Human transketolase (tk) mRNA, complete cds. L12711 3.09 0.45 
9580 Human transforming growth factor-beta 1 binding protein mRNA, complete cds. M34057 3.07 1.49 
1367 myosin, heavy polypeptide 11, smooth muscle NM_002474 3.04 1.28 
18517 glutathione peroxidase 1 BI908630 2.96 0.51 
2928 cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1 K03191 2.89 0.55 
18516 integral membrane protein 2A AA010378 2.86 0.75 
7437 transmembrane 4 superfamily member 2 AL568153 2.78 0.63 
13782 chitinase 3-like 1 (cartilage glycoprotein-39) AL035737 2.78 1.48 
5567 P311 protein AF119859 2.69 1.07 
4290 major histocompatibility complex, class I, B AL537877 2.68 1.07 
7592 collagen, type IV, alpha 1 NM_001845 2.66 0.50 
7348 phosphodiesterase 6D, cGMP-specific, rod, delta BC007831 2.65 0.49 
10644 ectodermal-neural cortex (with BTB-like domain) BC000418 2.65 0.27 
9156 transcriptional coactivator AI088790 2.63 0.20 
13200 Human gamma-filamin (FLNC) gene, complete cds. AF252549 2.58 0.78 
5797 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide NM_000702 2.58 0.75 
16118 Human MHC class I lymphocyte antigen (HLA-E) (HLA-6.2) gene, complete cds. M21533 2.57 1.04 
78 Human mRNA; cDNA DKFZp564F1016 (from clone DKFZp564F1016). AL110174 2.50 0.82 
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13466 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) S36219 2.50 0.66 
14791 Human cathepsin B mRNA, 3' UTR with a stem-loop structure providing mRNA stability. L22569 2.49 0.65 
9869 Human FK506-binding protein (FKBP63) mRNA, partial cds. AF089745 2.48 1.08 
9834 
Human, Rho GDP dissociation inhibitor (GDI) beta, 
clone MGC:15348 IMAGE:3621138, mRNA, 
complete cds. 
BC009200 2.47 0.20 
16878 2,3-bisphosphoglycerate mutase X04327 2.47 0.87 
859 biglycan BG111541 2.45 0.84 
1799 Human mRNA for ADP ribosylation factor-like protein, complete cds. AB016811 2.45 0.58 
2588 chaperonin containing TCP1, subunit 7 (eta) AA314436 2.42 1.01 
10567 heat shock 70kD protein 1A BG674024 2.42 0.79 
5596 Human OS-9 mRNA, complete cds. AB002806 2.41 0.67 
5908 immediate early response 3 AI911657 2.40 0.14 
4730 Human heparan sulfate proteoglycan (HSPG) core protein, 3' end. J04621 2.40 0.78 
16643 deleted in liver cancer 1 NM_006094 2.38 0.91 
13220 Human (clone CCG-B7) mRNA sequence. L10373 2.34 0.47 
10486 gelsolin (amyloidosis, Finnish type) BG763361 2.32 0.67 
7155 calcium channel, voltage-dependent, alpha 2/delta subunit 2 NM_006030 2.32 0.59 
9557 Human macrophage capping protein mRNA, complete cds. M94345 2.31 0.67 
2435 
aldo-keto reductase family 1, member C1 
(dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-
hydroxysteroid dehydrogenase) 
BI759009 2.29 0.26 
11964 prostaglandin I2 (prostacyclin) synthase D38145 2.29 0.64 
9006 nucleoside phosphorylase BE266250 2.29 0.42 
18356 FOS-like antigen 2 X16706 2.28 0.86 
11977 FK506-binding protein 9 (63 kD) AL555732 2.27 0.97 
4921 Human MacGAP mRNA, complete cds. AB053293 2.27 0.31 
17659 Human 26-kDa cell surface protein TAPA-1 mRNA, complete cds. M33680 2.26 0.46 
7441 NADH dehydrogenase (ubiquinone) flavoprotein 1 (51kD) AW250734 2.26 0.74 
6440 Human hepatocellular carcinoma associated protein (JCL-1) mRNA, complete cds. U92544 2.25 0.35 
3460 Human mRNA for collagen alpha 1(V) chain, complete cds. D90279 2.25 0.77 
17356 Human mRNA for purine nucleoside phosphorylase (PNP; EC 2.4.2.1). X00737 2.24 0.32 
2757 adenine phosphoribosyltransferase BG612479 2.23 0.47 
2697 LIM domain only 2 (rhombotin-like 1) X61118 2.21 0.94 
4356 enolase 3, (beta, muscle) X51957 2.19 0.68 
8415 nonmuscle myosin heavy chain AAA48988 2.19 0.82 
499 
Human, transmembrane 4 superfamily member 
(tetraspan NET-7), clone MGC:4120 
IMAGE:2958221, mRNA, complete cds. 
BC003157 2.17 0.71 
4137 capping protein (actin filament), gelsolin-like BF978545 2.15 0.55 
7047 histone deacetylase 5 BF305705 2.15 0.39 
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280 Human cDNA FLJ14035 fis, clone HEMBA1004638. AK024097 2.15 0.47 
8059 Na,K-ATPase alpha-4 subunit AAD43813 2.15 0.55 
8992 phospholipase C, delta 1 BI489731 2.12 0.61 
9787 Human proto-oncogene Bcd orf1 and orf2 mRNA, complete cds. U51869 2.11 0.20 
5160 Human, clone MGC:14256 IMAGE:4129368, mRNA, complete cds. BC007847 2.09 0.46 
14096 Human palmitoylated erythrocyte membrane protein (MPP1) mRNA, complete cds. M64925 2.07 0.37 
17481 Human, clone MGC:10986 IMAGE:3636469, mRNA, complete cds. BC004400 2.07 0.53 
15398 KIAA0138 gene product BE856759 2.06 0.37 
6349 Macaque brain cDNA, clone:QflA-11789. AB055286 2.05 0.93 
10171 upstream binding transcription factor, RNA polymerase I BI088564 2.03 0.71 
4932 Human mRNA; cDNA DKFZp586A1519 (from clone DKFZp586A1519); partial cds. AL050095 2.03 0.64 
7430 nuclear factor I/X (CCAAT-binding transcription factor) D51465 2.02 0.18 
8346 Human transcription factor junB (junB) gene, 5' region and complete cds. U20734 2.02 0.23 
5672 tyrosyl-tRNA synthetase BC004151 2.02 0.73 
3708 Human, tubulin alpha 1, clone MGC:16616 IMAGE:4111591, mRNA, complete cds. BC009314 2.02 0.29 
11972 Niemann-Pick disease, type C2 gene BG397837 2.01 0.54 
14060 Human GP36b glycoprotein mRNA, complete cds. U10362 2.01 0.51 
16772 NBR2 U88573 2.01 0.18 
16410 hematopoietic PBX-interacting protein BI754234 2.01 0.76 
12173 superoxide dismutase 2, mitochondrial BG773219 1.99 0.39 
11460 Human genomic DNA, chromosome 8q23, clone:KB1747F8. AP003113 1.99 0.59 
14998 cathepsin C AV717480 1.98 0.38 
3338 Human putative tRNA synthetase-like protein mRNA, complete cds. U07424 1.96 0.60 
17654 N-RAP AAC53323 1.96 0.48 
6996 
Human cDNA FLJ20299 fis, clone HEP06342, 
highly similar to AB023137 Human mRNA for 
KIAA0920 protein. 
AK000306 1.96 0.59 
837 sperm associated antigen 7 BI858087 1.94 0.21 
7808 Human cDNA: FLJ21343 fis, clone COL02679. AK024996 1.93 0.63 
9535 Human cDNA: FLJ23436 fis, clone HRC12692. AK027089 1.92 0.48 
10654 sialyltransferase 8 (alpha-2, 8-polysialytransferase) D L41680 1.92 0.46 
8991 nuclear RNA helicase, DECD variant of DEAD box family BC010455 1.92 0.34 
5572 U2(RNU2) small nuclear RNA auxillary factor 1 (non-standard symbol) BF968650 1.89 0.21 
7534 chloride intracellular channel 1 AA291390 1.88 0.34 
7192 putative glialblastoma cell differentiation-related BE892211 1.88 0.43 
1776 Human mRNA for KIAA0615 protein, complete cds. AB014515 1.88 0.42 
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16146 
Human, chromosome 14 open reading frame 2, 
clone MGC:8356 IMAGE:2819801, mRNA, 
complete cds. 
BC000429 1.88 0.40 
1925 
Human, Similar to src homology 3 domain-
containing protein HIP-55, clone MGC:15142 
IMAGE:4299867, mRNA, complete cds. 
BC011677 1.87 0.59 
12722 Human receptor protein-tyrosine kinase (TEK) mRNA, complete cds. L06139 1.86 0.33 
14156 
Human cDNA FLJ11937 fis, clone 
HEMBB1000556, weakly similar to Human mRNA 
for KIAA0750 protein. 
AK021999 1.86 0.31 
12829 Human mRNA; cDNA DKFZp762G216 (from clone DKFZp762G216). AL512709 1.86 0.40 
14300 Human glutathione S-transferase mRNA, complete cds. J03746 1.85 0.11 
13352 ornithine aminotransferase (gyrate atrophy) BG577287 1.85 0.72 
14750 Human myosin light chain 1 slow a (MLC1sa) mRNA, complete cds. M31211 1.85 0.76 
10470 protein tyrosine kinase 9-like (A6-related protein) BF220316 1.85 0.17 
3700 Human PHD-finger protein (GRC5) mRNA, complete cds. AF043725 1.85 0.31 
11001 Human mRNA for KIAA0820 protein, partial cds. AB020627 1.85 0.35 
2432 cathepsin Z AI913006 1.84 0.24 
14621 Human, splicing factor 3b, subunit 2, 145kD, clone IMAGE:2822659, mRNA, partial cds. BC000401 1.83 0.32 
7159 Human alpha-2,8-polysialyltransferase (PST) gene, complete cds. L41680 1.83 0.37 
6871 
Human, eukaryotic translation elongation factor 1 
delta (guanine nucleotide exchange protein), clone 
MGC:2544 IMAGE:2961609, mRNA, complete cds. 
BC009907 1.82 0.27 
4113 heat shock 27kD protein 2 D89617 1.82 0.36 
9709 Human mRNA for smooth muscle myosin. X69292 1.82 0.31 
1571 Human U1-snRNP binding protein homolog mRNA, complete cds. U44799 1.82 0.42 
14237 
Human, holocytochrome c synthase (cytochrome c 
heme-lyase), clone MGC:1443 IMAGE:3030501, 
mRNA, complete cds. 
BC001691 1.81 0.29 
7935 Human mRNA for Mn superoxide dismutase (EC 1.15.1.1.). Y00472 1.81 0.34 
10166 tubulin, alpha 1 (testis specific) BE742772 1.81 0.27 
2924 translocase of inner mitochondrial membrane 17 (yeast) homolog A BG506029 1.81 0.43 
9097 peanut (Drosophila)-like 2 AI632238 1.80 0.37 
6849 
Human, DR1-associated protein 1 (negative 
cofactor 2 alpha), clone MGC:19653 
IMAGE:3029273, mRNA, complete cds. 
BC010025 1.80 0.19 
9138 ESTs, Highly similar to ITF2_HUMAN TRANSCRIPTION FACTOR 4 [H.sapiens] AA936434 1.80 0.68 
16774 Ras association (RalGDS/AF-6) domain family 1 AL543484 1.80 0.24 
6302 Human, Similar to threonyl-tRNA synthetase, clone MGC:3031 IMAGE:3163506, mRNA, complete cds. BC000541 1.79 0.20 
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9546 Human cDNA: FLJ21971 fis, clone HEP05790. AK025624 1.79 0.25 
201 Human replication factor C, 40-kDa subunit (A1) mRNA, complete cds. M87338 1.79 0.15 
16115 Human brain my036 protein mRNA, complete cds. AF063594 1.78 0.25 
4466 small nuclear ribonucleoprotein polypeptides B and B1 BE535667 1.78 0.38 
15877 Human MAP1 light chain 3-like protein 1 mRNA, complete cds. AF276658 1.77 0.19 
4073 ribose 5-phosphate isomerase A (ribose 5-phosphate epimerase) BG571262 1.77 0.38 
10514 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 U76368 1.76 0.50 
4889 Human iroquois homeobox protein 4 (IRX4) mRNA, complete cds. AF124733 1.76 0.12 
9010 keratin 15 AU122673 1.76 0.37 
15241 class I cytokine receptor AF265242 1.75 0.41 
6891 Human mRNA; cDNA DKFZp434I0812 (from clone DKFZp434I0812); partial cds. AL137751 1.75 0.24 
16907 ribophorin I BE780549 1.74 0.10 
1601 Human zinc finger protein ZNF224 mRNA, complete cds. AF187990 1.74 0.38 
3624 
Human mitochondrial glutathione reductase 
(GRD1) mRNA, complete cds; nuclear gene for 
mitochondrial product. 
AF228704 1.74 0.37 
4078 isocitrate dehydrogenase 3 (NAD+) beta BI553471 1.74 0.55 
13667 ribosomal protein L3 AV756387 1.73 0.36 
6035 growth arrest-specific 1 BE619835 1.73 0.19 
2345 fusion, derived from t(12;16) malignant liposarcoma AL549027 1.73 0.22 
5374 Human zinc finger protein (ZNF154) mRNA, partial cds. U20648 1.72 0.53 
6534 Human cDNA FLJ11773 fis, clone HEMBA1005852. AK021835 1.72 0.20 
6603 Human, KIAA1049 protein, clone MGC:19865 IMAGE:3678670, mRNA, complete cds. BC011884 1.72 0.39 
3414 
Human vascular endothelial cell growth factor 165 
receptor/neuropilin (VEGF165) mRNA, complete 
cds. 
AF016050 1.72 0.18 
420 Human mRNA for rap2b gene. X52987 1.72 0.32 
14854 KIAA0172 protein D79994 1.72 0.33 
11262 Human EF-1delta gene encoding Human elongation factor-1-delta. Z21507 1.71 0.13 
3150 Human ARF GTPase-activating protein GIT1 mRNA, complete cds. AF124490 1.71 0.11 
17484 Human mRNA for RNA polymerase II associated protein RAP74. X64037 1.71 0.17 
4447 nucleolar and coiled-body phosphprotein 1 AL553791 1.70 0.25 
10493 cyclin D1 (PRAD1: parathyroid adenomatosis 1) X59798 1.70 0.12 
1135 hyaluronoglucosaminidase 2 AU137033 1.70 0.52 
6728 Human mRNA for KIAA0049 gene, complete cds. D30756 1.70 0.54 
18026 Human, clone MGC:2491 IMAGE:3353174, mRNA, complete cds. BC000262 1.70 0.25 
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6002 delta sleep inducing peptide, immunoreactor AL525317 1.70 0.42 
6046 biliverdin reductase A AI765830 1.69 0.18 
10188 
Human genomic DNA of 8p21.3-p22 anti-oncogene 
of hepatocellular colorectal and non-small cell lung 
cancer , segment 6/11. 
AB020863 1.69 0.38 
16652 coronin, actin-binding protein, 1A BG758313 1.69 0.42 
2858 cyclin-dependent kinase 9 (CDC2-related kinase) BM009991 1.68 0.41 
9410 Human HOK-2 mRNA for zinc finger protein. X82125 1.68 0.29 
2227 
cytoplasmic antiprotease=38 kda intracellular 
serine protease inhibitor [Human, placenta, mRNA, 
1465 nt]. 
S69272 1.67 0.54 
393 Human cation-chloride cotransporter-interacting protein mRNA, complete cds. AF284422 1.67 0.21 
10365 UDP-glucose pyrophosphorylase 2 AL533518 1.67 0.08 
6751 Human 90 kD heat shock protein gene, complete cds. J04988 1.66 0.36 
16597 serum response factor (c-fos serum response element-binding transcription factor) BG744841 1.66 0.19 
16805 disabled (Drosophila) homolog 2 (mitogen-responsive phosphoprotein) U39050 1.66 0.45 
16940 transformer-2 alpha (htra-2 alpha) BG250879 1.66 0.22 
54 Human (clone pAT 464) potential lymphokine/cytokine mRNA, complete cds. M25315 1.65 0.54 
9383 Human apoptosis-associated nuclear protein PHLDA1 (PHLDA1) mRNA, partial cds. AF220656 1.65 0.24 
10512 zinc finger protein 173 U09825 1.65 0.17 
13191 Human, Similar to ribophorin I, clone MGC:5072 IMAGE:3461167, mRNA, complete cds. BC010839 1.65 0.13 
17630 
Human, aldo-keto reductase family 1, member B1 
(aldose reductase), clone MGC:1804 
IMAGE:3357652, mRNA, complete cds. 
BC000260 1.65 0.19 
12591 
Human mitochondrial outer membrane protein 
(TOM40) mRNA, nuclear gene encoding 
mitochondrial protein, complete cds. 
AF043250 1.65 0.16 
10383 ribosomal protein S14 BG169146 1.65 0.08 
15308 Bcl-2 binding component 3 BG258126 1.64 0.18 
422 
Human cDNA FLJ14781 fis, clone NT2RP4000455, 
weakly similar to TRANS-ACTING 
TRANSCRIPTIONAL PROTEIN ICP0. 
AK027687 1.64 0.29 
12566 Human mRNA for KIAA1209 protein, partial cds. AB033035 1.63 0.25 
17690 Human, LIM domain only 4, clone MGC:872 IMAGE:3355972, mRNA, complete cds. BC003600 1.63 0.39 
13290 nucleolin AV724878 1.63 0.23 
6566 Human mRNA; cDNA DKFZp434K0220 (from clone DKFZp434K0220); complete cds. AL136801 1.62 0.26 
5697 v-maf musculoaponeurotic fibrosarcoma (avian) oncogene homolog AF055376 1.62 0.17 
16565 major histocompatibility complex, class II, DQ beta 1 U83582 1.62 0.14 
16491 eukaryotic translation initiation factor 3, subunit 5 (epsilon, 47kD) BG258493 1.62 0.18 
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5748 GCN1 (general control of amino-acid synthesis 1, yeast)-like 1 BI259893 1.62 0.41 
15763 Human mRNA for integrin beta(4)subunit. X51841 1.62 0.30 
911 Human cDNA FLJ12993 fis, clone NT2RP3000197. AK023055 1.61 0.31 
3139 Human beta-tubulin (TUB4q) mRNA, complete cds. U83110 1.61 0.29 
10945 
Human, putative glialblastoma cell differentiation-
related, clone MGC:2352 IMAGE:3535682, mRNA, 
complete cds. 
BC004967 1.61 0.41 
16612 adaptor-related protein complex 4, mu 1 subunit AW170559 1.61 0.37 
14925 KIAA0225 protein D86978 1.61 0.16 
9853 Human claudin 3 (CLDN3) gene, complete cds. AF007189 1.61 0.34 
14254 Human TESTIN 2 and TESTIN 3 genes, complete cds, alternatively spliced. AF260225 1.61 0.31 
6635 Human Na K-ATPase beta-3 subunit (atp1b3) gene, exon 7 and complete cds. AF005896 1.61 0.19 
11130 Human transcription factor (CBFB) mRNA, 3' end. L20298 1.61 0.32 
9443 Human TUBB1 gene for Human beta tubulin 1, class VI. AJ292757 1.61 0.33 
17830 Human mRNA for KIAA1308 protein, partial cds. AB037729 1.61 0.23 
3223 Human chloride channel ABP mRNA, complete cds. AF034607 1.61 0.08 
15232 death-associated protein 6 AL549502 1.61 0.24 
2758 transaldolase 1 BE538166 1.61 0.18 
7086 BTG family, member 2 BG750101 1.61 0.48 
12654 Human, clone IMAGE:2989556, mRNA, partial cds. BC001699 1.60 0.25 
872 angio-associated, migratory cell protein BI091422 1.60 0.23 
18175 LIM domain only 4 U24576 1.60 0.37 
16714 adenylosuccinate lyase AL022238 1.59 0.30 
8672 radixin BF194976 1.59 0.15 
2540 melanoma-associated antigen recognised by cytotoxic T lymphocytes BC000507 1.58 0.35 
17249 Human poly(ADP-ribose) polymerase mRNA, complete cds. M32721 1.57 0.16 
6267 Human connexin45 gene, complete cds. U03493 1.57 0.11 
2385 STIP1 homology and U-Box containing protein 1 AL560352 1.57 0.39 
4006 LIM domain kinase 1 D26309 1.57 0.37 
13216 Human mRNA for KIAA1296 protein, partial cds. AB037717 1.57 0.13 
7121 aldehyde dehydrogenase 3 family, member B1 U10868 1.56 0.34 
5733 Homo sapiens clone 23763 unknown mRNA, partial cds BG743005 1.56 0.18 
6319 
Human, putative receptor protein, clone 
MGC:12310 IMAGE:4051155, mRNA, complete 
cds. 
BC005268 1.56 0.10 
5707 zinc finger protein 22 (KOX 15) AL528233 1.56 0.27 
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740 Human cytosolic inhibitor of NRF2 (INRF2) mRNA, complete cds. AF361886 1.56 0.12 
7532 slit (Drosophila) homolog 3 BF061381 1.56 0.23 
3648 Human gene for prostacyclin synthase, exon 10 and complete cds. D83402 1.55 0.35 
6470 
Human, ATPase, H+ transporting, lysosomal 
(vacuolar proton pump) 21kD, clone MGC:4498 
IMAGE:2964510, mRNA, complete cds. 
BC005876 1.55 0.32 
4913 Human complement-c1q tumor necrosis factor-related protein (CTRP6) mRNA, complete cds. AF329842 1.55 0.26 
211 Human genomic DNA, chromosome 22q11.2, BCRL2 region, clone:KB1440D3. AP000553 1.55 0.38 
4229 cyclin-dependent kinase inhibitor 1C (p57, Kip2) BF055303 1.55 0.34 
916 Human unknown mRNA. AF058918 1.55 0.37 
5196 Human mRNA for neurite outgrowth-promoting protein. X55110 1.54 0.14 
7937 Human SBBI26 mRNA, complete cds. AF111113 1.54 0.26 
523 Human, clone MGC:3977 IMAGE:2821990, mRNA, complete cds. BC003000 1.54 0.34 
14382 Human mRNA for KIAA0059 gene, complete cds. D31883 1.53 0.20 
3704 
Human, heterogeneous nuclear ribonucleoprotein 
H1 (H), clone MGC:8619 IMAGE:2961378, mRNA, 
complete cds. 
BC001348 1.53 0.19 
3382 Human cDNA FLJ12566 fis, clone NT2RM4000852. AK022628 1.53 0.27 
5965 peroxisomal long-chain acyl-coA thioesterase AA825544 1.53 0.25 
5743 structure specific recognition protein 1 M86737 1.53 0.12 
901 H3 histone, family 3B (H3.3B) BG338936 1.53 0.24 
16276 Human leukemia virus receptor 2 (GLVR2) mRNA, complete cds. L20852 1.53 0.28 
17865 
Human, farnesyl diphosphate synthase (farnesyl 
pyrophosphate synthetase, 
dimethylallyltranstransferase, 
geranyltranstransferase), clone MGC:15352 
IMAGE:4132071, mRNA, complete cds. 
BC010004 1.53 0.04 
9112 Friend leukemia virus integration 1 X67001 1.52 0.32 
6270 Human blood plasma glutamate carboxypeptidase precursor (PGCP) mRNA, complete cds. AF119386 1.52 0.12 
6532 Human cDNA: FLJ22405 fis, clone HRC08294. AK026058 1.52 0.21 
16604 S-adenosylhomocysteine hydrolase BG258011 1.52 0.23 
7294 signal sequence receptor, beta (translocon-associated protein beta) BE887942 1.52 0.33 
4414 gp25L2 protein BI822721 1.52 0.11 
8783 Homo sapiens SRp46 splicing factor transcribed retropseudogene AF031165 1.51 0.12 
13786 protease, serine, 15 BC000235 1.51 0.30 
2371 hypothetical protein F23149_1 BE562607 1.51 0.17 
586 Human platelet-derived growth factor A chain (PDGFA) gene, exons only. M83575 1.51 0.13 
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6874 
Human, Similar to hyaluronoglucosaminidase 2, 
clone MGC:1922 IMAGE:3347760, mRNA, 
complete cds. 
BC000692 1.51 0.18 
810 carcinoembryonic antigen-related cell adhesion molecule 5 AW951446 1.50 0.19 
16034 Human, tubulin, beta 5, clone MGC:15683 IMAGE:3350604, mRNA, complete cds. BC007605 1.50 0.22 
12638 Human macrophage-specific colony-stimulating factor (CSF-1) mRNA, complete cds. M37435 1.50 0.38 
4927 
Human, Similar to RIKEN cDNA 1500041N16 
gene, clone MGC:4238 IMAGE:2961616, mRNA, 
complete cds. 
BC005870 1.50 0.19 
7302 bridging integrator 1 BF529230 1.50 0.17 
1590 Human high mobility group box (SSRP1) mRNA, complete cds. M86737 1.50 0.24 
7974 Human mRNA for KIAA0664 protein, partial cds. AB014564 1.50 0.32 
12042 TGFB-induced factor (TALE family homeobox) AL549846 1.50 0.17 
4403 N-methylpurine-DNA glycosylase AL530962 1.49 0.31 
10655 activated p21cdc42Hs kinase BG742978 1.49 0.26 
6050 v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog AI740449 1.49 0.28 
5802 dihydropyrimidinase-like 3 AU133750 1.49 0.22 
13067 Human, profilin 1, clone MGC:5227 IMAGE:2900010, mRNA, complete cds. BC006768 1.48 0.17 
4075 guanylate kinase 1 T36282 1.48 0.31 
5052 Human gene for ribosomal protein S2, partial cds. AB007147 1.48 0.15 
4344 adenosine monophosphate deaminase 2 (isoform L) BF894450 1.47 0.30 
12126 RNA binding motif protein 10 BI115686 1.47 0.19 
2101 Human mRNA for TIP49, complete cds. AB012122 1.47 0.17 
9888 Human M4 protein deletion mutant mRNA, complete cds. AF061832 1.47 0.22 
4783 Human mRNA for FLJ00083 protein, partial cds. AK024484 1.47 0.20 
12530 Human, hydroxymethylbilane synthase, clone MGC:8561 IMAGE:2822949, mRNA, complete cds. BC000520 1.47 0.26 
571 Human integrin alpha 10 subunit (ITGA10) mRNA, complete cds. AF112345 1.46 0.19 
351 Human mRNA for DNA replication licensing factor (huMCM5), complete cds. D83986 1.46 0.26 
9155 bleomycin hydrolase AA044158 1.46 0.10 
1576 Human, F-box only protein 7, clone MGC:16046 IMAGE:3611049, mRNA, complete cds. BC008361 1.46 0.21 
6332 Human clone CDABP0155 mRNA sequence. AY007163 1.46 0.31 
8743 Kelch-like ECH-associated protein 1 BC002417 1.46 0.11 
13348 non-POU-domain-containing, octamer-binding BI254716 1.46 0.20 
6973 Human mRNA for putative ATPase, partial. AJ006268 1.45 0.27 
4786 Human sorting nexin 8 (SNX8) mRNA, complete cds. AF121858 1.45 0.33 
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7050 ribosomal protein S6 kinase, 90kD, polypeptide 1 BG878337 1.45 0.18 
13633 proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) BE879690 1.45 0.19 
4858 epithelial protein lost in neoplasm alpha AAF23756 1.45 0.11 
4253 KIAA0670 protein/acinus AF124727 1.45 0.20 
6742 Human CTP:phosphocholine cytidyltransferase mRNA, complete cds. L28957 1.45 0.27 
8359 Human mRNA; cDNA DKFZp564K2478 (from clone DKFZp564K2478); complete cds. AL136690 1.45 0.29 
8229 
Human cDNA FLJ13300 fis, clone 
OVARC1001342, highly similar to 40S 
RIBOSOMAL PROTEIN S8. 
AK023362 1.44 0.14 
10684 KIAA0601 protein AB011173 1.44 0.32 
2571 mitogen-activated protein kinase 11 AI394426 1.44 0.21 
16936 clones 23667 and 23775 zinc finger protein BG498371 1.44 0.27 
16095 
Human clone ID 193225 NAD (H)-specific isocitrate 
dehydrogenase gamma subunit mRNA, 
alternatively spliced, partial cds. 
U69268 1.44 0.24 
17202 
Human, interleukin enhancer binding factor 2, 
45kD, clone MGC:8391 IMAGE:2820505, mRNA, 
complete cds. 
BC000382 1.44 0.12 
14249 Human cysteine protease CPP32 isoform alpha mRNA, complete cds. U13737 1.43 0.22 
4307 cytochrome c oxidase subunit IV BF726186 1.43 0.12 
7279 mesoderm development candidate 2 BC012746 1.43 0.13 
7355 putative breast adenocarcinoma marker (32kD) BC002502 1.43 0.17 
8772 MYC-associated zinc finger protein (purine-binding transcription factor) BG260604 1.43 0.13 
8920 splicing factor, arginine/serine-rich 4 BF855449 1.43 0.23 
1642 Human ornithine aminotransferase (OAT) gene, exon 6 and partial cds. M88760 1.42 0.10 
9778 Human RET ligand 2 (RETL2) mRNA, complete cds. U97145 1.42 0.06 
5977 D123 gene product BE792735 1.42 0.24 
13519 replication factor C (activator 1) 2 (40kD) BE295474 1.42 0.29 
13587 hypothetical protein AW006162 1.42 0.20 
2731 glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase) AL555400 1.42 0.14 
18019 activating transcription factor 3 BI834286 1.42 0.21 
5384 
Human, ornithine aminotransferase (gyrate 
atrophy), clone MGC:5182 IMAGE:3449883, 
mRNA, complete cds. 
BC000964 1.42 0.18 
3229 Human CpG island DNA genomic Mse1 fragment, clone 71f4, forward read cpg71f4.ft1a. Z55905 1.41 0.28 
15631 Human thioredoxin mRNA, nuclear gene encoding mitochondrial protein, complete cds. U78678 1.41 0.18 
16737 methylthioadenosine phosphorylase AL048242 1.41 0.15 
2271 Human alphaCP-4 (PCBP4) mRNA, complete cds. AF176330 1.41 0.15 
17633 Human histidine-rich calcium binding protein (HRC) mRNA, complete cds. M60052 1.41 0.07 
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6569 Human full length insert cDNA clone ZD48C09. AF086289 1.41 0.17 
16575 six transmembrane epithelial antigen of the prostate AC004969 1.40 0.25 
5387 Human, Similar to RIKEN cDNA 9430029K10 gene, clone IMAGE:3534558, mRNA, partial cds. BC007644 1.40 0.16 
16180 Human cDNA FLJ20845 fis, clone ADKA01901. AK000852 1.40 0.23 
8688 cytoplasmic FMRP interacting protein 1 BI522540 1.40 0.23 
3697 Human clone 23600 cytochrome c oxidase subunit IV mRNA, complete cds. U90915 1.39 0.10 
11129 Human lysosomal membrane glycoprotein CD63 mRNA. M58485 1.39 0.26 
1965 cellular repressor of E1A-stimulated genes AAH08628 1.39 0.18 
6538 Human guanine nucleotide exchange factor mss4 mRNA, complete cds. U74324 1.39 0.21 
6846 Human CST gene for cerebroside sulfotransferase, exon 1, 2, 3, 4, 5. AB029900 1.39 0.08 
7469 IMP (inosine monophosphate) dehydrogenase 2 BI223795 1.39 0.17 
6909 
Human, hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase (trifunctional 
protein), alpha subunit, clone MGC:1728 
IMAGE:2966432, mRNA, complete cds. 
BC009235 1.38 0.22 
6415 Human mRNA for KIAA0842 protein, partial cds. AB020649 1.38 0.17 
16616 nucleolar and coiled-body phosphprotein 1 Z34289 1.38 0.12 
12072 PHD finger protein 1 BF342325 1.38 0.11 
5405 Human gene encoding retina-specific guanylyl cyclase. AJ222657 1.38 0.23 
5667 H1 histone family, member 2 AW316807 1.38 0.25 
16727 zinc finger protein 184 (Kruppel-like) N80080 1.38 0.15 
10505 ubiquitin-protein ligase NEDD4-like BE391083 1.37 0.20 
5351 
Human, NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 10 (42kD), clone MGC:5103 
IMAGE:3451514, mRNA, complete cds. 
BC003417 1.37 0.20 
13515 HLA-G histocompatibility antigen, class I, G AF071019 1.37 0.17 
3681 Human, clone MGC:2663 IMAGE:3543910, mRNA, complete cds. BC001791 1.37 0.15 
5061 Human mRNA for GCP170, complete cds. D63997 1.37 0.20 
6037 guanine nucleotide binding protein-like 1 BE798151 1.37 0.07 
31 Human Golgi membrane sialoglycoprotein MG160 (GLG1) mRNA, complete cds. U64791 1.37 0.08 
62 Human SM22 alpha gene, 5' flanking region. D84344 1.37 0.19 
4014 chromosome 19 open reading frame 3 AW409924 1.36 0.20 
12875 Human NJAC protein (NJAC) mRNA, complete cds. AF144103 1.36 0.26 
2295 Human copper chaperone for superoxide dismutase (CCS) mRNA, complete cds. AF002210 1.36 0.20 
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15624 
Human, procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), beta 
polypeptide (protein disulfide isomerase; thyroid 
hormone binding protein p55), clone MGC:9192 
IMAGE:3879411, mRNA, complete cds. 
BC010859 1.36 0.15 
9077 splicing factor, arginine/serine-rich (transformer 2 Drosophila homolog) 10 BC000160 1.36 0.15 
8615 Human cDNA FLJ14084 fis, clone HEMBB1002383. AK024146 1.36 0.22 
4739 
Human cDNA FLJ10162 fis, clone 
HEMBA1003560, highly similar to GUANINE 
NUCLEOTIDE-BINDING PROTEIN G(I)/G(S)/G(O) 
GAMMA-2 SUBUNIT. 
AK001024 1.36 0.18 
8972 APEX nuclease (multifunctional DNA repair enzyme) AI207650 1.36 0.13 
4754 Human cDNA FLJ14493 fis, clone MAMMA1002972. AK027399 1.36 0.16 
1963 Human mRNA for Cdc42-interacting protein 4 (CIP4). AJ000414 1.35 0.20 
14562 Human pcnp mRNA for PEST-containing nuclear protein, complete cds. AB037675 1.35 0.20 
10685 neural precursor cell expressed, developmentally down-regulated 8 AW960243 1.35 0.10 
7195 CGI-01 protein AK027886 1.35 0.23 
4692 
Human cDNA FLJ12255 fis, clone 
MAMMA1001476, highly similar to URIDINE 
KINASE (EC 2.7.1.48). 
AK022317 1.35 0.20 
10170 ring finger protein 1 AL576514 1.35 0.15 
13295 Human beta-myosin heavy chain (MYH7) mRNA, complete cds. M58018 1.35 0.18 
15982 Human keratin type II (58 kD) mRNA, complete cds. M21389 1.35 0.09 
4179 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) BC007951 1.34 0.16 
2447 eukaryotic translation initiation factor 3, subunit 8 (110kD) AL529959 1.34 0.17 
3662 zinc finger protein AAC60294 1.34 0.14 
6327 Human mRNA for Ig kappa light chain, anti-RhD, therad 7. AJ010442 1.34 0.17 
7871 Human bone morphogenetic protein 2A (BMP-2A) mRNA. M22489 1.34 0.20 
14611 Human kruppel-like zinc finger protein (ZNF300) mRNA, complete cds. AF395541 1.34 0.16 
2925 ATPase, H+ transporting, lysosomal (vacuolar proton pump) 21kD BG108730 1.33 0.19 
10332 Homo sapiens GT212 mRNA L38935 1.33 0.14 
3201 Human mRNA for KIAA0671 protein, complete cds. AB014571 1.33 0.12 
807 protein phosphatase 4, regulatory subunit 1 AW865929 1.33 0.18 
6042 
siah binding protein 1; FBP interacting repressor; 
pyrimidine tract binding splicing factor; Ro 
ribonucleoprotein-binding protein 1 
AW245149 1.33 0.20 
206 Human mRNA for KIAA1290 protein, partial cds. AB033116 1.33 0.23 
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18317 ESTs, Highly similar to DDP_HUMAN X-LINKED DEAFNESS DYSTONIA PROTEIN [H.sapiens] BG612847 1.33 0.19 
7281 non-histone chromosome protein 2 (S. cerevisiae)-like 1 BE748666 1.32 0.08 
4090 tubby like protein 1 AI344222 1.32 0.14 
11291 Human set gene, complete cds. M93651 1.32 0.06 
11939 acetyl-Coenzyme A acetyltransferase 1 (acetoacetyl Coenzyme A thiolase) BG740338 1.32 0.11 
6472 Human, thioredoxin-like, clone MGC:12349 IMAGE:3686411, mRNA, complete cds. BC005289 1.32 0.20 
7976 Human SH2-containing protein Nsp3 mRNA, complete cds. AF124251 1.32 0.13 
3507 
Human, replication factor C (activator 1) 5 
(36.5kD), clone MGC:1155 IMAGE:3544137, 
mRNA, complete cds. 
BC001866 1.31 0.10 
6807 Human CpG island DNA genomic Mse1 fragment, clone 186c1, reverse read cpg186c1.rt1b. Z55026 1.31 0.13 
11012 Human plectin (PLEC1) mRNA, complete cds. U53204 1.31 0.11 
7507 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 AI380263 1.31 0.28 
3161 Human serum amyloid A protein mRNA, complete cds. M81349 1.30 0.19 
4156 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 BE745439 1.30 0.09 
1668 
Human, MpV17 transgene, murine homolog, 
glomerulosclerosis, clone MGC:1703 
IMAGE:2967261, mRNA, complete cds. 
BC001115 1.30 0.21 
2103 Human cysteine sulfinic acid decarboxylase-related protein 1 (CSAD) mRNA, complete cds. AF116545 1.30 0.12 
16028 Human, peroxiredoxin 1, clone MGC:12514 IMAGE:3961375, mRNA, complete cds. BC007063 1.30 0.10 
12074 zinc finger protein 239 BF972810 1.30 0.20 
4724 Human mRNA; cDNA DKFZp434F054 (from clone DKFZp434F054); complete cds. AL136863 1.30 0.08 
6019 cysteine-rich protein 1 (intestinal) BI222747 1.29 0.19 
7051 mitochondrial ribosomal protein S27 BG746580 1.29 0.14 
3230 Human mRNA for transcription factor. AJ012463 1.28 0.18 
3291 Human DAZ associated protein 1 (DAZAP1) mRNA, complete cds. AF181719 1.28 0.06 
3374 Human dematin (HRD1) mRNA, complete cds. L19713 1.28 0.05 
10079 Human, clone IMAGE:3352566, mRNA, partial cds. BC000113 1.28 0.13 
13758 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiolase) BC011977 1.27 0.16 
6666 
Human cDNA FLJ14937 fis, clone PLACE1010231, 
weakly similar to CELL SURFACE 
GLYCOPROTEIN EMR1 PRECURSOR. 
AK027843 1.27 0.09 
14436 Human translation initiation factor eIF-2 gamma subunit mRNA, complete cds. L19161 1.27 0.15 
3933 asparagine synthetase BC014621 1.27 0.10 
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3860 
Human, N-acetylneuraminic acid phosphate 
synthase; sialic acid synthase, clone MGC:934 
IMAGE:3505324, mRNA, complete cds. 
BC000008 1.27 0.06 
6812 Human mRNA for KIAA1798 protein, partial cds. AB058701 1.26 0.14 
15326 vesicle-associated membrane protein 8 (endobrevin) AV716151 1.26 0.10 
3541 Human sodium channel beta-1 subunit (SCN1B) mRNA, complete cds. L10338 1.26 0.09 
15966 BcDNA:GH03108 gene product AAF47301 1.26 0.08 
356 Human HT025 mRNA, complete cds. AF245436 1.26 0.14 
6813 
Human cDNA: FLJ22923 fis, clone KAT06970, 
highly similar to HSP6973 Human mRNA for TOM1 
protein. 
AK026576 1.26 0.12 
1671 Human helicase-like protein (HLP) mRNA, complete cds. U09877 1.26 0.16 
10201 chaperonin containing TCP1, subunit 6B (zeta 2) D78333 1.25 0.11 
3146 Human, cysteine-rich protein 1 (intestinal), clone MGC:3888 IMAGE:3631097, mRNA, complete cds. BC002738 1.25 0.16 
3657 Human mRNA; cDNA DKFZp434B1272 (from clone DKFZp434B1272); partial cds. AL162032 1.25 0.12 
18299 hypothetical protein MGC3101 BF196967 1.25 0.10 
7844 Human transcription factor IL-4 Stat mRNA, complete cds. U16031 1.25 0.10 
6522 Human creatine transporter mRNA, complete cds. L31409 1.25 0.14 
1947 Human udulin 2 mRNA, 3' end. M64109 1.24 0.15 
4464 protocadherin 17 NM_014459 1.24 0.11 
2379 ribonuclease HI, large subunit BE045964 1.24 0.13 
10660 B-cell translocation gene 1, anti-proliferative AA807633 1.24 0.14 
10088 
Human testis-specific PGK-2 gene for 
phosphoglycerate kinase (ATP:3-phospho-D-
glycerate 1-phosphotransferase, EC 2.7.2.3). 
X05246 1.23 0.09 
1972 Human mRNA for KIAA0575 protein, complete cds. AB011147 1.22 0.16 
4441 KIAA0998 protein AV687594 1.20 0.10 
596 Human antigen CD9 gene, exon 4. L08121 1.20 0.16 
6480 
Human, Similar to RIKEN cDNA 2610100E10 
gene, clone MGC:2404 IMAGE:2821736, mRNA, 
complete cds. 
BC006505 1.20 0.11 
5833 SELENOPHOSPHATE SYNTHETASE ; Human selenium donor protein BG574707 1.20 0.03 
1120 NADH dehydrogenase (ubiquinone) Fe-S protein 8 (23kD) (NADH-coenzyme Q reductase) NM_002496 1.19 0.14 
7518 ribosomal protein S4, Y-linked M58459 1.19 0.11 
16138 
Human, Similar to katanin p60 (ATPase-containing) 
subunit A 1, clone MGC:2599 IMAGE:3347282, 
mRNA, complete cds. 
BC000612 1.19 0.12 
7237 ATP-binding cassette, sub-family B (MDR/TAP), member 4 X06181 1.17 0.09 
12836 Human putative transcription factor (WBSCR12) mRNA, complete cds. AF156489 1.16 0.11 
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8328 Human cDNA: FLJ22528 fis, clone HRC12825. AK026181 1.15 0.07 
7132 activator of S phase kinase AI289307 1.14 0.04 





Genes Significantly (P<0.005) Abundant In PAEC 
In comparison to PAVEC in shear 
Group 4 
Agilent  Count 511  
Feature # Gene Name/Description Gene ID Fold AVE Fold STD 
18199 slit (Drosophila) homolog 2 AW263423 9.43 1.39 
1676 Human aldehyde dehydrogenase 6 mRNA, complete cds. U07919 8.85 1.85 
15264 ESTs, Highly similar to AF078844 1 hqp0376 protein [H.sapiens] BG165945 7.42 2.07 
16812 metallothionein 1X BF130769 7.24 2.11 
14302 Human factor I (C3b/C4b inactivator) mRNA, complete cds. J02770 6.60 1.60 
5731 ankyrin-like with transmembrane domains 1 NM_007332 6.22 1.77 
504 Human metallothionein-I-A gene, complete coding sequence. K01383 5.97 1.17 
11089 Human mRNA for Slit-2 protein, complete cds. AB017168 5.77 1.38 
8985 somatostatin BI713774 5.20 1.30 
18197 metallothionein 1E (functional) H72532 4.88 1.25 
18437 protease, serine, 12 (neurotrypsin, motopsin) AJ001531 4.72 1.05 
9935 Human cDNA FLJ20129 fis, clone COL06190. AK000136 4.54 0.40 
9768 
Translation may initiate at the ATG codon at 
nucleotides 40-42 or the ATG at nucleotides 43-
45 
CAC32434 4.42 1.25 
9369 Human GABAA receptor subunit alpha4 mRNA, complete cds. U30461 4.33 0.94 
18292 cerebellar degeneration-related protein (34kD) M16965 4.28 1.06 
6907 Human, cathepsin S, clone MGC:3886 IMAGE:3610589, mRNA, complete cds. BC002642 4.26 1.11 
6648 Human metallothionein (MT)I-F gene, complete cds. M13003 4.19 0.56 
11616 Human mRNA for phospholipase C, complete cds. D42108 4.02 0.65 
18467 gap junction protein, alpha 1, 43kD (connexin 43) X52947 3.84 0.47 
1214 neuro-oncological ventral antigen 1 NM_006489 3.70 0.51 
17723 Human onconeural ventral antigen-1 (Nova-1) mRNA, complete cds. U04840 3.49 0.84 
4864 Human transmembrane protein Jagged mRNA, partial cds. U77720 3.40 0.52 
6749 Human mRNA full length insert cDNA clone EUROIMAGE 345330. AL079274 3.25 1.20 
3456 Human CD39L3 (CD39L3) mRNA, complete cds. AF039917 3.22 1.37 
12929 Human mRNA for neurotrypsin. AJ001531 3.03 0.70 
8774 mannosidase, alpha, class 1A, member 1 AU119410 2.97 0.60 
13807 GTP-binding protein overexpressed in skeletal muscle AW297828 2.96 0.29 
18492 PTH-responsive osteosarcoma B1 protein AA002033 2.92 0.28 
5561 aldehyde dehydrogenase 1 family, member A1 AV649527 2.92 1.36 
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14142 Human cerebellar-degeneration-related antigen (CDR34) gene, complete cds. M31423 2.87 1.11 
1201 mannosidase, alpha, class 1A, member 1 NM_005907 2.83 1.14 
3902 Human mRNA for GRIP1 protein. AJ133439 2.82 0.67 
2397 matrix Gla protein AW999947 2.82 0.55 
10091 Human leukemogenic homolog protein (MEIS1) mRNA, complete cds. U85707 2.82 0.67 
16607 downregulated in ovarian cancer 1 U53445 2.80 0.28 
13852 acid sphingomyelinase-like phosphodiesterase Y08136 2.75 0.42 
12071 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 U84573 2.74 1.28 
10571 Rho GTPase activating protein 5 U17032 2.69 0.61 
5696 fibroblast growth factor 13 NM_033642 2.69 0.54 
5786 Ewing sarcoma breakpoint region 1 BI871381 2.68 0.53 
9932 Human caveolin 1 (CAV1) gene, exon 3 and partial cds. AF125348 2.63 0.39 
10982 Human mRNA for NOTCH4, partial cds. D63395 2.61 0.30 
7555 phosphodiesterase 3B, cGMP-inhibited BI756567 2.61 0.42 
8825 caveolin 1, caveolae protein, 22kD NM_001753 2.58 0.36 
3508 Human, matrix Gla protein, clone MGC:12316 IMAGE:3930143, mRNA, complete cds. BC005272 2.54 0.34 
14123 Human TALE homeobox protein Meis2b mRNA, complete cds. AF179896 2.42 0.33 
17217 MAM domain protein AAC59868 2.41 1.08 
5503 RAS p21 protein activator (GTPase activating protein) 1 NM_022650 2.39 0.23 
10569 growth arrest and DNA-damage-inducible, alpha AI814872 2.39 0.12 
13676 glutaminase BI764185 2.39 0.22 
11439 Human uveal autoantigen mRNA, complete cds. AF322916 2.38 0.43 
16905 KIAA0368 protein AB002366 2.37 0.31 
1069 UDP-glucose ceramide glucosyltransferase AI609116 2.35 0.64 
897 tissue factor pathway inhibitor 2 BG621010 2.35 0.69 
16721 interleukin 9 receptor NM_002186 2.33 0.32 
4346 caspase 5, apoptosis-related cysteine protease NM_004347 2.32 1.00 
12259 bone morphogenetic protein 4 NM_001202 2.30 0.83 
13444 homeo box A7 NM_006896 2.30 0.81 
14079 
Human cDNA FLJ14357 fis, clone 
HEMBA1000005, highly similar to DNAJ 
PROTEIN HOMOLOG MTJ1. 
AK027263 2.28 0.56 
9416 Human cDNA FLJ10500 fis, clone NT2RP2000369. AK001362 2.26 0.30 
13583 vinculin NM_014000 2.26 0.68 
11598 Human mRNA for KIAA0212 gene, complete cds. D86967 2.25 0.27 
11655 dJ12G14.2 (novel protein similar to predicted chicken protein) CAB88112 2.24 0.43 
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4753 
Human, angiotensinogen (serine (or cysteine) 
protease inhibitor, clade A (alpha-1 antiprotease, 
antitrypsin), member 8), clone MGC:17092 
IMAGE:4213559, mRNA, complete cds. 
BC011519 2.23 0.30 
4827 Human mRNA for KIAA0369 gene, complete cds. AB002367 2.21 0.57 
3763 Human G-protein-coupled receptor 48 (GPR48) mRNA, complete cds. AF257182 2.21 0.23 
16409 hypothetical protein DKFZp564F013 AA215791 2.20 0.35 
11486 Human mRNA for KIAA0705 protein, complete cds. AB014605 2.19 0.39 
5958 
myeloid/lymphoid or mixed-lineage leukemia 
(trithorax (Drosophila) homolog); translocated to, 
3 
AI110630 2.19 0.59 
7055 Human glioma amplified on chromosome 1 protein (GAC1) mRNA, complete cds. AF030435 2.16 0.65 
2878 
dystrophin (muscular dystrophy, Duchenne and 
Becker types), includes DXS142, DXS164, 
DXS206, DXS230, DXS239, DXS268, DXS269, 
DXS270, DXS272 
AA889832 2.16 0.47 
6842 Human mRNA; cDNA DKFZp586B1817 (from clone DKFZp586B1817). AL050088 2.16 0.31 
17663 Human mRNA for neurexin I-alpha protein, complete cds. AB035356 2.15 0.32 
5854 
integrin, alpha M (complement component 
receptor 3, alpha; also known as CD11b (p170), 
macrophage antigen alpha polypeptide) 
NM_000632 2.15 0.21 
13316 baculoviral IAP repeat-containing 5 (survivin) AL571008 2.14 0.47 
11625 Human histidine decarboxylase (HDC) mRNA, complete cds. M60445 2.14 0.36 
4114 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 AL541089 2.13 0.53 
4446 KIAA0603 gene product BI906891 2.13 0.29 
7886 Human mRNA for NADP dependent leukotriene b4 12-hydroxydehydrogenase, partial cds. D49387 2.12 0.48 
2687 proteoglycan 1, secretory granule BG489803 2.10 0.30 
14245 Human placenta-specific ATP-binding cassette transporter (ABCP) mRNA, complete cds. AF103796 2.09 0.43 
14051 Human mRNA for KIAA0106 gene, complete cds. D14662 2.09 0.25 
4964 Human Bmx mRNA for cytoplasmic tyrosine kinase. X83107 2.08 0.16 
2768 very low density lipoprotein receptor BG028841 2.07 0.33 
4310 solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 U62966 2.07 0.67 
11978 vascular endothelial growth factor AI887978 2.06 0.27 
3487 Human receptor protein-tyrosine kinase (HEK8) mRNA, complete cds. L36645 2.05 0.58 
18152 chimerin (chimaerin) 1 BF940950 2.05 0.50 
4013 Notch (Drosophila) homolog 4 D63395 2.04 0.37 
13850 fibromodulin AI249821 2.04 0.40 
4311 caspase 4, apoptosis-related cysteine protease BG572762 2.03 0.78 
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5645 secretory carrier membrane protein 1 BG613898 2.01 0.40 
16498 RYK receptor-like tyrosine kinase BG740085 2.01 0.23 
17268 Human mRNA for Tob, complete cds. D38305 1.97 0.28 
4063 glycine receptor, beta AF094755 1.97 0.48 
13215 Human mRNA for KIAA0669 protein, complete cds. AB014569 1.97 0.43 
6789 Human vascular endothelial growth factor (VEGF) mRNA, 3'UTR. AF024710 1.96 0.30 
3140 Human insulin-stimulated protein kinase 1 (ISPK-1) mRNA, complete cds. U08316 1.96 0.20 
13263 Human E3 ubiquitin ligase Smurf2 mRNA, complete cds. AY014180 1.95 0.43 
2875 KIAA0161 gene product AW172840 1.95 0.36 
4395 cyclin H BC005280 1.93 0.68 
746 Human CAAX box protein TIMAP mRNA, complete cds. AF362910 1.93 0.28 
6008 
Homo sapiens cDNA: FLJ21930 fis, clone 
HEP04301, highly similar to HSU90916 Human 
clone 23815 mRNA sequence 
U90916 1.92 0.36 
892 profilin 2 AV724105 1.90 0.33 
4265 smg GDS-ASSOCIATED PROTEIN BG433239 1.90 0.19 
5971 Homo sapiens clone DT1P1B6 mRNA, CAG repeat region BI868318 1.90 0.22 
12987 CG11367 gene product AAF51854 1.88 0.78 
4064 interleukin 13 receptor, alpha 1 AL600856 1.88 0.51 
1985 Human Trio isoform mRNA, complete cds. AF091395 1.87 0.37 
12219 hypothetical protein PRO1489 AI536671 1.87 0.29 
17799 Human fibromodulin mRNA, partial cds. U05291 1.85 0.37 
6781 Human G-protein gamma-10 subunit mRNA, complete cds. U31383 1.85 0.11 
8681 glycogen synthase 1 (muscle) AL556228 1.85 0.59 
8037 Human mRNA; cDNA DKFZp667P184 (from clone DKFZp667P184). AL512742 1.85 0.31 
3496 Human nectin 3 mRNA, complete cds. AF282874 1.85 0.10 
181 Human gene for thrombomodulin precursor, complete cds. D00210 1.85 0.35 
10322 regulator of differentiation (in S. pombe) 1 NM_005156 1.83 0.13 
6965 Human mRNA full length insert cDNA clone EUROIMAGE 248114. AL079279 1.83 0.13 
3221 
Human, ATPase, Na+/K+ transporting, beta 1 
polypeptide, clone MGC:1798 IMAGE:3506311, 
mRNA, complete cds. 
BC000006 1.83 0.56 
15234 ATPase, H+ transporting, lysosomal (vacuolar proton pump) 9kD BG779549 1.83 0.14 
46 
Human, menage a trois 1 (CAK assembly factor), 
clone MGC:5154 IMAGE:3453943, mRNA, 
complete cds. 
BC000820 1.83 0.17 
4376 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) BI766434 1.82 0.23 
12553 
Human, pleckstrin 2 (Mouse) homolog, clone 
MGC:4867 IMAGE:3457876, mRNA, complete 
cds. 
BC001226 1.82 0.71 
2843 microsomal glutathione S-transferase 2 W73858 1.82 0.22 
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15097 cholinergic receptor, nicotinic, delta polypeptide BF306695 1.82 0.25 
8053 Human mRNA for MEMD protein. Y10183 1.81 0.08 
3725 Human elastin (ELN) gene, partial cds. U62292 1.81 0.51 
4304 tumor necrosis factor (ligand) superfamily, member 10 AW022060 1.79 0.18 
11260 Human phospholemman chloride channel mRNA, complete cds. U72245 1.79 0.31 
4726 
Human, protein phosphatase 5, catalytic subunit, 
clone MGC:5260 IMAGE:3459309, mRNA, 
complete cds. 
BC001970 1.78 0.45 
5663 regulator of G-protein signalling 7 AL566862 1.78 0.36 
18061 ATP-binding cassette, sub-family G (WHITE), member 2 BI497116 1.78 0.16 
10648 glioma tumor suppressor candidate region gene 1 AA290865 1.77 0.39 
2593 ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) L35594 1.77 0.19 
18033 KIAA0903 protein AI022927 1.76 0.14 
9058 ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42kD N75606 1.76 0.24 
4825 Human mRNA for hFat protein. X87241 1.75 0.40 
4876 Human metaxin 2 (MTX2) mRNA, nuclear gene encoding mitochondrial protein, complete cds. AF053551 1.75 0.18 
11463 Human nicotinic acetylcholine receptor alpha3 subunit precursor, mRNA, complete cds. U62432 1.75 0.36 
18311 exostoses (multiple)-like 2 AK001450 1.75 0.46 
8141 
Human cDNA FLJ14753 fis, clone 
NT2RP3003101, weakly similar to Mouse mRNA 
for tetracycline transporter-like protein. 
AK027659 1.74 0.47 
15652 Human sperm protein 17 mRNA, complete cds. AF334735 1.74 0.38 
9169 neurogranin (protein kinase C substrate, RC3) BF948983 1.74 0.05 
8605 Human mRNA for vacuolar proton-ATPase subunit M9.2. Y15286 1.74 0.14 
7368 KIAA0256 gene product BG107450 1.74 0.13 
6507 Human c-jun proto oncogene (JUN), complete cds, clone hCJ-1. J04111 1.74 0.14 
5162 Human DZIP3 mRNA, partial cds. AF279370 1.73 0.22 
8951 toll-like receptor 2 NM_003264 1.73 0.16 
14316 Human zinc finger protein ZNF191 (ZNF191) gene, complete cds. AF016052 1.73 0.17 
8510 Human 5T4 oncofetal trophoblast glycoprotein gene. AJ012159 1.73 0.24 
15861 Human 14 kDa beta-galactoside-binding lectin (ll4) gene, complete cds. M57678 1.73 0.29 
639 
Human, growth factor receptor-bound protein 2, 
clone MGC:1737 IMAGE:3345524, mRNA, 
complete cds. 
BC000631 1.73 0.29 
7504 xeroderma pigmentosum, complementation group A D14533 1.72 0.26 
18483 Human BAC clone RG083M05 from 7q21-7q22 AC000064 1.72 0.11 
8983 immunoglobulin superfamily containing leucine-rich repeat AB003184 1.71 0.19 
8900 target of myb1 (chicken) homolog-like 1 AI921588 1.70 0.22 
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271 Human tie mRNA for putative receptor tyrosine kinase. X60957 1.70 0.23 
7161 myosin X AU151619 1.70 0.31 
6003 spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, autosomal dominant, ataxin 2) U70323 1.70 0.31 
8806 hypothetical protein A-211C6.1 BG108225 1.70 0.32 
15879 
Human, Similar to RIKEN cDNA 0610013E23 
gene, clone MGC:12169 IMAGE:3930310, 
mRNA, complete cds. 
BC006971 1.69 0.19 
15969 Human pancreatic lipase related protein 1 (PLRP1) mRNA, complete cds. M93283 1.69 0.14 
4301 hypothetical protein FLJ11175 AI469703 1.69 0.21 
5287 Human ATP synthase beta subunit (ATPSB) gene, complete cds. M27132 1.68 0.09 
8826 troponin I, skeletal, slow AL596761 1.68 0.25 
7967 thymosin beta-10 [Human, metastatic melanoma cell line, mRNA, 453 nt]. S54005 1.68 0.15 
5948 old astrocyte specifically induced substance NM_052854 1.68 0.40 
4335 v-rel avian reticuloendotheliosis viral oncogene homolog X75042 1.68 0.27 
14320 Human host cell factor 2 (HCF-2) mRNA, complete cds. AF117210 1.68 0.13 
7386 sarcoglycan, epsilon AJ000534 1.68 0.35 
16177 Human thioredoxin mRNA, complete cds. AF313911 1.68 0.47 
18219 trophoblast glycoprotein Z29083 1.68 0.16 
10343 RNA polymerase II transcriptional regulation mediator (Med6, S. cerevisiae, homolog of) AL079635 1.67 0.32 
3147 Human mRNA for phospholipase C-beta-1b (PLCB1 gene). AJ278314 1.66 0.21 
13759 pregnancy specific beta-1-glycoprotein 4 M20881 1.66 0.19 
13178 C33 antigen=type III integral membrane protein [human, T cell line MOLT-4, Peptide, 267 aa] AAB23825 1.66 0.23 
11907 ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) BG939578 1.66 0.29 
8915 hypothetical protein FLJ11149 BI752967 1.66 0.18 
7902 Human clone 23742 mRNA, partial cds. AF035287 1.65 0.27 
18468 glutamate-cysteine ligase, modifier subunit L35546 1.65 0.38 
6040 ESTs AI869879 1.65 0.21 
1345 serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1 BI915951 1.64 0.16 
4141 erythropoietin receptor S45332 1.64 0.31 
2834 Human SH3 domain-containing protein SH3P18 mRNA, complete cds BE708457 1.63 0.25 
10007 Human cDNA FLJ14690 fis, clone NT2RP2005270. AK027596 1.63 0.57 
16640 hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) AU154668 1.62 0.37 
7286 ATP-binding cassette, sub-family G (WHITE), member 2 AU118354 1.62 0.29 
10416 KIAA0573 protein AB011145 1.62 0.36 
14948 hypothetical protein MGC4701 AF040964 1.62 0.36 
4815 
Human, Similar to protein phosphatase 2 
(formerly 2A), catalytic subunit, beta isoform, 
clone MGC:21354 IMAGE:4454972, mRNA, 
complete cds. 
BC012022 1.62 0.25 
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17592 Human activin beta-A subunit (exon 2). X57579 1.62 0.32 
8607 KIAA0759 protein AA527389 1.61 0.18 
15146 ribosomal protein S29 AA827393 1.61 0.24 
7590 ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens] BG718906 1.61 0.12 
11927 KIAA1441 protein BI859994 1.61 0.40 
12035 EphA5 L36644 1.61 0.47 
17539 Human partial mRNA for putative nuclear factor. AJ276691 1.61 0.22 
5896 protein kinase C, mu X75756 1.61 0.28 
5517 homeo box B6 NM_018952 1.60 0.25 
14618 Human, Similar to advillin, clone MGC:1461 IMAGE:2961396, mRNA, complete cds. BC004134 1.60 0.15 
4504 RAB5A, member RAS oncogene family BC001267 1.60 0.12 
15855 Human fibroblast growth factor receptor (FGFr) transmembrane form mRNA, complete cds. M34185 1.60 0.23 
14090 Human gcp60 mRNA for golgi resident protein GCP60, complete cds. AB043587 1.60 0.16 
7843 Human fetal brain adenylyl cyclase mRNA, 3' end. L05500 1.60 0.26 
13615 cytochrome c oxidase subunit Va BE538296 1.60 0.23 
1357 KIAA0355 gene product AB002353 1.60 0.08 
10341 eyes absent (Drosophila) homolog 2 U69178 1.60 0.60 
6631 Human mRNA for KIAA0636 protein, complete cds. AB014536 1.59 0.36 
2908 predicted osteoblast protein AI491952 1.59 0.19 
12702 Macaque brain cDNA clone:QmoA-10711, full insert sequence. AB062987 1.59 0.10 
5973 receptor-interacting serine-threonine kinase 2 BG170405 1.59 0.34 
16815 A kinase (PRKA) anchor protein (yotiao) 9 NM_005751 1.59 0.20 
6975 Human nidogen mRNA, complete cds. M30269 1.59 0.28 
7499 ESTs AA233775 1.59 0.41 
10232 collagen, type V, alpha 2 AU117484 1.58 0.19 
1800 
Human cDNA FLJ14494 fis, clone 
MAMMA1003035, weakly similar to RIBOSOMAL 
LARGE SUBUNIT PSEUDOURIDINE 
SYNTHASE C (EC 4.2.1.70). 
AK027400 1.58 0.30 
2212 
Human cDNA FLJ10783 fis, clone 
NT2RP4000417, weakly similar to MANNOSYL-
OLIGOSACCHARIDE ALPHA-1,2-
MANNOSIDASE (EC 3.2.1.113). 
AK001645 1.58 0.22 
16970 calumenin AW614911 1.58 0.11 
9412 Human mRNA for UDP-N-acetylglucosamine transporter, complete cds. AB021981 1.58 0.27 
2829 quinone oxidoreductase homolog BF058741 1.57 0.29 
13188 Human mRNA; cDNA DKFZp434H0413 (from clone DKFZp434H0413); partial cds. AL137261 1.57 0.24 
4316 UDP-N-acteylglucosamine pyrophosphorylase 1 AL520091 1.56 0.37 
710 Human, Similar to plastin 3 (T isoform), clone IMAGE:3447893, mRNA, partial cds. BC008588 1.56 0.13 
11752 hypothetical protein A-211C6.1 AL537232 1.56 0.25 
11473 Human MARK (MARK) mRNA, complete cds. AF154845 1.55 0.36 
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5994 frizzled (Drosophila) homolog 6 BG180759 1.55 0.29 
262 Human MAGUK protein VAM-1 mRNA, complete cds. AF162130 1.55 0.21 
1784 Human calumein (Calu) mRNA, complete cds. AF013759 1.55 0.14 
11969 pleckstrin homology, Sec7 and coiled/coil domains 1(cytohesin 1) NM_017456 1.55 0.21 
1349 ESTs AA973023 1.55 0.17 
11620 Human mRNA for Ste24p, complete cds. AB016068 1.55 0.24 
8407 Human (clone Q-2OD3) interferon receptor (IFNAR2) gene, exon 1. L42237 1.54 0.21 
5660 erythrocyte membrane protein band 4.1-like 1 AB002336 1.54 0.08 
4094 adaptor-related protein complex 3, sigma 1 subunit BF032683 1.54 0.08 
9438 Human orphan hormone nuclear receptor RORalpha1 mRNA, complete cds. U04897 1.54 0.19 
1110 
membrane-spanning 4-domains, subfamily A, 
member 2 (Fc fragment of IgE, high affinity I, 
receptor for; beta polypeptide) 
NM_000139 1.54 0.19 
8374 
Human, reticulocalbin 2, EF-hand calcium binding 
domain, clone MGC:1650 IMAGE:3505241, 
mRNA, complete cds. 
BC004892 1.53 0.19 
4412 Homo sapiens cDNA: FLJ22044 fis, clone HEP09141 AW058438 1.53 0.25 
2099 Human hox11 proto-oncogene, exons 1 to 3 and hug-1 gene. AJ009794 1.53 0.21 
7453 nuclear transcription factor, X-box binding 1 BG327231 1.53 0.23 
13456 aryl hydrocarbon receptor AA844153 1.53 0.12 
7284 reticulocalbin 2, EF-hand calcium binding domain BG390232 1.53 0.22 
13197 
Human myocyte-specific enhancer factor 2A 
(MEF2A) gene, last coding exon, and complete 
cds. 
U49020 1.52 0.29 
16983 Janus kinase 1 (a protein tyrosine kinase) AA131737 1.52 0.20 
16398 Human mRNA for cytokine inducible nuclear protein. X83703 1.52 0.24 
4429 myotubular myopathy 1 U46024 1.52 0.21 
11097 Human mRNA; cDNA DKFZp586D0724 (from clone DKFZp586D0724). AL110150 1.52 0.15 
963 growth hormone receptor X06562 1.51 0.23 
6007 capping protein (actin filament) muscle Z-line, alpha 2 BC005338 1.50 0.05 
797 G protein-coupled receptor 56 BF593277 1.50 0.28 
12838 
Human, ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit F6, clone 
MGC:2243 IMAGE:3357779, mRNA, complete 
cds. 
BC001178 1.50 0.13 
6295 Human, clone MGC:14796 IMAGE:4050837, mRNA, complete cds. BC005993 1.50 0.27 
11431 Human cDNA: FLJ21270 fis, clone COL01749. AK024923 1.49 0.39 
8839 CLIP-associating protein 1 AB014522 1.49 0.22 
18323 kinesin 2 (60-70kD) AW963252 1.49 0.18 
12064 kinectin 1 (kinesin receptor) Z22551 1.49 0.21 
2519 KIAA0284 protein AK025023 1.49 0.27 
2457 MAGUK protein p55T; Protein Associated with Lins 2 NM_016447 1.49 0.21 
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18142 paired mesoderm homeo box 1 NM_022716 1.49 0.23 
4691 Human ERGIC-53 mRNA. X71661 1.49 0.26 
12803 Human transcription factor HOXA13 (HOXA13) gene, complete cds. U82827 1.49 0.22 
15028 selectin L (lymphocyte adhesion molecule 1) X17519 1.48 0.23 
3415 Human Rho-associated, coiled-coil containing protein kinase p160ROCK mRNA, complete cds. U43195 1.48 0.19 
14709 Human serine-threonine protein kinase NKIAMRE (NKIAMRE) mRNA, complete cds. AF130372 1.48 0.22 
7600 FSHD region gene 1 T41211 1.48 0.31 
17497 Human cDNA FLJ13053 fis, clone NT2RP3001459. AK023115 1.48 0.21 
1368 membrane-bound transcription factor protease, site 1 AL133583 1.48 0.18 
11565 Human 10kD protein (BC10) mRNA, complete cds. AF053470 1.48 0.16 
1684 Human cDNA FLJ14393 fis, clone HEMBA1003222. AK027299 1.47 0.37 
1365 hypothetical protein DKFZp547M136 similar to widely-interspaced zinc finger motifs BF062131 1.47 0.25 
16591 chromodomain helicase DNA binding protein 1 AF006513 1.47 0.31 
6355 Human displacement protein (CCAAT) mRNA. M74099 1.47 0.12 
1337 ceruloplasmin (ferroxidase) M13699 1.47 0.20 
13582 argininosuccinate synthetase BF305206 1.47 0.10 
4230 NCK adaptor protein 1 AI591085 1.47 0.24 
7373 solute carrier family 16 (monocarboxylic acid transporters), member 1 AI565092 1.46 0.30 
10618 KIAA0652 gene product AI915504 1.46 0.38 
13754 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein AI299309 1.46 0.15 
2910 Down syndrome critical region gene 1 BG287042 1.46 0.26 
3779 Human casein kinase I gamma 3L (CSNK1G3L) mRNA, complete cds. AF049090 1.46 0.19 
11313 
Human cDNA FLJ11028 fis, clone 
PLACE1004128, highly similar to GUANINE 
NUCLEOTIDE-BINDING PROTEIN BETA 
SUBUNIT 4. 
AK001890 1.46 0.30 
5947 CDC14 (cell division cycle 14, S. cerevisiae) homolog A AF000367 1.46 0.11 
56 Human hypoxanthine phosphoribosyltransferase (HPRT) mRNA, complete cds. M31642 1.46 0.10 
15324 inositol 1,4,5-triphosphate receptor, type 2 D26350 1.46 0.28 
14447 
Human cDNA: FLJ22970 fis, clone KAT10766, 
highly similar to HUMCOXNE Human nuclear-
encoded mitochondrial cytochrome c oxidase Va 
subunit mRNA. 
AK026623 1.46 0.19 
1340 KIAA0594 protein AB011166 1.46 0.22 
6252 Human mRNA for connective tissue growth factor. X78947 1.45 0.26 
3313 
Human homeobox B7 (HOXB7) gene, partial cds; 
and homeobox B6 (HOXB6), homeobox B5 
(HOXB5), homeobox B4 (HOXB4), and 
homeobox B3 (HOXB3) genes, complete cds. 
AF287967 1.45 0.15 
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10335 dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) AI478561 1.45 0.30 
5853 zinc finger protein 187 BC013951 1.45 0.16 
541 Human ELP-1 mRNA sequence. M88458 1.45 0.21 
12772 Human cDNA: FLJ22135 fis, clone HEP20858. AK025788 1.44 0.17 
17945 sushi-repeat protein NM_014467 1.44 0.28 
16881 core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D-related D43638 1.44 0.27 
2293 Human h-Sp1 mRNA. X68194 1.44 0.12 
5720 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I AL574109 1.44 0.14 
3789 Human genomic DNA, chromosome 8q23, clone:KB1171G1. AP000427 1.44 0.21 
5682 retinoblastoma 1 (including osteosarcoma) BI092056 1.44 0.10 
8129 Human phosphoinositide-specific phospholipase C PLC-epsilon mRNA, complete cds. AF190642 1.44 0.28 
5182 Human beta 3-endonexin mRNA, long form and short form, complete cds. U37139 1.43 0.19 
5689 adaptor-related protein complex 3, beta 1 subunit U81504 1.43 0.18 
18435 acyl-Coenzyme A oxidase 2, branched chain BG545036 1.43 0.04 
6910 Human FUSE binding protein 3 (FBP3) mRNA, partial cds. U69127 1.43 0.17 
16918 cathepsin K (pycnodysostosis) AL544409 1.43 0.24 
731 Human mRNA for KIAA1665 protein, partial cds. AB051452 1.43 0.19 
8168 Human mRNA for KIAA0769 protein, complete cds. AB018312 1.43 0.13 
8074 
Human, Similar to glucosamine-phosphate N-
acetyltransferase, clone MGC:20441 
IMAGE:4661046, mRNA, complete cds. 
BC012179 1.43 0.22 
16894 B-factor, properdin AF349679 1.43 0.26 
12176 tousled-like kinase 1 AA701891 1.43 0.21 
14068 Human mRNA for KIAA1249 protein, partial cds. AB033075 1.43 0.17 
6892 
Human, Similar to CG9602 gene product, clone 
MGC:3733 IMAGE:3619626, mRNA, complete 
cds. 
BC002775 1.42 0.13 
13128 
Human, argininosuccinate synthetase, clone 
MGC:3634 IMAGE:3010137, mRNA, complete 
cds. 
BC009243 1.42 0.10 
4407 tRNA isopentenylpyrophosphate transferase BE156258 1.42 0.21 
15323 Rho-associated, coiled-coil containing protein kinase 1 U43195 1.42 0.20 
13177 
Human cDNA FLJ14929 fis, clone 
PLACE1009130, weakly similar to UBIQUITIN-
PROTEIN LIGASE E3A (EC 6.3.2.-). 
AK027835 1.42 0.11 
2774 sialyltransferase 4C (beta-galactosidase alpha-2,3-sialytransferase) AA453813 1.42 0.28 
12190 hypothetical protein FLJ20366 AW976023 1.42 0.20 
12091 
fms-related tyrosine kinase 1 (vascular endothelial 
growth factor/vascular permeability factor 
receptor) 
X51602 1.42 0.36 
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16951 nuclear receptor subfamily 1, group H, member 3 BF570118 1.42 0.11 
6500 
Human, general transcription factor IIA, 2 (12kD 
subunit), clone MGC:3613 IMAGE:2819215, 
mRNA, complete cds. 
BC001919 1.42 0.16 
12244 general transcription factor IIH, polypeptide 2 (44kD subunit) AF078847 1.41 0.17 
13761 calmegin D86322 1.41 0.15 
9863 
Human, ATPase, H+ transporting, lysosomal 
(vacuolar proton pump), member J, clone 
MGC:1970 IMAGE:3546257, mRNA, complete 
cds. 
BC003564 1.41 0.21 
10384 SPARC-like 1 (mast9, hevin) X82157 1.41 0.23 
7128 LIM and SH3 protein 1 AU159460 1.41 0.12 
6471 Human casein kinase I gamma 3L (CSNK1G3L) mRNA, complete cds. AF049090 1.41 0.38 
13187 
Human protein phosphatase type-1 catalytic 
subunit delta isoform (PPCS1D) mRNA, complete 
cds. 
AF092905 1.41 0.12 
1350 U2 small nuclear ribonucleoprotein auxiliary factor (65kD) BI962886 1.41 0.18 
3568 unnamed protein product CAC38896 1.41 0.15 
10397 calcium/calmodulin-dependent protein kinase kinase 2, beta AI925424 1.41 0.25 
3373 Human, hypothetical protein, clone MGC:3375 IMAGE:3609357, mRNA, complete cds. BC002677 1.41 0.17 
16809 myosin, light polypeptide kinase AW951177 1.41 0.23 
11284 
Human (clones HGPCD2 and HGPCD15) pterin-
4a-carbinolamine dehydratase (PCBD) gene, 
complete cds. 
L41560 1.41 0.17 
9938 Human pephBGT-1 betaine-GABA transporter mRNA, complete cds. U27699 1.40 0.26 
3917 Homo sapiens cDNA: FLJ23197 fis, clone REC00917 AI079280 1.40 0.13 
12842 Human sushi-repeat protein (SRPUL) mRNA, complete cds. AF060567 1.40 0.25 
9415 Human mRNA for KIAA0048 gene, complete cds. D28588 1.39 0.16 
16461 Human lysyl oxidase-like 3 protein (LOXL3) mRNA, complete cds. AF311313 1.39 0.25 
18022 Human mRNA for AP-2 beta transcription factor. X95694 1.39 0.35 
11878 KIAA0155 gene product D63875 1.38 0.16 
9851 Human genes TAP1, TAP2, LMP2, LMP7 and DOB. X66401 1.38 0.14 
9737 Human ubiquitous alpha-2,3-sialyltransferase VI mRNA, complete cds. AF119391 1.38 0.16 
14755 Human mRNA; cDNA DKFZp434B105 (from clone DKFZp434B105); partial cds. AL117626 1.38 0.21 
663 Human excision repair protein ERCC6 mRNA, complete cds. L04791 1.38 0.24 
14979 KIAA0781 protein BF984909 1.38 0.26 
2459 cyclin-dependent kinase 5, regulatory subunit 1 (p35) BE797921 1.38 0.11 
10665 chromosome 2 open reading frame 6 AL122062 1.38 0.20 
13455 KIAA0645 gene product BE646437 1.38 0.18 
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5485 Human BRCA1, Rho7 and vatI genes, complete cds, and ipf35 gene, partial cds. L78833 1.38 0.22 
7341 MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) AI952550 1.37 0.21 
8926 FK506-binding protein 1B (12.6 kD) BC002614 1.37 0.25 
15843 Human nuclear orphan receptor LXR-alpha mRNA, complete cds. U22662 1.37 0.03 
5501 Sob protein AAC47282 1.37 0.18 
12498 Human mRNA for KIAA0338 gene, partial cds. AB002336 1.37 0.10 
2560 branched chain keto acid dehydrogenase E1, beta polypeptide (maple syrup urine disease) M55575 1.37 0.22 
7057 ISL1 transcription factor, LIM/homeodomain, (islet-1) U07559 1.37 0.11 
9549 Human retinoic acid receptor gamma 1 mRNA, complete cds. M38258 1.37 0.21 
7530 EphA2 AI568135 1.37 0.18 
5496 Human normal mucosa of esophagus specific 1 (NMES1) mRNA, complete cds. AF228422 1.37 0.18 
9158 M-phase phosphoprotein 9 AA843678 1.37 0.14 
16334 Human mRNA for KIAA0696 protein, partial cds. AB014596 1.37 0.19 
7215 interferon-stimulated transcription factor 3, gamma (48kD) AA404652 1.36 0.19 
3821 Human tubulin-folding cofactor C mRNA, complete cds. U61234 1.36 0.21 
2366 myosin ID BE502669 1.36 0.19 
5644 phosphoribosylformylglycinamidine synthase (FGAR amidotransferase) AB002359 1.35 0.26 
2551 phosphorylase kinase, beta AL079451 1.35 0.19 
1937 Human mRNA for semaphorin sem2, complete cds. AB029496 1.35 0.11 
11111 Human LDLC mRNA. Z34975 1.35 0.20 
7298 ESTs, Moderately similar to KIAA0696 protein [H.sapiens] AA436684 1.35 0.18 
5998 gene with multiple splice variants near HD locus on 4p16.3 AB000460 1.35 0.13 
15846 Human cDNA FLJ20731 fis, clone HEP10272. AK000738 1.35 0.13 
7243 FK506-binding protein 1A (12kD) BF971255 1.35 0.11 
16700 archain 1 AI700509 1.35 0.09 
4944 
Human cDNA FLJ11756 fis, clone 
HEMBA1005595, weakly similar to DYNEIN 
HEAVY CHAIN, CYTOSOLIC. 
AK021818 1.35 0.14 
16879 replication factor C (activator 1) 4 (37kD) BF062845 1.35 0.19 
12043 KIAA0107 gene product NM_014814 1.34 0.14 
15796 Human cathepsin O (CTSO) mRNA, complete cds. U13665 1.34 0.18 
17186 Human homeobox 1.4 protein mRNA, complete cds. M74297 1.34 0.18 
9069 
serine (or cysteine) proteinase inhibitor, clade F 
(alpha-2 antiplasmin, pigment epithelium derived 
factor), member 1 
AL541945 1.34 0.21 
16748 hippocalcin-like 1 AI566904 1.34 0.12 
10073 Human mRNA for MEGF9, partial cds. AB011542 1.34 0.19 
10651 ATP-binding cassette, sub-family A (ABC1), member 1 R01051 1.34 0.15 
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5831 adenomatosis polyposis coli AA621432 1.34 0.12 
8848 low density lipoprotein receptor defect C complementing AW299301 1.34 0.25 
3501 Human cDNA FLJ10976 fis, clone PLACE1001399. AK001838 1.34 0.12 
5489 hepatocellular carcinoma-associated antigen 58 AI992137 1.34 0.13 
3760 Human mRNA for KIAA0271 gene, complete cds. D87461 1.33 0.11 
232 Human mRNA for KIAA0259 gene, partial cds. D87448 1.33 0.12 
8474 Human mRNA; cDNA DKFZp564L023 (from clone DKFZp564L023); complete cds. AL136643 1.33 0.09 
3798 Human hairy (HRY) mRNA, complete cds. AF264785 1.33 0.13 
497 
Human, tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, epsilon 
polypeptide, clone MGC:1250 IMAGE:3139004, 
mRNA, complete cds. 
BC001440 1.33 0.11 
16556 phosphotriesterase related BG170397 1.33 0.15 
17950 ubiquitin-conjugating enzyme E2E 1 (homologous to yeast UBC4/5) BI523924 1.33 0.14 
6473 Human mRNA for KIAA0483 protein, partial cds. AB007952 1.33 0.10 
14674 Human cellular co-factor (RAB) gene, complete cds. L42025 1.32 0.19 
11583 Human Rab-related GTP-binding protein mRNA, complete cds. AF235022 1.32 0.15 
13620 calcium channel, voltage-dependent, alpha 2/delta subunit 1 AC006145 1.32 0.22 
3672 
Human type IV collagen alpha 5 chain (COL4A5) 
gene, exon 51 and complete cds, alternatively 
spliced. 
U04520 1.32 0.16 
952 solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16 AL574883 1.32 0.09 
12246 malic enzyme 1, NADP(+)-dependent, cytosolic BG211824 1.32 0.08 
1892 Human nucleolysin TIAR mRNA, complete cds. M96954 1.32 0.11 
14398 Human CGI-142 protein mRNA, complete cds. AF151900 1.32 0.13 
8788 JM4 protein BI818455 1.32 0.20 
5350 Human RCC1-like G exchanging factor RLG mRNA, complete cds. AF060219 1.31 0.13 
14297 Human mRNA for putative transcription factor-like nuclear regulator (TFNR gene). AJ238520 1.31 0.10 
7583 BN51 (BHK21) temperature sensitivity complementing M17754 1.31 0.18 
7519 RAN binding protein 2-like 1 AI859613 1.31 0.17 
6433 Human subunit of coatomer complex. X70476 1.31 0.08 
17277 Human mRNA for phosphatidylinositol transfer protein (PI-TPbeta), complete cds. D30037 1.31 0.17 
14280 
Human, voltage-dependent anion channel 3, 
clone MGC:1966 IMAGE:3343379, mRNA, 
complete cds. 
BC002456 1.31 0.12 
11561 Human tumor-related protein (PDRC2) mRNA, complete cds. AF081497 1.31 0.22 
12260 interleukin 15 receptor, alpha U31628 1.31 0.18 
 393
7408 RAS protein activator like 2 NM_004841 1.31 0.10 
1286 R3H domain (binds single-stranded nucleic acids) containing AW973355 1.31 0.15 
17335 Human mRNA for phospholipase C-beta-1a (PLCB1 gene). AJ278313 1.31 0.17 
4292 glutathione synthetase AL573289 1.31 0.17 
14094 Human S1R protein (S1R) mRNA, complete cds. AF113127 1.31 0.17 
13747 TATA box binding protein (TBP)-associated factor, RNA polymerase II, J, 20kD AI681931 1.30 0.16 
7275 ESTs, Highly similar to Unknown gene product [H.sapiens] N51995 1.30 0.12 
13517 synaptosomal-associated protein, 91 kDa (mouse) homolog N62961 1.30 0.09 
179 Human mRNA; cDNA DKFZp434F0272 (from clone DKFZp434F0272). AL137330 1.30 0.15 
5651 RAD51 (S. cerevisiae) homolog C BC000667 1.30 0.08 
12720 Human HSKM-B (HSKM-B) mRNA, complete cds. AF226053 1.30 0.20 
16278 Human mRNA for five-lipoxygenase activating protein (FLAP). X52195 1.30 0.11 
5225 Human asialoglycoprotein receptor H1 mRNA, complete cds. M10058 1.29 0.20 
3455 Human cDNA FLJ12082 fis, clone HEMBB1002492. AK022144 1.29 0.12 
7024 actin filament associated protein D25248 1.29 0.09 
7434 prolactin BG393056 1.29 0.20 
7344 formin-like BG235961 1.29 0.11 
15953 Human, clone IMAGE:3957484, mRNA. BC006415 1.28 0.13 
5282 Human mRNA for growth hormone receptor. X06562 1.28 0.18 
7510 stromal interaction molecule 1 U52426 1.28 0.07 
12211 epithelial membrane protein 1 AW265568 1.28 0.17 
12187 putative nucleic acid binding protein RY-1 AI358942 1.28 0.14 
10647 DKFZP434P1750 protein AI634733 1.28 0.13 
9594 Human mRNA for proteasome subunit HsC10-II, complete cds. D26598 1.28 0.14 
11920 ret finger protein 2 AF241850 1.28 0.12 
11746 Protein P3 NM_019848 1.28 0.20 
16326 Human mRNA; cDNA DKFZp586C1622 (from clone DKFZp586C1622); partial cds. AL050164 1.28 0.13 
5552 
ESTs, Moderately similar to JG0186 vesicle-
associated membrane protein-associated protein 
B [H.sapiens] 
N38854 1.28 0.14 
1259 Homo sapiens cDNA FLJ11904 fis, clone HEMBB1000048 AI908481 1.28 0.16 
1796 
Human cDNA FLJ10679 fis, clone 
NT2RP2006565, moderately similar to Sus scrofa 
mRNA for SCAMP1 protein. 
AK001541 1.28 0.11 
7369 Thy-1 cell surface antigen N94350 1.28 0.17 
7247 chromosome 1 open reading frame 9 BE466870 1.27 0.14 
12221 pancreatitis-associated protein NM_002580 1.27 0.19 
12110 GRO3 oncogene X53800 1.27 0.15 
8075 Human mRNA for TBX18 protein, partial. AJ010278 1.27 0.14 
13643 activated leucocyte cell adhesion molecule AI050952 1.27 0.12 
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4100 phosphoserine phosphatase Y10275 1.27 0.09 
2622 succinate dehydrogenase complex, subunit D, integral membrane protein AB006202 1.27 0.10 
9064 acylphosphatase 1, erythrocyte (common) type AW958424 1.27 0.14 
12915 Human neurocan (CSPG3) mRNA, complete cds. AF026547 1.26 0.19 
5822 potassium large conductance calcium-activated channel, subfamily M, alpha member 1 BI084703 1.26 0.14 
11434 Human HOX3D gene for homeoprotein HOX3D. X61755 1.26 0.18 
11892 B melanoma antigen NM_001187 1.26 0.11 
12984 Human putative protein kinase NY-REN-64 antigen mRNA, complete cds. AF155118 1.26 0.07 
5899 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 AI620652 1.26 0.11 
14441 
Human clone cDSC1 Down syndrome cell 
adhesion molecule (DSCAM) mRNA, complete 
cds. 
AF217525 1.26 0.14 
6529 Human mRNA for ATP synthase subunit e, complete cds. D50371 1.26 0.14 
2428 KIAA0831 protein AW662896 1.26 0.10 
13458 phosphomannomutase 2 AI927764 1.25 0.17 
10103 Human G-protein-coupled receptor APJ gene, complete cds. U03642 1.25 0.10 
11890 KIAA0076 gene product AI741847 1.24 0.13 
2906 TRAF family member-associated NFKB activator BF439429 1.24 0.12 
535 Human chromosome 21 segment HS21C003. AL163203 1.24 0.09 
7213 gamma-aminobutyric acid (GABA) A receptor, alpha 6 BG211331 1.24 0.12 
696 
Human cDNA FLJ13093 fis, clone 
NT2RP3002151, highly similar to G1 TO S 
PHASE TRANSITION PROTEIN 1 HOMOLOG. 
AK023155 1.24 0.09 
12834 Human mRNA for DNA polymerase beta, complete cds. D29013 1.24 0.15 
5963 corticotropin releasing hormone AW513199 1.24 0.06 
16923 protein kinase C, iota AA969093 1.24 0.09 
3193 Human, clone IMAGE:3355813, mRNA, partial cds. BC000282 1.24 0.13 
6469 Human, clone MGC:16924 IMAGE:3855040, mRNA, complete cds. BC010627 1.23 0.14 
9879 Human calnexin mRNA, complete cds. M94859 1.23 0.09 
3603 
Human Bruton's tyrosine kinase (BTK), alpha-D-
galactosidase A (GLA), L44-like ribosomal protein 
(L44L) and FTP3 (FTP3) genes, complete cds. 
U78027 1.23 0.10 
5632 D-dopachrome tautomerase BG478996 1.23 0.11 
6571 Human mRNA for Nop10p, complete cds. AB043104 1.23 0.10 
11910 replication factor C (activator 1) 1 (145kD) AW840383 1.23 0.11 
5412 
Human cDNA FLJ11191 fis, clone 
PLACE1007598, weakly similar to ZINC FINGER 
PROTEIN 184. 
AK002053 1.23 0.14 
2739 coronin, actin-binding protein, 2A BC000010 1.22 0.11 
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4071 interferon consensus sequence binding protein 1 AW964220 1.22 0.14 
979 cytoplasmic FMRP interacting protein 1 AA430381 1.22 0.08 
3551 Human mRNA for steroid receptor coactivator 1a. AJ000881 1.22 0.11 
8500 Human endonexin II mRNA, complete cds. J03745 1.21 0.08 
14876 Homo sapiens clone 24400 mRNA sequence AF052145 1.21 0.09 
5508 Human cDNA: FLJ22269 fis, clone HRC03179. AK025922 1.21 0.05 
14685 Human mRNA for KIAA0959 protein, partial cds. AB023176 1.21 0.12 
13222 Human mRNA for epsilon isoform of 61kDa regulatory subunit of PP2A. Z69029 1.21 0.13 
15871 
Human cDNA FLJ12469 fis, clone 
NT2RM1000874, highly similar to Human death 
effector domain-containing testicular molecule 
mRNA. 
AK022531 1.20 0.10 
10344 ESTs, Highly similar to I58410 Erg-3 [H.sapiens] BI712083 1.20 0.06 
5882 amiloride-sensitive cation channel 2, neuronal NM_020039 1.20 0.10 
2503 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C BG938585 1.19 0.14 
8621 
Human, melanoma inhibitory activity, clone 
MGC:14503 IMAGE:4333499, mRNA, complete 
cds. 
BC005910 1.18 0.06 
13435 adenosine deaminase BG257096 1.18 0.14 
4239 
ESTs, Weakly similar to CA18 MOUSE 
COLLAGEN ALPHA 1(VIII) CHAIN PRECURSOR 
[M.musculus] 
AW275800 1.18 0.10 
3400 
Human, transforming growth factor beta-
stimulated protein TSC-22, clone MGC:8464 
IMAGE:2821602, mRNA, complete cds. 
BC000456 1.17 0.09 
5719 ets variant gene 6 (TEL oncogene) BE217961 1.17 0.07 
1587 
Human cDNA FLJ11830 fis, clone 
HEMBA1006559, moderately similar to Mouse 
(Mus musculus) PRAJA1 (Praja1) mRNA. 
AK021892 1.17 0.07 
12686 Human mRNA for frizzled-7, complete cds. AB017365 1.17 0.06 
3489 Human two-pore potassium channel TPKC1 mRNA, complete cds. AF004711 1.17 0.09 
8191 Human cyclophilin-related processed pseudogene. X52855 1.16 0.05 
2104 Human mRNA for ryudocan core protein. D13292 1.16 0.09 
5500 glutathione S-transferase M3 (brain) AA623012 1.16 0.06 
5108 Human AF5q31 protein (AF5q31) mRNA, complete cds. AF197927 1.16 0.05 
3644 
Human complete genomic sequence between 
D16S3070 and D16S3275, containing Familial 
Mediterranean Fever gene disease. 
AJ003147 1.16 0.05 
13644 intersectin 1 (SH3 domain protein) AA582575 1.15 0.09 
17842 
Human cDNA FLJ11160 fis, clone 
PLACE1007014, weakly similar to 36 KD 
NUCLEOLAR PROTEIN HNP36. 
AK002022 1.15 0.09 
5979 EST AI025099 1.15 0.07 
3800 pN44=prostate secretory protein [Human, prostate tissue, mRNA, 475 nt]. S67815 1.15 0.08 
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16562 
laminin, gamma 2 (nicein (100kD), kalinin 
(105kD), BM600 (100kD), Herlitz junctional 
epidermolysis bullosa)) 
AA677534 1.14 0.08 
18161 KIAA0690 protein BF843103 1.14 0.10 
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